



(86) Date de dépôt PCT/PCT Filing Date: 2010/12/10

(87) Date publication PCT/PCT Publication Date: 2012/06/14

(85) Entrée phase nationale/National Entry: 2013/06/05

(86) N° demande PCT/PCT Application No.: EP 2010/069355

(87) N° publication PCT/PCT Publication No.: 2012/076063

(51) Cl.Int./Int.Cl. *C07D 401/04* (2006.01),
A61K 31/4439 (2006.01), *A61P 29/00* (2006.01),
C07D 401/14 (2006.01), *C07D 413/14* (2006.01)


(71) Demandeur/Applicant:
ROTTAPHARM S.P.A., IT

(72) Inventeurs/Inventors:
BORRIELLO, MANUELA, IT;
ROVATI, LUCIO, IT;
STASI, LUIGI PIERO, IT;
BUZZI, BENEDETTA, IT;
COLACE, FABRIZIO, IT

(74) Agent: BERESKIN & PARR LLP/S.E.N.C.R.L.,S.R.L.

(54) Titre : DERIVES DE PYRIDINAMIDE EN TANT QU'ANTAGONISTES DE RECEPTEUR EP4

(54) Title: PYRIDINE AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS



(57) **Abrégé/Abstract:**

The invention relates pyridine amide derivative of Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are independently hydrogen, linear or branched (C1-C3)alkyl or joined together they form a cyclopropyl ring; R is independently selected from the group consisting of halogens and trifluoromethyl and p is 1, 2 or 3; A is C or N; E is a group of formula (B) or (C), wherein B is C(O)OH, C(O)O(C1-C3)alkyl, and C is selected from the group consisting of formula (I) m is 1,2 or 3, n is 0 or 1, W is -O-, -O(C1-C3 alkyl)-; -(C1-C3 alkyl)O-; -C(O)-; -C(=N-O(C1-C3 alkyl))-; -NH- or -NH(C1-C3alkyl)-; Ar is phenyl, optionally substituted with one or more substituents selected from the group consisting of halogen, trifluoromethyl, trifluoromethoxy, methyl, -NH(C1-C3alkyl)-; -N(C1-C3alkyl)(C1-C3alkyl)-, a from 5 to 7 membered heterocyclic ring containing one nitrogen atom which is covalently bonded to Ar and optionally containing one or two heteroatoms selected from N, O and S; and a 5- or 6-membered heteroaromatic ring containing 1 to 3 heteroatoms selected from S, O and N, such heteroaromatic ring being substituted with one or two substituents selected from the group consisting of (C1-C3)alkyl, (C3-C5)cycloalkyloxy, (C1-C3)alkylcarbonyl. The compounds of the invention could be used for manufacturing a medicament for the treatment of pathologies which require the use of an antagonist of the EP4 receptor, such as the treatment of acute and chronic pain, inflammatory pain, osteoarthritis, inflammation-associated disorder as arthritis, rheumatoid arthritis, cancer, endometriosis and migraine.



(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property

Organization

International Bureau

(43) International Publication Date
14 June 2012 (14.06.2012)

(10) International Publication Number

WO 2012/076063 A1

(51) International Patent Classification:

C07D 401/04 (2006.01) **A61K 31/4439** (2006.01)**C07D 401/14** (2006.01) **A61P 29/00** (2006.01)**C07D 413/14** (2006.01)

(21) International Application Number:

PCT/EP2010/069355

(22) International Filing Date:

10 December 2010 (10.12.2010)

(25) Filing Language:

English

(26) Publication Language:

English

(71) **Applicant** (for all designated States except US): **ROT-TAPHARM S.P.A.** [IT/IT]; Galleria Unione, 5, I-20122 Milano (IT).

(72) Inventors; and

(75) **Inventors/Applicants** (for US only): **BORRIELLO, Manuela** [IT/IT]; Via della Signora, 4, I-20052 Monza (IT). **ROVATI, Lucio** [IT/IT]; Via Ramazzotti, 1, I-20052 Monza (IT). **STASI, Luigi Piero** [IT/IT]; Via Biancamano, 7, I-20052 Monza (IT). **BUZZI, Benedetta** [IT/IT]; C.so Resistenza, 13, I-20036 Meda (IT). **COLACE, Fabrizio** [IT/IT]; Via Montanari, 19, I-20052 Monza (IT).(74) **Agents:** **CATTANEO, Elisabetta** et al.; Corso di Porta Vittoria 9, I-20122 Milano (IT).(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,





AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).**Declarations under Rule 4.17:**

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report (Art. 21(3))

(54) **Title:** PYRIDINE AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS

(I)

(57) **Abstract:** The invention relates pyridine amide derivative of Formula (I) or a pharmaceutically acceptable salt thereof, wherein R_1 and R_2 are independently hydrogen, linear or branched (C1-C3)alkyl or joined together they form a cyclopropyl ring; R is independently selected from the group consisting of halogens and trifluoromethyl and p is 1, 2 or 3; A is C or N; E is a group of formula (B) or (C), wherein B is $C(O)OH$, $C(O)O(C1-C3)alkyl$, and C is selected from the group consisting of formula (I) m is 1, 2 or 3, n is 0 or 1, W is $-O-$, $-O(C1-C3 alkyl)-$; $-(C1-C3 alkyl)O-$; $-C(O)-$; $-C(=N-O(C1-C3 alkyl))-$; $-NH-$ or $-NH(C1-C3alkyl)-$; Ar is phenyl, optionally substituted with one or more substituents selected from the group consisting of halogen, trifluoromethyl, trifluoromethoxy, methyl, $-NH(C1-C3alkyl)-$; $-N(C1-C3alkyl)(C1-C3alkyl)-$, a from 5 to 7 membered heterocyclic ring containing one nitrogen atom which is covalently bonded to Ar and optionally containing one or two heteroatoms selected from N, O and S; and a 5- or 6-membered heteroaromatic ring containing 1 to 3 heteroatoms selected from S, O and N, such heteroaromatic ring being substituted with one or two substituents selected from the group consisting of (C1-C3)alkyl, (C3-C5)cycloalkyloxy, (C1-C3)alkylcarbonyl. The compounds of the invention could be used for manufacturing a medicament for the treatment of pathologies which require the use of an antagonist of the EP4 receptor, such as the treatment of acute and chronic pain, inflammatory pain, osteoarthritis, inflammation-associated disorder as arthritis, rheumatoid arthritis, cancer, endometriosis and migraine.



WO 2012/076063 A1

“Pyridine amide derivatives as EP4 receptor antagonists”

FIELD OF THE INVENTION

The present invention relates to novel pyridine amide derivative compounds, processes for their preparation, pharmaceutical compositions containing them and their use as medicaments, *inter alia* for the treatment or alleviation of Prostaglandin E mediated diseases such as acute and chronic pain, osteoarthritis, inflammation-associated disorder as arthritis, rheumatoid arthritis, cancer, migraine and endometriosis.

BACKGROUND OF THE INVENTION

A number of review articles describe the characterization and therapeutic relevance of the prostanoid receptors as well as the most commonly used selective agonists and antagonists; *Eicosanoids: From Biotechnology to therapeutic Applications*, Folco, Samuelson, Maclouf and Velo eds, Plenum Press, New York, 1996, chap.14, 137-154; “*Molecular aspects of the structures and functions of the prostaglandin E receptors*”, Journal of Lipid Mediators and Cell Signalling, 1996, 14, 83-87; “*Function of prostanoid receptors: studies on knockout mice*”, Prostaglandins & other Lipid Mediators, 2002, 68-69, 557-573 and “*Prostanoid receptor antagonists: development strategies and therapeutic applications*”, British Journal of Pharmacology (2009), 158, 104-145. Prostaglandin E2 (PGE2) is a member of the prostanoid family with a variety of physiological effects, including mucosal protection, induction of gastris acid secretion in stomach, generation of fever, hyperalgesia, inflammation and immunity. These actions of PGE2 are mediated by four G-protein-coupled PGE2 receptors, EP1, EP2, EP3 and EP4.

The EP4 receptor is a 7-transmembrane receptor whose activation is normally associated with elevation of intracellular cyclic adenosine monophosphate (cAMP) levels. PGE2-activated EP4 receptor signalling may be involved in various pathologic states, such as pain, inflammation, cancer, dermatitis, bone disease and immune system dysfunction.

In The Journal of Immunology (2008, 181, 5082–5088) studies suggest that PGE2 inhibits proteoglycan synthesis and stimulates matrix degradation in

osteoarthritic chondrocytes via the EP4 receptor. Targeting EP4, rather than cyclooxygenase 2, could represent a future strategy for osteoarthritis disease modification.


In European Journal of Pharmacology (2008, 580, 116–121) studies suggest that that a pharmacological blockade of the prostanoid EP4 receptor may represent a new therapeutic strategy in signs and symptomatic relief of osteoarthritis and/or rheumatoid arthritis.

Certain nicotinamide compounds are generally disclosed in US20022111495A, said compounds being described as inhibitors of phosphodiesterases 4 isoenzymes. Patent application publications WO2005021508, WO2005105732, WO2005105733, WO2007121578 and WO2009139373 disclose compounds as being useful in the treatment of prostaglandin mediated disease.

SUMMARY OF THE INVENTION

The present invention is directed to novel compounds that are selective antagonists of the EP4 subtype of PGE2 receptors, specifically with analgesic and antiinflammatory activity.

Therefore, the invention concerns pyridine compound of Formula (I):



or a pharmaceutically acceptable salt thereof,
wherein:

R_1 and R_2 are independently hydrogen, linear or branched (C1-C3)alkyl or joined together they form a cyclopropyl ring;


R is independently selected from the group consisting of halogens and trifluoromethyl and p is 1, 2 or 3;

A is C or N;

E is a group of formula (B) or (C), wherein

B is $C(O)OH$, $C(O)O(C1-C3)alkyl$, and

C is selected from the group consisting of:



m is 1,2 or 3,

n is 0 or 1,

- 5 W is -O-, -O(C1-C3 alkyl)-; -(C1-C3 alkyl)O-; -C(O)-; -C(=N-O(C1-C3 alkyl))-; -NH- or -NH(C1-C3alkyl)-;


Ar is phenyl, optionally substituted with one or more substituents selected from the group consisting of halogen, trifluoromethyl, trifluoromethoxy, methyl, -NH(C1-C3alkyl)-; -N(C1-C3alkyl)(C1-C3alkyl)-, a from 5 to 7 membered heterocyclic ring
 10 containing one nitrogen atom which is covalently bonded to Ar and optionally containing one or two heteroatoms selected from N,O and S; and a 5- or 6-membered heteroaromatic ring containing 1 to 3 heteroatoms selected from S, O e N, such heteroaromatic ring being substituted with one or two substituents selected from the group consisting of (C1-C3)alkyl, (C3-C5)cycloalkyloxy, (C1-
 15 C3)alkylcarbonyl.

In this invention compounds of Formula (I) may exist as R and S enantiomers and as racemic mixture. This invention includes in its scope of protection all the possible isomers and racemic mixtures. Wherever should be present further symmetry centres, this invention includes all the possible
 20 diastereoisomers and relative mixtures as well.

In another aspect the invention concerns a compound of Formula (I) as medicament, in particular it concerns its use for the treatment of pathologies where an antagonist of the EP4 receptor is needed, such as the treatment of acute and chronic pain, inflammatory pain, osteoarthritis, inflammation-associated disorder
 25 as arthritis, rheumatoid arthritis, cancer endometriosis and migraine.

DETAILED DESCRIPTION OF THE INVENTION

The invention thus concerns pyridine amide derivative of Formula (I):



(I)

or a pharmaceutically acceptable salt thereof,

wherein:

R₁ and R₂ are independently hydrogen, linear or branched (C1-C3)alkyl or joined together they form a cyclopropyl ring;


R is independently selected from the group consisting of halogens and trifluoromethyl and p is 1, 2 or 3;

A is C or N;

E is a group of formula (B) or (C), wherein

B is C(O)OH, C(O)O(C1-C3)alkyl, and

C is selected from the group consisting of:



m is 1,2 or 3,

n is 0 or 1,

W is -O-, -O(C1-C3 alkyl)-; -(C1-C3 alkyl)O-; -C(O)-; -C(=N-O(C1-C3 alkyl))-; -NH- or -NH(C1-C3alkyl)-;


Ar is phenyl, optionally substituted with one or more substituents selected from the group consisting of halogen, trifluoromethyl, trifluoromethoxy, methyl, -NH(C1-C3alkyl)-; -N(C1-C3alkyl)(C1-C3alkyl)-, a from 5 to 7 membered heterocyclic ring containing one nitrogen atom which is covalently bonded to Ar and optionally containing one or two heteroatoms selected from N,O and S; and a 5- or 6-membered heteroaromatic ring containing 1 to 3 heteroatoms selected from S, O or N, such heteroaromatic ring being substituted with one or two substituents selected from the group consisting of (C1-C3)alkyl, (C3-C5)cycloalkyloxy, (C1-C3)alkylcarbonyl.

Preferably p is 1 and R is selected from alogen and trifluoromethyl, more preferably p is 1 and R is alogen, still more preferably R is chloro.

R1 and R2 are indipendently preferably selected from hydrogen, methyl or they form together a cyclopropane ring, and more preferably R1 and R2 form
5 together a cyclopropane ring.

In a first aspect of the invention embodiment, pyridine amide derivative of Formula (I) contains E which is COOH.

This is a compound of Formula **(Ia)**:



(Ia)

10 In this embodiment, preferably m is 1 and 2 and when n is 0, W is bond.

A preferred embodiment of the first aspect of the invention concerns compounds with W is selected from the group consisting of O, NH and N(C1-C3)alkyl.

15 In a first embodiment, Ar is phenyl, optionally substituted with one or more substituents selected from the group consisting of halogen, trifluoromethyl, trifluoromethoxy, methyl, -NH(C1-C3alkyl)-; -N(C1-C3alkyl)(C1-C3alkyl)-, a from 5 to 7 membered heterocyclic ring containing one nitrogen atom, which is convalently bonded to Ar, and optionally containing one or two heteroatoms selected from N,O and S.

20 Examples of heterocyclic ring include piperazinyl, piperidinyl, morpholinyl and the like. More preferably Ar is phenyl substituted by alogen, still more preferably said halogen is F.

In a second embodiment Ar is preferably a 5- or 6-membered heteroaromatic ring containing 1 to 3 heteroatoms selected from S, O e N, such
25 ring being substituted with one or two substituents selected from the group consisting of (C1-C3)alkyl, (C3-C5)cycloalkyloxy, (C1-C3)alkylcarbonyl.

In a second aspect of the invention, pyridine amide derivative of Formula (I) contains E which is B.

In this embodiment, preferably m is 1 and 2 and when n is 0, W is bond.

In a first embodiment, Ar is preferably phenyl optionally substituted with one or more halogen atoms, trifluoromethyl, trifluoromethoxy, methyl, -NH(C1-C3alkyl)-; -N(C1-C3alkyl)(C1-C3alkyl)-, a from 5 to 7 membered heterocyclic ring containing one nitrogen atom, which is covalently bonded to Ar, and optionally containing one or two heteroatoms selected from N,O and S.

Examples of heterocyclic include piperazinyl, piperidinyl, morpholinyl and the like. More preferably Ar is phenyl substituted by alogen, still more preferably F. In a second embodiment Ar is preferably a 5- or 6-membered heteroaromatic ring containing 1 to 3 heteroatoms selected from S, O e N, such ring being substituted with one or two substituents selected from the group consisting of (C1-C3)alkyl, (C3-C5)cycloalkyloxy, (C1-C3)alkylcarbonyl.

Examples of 5- or 6-membered heteroaromatic ring are pyridine, pyrimidine, oxazole, isoxazole, oxadiazole. Advantageously, Ar is pyridine

The term "pharmaceutically acceptable salts" refers to salts prepared from pharmaceutically acceptable non-toxic bases or acids including inorganic or organic bases and inorganic or organic acids. Salts derived from inorganic bases include aluminum, ammonium, calcium, copper, ferric, ferrous, lithium,

magnesium, manganic salts, manganous, potassium, sodium, zinc, and the like. Particularly preferred are the ammonium, calcium, magnesium, potassium, and sodium salts. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, substituted amines
 5 including naturally occurring substituted amines, cyclic amines, and basic ion exchange resins, such as arginine, betaine, caffeine, choline, N,N'-dibenzylethylenediamine, diethylamine, 2-diethyl-aminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethyl-morpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine,
 10 lysine, methyl-glucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, and the like.

When the compound of the present invention is basic, salts may be prepared from pharmaceutically acceptable non-toxic acids, including inorganic
 15 and organic acids. Such acids include acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethanesulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric, p-toluenesulfonic acid, and the like. Particularly preferred are citric, hydrobromic,
 20 hydrochloric, maleic, phosphoric, sulfuric, and tartaric acids.

It will be understood that, as used herein, references to the compounds of Formula (I), (Ia) and (Ib) are meant to also include the pharmaceutically acceptable salts.

The preferred compounds of the invention are selected from the group consisting of:

- 25 4-(1-(5-chloro-2-(2-phenylpyrrolidin-1-yl)nicotinamido)cyclopropyl)benzoic acid (racemic mixture)
- 4-(1-(5-chloro-2-(2-phenylpyrrolidin-1-yl)nicotinamido)cyclopropyl)benzoic acid (enantiomer 1)
- 4-(1-(5-chloro-2-(2-phenylpyrrolidin-1-yl)nicotinamido)cyclopropyl)benzoic acid (enantiomer 2)
- 30 4-(1-(5-chloro-2-(3-phenylpyrrolidin-1-yl)nicotinamido)cyclopropyl)benzoic acid

- 4-(1-(5-chloro-2-(3-phenylpyrrolidin-1-yl)nicotinamido)cyclopropyl)benzoic acid
(enantiomer 1)
- 4-(1-(5-chloro-2-(3-phenylpyrrolidin-1-yl)nicotinamido)cyclopropyl)benzoic acid
(enantiomer 2)
- 5 4-(1-(2-(2-benzylpyrrolidin-1-yl)-5-chloronicotinamido)cyclopropyl)benzoic acid
(racemic mixture)
- 4-(1-(2-(2-benzylpyrrolidin-1-yl)-5-chloronicotinamido)cyclopropyl)benzoic acid
(enantiomer 1)
- 4-(1-(2-(2-benzylpyrrolidin-1-yl)-5-chloronicotinamido)cyclopropyl)benzoic acid
(enantiomer 2)
- 10 4-(1-(5-chloro-2-(3-phenoxyazetidin-1-yl)nicotinamido)cyclopropyl)benzoic acid
(S)-4-(1-(5-chloro-2-(3-(4-fluorophenoxy)azetidin-1-yl)nicotinamido)ethyl)benzoic acid
- (S)-4-(1-(5-chloro-2-(3-(3-fluorophenoxy)azetidin-1-yl)nicotinamido)ethyl)benzoic acid
- 15 4-(1-(5-chloro-2-(3-(4-(trifluoromethyl)phenoxy)azetidin-1-yl)nicotinamido)cyclopropyl)benzoic acid
- 4-(1-(5-chloro-2-(3-(3-(trifluoromethyl)phenoxy)azetidin-1-yl)nicotinamido)cyclopropyl)benzoic acid
- 20 4-(1-(5-chloro-2-(3-(4-fluorophenoxy)azetidin-1-yl)nicotinamido)cyclopropyl)-benzoic acid
- 4-(1-(5-chloro-2-(3-(3-fluorophenoxy)azetidin-1-yl)nicotinamido)cyclopropyl)-benzoic acid
- 4-(1-(5-chloro-2-(3-(4-fluoro-3-(trifluoromethyl)phenoxy)azetidin-1-yl)nicotinamido)cyclopropyl)-benzoic acid
- 25 4-(1-(5-chloro-2-(3-(3-(trifluoromethoxy)phenoxy)azetidin-1-yl)nicotinamido)cyclopropyl)-benzoic acid
- 4-(1-(5-chloro-2-(3-(2,4-difluorophenoxy)azetidin-1-yl)nicotinamido)cyclopropyl)-benzoic acid
- 30 4-(1-(5-chloro-2-(3-(3,4-difluorophenoxy)azetidin-1-yl)nicotinamido)cyclopropyl)-benzoic acid

- 4-(1-(5-chloro-2-(3-(3-(piperazin-1-yl)phenoxy)azetidin-1-yl)nicotinamido)cyclopropyl)benzoic acid
- 4-((5-chloro-2-(3-(3-fluorophenoxy)azetidin-1-yl) nicotinamido) methyl)benzoic acid
- 6-((5-chloro-2-(3-(3-fluorophenoxy)azetidin-1-yl)nicotinamido)methyl)nicotinic acid
- 5 6-((5-chloro-2-(3-(3-fluorophenoxy)azetidin-1-yl)nicotinamido)methyl)nicotinic acid
- 4-(1-(5-chloro-2-(3-(3-fluorobenzoyl)azetidin-1-yl)nicotinamido)cyclopropyl)benzoic acid
- 4-(1-(5-chloro-2-(3-((3-fluorophenyl)(methoxyimino)methyl)azetidin-1-yl)-nicotinamido)cyclopropyl)benzoic acid (isomeric mixture)
- 10 4-(1-(5-chloro-2-(3-(3-fluorophenyl)-3-hydroxyazetidin-1-yl)nicotinamido)cyclopropyl)benzoic acid
- 4-(1-(5-chloro-2-(3-(4-fluorophenyl)-3-hydroxyazetidin-1-yl)nicotinamido)cyclopropyl)benzoic acid
- 4-(1-(5-chloro-2-(3-((4-fluorophenoxy)methyl)azetidin-1-yl)nicotinamido)cyclopropyl)benzoic acid
- 15 4-(1-(5-chloro-2-(3-((4-fluorophenoxy)methyl)azetidin-1-yl)nicotinamido)cyclopropyl)benzoic acid
- 4-(1-(5-chloro-2-(3-((3-(trifluoromethyl)phenyl)amino)azetidin-1-yl)nicotinamido)-cyclopropyl)benzoic acid
- 20 4-(1-(5-chloro-2-(3-((3-fluorophenyl)amino)azetidin-1-yl)nicotinamido)-cyclopropyl)benzoic acid
- 4-(1-(5-chloro-2-(3-((4-fluorophenyl)amino)azetidin-1-yl)nicotinamido)cyclopropyl)-benzoic acid
- 4-(1-(5-chloro-2-(3-((4-fluoro-2-methylphenyl)amino)azetidin-1-yl)nicotinamido)-cyclopropyl)benzoic acid
- 25 4-(1-(5-chloro-2-(3-((2,4-difluorophenyl)amino)azetidin-1-yl)nicotinamido)-cyclopropyl)benzoic acid
- 4-(1-(5-chloro-2-(3-((2-methyl-4-(trifluoromethyl)phenyl)amino)azetidin-1-yl)-nicotinamido)cyclopropyl) benzoic acid
- 30 4-(1-(5-chloro-2-(3-((4-fluoro-2-methylphenyl)(methyl)amino)azetidin-1-yl)-nicotinamido)cyclopropyl)benzoic acid

- 4-(1-(2-(3-(3-fluorophenoxy)azetidin-1-yl)-5-(trifluoromethyl)nicotinamido)-cyclopropyl)benzoic acid
- 4-(1-(2-(3-(4-fluorophenoxy)azetidin-1-yl)-5-(trifluoromethyl)nicotinamido)-cyclopropyl)benzoic acid
- 5 4-(1-(2-(3-(4-chlorophenoxy)azetidin-1-yl)-5-(trifluoromethyl)nicotinamido)-cyclopropyl)benzoic acid
- 4-(1-(2-(3-(3-chlorophenoxy)azetidin-1-yl)-5-(trifluoromethyl)nicotinamido)-cyclopropyl)benzoic acid
- 4-(1-(2-(3-(4-fluoro-3-(trifluoromethyl)phenoxy)azetidin-1-yl)-5-(trifluoromethyl)-nicotinamido)cyclopropyl)benzoic acid
- 10 4-(1-(2-(3-(3-(trifluoromethoxy)phenoxy)azetidin-1-yl)-5-(trifluoromethyl)-nicotinamido)cyclopropyl)benzoic acid
- 4-(1-(2-(3-(2,4-difluorophenoxy)azetidin-1-yl)-5-(trifluoromethyl)nicotinamido)-cyclopropyl)benzoic acid
- 15 4-(1-(2-(3-(3,4-difluorophenoxy)azetidin-1-yl)-5-(trifluoromethyl)nicotinamido)-cyclopropyl)benzoic acid
- 4-(1-(2-(3-((5-methylisoxazol-3-yl)oxy)azetidin-1-yl)-5-(trifluoromethyl)-nicotinamido)cyclopropyl)benzoic acid
- 4-(1-(5-(trifluoromethyl)-2-(3-((6-(trifluoromethyl)pyridin-2-yl)oxy)azetidin-1-yl)nicotinamido)cyclopropyl)benzoic acid
- 20 4-(1-(2-(3-((5-fluoropyrimidin-2-yl)oxy)azetidin-1-yl)-5-(trifluoromethyl)-nicotinamido)cyclopropyl)benzoic acid
- 4-(1-(2-(3-((3-fluorophenyl)amino)azetidin-1-yl)-5-(trifluoromethyl)-nicotinamido)cyclopropyl)benzoic acid
- 25 4-(1-(2-(3-((4-fluorophenyl)amino)azetidin-1-yl)-5-(trifluoromethyl)nicotinamido)-cyclopropyl)benzoic acid
- 4-(1-(2-(3-((4-fluoro-2-methylphenyl)amino)azetidin-1-yl)-5-(trifluoromethyl)-nicotinamido)cyclopropyl)benzoic acid
- 4-(1-(2-(3-((2,4-difluorophenyl)amino)azetidin-1-yl)-5-(trifluoromethyl)-nicotinamido)cyclopropyl)benzoic acid
- 30 4-(1-(5-fluoro-2-(3-(3-fluorophenoxy)azetidin-1-yl)nicotinamido)cyclopropyl)benzoic acid

- 4-(1-(5-fluoro-2-(3-(3-chlorophenoxy)azetidin-1-yl)nicotinamido)cyclopropyl)-
benzoic acid (
- 4-(1-(5-fluoro-2-(3-(3-(trifluoromethoxy)phenoxy)azetidin-1-yl)nicotinamido)-
cyclopropyl)benzoic acid
- 5 4-(1-(5-fluoro-2-(3-((4-fluoro-2-methylphenyl)amino)azetidin-1-yl)nicotinamido)-
cyclopropyl)benzoic acid
- 4-((1S)-1-(5-chloro-2-(3-(4-(trifluoromethyl)phenoxy)pyrrolidin-1-yl)nicotinamido)-
ethyl)benzoic acid
- 4-((1S)-1-(5-chloro-2-(3-(3-(trifluoromethyl)phenoxy)pyrrolidin-1-yl)nicotinamido)-
ethyl)benzoic acid
- 10 4-((1S)-1-(5-chloro-2-(3-(4-fluorophenoxy)pyrrolidin-1-yl)nicotinamido)-
ethyl)benzoic acid
- 4-(1-(5-chloro-2-(3-phenoxy)pyrrolidin-1-yl)nicotinamido)cyclopropyl)benzoic acid
(racemic mixture)
- 15 4-(1-(5-chloro-2-(3-phenoxy)pyrrolidin-1-yl)nicotinamido)cyclopropyl)benzoic acid
(enantiomer 1)
- 4-(1-(5-chloro-2-(3-phenoxy)pyrrolidin-1-yl)nicotinamido)cyclopropyl)benzoic acid
(enantiomer 2)
- 4-(1-(5-chloro-2-(3-(3-(trifluoromethyl)phenoxy)pyrrolidin-1-yl)nicotinamido)-
cyclopropyl)benzoic acid (racemic mixture)
- 20 4-(1-(5-chloro-2-(3-(3-(trifluoromethyl)phenoxy)pyrrolidin-1-yl)nicotinamido)-
cyclopropyl)benzoic acid (enantiomer 1)
- 4-(1-(5-chloro-2-(3-(3-(trifluoromethyl)phenoxy)pyrrolidin-1-yl)nicotinamido)-
cyclopropyl)benzoic acid (enantiomer 2)
- 25 4-(1-(5-chloro-2-(3-(4-fluorophenoxy)pyrrolidin-1-yl)nicotinamido)cyclopropyl)-
benzoic acid (racemic mixture)
- 4-(1-(5-chloro-2-(3-(4-fluorophenoxy)pyrrolidin-1-yl)nicotinamido)cyclopropyl)-
benzoic acid (enantiomer 1)
- 4-(1-(5-chloro-2-(3-(4-fluorophenoxy)pyrrolidin-1-yl)nicotinamido)cyclopropyl)-
benzoic acid (enantiomer 2)
- 30 4-(1-(5-chloro-2-(3-(3-fluorophenoxy)pyrrolidin-1-yl)nicotinamido)-
cyclopropyl)benzoic acid (racemic mixture)

4-(1-(5-chloro-2-(3-(3-fluorophenoxy)pyrrolidin-1-yl)nicotinamido)cyclopropyl)-
benzoic acid (enantiomer 1)

4-(1-(5-chloro-2-(3-(3-fluorophenoxy)pyrrolidin-1-yl)nicotinamido)cyclopropyl)-
benzoic acid (enantiomer 2)

5 4-(1-(5-chloro-2-(3-(m-tolyloxy)pyrrolidin-1-yl)nicotinamido)cyclopropyl)benzoic
acid

4-(1-(5-chloro-2-(3-(4-(trifluoromethyl)phenoxy)pyrrolidin-1-yl)nicotinamido)-
cyclopropyl)benzoic acid (racemic mixture)

10 4-(1-(5-chloro-2-(3-(4-(trifluoromethyl)phenoxy)pyrrolidin-1-yl)nicotinamido)cyclo-
propyl)benzoic acid (enantiomer 1)

4-(1-(5-chloro-2-(3-(4-(trifluoromethyl)phenoxy)pyrrolidin-1-yl)nicotinamido)cyclo-
propyl)benzoic acid (enantiomer 2)

4-(1-(5-chloro-2-(3-((3-fluorophenoxy)methyl)pyrrolidin-1-yl)nicotinamido)cyclo-
propyl)benzoic acid

15 4(R)-4-(1-(5-chloro-2-(2-((3-fluorophenoxy)methyl)pyrrolidin-1-
yl)nicotinamido)cyclopropyl)benzoic acid

4(S)-4-(1-(5-chloro-2-(2-((3-fluorophenoxy)methyl)pyrrolidin-1-yl)nicotinamido)-
cyclopropyl)benzoic acid

20 4-(1-(5-chloro-2-(3-((3-fluorophenoxy)methyl)piperidin-1-yl)nicotinamido)cyclo-
propyl)benzoic acid

(R)-4-(1-(5-chloro-2-(3-(3-fluorophenoxy)pyrrolidin-1-yl)nicotinamido)cyclo-
propyl)benzoic acid

(S)-4-(1-(5-chloro-2-(3-(3-fluorophenoxy)pyrrolidin-1-yl)nicotinamido)cyclo-
propyl)benzoic acid

25 N-(1-(4-(1H-tetrazol-5-yl)phenyl)cyclopropyl)-5-chloro-2-(3-(3-fluorophenoxy)-
azetidin-1-yl)nicotinamide

More preferred compounds of the invention are selected from the group
consisting of:

30 4-(1-(5-chloro-2-(2-phenylpyrrolidin-1-yl)nicotinamido)cyclopropyl)benzoic acid
(racemic mixture)

4-(1-(5-chloro-2-(2-phenylpyrrolidin-1-yl)nicotinamido)cyclopropyl)benzoic acid
(enantiomer 2)

- 4-(1-(5-chloro-2-(3-phenylpyrrolidin-1-yl)nicotinamido)cyclopropyl)benzoic acid
- 4-(1-(5-chloro-2-(3-phenoxyazetidin-1-yl)nicotinamido)cyclopropyl)benzoic acid
- (S)-4-(1-(5-chloro-2-(3-(4-fluorophenoxy)azetidin-1-yl)nicotinamido)ethyl)benzoic acid
- 5 (S)-4-(1-(5-chloro-2-(3-(3-fluorophenoxy)azetidin-1-yl)nicotinamido)ethyl)benzoic acid
- 4-(1-(5-chloro-2-(3-(4-(trifluoromethyl)phenoxy)azetidin-1-yl)nicotinamido)cyclopropyl)benzoic acid
- 4-(1-(5-chloro-2-(3-(3-(trifluoromethyl)phenoxy)azetidin-1-yl)nicotinamido)-
- 10 cyclopropyl)benzoic acid
- 4-(1-(5-chloro-2-(3-(4-fluorophenoxy)azetidin-1-yl)nicotinamido)cyclopropyl)-benzoic acid
- 4-(1-(5-chloro-2-(3-(3-fluorophenoxy)azetidin-1-yl)nicotinamido)cyclopropyl)-benzoic acid
- 15 4-(1-(5-chloro-2-(3-(4-fluoro-3-(trifluoromethyl)phenoxy)azetidin-1-yl)nicotinamido)-cyclopropyl)benzoic acid
- 4-(1-(5-chloro-2-(3-(3-(trifluoromethoxy)phenoxy)azetidin-1-yl)nicotinamido)cyclopropyl)benzoic acid
- 4-(1-(5-chloro-2-(3-(2,4-difluorophenoxy)azetidin-1-yl)nicotinamido)cyclopropyl)-
- 20 benzoic acid
- 4-(1-(5-chloro-2-(3-(3,4-difluorophenoxy)azetidin-1-yl)nicotinamido)cyclopropyl)-benzoic acid
- 4-(1-(5-chloro-2-(3-(3-(piperazin-1-yl)phenoxy)azetidin-1-yl)nicotinamido)cyclopropyl)benzoic acid
- 25 4-((5-chloro-2-(3-(3-fluorophenoxy)azetidin-1-yl) nicotinamido) methyl)benzoic acid
- 6-((5-chloro-2-(3-(3-fluorophenoxy)azetidin-1-yl)nicotinamido)methyl)nicotinic acid
- 4-(1-(5-chloro-2-(3-(3-fluorobenzoyl)azetidin-1-yl)nicotinamido)cyclopropyl)benzoic acid
- 4-(1-(5-chloro-2-(3-(4-fluorophenyl)-3-hydroxyazetidin-1-yl)nicotinamido)cyclo-
- 30 propyl)benzoic acid
- 4-(1-(5-chloro-2-(3-((4-fluorophenoxy)methyl)azetidin-1-yl)nicotinamido)cyclopropyl)benzoic acid

4-(1-(5-chloro-2-(3-((4-fluorophenoxy)methyl)azetidin-1-yl)nicotinamido)cyclopropyl)benzoic acid

4-(1-(5-chloro-2-(3-((3-(trifluoromethyl)phenyl)amino)azetidin-1-yl)nicotinamido)-cyclopropyl)benzoic acid

5 4-(1-(5-chloro-2-(3-((3-fluorophenyl)amino)azetidin-1-yl)nicotinamido)cyclopropyl)-benzoic acid

4-(1-(5-chloro-2-(3-((4-fluorophenyl)amino)azetidin-1-yl)nicotinamido)cyclopropyl)-benzoic acid

10 4-(1-(5-chloro-2-(3-((4-fluoro-2-methylphenyl)amino)azetidin-1-yl)nicotinamido)-cyclopropyl)benzoic acid

4-(1-(5-chloro-2-(3-((2,4-difluorophenyl)amino)azetidin-1-yl)nicotinamido)-cyclopropyl)benzoic acid

4-(1-(5-chloro-2-(3-((2-methyl-4-(trifluoromethyl)phenyl)amino)azetidin-1-yl)-nicotinamido)cyclopropyl) benzoic acid

15 4-(1-(5-chloro-2-(3-((4-fluoro-2-methylphenyl)(methyl)amino)azetidin-1-yl)-nicotinamido)cyclopropyl)benzoic acid

4-(1-(2-(3-(3-fluorophenoxy)azetidin-1-yl)-5-(trifluoromethyl)nicotinamido)-cyclopropyl)benzoic acid

20 4-(1-(2-(3-(4-fluorophenoxy)azetidin-1-yl)-5-(trifluoromethyl)nicotinamido)-cyclopropyl)benzoic acid

4-(1-(2-(3-(4-chlorophenoxy)azetidin-1-yl)-5-(trifluoromethyl)nicotinamido)-cyclopropyl)benzoic acid

4-(1-(2-(3-(3-chlorophenoxy)azetidin-1-yl)-5-(trifluoromethyl)nicotinamido)-cyclopropyl)benzoic acid

25 4-(1-(2-(3-(4-fluoro-3-(trifluoromethyl)phenoxy)azetidin-1-yl)-5-(trifluoromethyl)-nicotinamido)cyclopropyl)benzoic acid

4-(1-(2-(3-(3-(trifluoromethoxy)phenoxy)azetidin-1-yl)-5-(trifluoromethyl)-nicotinamido)cyclopropyl)benzoic acid

30 4-(1-(2-(3-(2,4-difluorophenoxy)azetidin-1-yl)-5-(trifluoromethyl)-nicotinamido)cyclopropyl)benzoic acid

4-(1-(2-(3-(3,4-difluorophenoxy)azetidin-1-yl)-5-(trifluoromethyl)nicotinamido)-cyclopropyl)benzoic acid

- 4-(1-(5-(trifluoromethyl)-2-(3-((6-(trifluoromethyl)pyridin-2-yl)oxy)azetidin-1-yl)-nicotinamido)cyclopropyl)benzoic acid
- 4-(1-(2-(3-((3-fluorophenyl)amino)azetidin-1-yl)-5-(trifluoromethyl)nicotinamido)-cyclopropyl)benzoic acid
- 5 4-(1-(2-(3-((4-fluorophenyl)amino)azetidin-1-yl)-5-(trifluoromethyl)nicotinamido)-cyclopropyl)benzoic acid
- 4-(1-(2-(3-((4-fluoro-2-methylphenyl)amino)azetidin-1-yl)-5-(trifluoromethyl)-nicotinamido)cyclopropyl)benzoic acid
- 4-(1-(2-(3-((2,4-difluorophenyl)amino)azetidin-1-yl)-5-(trifluoromethyl)-nicotinamido)cyclopropyl)benzoic acid
- 10 4-(1-(5-fluoro-2-(3-(3-fluorophenoxy)azetidin-1-yl)nicotinamido)cyclopropyl)benzoic acid
- 4-(1-(5-fluoro-2-(3-(3-chlorophenoxy)azetidin-1-yl)nicotinamido)cyclopropyl)-benzoic acid
- 15 4-(1-(5-fluoro-2-(3-(3-(trifluoromethoxy)phenoxy)azetidin-1-yl)nicotinamido)cyclopropyl)benzoic acid
- 4-(1-(5-fluoro-2-(3-((4-fluoro-2-methylphenyl)amino)azetidin-1-yl)nicotinamido)-cyclopropyl)benzoic acid
- 4-(1-(5-chloro-2-(3-phenoxy)pyrrolidin-1-yl)nicotinamido)cyclopropyl)benzoic acid
- 20 (racemic mixture)
- 4-(1-(5-chloro-2-(3-phenoxy)pyrrolidin-1-yl)nicotinamido)cyclopropyl)benzoic acid (enantiomer 2)
- 4-(1-(5-chloro-2-(3-(3-(trifluoromethyl)phenoxy)pyrrolidin-1-yl)nicotinamido)cyclopropyl)benzoic acid (racemic mixture)
- 25 4-(1-(5-chloro-2-(3-(3-(trifluoromethyl)phenoxy)pyrrolidin-1-yl)nicotinamido)-cyclopropyl)benzoic acid (enantiomer 1)
- 4-(1-(5-chloro-2-(3-(3-(trifluoromethyl)phenoxy)pyrrolidin-1-yl)nicotinamido)-cyclopropyl)benzoic acid (enantiomer 2)
- 4-(1-(5-chloro-2-(3-(4-fluorophenoxy)pyrrolidin-1-yl)nicotinamido)cyclopropyl)-benzoic acid (racemic mixture)
- 30 4-(1-(5-chloro-2-(3-(4-fluorophenoxy)pyrrolidin-1-yl)nicotinamido)cyclopropyl)-benzoic acid (enantiomer 2)

4-(1-(5-chloro-2-(3-(3-fluorophenoxy)pyrrolidin-1-yl)nicotinamido)cyclopropyl)-benzoic acid (racemic mixture)

4-(1-(5-chloro-2-(3-(3-fluorophenoxy)pyrrolidin-1-yl)nicotinamido)cyclopropyl)-benzoic acid (enantiomer 2)

5 4-(1-(5-chloro-2-(3-((3-fluorophenoxy)methyl)pyrrolidin-1-yl)nicotinamido)cyclopropyl)benzoic acid

(R)-4-(1-(5-chloro-2-(2-((3-fluorophenoxy)methyl)pyrrolidin-1-yl)nicotinamido)cyclopropyl)benzoic acid

(S)-4-(1-(5-chloro-2-(3-(3-fluorophenoxy)pyrrolidin-1-yl)nicotinamido)

10 cyclopropyl)benzoic acid

N-(1-(4-(1H-tetrazol-5-yl)phenyl)cyclopropyl)-5-chloro-2-(3-(3-fluorophenoxy)-azetidin-1-yl)nicotinamide

Still more preferred compounds of the invention are selected from the group consisting of:

15 4-(1-(5-chloro-2-(3-phenoxyazetidin-1-yl)nicotinamido)cyclopropyl)benzoic acid

4-(1-(5-chloro-2-(3-(3-fluorophenoxy)azetidin-1-yl)nicotinamido)cyclopropyl)-benzoic acid

6-((5-chloro-2-(3-(3-fluorophenoxy)azetidin-1-yl)nicotinamido)methyl)nicotinic acid

4-(1-(5-chloro-2-(3-((4-fluoro-2-methylphenyl)amino)azetidin-1-yl)nicotinamido)-


20 cyclopropyl)benzoic acid

4-(1-(2-(3-(3-fluorophenoxy)azetidin-1-yl)-5-(trifluoromethyl)nicotinamido)cyclopropyl)benzoic acid

4-(1-(2-(3-((4-fluoro-2-methylphenyl)amino)azetidin-1-yl)-5-(trifluoromethyl)-nicotinamido)cyclopropyl)benzoic acid

25 A further aspect of this invention concerns a process for the preparation of a compound of Formula (I) comprising the following steps represented in the general scheme below:

GENERAL SCHEME



a) reacting a compound (II) with compound of (III) with suitable base thus obtaining a compound of Formula (IV);

b) reacting a compound of Formula (IV) or the corresponding acyl chlorides RCOCl with a compound of formula (V) in the presence of coupling reagents in the presence of a base thus obtaining a compound of Formula (I);


c) reacting a compound of formula (II) with a compound of formula (V) in the presence of coupling reagents and in the presence of a base thus obtaining a compound of Formula (VI);

d) reacting a compound of formula (VI) with compound of (III) with suitable base thus obtaining a compound of Formula (I)

In the above general scheme, Y represents a leaving group selected from the group of halogen atoms, such as chlorine, bromine and iodine.

A further aspect of this invention concerns a process for the preparation of a compound of Formula (Ia), when E is COOH , W is selected from the group consisting of O, NH and $\text{N}(\text{C}_1\text{-C}_3)\text{alkyl}$ and n is 1, comprising the following steps represented in the scheme below (Scheme 1):

SCHEME 1



a') reacting a compound (II) with compound of (III) with suitable base thus obtaining a compound of Formula (IV);

5 b') reacting a compound of Formula (IV) or the corresponding acyl chlorides RCOCl with a compound of formula (V) in the presence of coupling reagents in the presence of a base thus obtaining a compound of Formula (VII);

c') hydrolysing an ester compound (VIa) with strong bases in 1,4-dioxane/H₂O, thus obtaining a compound of Formula (Ia);

10 d') reacting a compound (II) with compound of (VIII) with suitable base thus obtaining a compound of Formula (VIII);

e') converting a free hydroxy group of compound (IX), in presence of a suitable base, into a suitable leaving group L₁, thus obtaining compound (X);


15 f') reacting a compound of formula (X) with a compound of formula (XI) in presence of a base, thus obtaining a compound of formula (IV);

g') reacting a compound of formula (II) with a compound of formula (Va) in the presence of coupling reagents in the presence of a base thus obtaining a compound of Formula (VIa); and

h') reacting a compound of formula (VIa) with compound of (III) with suitable base thus obtaining a compound of Formula (Ia).

A further aspect of this invention concerns a process for the preparation of a compound of Formula (Ib), when E is the group B, W is selected from the group consisting of O, NH and N(C1-C3)alkyl and n is 1, comprising the following steps represented in the scheme below (Scheme 2):

SCHEME 2



a'') reacting a compound of Formula (IV) or the corresponding acyl chlorides $RCOCl$ with a compound of formula (Vb) in the presence of coupling reagents and in the presence of a base thus obtaining a compound of Formula (Ib);

b'') reacting a compound of Formula (IV) or the corresponding acyl chlorides $RCOCl$ with a compound of formula (Va) in the presence of coupling reagents in the presence of a base thus obtaining a compound of Formula (VIIa);

c'') converting a compound (VIIa) in a compound of Formula (Ib).

It will be appreciated that compounds of formula (I), (Ia), and (IV), may be converted into other compounds of formula (I), (Ia), and (IV), by synthetic methods known to the skilled person in the art.

Examples of such conversion reactions are:

i) compounds of formula (IV), when R³ is H, may be prepared by hydrolysis of the corresponding compounds, wherein R³ is (C1-C3) alkyl. The hydrolysis is carried out in the presence of a base (e.g lithium hydroxide) in aqueous 1,4-dioxane at a high temperature and/or by application of microwaves.

5 ii) compounds of formula (I) when E is COOH may be prepared by hydrolysis of the corresponding compounds wherein E is COO(C1-C3)alkyl. The hydrolysis is carried out in the presence of a base (e.g lithium hydroxide) in aqueous 1,4-dioxane at a high temperature and/or by application of microwaves.

10 iii) compounds of formula (I) when E is CONH₂ may be prepared by amide formation reaction from the corresponding compounds wherein E is COOH by reacting the corresponding acyl chloride with ammonia in the presence of a base (triethylamine) in tetrahydrofuran at room temperature.

The invention concerns a compound of Formula (I) as medicament, in particular it concerns its use for the treatment of pathologies where an antagonist
15 of the EP4 receptor is needed, such as the treatment of acute and chronic pain, inflammatory pain, osteoarthritis, inflammation-associated disorder as arthritis, rheumatoid arthritis, cancer endometriosis and migraine.

In another aspect the invention concerns a compound of Formula (I) as medicament, in particular it concerns its use for the treatment of pathologies where
20 an antagonist of the EP4 receptor is needed, such as the treatment of acute and chronic pain, inflammatory pain, osteoarthritis, inflammation-associated disorder as arthritis, rheumatoid arthritis, cancer endometriosis and migraine.

Compounds of the invention are useful as analgesics. For example they are useful in the treatment of chronic articular pain (e.g. rheumatoid arthritis,
25 osteoarthritis, rheumatoid spondylitis, gouty arthritis and juvenile arthritis) including the property of disease modification and joint structure preservation; musculoskeletal pain; lower back and neck pain; sprains and strains; neuropathic pain; sympathetically maintained pain; myositis; pain associated with cancer and fibromyalgia; pain associated with migraine; pain associated with influenza or
30 other viral infections, such as the common cold; rheumatic fever; pain associated with functional bowel disorders such as non-ulcer dyspepsia, non-cardiac chest

pain and irritable bowel syndrome; pain associated with myocardial ischemia; post operative pain; headache; toothache; and dysmenorrhea.

Compounds of the invention are useful in the treatment of neuropathic pain. Neuropathic pain syndromes can develop following neuronal injury and the
5 resulting pain may persist for months or years, even after the original injury has healed. Neuronal injury may occur in the peripheral nerves, dorsal roots, spinal cord or certain regions in the brain. Neuropathic pain syndromes are traditionally classified according to the disease or event that precipitated them. Neuropathic pain syndromes include: diabetic neuropathy; sciatica; non-specific lower back
10 pain; multiple sclerosis pain; fibromyalgia; HIV related neuropathy; post-herpetic neuralgia; trigeminal neuralgia; and pain resulting from physical trauma, amputation, cancer, toxins or chronic inflammatory conditions. These conditions are difficult to treat and although several drugs are known to have limited efficacy, complete pain control is rarely achieved. The symptoms of neuropathic pain are
15 incredibly heterogeneous and are often described as spontaneous shooting and lancinating pain, or ongoing, burning pain. In addition, there is pain associated with normally non-painful sensations such as "pins and needles" (paraesthesias and dysesthesias), increased sensitivity to touch (hyperesthesia), painful sensation following innocuous stimulation (dynamic, static or thermal allodynia), increased
20 sensitivity to noxious stimuli (thermal, cold, mechanical hyperalgesia), continuing pain sensation after removal of the stimulation (hyperpathia) or an absence of or deficit in selective sensory pathways (hypoalgesia).

Compounds of the invention are also useful in the treatment of inflammation, for example in the treatment of skin conditions (e.g. sunburn, burns,
25 eczema, dermatitis, psoriasis); ophthalmic diseases such as glaucoma, retinitis, retinopathies, uveitis and of acute injury to the eye tissue (e.g. conjunctivitis); lung disorders (e.g. asthma, bronchitis, emphysema, allergic rhinitis, respiratory distress syndrome, pigeon fancier's disease, farmer's lung, COPD); gastrointestinal tract disorders (e.g. aphthous ulcer, Crohn's disease, atopic
30 gastritis, gastritis varioliforme, ulcerative colitis, coeliac disease, regional ileitis, irritable bowel syndrome, inflammatory bowel disease, gastrointestinal reflux disease); organ transplantation; other conditions with an inflammatory component

such as vascular disease, migraine, periarteritis nodosa, thyroiditis, aplastic anaemia, Hodgkin's disease, sclerodoma, myaesthesia gravis, multiple sclerosis, sarcoidosis, nephrotic syndrome, Bechet's syndrome, polymyositis, gingivitis, myocardial ischemia, pyrexia, systemic lupus erythematosus, polymyositis, tendinitis, bursitis, and Sjogren's syndrome.

Compounds of the invention are also useful in the treatment of immunological diseases such as autoimmune diseases, immunological deficiency diseases or organ transplantation. The compounds of the invention are also effective in increasing the latency of HIV infection.

Compounds of the invention are also useful in the treatment of diseases of abnormal platelet function (e.g. occlusive vascular diseases).

Compounds of the invention are also useful for the preparation of a drug with diuretic action.

Compounds of the invention are also useful in the treatment of impotence or erectile dysfunction.

Compounds of the invention are also useful in the treatment of bone disease characterized by abnormal bone metabolism or resorption such as osteoporosis (especially postmenopausal osteoporosis), hyper-calcemia, hyperparathyroidism, Paget's bone diseases, osteolysis, hypercalcemia of malignancy with or without bone metastases, rheumatoid arthritis, periodontitis, osteoarthritis, ostealgia, osteopenia, cancer cachexia, calculosis, lithiasis (especially urolithiasis), solid carcinoma, gout and ankylosing spondylitis, tendinitis and bursitis. In a further aspect compounds of the invention may be useful in inhibiting bone resorption and/or promoting bone generation.

Compounds of the invention are also useful for attenuating the hemodynamic side effects of NSAIDs and COX-2 inhibitors.

Compounds of the invention are also useful in the treatment of cardiovascular diseases such as hypertension or myocardiac ischemia; functional or organic venous insufficiency; varicose therapy; haemorrhoids; and shock states associated with a marked drop in arterial pressure (e.g. septic shock).

Compounds of the invention are also useful in the treatment of neurodegenerative diseases and neurodegeneration such as dementia,

particularly degenerative dementia (including senile dementia, Alzheimer's disease, Pick's disease, Huntingdon's chorea, Parkinson's disease and Creutzfeldt-Jakob disease, ALS, motor neuron disease); vascular dementia (including multi-infarct dementia); as well as dementia associated with intracranial
5 space occupying lesions; trauma; infections and related conditions (including HIV infection); metabolism; toxins; anoxia and vitamin deficiency; and mild cognitive impairment associated with ageing, particularly Age Associated Memory Impairment.

The compounds of Formula (I), (Ia) and (Ib) are also useful in the treatment
10 of neuroprotection and in the treatment of neurodegeneration following stroke, cardiac arrest, pulmonary bypass, traumatic brain injury, spinal cord injury or the like. Compounds of the invention are also useful for the treatment of stroke and multiple sclerosis.

Compounds of the invention are also useful in the treatment of tinnitus.

15 Compounds of the invention are also useful in preventing or reducing dependence on, or preventing or reducing tolerance or reverse tolerance to, a dependence - inducing agent. Examples of dependence inducing agents include opioids (e.g. morphine), CNS depressants (e.g. ethanol), psychostimulants (e.g. cocaine) and nicotine.

20 Compounds of the invention are also useful in the treatment of complications of Type 1 diabetes (e.g. diabetic microangiopathy, diabetic retinopathy, diabetic nephropathy, macular degeneration, glaucoma), nephrotic syndrome, aplastic anaemia, uveitis, Kawasaki disease and sarcoidosis.

Compounds of the invention are also useful in the treatment of kidney
25 dysfunction (nephritis, particularly mesangial proliferative glomerulonephritis, nephritic syndrome), liver dysfunction (hepatitis, cirrhosis), gastrointestinal dysfunction (diarrhoea) and colon cancer.

Compounds of the invention are also useful for treating or preventing a neoplasia in a subject in need of such treatment or prevention. The term
30 "treatment" includes partial or total inhibition of the neoplasia growth, spreading or metastasis, as well as partial or total destruction of the neoplastic cells and/or symptoms associated with neoplasia including pain, anorexia or weight loss. The

term also includes the use of compounds as sensitizing agents for other chemotherapies. The term "prevention" includes either preventing the onset of clinically evident neoplasia altogether or preventing the onset of a preclinically evident stage of neoplasia in individuals at risk. Also intended to be encompassed by this definition is the prevention of initiation for malignant cells or to arrest or reverse the progression of premalignant cells to malignant cells. This includes prophylactic treatment of those at risk of developing the neoplasia. The term "subject" for purposes of treatment includes any human or mammal subject who has any one of the known neoplasias, and preferably is a human subject. For methods of prevention, the subject is any human or animal subject, and preferably is a human subject who is at risk for obtaining a neoplasia. The subject may be at risk due to exposure to carcinogenic agents, being genetically predisposed to have the neoplasia, and the like. The term "neoplasia" includes both benign and cancerous tumors, growths and polyps. Thus, the compounds of the invention are useful for treating or preventing benign tumors, growths and polyps including squamous cell papilloma, basal cell tumor, transitional cell papilloma, adenoma, gastrinoma, cholangiocellular adenoma, hepatocellular adenoma, renal tubular adenoma, oncocytoma, glomus tumor, melanocyte nevus, fibroma, myxoma, lipoma, leiomyoma, rhabdomyoma, benign teratoma, hemangioma, osteoma, chondroma and meningioma. The compounds of the invention are also useful for treating or preventing cancerous tumors, growths and polyps including squamous cell carcinoma, basal cell carcinoma, transitional cell carcinoma, adenocarcinoma, malignant gastrinoma, cholangiocellular carcinoma, hepatocellular carcinoma, renal cell carcinoma, malignant melanoma, fibrosarcoma, myxosarcoma, liposarcoma, leiomyosarcoma, rhabdomyosarcoma, malignant teratoma, hemangiosarcoma, Kaposi sarcoma, lymphangiosarcoma, osteosarcoma, chondrosarcoma, malignant meningioma, non-Hodgkin lymphoma, Hodgkin lymphoma and leukemia. For purposes of this specification, "neoplasia" includes brain cancer, bone cancer, epithelial cell-derived neoplasia (epithelial carcinoma), basal cell carcinoma, adenocarcinoma, gastrointestinal cancer such as lip cancer, mouth cancer, esophageal cancer, small bowel cancer and stomach cancer, colon cancer, rectal cancer, liver cancer, bladder cancer, pancreas cancer, ovary

cancer, cervical cancer, lung cancer, breast cancer and skin cancer, such as squamous cell and basal cell cancers, prostate cancer, renal cell carcinoma, and other known cancers that affect epithelial, mesenchymal or blood cells throughout the body. The compounds of the invention are useful for treating or preventing any
5 of the aforementioned cancers. The compounds of the invention are useful for treating or preventing benign and cancerous tumors, growths and polyps of the following cell types: squamous epithelium, basal cells, transitional epithelium, glandular epithelium, G cells, bile ducts epithelium, hepatocytes, tubules epithelium, melanocytes, fibrous connective tissue, cardiac skeleton, adipose
10 tissue, smooth muscle, skeletal muscle, germ cells, blood vessels, lymphatic vessels, bone, cartilage, meninges, lymphoid cells and hematopoietic cells. The compounds can be used to treat subjects having adenomatous polyps, including those with familial adenomatous polyposis (FAP). Additionally, the compounds can be used to prevent polyps from forming in patients at risk of FAP. Preferably, the
15 compounds of the invention are useful for treating or preventing the following cancers: colorectal, esophagus stomach, breast, head and neck, skin, lung, liver, gall bladder, pancreas, bladder, endometrium cervix, prostate, thyroid and brain. It is to be understood that reference to treatment includes both treatment of established symptoms and prophylactic treatment, unless explicitly stated
20 otherwise.

In another aspect the invention concerns pharmaceutical compositions comprising a compound of Formula (I) and a pharmaceutically acceptable carrier.

They could be used in combination with a pharmaceutically acceptable carrier and, optionally, with suitable excipients, to obtain pharmaceutical compositions. The
25 term "pharmaceutically acceptable carrier" means solvents, carrier agents, diluting agents and the like which are used in the administration of compounds of the invention. Such pharmaceutical compositions can be administered by parenteral, oral, buccal, sublingual, nasal, rectal, topical or transdermal administration. Compositions of this invention suitable for the oral administration will be
30 conveniently discrete units such as tablets, capsules, cachet, powders or pellets, or as liquid suspension.

The tablets can contain also suitable excipients routinely used in pharmaceutical field such as pre-gelatinised starch, microcrystalline cellulose, sodium glycolate starch, talc, lactose, magnesium stearate, sucrose, stearic acid, mannitol.

Compositions for parenteral administration conveniently include sterile preparations.

Compositions for topical administration may conveniently be formulated as creams, pastes, oils, ointments, emulsions, foams, gels, drops, spray solutions and transdermal patches.


The compounds of the invention could be used for manufacturing a medicament for the treatment of pathologies which require the use of an antagonist of the EP4 receptor, such as the treatment of inflammatory pain, osteoarthritis, arthritis.

METHOD OF SYNTHESIS

As above shown, according to a further aspect of this invention there is provided a process for the preparation of compound of formula (I), and (Ia) and (Ib). In a more detailed way, the compounds of the present invention may be prepared according to the following schemes. Unless otherwise indicated R₁, R₂, R₃, R_p, W, and Ar in the reaction schemes and discussion that follow are defined above. The term “protecting group”, as used hereinafter, means a hydroxyl or amino protecting group which is selected from typical Hydroxy or amino protecting groups as described in Protective Groups in Organic Synthesis edited by T. W. Greene et al. (John Wiley & Sons, 1999);


Compounds of formula (Ia) may be prepared by hydrolysis reaction of ester compounds of formula (VIIa) according to the reaction scheme 3.

SCHEME3



Compounds of formula (VIIa) may be prepared according to reaction scheme 4.

SCHEME 4




Compounds of formula (IV) are reacted with compounds of formula (Va) in the presence of a suitable coupling reagent, such as (Benzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate (PyBOP), (1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride) and 1-Hydroxybenzotriazole.

The reaction is carried out in an aprotic solvent (such as a halohydrocarbon, e.g. dichloromethane, N,N-dimethylformamide, or acetonitrile) at room temperature, or mixture thereof) in presence of a suitable base (such as triethylamine).

Compounds of formula (Va) wherein A is C are either commercially available or known (See published International Patent application WO 2005/105733 and WO2008/104055) or may be prepared in a similar procedure to those described in WO 2005/105733 WO2008017164 and WO2008/104055.

Compounds of formula (Va) wherein at least one A is N may be prepared according to reaction scheme 5

SCHEME 5



- compounds of formula (XVII) when only one A is N may be prepared by transformation of carboxylic acid group in compound (XVI) into a cyano group of compound (XVII) through the preparation of the corresponding amide derivative and subsequent reduction to cyano derivative as reported in step a of scheme 5.

5 - compounds of formula (XVII) when both A are N may be prepared by substitution of the chloro group with cyano group of compound (XVII) 5.

- compounds of formula (XIX) are prepared starting from compound (XVII) *via* Kulinkovich-SzymoniaK reaction using appropriate Grignard reagent in presence of titanium isopropoxide followed by exposure to Lewis acid in a subsequent step.

10 - In the above scheme 5, Pg represents an appropriate protecting group such as Boc. Compound of formula (XX) are prepared by reacting compound of formula (XIX) with an appropriate protecting agent such as di-tert-butyl dicarbonate in presence of a base.


15 - compounds of formula (XXI) may be prepared by carbonylation of the corresponding bromo derivatives (XX) and subsequent ester formation.

having protected the amine with the appropriate protecting group (Pg) as in compound of formula (XX).

20 - compounds of formula (Va) may be prepared by deprotection of amine group of compound of formula (XXI) in presence of hydrochloric acid in ethylacetate as solvent

Alternatively compound of formula (VIIa) may be prepared according to reaction scheme 6 with a reaction sequence starting from compound of formula (II).

SCHEME 6



25 Reaction conditions for the first step of the sequence are hydrolysis reaction of compounds of formula (II) carried out in presence of a base (e.g lithium hydroxide) in a mixture of organic solvents such as dioxane/water. This reaction may be


carried out at room temperature or, preferably, at high temperature and/or by application of microwaves.

Reaction for the second step is the reaction of compounds of formula (II) wherein R₃ is H with compounds of formula (Va) in the presence of a suitable
5 coupling reagent, such as (Benzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate (PyBOP), (1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride) and 1-Hydroxybenzotriazole.

The reaction is carried out in an aprotic solvent (such as a halohydrocarbon, e.g. dichloromethane, N,N-dimethylformamide, or acetonitrile) at room
10 temperature, or mixture thereof) in presence of a suitable base (such as triethylamine).


Reaction for the third is the reaction of compounds of formula (VIa) with compound of formula (III) in presence of a suitable base (such as triethylamine), in a suitable solvent (tetrahydrofuran/methanol mixture) heating at reflux.

15 Compounds of formula (IV) wherein R₃ is H, may be prepared by hydrolysis reaction of related ester compounds of formula (IV) wherein R₃ is (C1-C3)alkyl, according to the reaction scheme 7.



Hydrolysis is carried out in presence of a base (e.g. lithium hydroxide) in aqueous
20 1,4-dioxane as solvents at high temperature and/or by application of microwaves.

Compound of formula (IV) wherein R₃ is (C1-C3)alkyl, may be prepared according to scheme 8.




25 Compounds of formula (II), are reacted with compound of formula (III) in presence of a suitable base (such as triethylamine, diisopropylethylamine). The

reaction is preferably carried out in alcohols as solvent (such as methanol, ethanol) heating at high temperature by application of microwaves.

Alternatively compound of formula (IV) may be prepared according to reaction scheme 9 with a reaction sequence starting from compound of formula (II).


SCHEME 9



Preferred reaction condition for the first step of the sequence are reactions of compound of formula (II) with commercially available amino alcohols of formula (XII) in presence of a suitable base (such as triethylamine), heating at high temperature by application of microwaves, in suitable solvents (such as methanol), thus obtaining compounds of formula (IX).

Preferred reaction for the second step include the use of methanesulfonyl chloride, more preferably at 0°C, in presence of a suitable base (such as triethylamine) in a suitable organic solvent (such as dimethylformamide) to convert the free hydroxy group of compounds of formula (IX) into a leaving group L₁ (described as above) of compounds of formula (X). Compounds (IV) are obtained in the third step by reaction of compound of formula (X) with compound of formula H-W-Ar in presence of a suitable base (such as potassium carbonate), heating at high temperature by application of microwaves, in a suitable solvent (such as acetonitrile).

Compounds of formula (III) may be prepared according to scheme 10.



Step (a) is the conversion of free hydroxy group of compound of formula (XII) into an appropriate leaving group L1 of compounds of formula (XIII). Examples of suitable leaving group L1 include sulfonic esters such as TfO (triflates), MsO (mesitates) and TsO (tosylates). The reaction preferably include the use of appropriate sulfonyl chloride, more preferably at 0°C, in presence of a suitable base (such as triethylamine) and in a suitable organic solvent (such as toluene).

When W is O, preferred reaction for step (b), include the reaction of compounds of formula (XIII) with appropriate substituted phenols, in presence of a suitable base (such as potassium carbonate) and in a suitable organic solvent (such as acetonitrile) thus obtaining compounds of formula (XIV) when W is NH.

When m is 2 and W is O, compounds of formula (XIV) may be prepared by direct conversion of compounds of formula (XII) into compounds of formula (XIV) as reported in step (c) (scheme 9).

Reaction in step (c) is the reaction of compounds of formula (XII) with a substituted phenol in presence of diisopropyl azodicarboxylate and triphenylphosphine in a suitable solvent, (such as tetrahydrofuran), preferably at room temperature.

When m is 1 and W is NH, a number of compounds of formula (XIV) may be prepared by conversion of compound of formula (XV) into compounds of formula (XIV) as reported in step (e) (scheme 10). Step (e) is the reaction of compounds of formula (XV) with a substituted amine in presence of a suitable reducing agent, such as sodium cyanoborohydride in presence of acetic acid and in a suitable solvent, (such as dichloroethane), preferably at room temperature.

Step (d) is the deprotection of aminic group of compounds of formula (XIV) according to suitable standard techniques well known to those skilled in the art, thus obtaining deprotected amin compounds of formula (IIIa).

According to the invention, the compounds are obtained using a simple
5 process, easy to scale-up and avoiding lengthy and expensive preparation steps, obtaining high yield of a stable pharmaceutical grade compound.

The various methods described above may be useful for the introduction of the desired group at any stage in the stepwise formation of the required compound, and it will be appreciated that these general methods can be combined in
10 different way in such multi-stage processes. The sequence of the reactions in multi-stage processes should of course be chosen so that the reaction conditions used do not affect groups in the molecule which are in the final product.

The invention will be now detailed by means of the following examples relating to the preparation of some invention compounds and to the evaluation of
15 their activity against EP4 receptor.

The following Descriptions relating to intermediate products and Examples illustrating the preparation of certain compounds of formula (Ia) and (Ib) or salts thereof follow below. The descriptions illustrate the preparation of intermediates used to make compounds of formula (Ia) and (Ib) or salts thereof.

20 In the procedures that follow, after each starting material, reference to a description is provided. This is provided merely for assistance to the skilled chemist. The starting material may not necessarily have been prepared from the Description referred to. The stereochemistry of Descriptions and Examples has been assigned on the assumption that the absolute configuration centers are
25 retained.

The yields are calculated assuming that products were 100% pure if not stated otherwise.

Compound are named using ChemBioDraw Ultra 12.0 (CambridgeSoft Corp., 100 CambridgePark Drive, Cambridge, MA 02140)

30 Reagents used in the following examples were commercially available from various suppliers (for example Sigma-Aldrich, Acros, Matrix scientific, Manchester or Apollo) and used without further purifications.

Reactions in anhydrous environment were run under a positive pressure of dry N₂ and solvents were used in dry form.

For reaction involving microwave irradiation, an Initiator 2.5 System was used.

5 Purification was performed using Biotage automatic flash chromatography systems (Sp1 and Isolera systems), Companion CombiFlash (ISCO) automatic flash chromatography, Flash Master or Vac Master systems.

Flash chromatography was carried out on silica gel 230-400 mesh (supplied by Merck AG Darmstadt, Germany), Varian Mega Be-Si pre-packed cartridges, 10 pre-packed Biotage silica cartridges (e.g. Biotage SNAP-Si cartridges), Waters PoraPak RXN RP cartridges, Biotage SNAP-C18.

SPE-Si cartridges are silica solid phase extraction columns.

PoraPakRXN RP cartridges are polymer based reverse phase resin.

Biotage SNAP C18 Gold cartridges are silica based reverse phase column.

15 SPE-SCX cartridges are ion exchange solid phase extraction columns supplied by Varian. The eluent used with SPE-SCX cartridges is dichloromethane and methanol or only methanol followed by 2N ammonia solution in methanol. The collected fractions are those eluted with ammonia solution in methanol.

Thin layer chromatography was carried out using Merck TLC plates 20 Kieselgel 60F-254, visualized with UV light, aqueous permanganate solution, iodine vapours.

Proton Nuclear Magnetic Resonance (¹H NMR) spectra were recorded on Bruker Avance 400 MHz instrument and on Bruker Avance III plus 400MHz. TMS was used as internal standard. Chemical shifts are reported in ppm (δ) using the 25 residual solvent line as internal standard. Splitting patterns are designated as: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; b, broad signal. The NMR spectra were recorded at temperature ranging from 25°C to 90°C. When more than one conformer was detected the chemical shifts of the most abundant one is usually reported.

30 In the analytical characterisation of the described compounds "MS" refers to Mass Spectra taken by Direct infusion Mass or to a mass Spectra associated with

peaks taken by UPLC/MS or HPLC/MS analysis, where the Mass Spectrometer used is as mentioned below.

Direct infusion Mass Spectra (MS) were run on a Ion Trap Thermo LCQ classic spectrometer, operating in positive ES (+) and negative ES (-) ionization mode using different columns and operating procedures listed below:

Phenomenex Gemini-NX C18 column (100x2mm, 3 μ m particle size), column T= 35 °C. Mobile phase: A (water +0,1% formic acid)/ B (acetonitrile+ 0,1% formic acid), Gradient: 10% B at t=0min up to 90% B at t=12min using different gradient curves, flow rate: 0.3 ml/min;

10 AcquityTMUPLC-BEH C18 column (50x21mm, 1.7 μ m particle size), column T = 35 °C. Mobile phase: A (water +0,1% formic acid)/ B (acetonitrile+ 0,1% formic acid), Gradient: 5% B at t=0min up to 100% B at t=4.5min, using different gradient curves, flow rate: 0.5 ml/min;

15 Zorbax SB C18 column (2.1x 50mm, 3,5 μ m particle size) column T= 35 °C. Mobile phase: A (water +0,1% formic acid)/ B (acetonitrile+ 0,1% formic acid), Gradient: 10% B at t=0min up to 90% B at t=12min using different gradient curves, flow rate: 0.4 ml/min.

HPLC spectra were performed on a Waters Alliance 2965 instrument equipped with a Waters 2996 UV-Vis detector using a Phenomenex Luna C18 column (150x4.6mm, 5 μ m particle size). [Mobile phase: different mixtures of acetonitrile/methanol/KH₂PO₄ (20mM pH 2.5); Elution time: 35 min; column T= 30 °C; flow rate= 0.6 ml/min. UV detection wavelenght range from 220 up to 300 nm]

25 Total ion current (TIC) and DAD UV chromatografic traces together with MS and UV spectra were taken on a UPLC/MS AcquityTM system equipped with 2996 PDA detector and coupled to a Waters Micromass ZQTM Mass Spectrometer operating in positive or negative electrospray ionisation mode. UPLC analysis were performed using an AcquityTMUPLC-BEH C18 column (50x21mm, 1.7 μ m particle size), column T= 35 °C. Mobile phase: A (water +0,1% formic acid)/ B (acetonitrile+ 0,1% formic acid), Gradient: 5% B at t=0min, up to 100% B at t=2 min or 4.5 min using different gradient curves, flow rate: 0.5 ml/min.

LCMS were taken on a quadrupole Mass spectrometer on Agilent LC/MSD 1200 Series using Column: Welchrom XB-C18 (50x4.6mm, 5 μ m) operating in ES (+) or (-) ionization mode at T=30°C and with a flow rate=1.5 ml/min.

HPLC spectra for chiral purity determinations were performed on Agilent 1200 instrument and UV detector DAD G1315D using a Daicel Chiralpack IC column (250x4.6mm, 5 μ m particle size) or a Daicel Chiralpack AD-H column (250x4.6mm, 5 μ m particle size). [Mobile phases: isocratic mixtures A (70% n-heptane 30% ethanol + 0.1% trifluoroacetic acid) or B (80% n-hexane 20% isopropanol + 0.2% trifluoroacetic acid), up to 60 min of elution at 30°C, flow rate of 0.5 ml/min].


Purifications by means of preparative chiral HPLC were performed on Shimadzu Preparative Liquid Chromatograph LC-8A apparatus and UV detector SPD-20A using a Daicel Chiralpack IC column (2x25 cm, 5 μ m particle size) or a Daicel Chiralpack AD-H column (2x25 cm, 5 μ m particle size).

[Mobile phases: isocratic premixed mixtures A (70% n-heptane 30% ethanol + 0.1% trifluoroacetic acid) or B (80% n-hexane 20% isopropanol + 0.2% trifluoroacetic acid).

Specific Mobile phase and operating conditions will be specified each time.

DESCRIPTIONS


Description 1: (S)-tert-butyl (1-(4-bromophenyl)ethyl)carbamate (D1)



A mixture of (S)-(-)-1-(4-Bromophenyl)ethylamine hydrochloride (9 g, 38.0 mmol, available from Bepharma Ltd #B157615), di-tert-butyl dicarbonate (8.72 g, 1.05 mmol), and triethylamine (16ml, 114 mmol) in dichloromethane (120ml) was stirred at room temperature overnight. The mixture was diluted with dichloromethane (200ml) and washed with water (100ml). The organic solution was dried over Na₂SO₄ and solvents were evaporated in vacuo to afford the title compound (**D1**) (12.7 g) as a white solid.

¹H NMR (400MHz, CHLOROFORM-d) δ (ppm): 7.47- 7.42 (2H, m), 7.18 (2H, d, *J*= 8.4 Hz), 5.30 (2H, br s), 1.41 (12H, br s).


Description 2: (S)-methyl 4-(1-((tert-butoxycarbonyl)amino)ethyl)benzoate (D2)



5 A mixture of (S)-tert-butyl (1-(4-bromophenyl)ethyl)carbamate (D1) (9.20 g, 27.3 mmol), 1,3-bis(diphenylphosphino)-propane (2.25 g, 5.46 mmol), palladium (II) acetate (1.22 g, 5.46 mmol), and triethylamine (11.5ml, 81.9 mmol) in *N,N*-dimethylformamide/methanol (60ml/ 60ml) was stirred at 80°C overnight under carbon monoxide atmosphere. After cooling to room temperature, the mixture was
10 diluted with ether (300ml) and washed with water (3x100ml). The organic layer was dried over Na₂SO₄ and evaporated in vacuo. The residue was purified by flash chromatography on silica gel eluting with a mixture petroleum ether/ethyl acetate 5:1 to afford the title compound **(D2)** (6.72 g) as white solid.

¹H NMR (400MHz, CHLOROFORM-d) δ (ppm): 8.00 (2H, d, *J*= 8.4 Hz), 7.36 (2H, d, *J*= 8.4 Hz), 4.83 (2H, br s), 3.91 (3H, s), 1.46 -1.42 (12H, m).
15

Description 3: (S)-methyl 4-(1-aminoethyl)benzoate hydrochloride (D3)




To a cooled solution of (S)-methyl 4-(1-((tert-butoxycarbonyl)amino)ethyl)benzoate
20 (D2) (8.20 g, 29.4 mmol) in ethyl acetate (10ml) HCl(g)/ethyl acetate (4N, 50ml) was added and the resulting mixture was stirred at room temperature overnight. Solvents were evaporated in vacuo and the resulting residue was washed with petroleum ether to afford the title compound **(D3)** (5.7 g) as a white solid.

LCMS: (ES/+) *m/z*: 180 [MH⁺] C₁₀H₁₃NO₂ requires 179.09

25 ¹H NMR (400 MHz, DMSO-*d*₆) δ (ppm): 8.86 (3H, br s), 7.99 (2H, d, *J*= 8.4 Hz), 7.72 (2H, d, *J*= 8.4 Hz), 4.48 (1H, br s), 3.86 (3H, s), 1.54 (3H, d, *J*= 6.8 Hz).


Description 4: tert-butyl (1-(4-bromophenyl)cyclopropyl)carbamate (D4)



To the solution of 1-(4-bromophenyl)cyclopropanecarboxylic acid (40 g, 165 mmol, available from Amatek Chemical #AC-0350) in toluene (800ml), in the presence of activated molecular sieves (15 g), N,N-diisopropylethylamine (27.5 g, 497 mmol),
 5 Diphenylphosphoryl azide (54.7 g, 215 mmol) and tert-Butanol (380ml) were added. The resulting mixture was refluxed 5 hours. The mixture was cooled to room temperature and the solvents evaporated in vacuo. The residue was dissolved in ethyl acetate (200ml) and washed with 5% citric acid (200ml), aqueous NaHCO₃ (200ml) and brine (200ml). Collected organics after drying over
 10 Na₂SO₄ and solvent evaporation afforded a crude residue which was purified by flash chromatography on silica gel eluting with a mixture petroleum ether/ethyl acetate 4:1. Collected fractions after solvent evaporation afforded the title compound (**D4**) (23.0 g) as a solid.

¹H NMR (400MHz, CHLOROFORM-d) δ (ppm): 7.39 (2H, d, *J* = 8.0 Hz), 7.09 (2H, d, *J* = 8.0 Hz), 5.27 (1H, s), 1.43 - 1.37 (9H, s), 1.19-1.28 (4H, m).
 15

Description 5: methyl 4-(1-((tert-butoxycarbonyl)amino)cyclopropyl)benzoate (D5)




20 A mixture of tert-butyl (1-(4-bromophenyl)cyclopropyl)carbamate (D4) (2.6 g, 8.33 mmol), 1.3-bis(diphenylphosphine)-propane (680 mg, 0.83 mmol), Palladium(II) acetate (370 mg, 0.83 mmol) and triethylamine (2.52 g, 24.9 mmol) in dimethylformamide (40ml) and methanol (60ml) was stirred at 80°C for 2 days under 4.0 Mpa CO atmosphere. The resulting mixture was cooled to room
 25 temperature and water was added. The mixture was extracted with diethylether (3x200ml) and the collected organics were washed with water (500ml) and brine (500ml), dried (Na₂SO₄) and evaporated in vacuo. The residue was purified by flash chromatography on silica gel eluting with a mixture petroleum ether/ethyl

acetate from 40:1 to 10:1. Collected fractions after solvent evaporation afforded the title compound **(D5)** (1g).

^1H NMR (400MHz, CHLOROFORM- d) δ (ppm): 7.95 (2H, d, $J=8.8$ Hz), 7.22 (2H, d, $J=8.8$ Hz), 3.90 (3H, s), 5.32 (1H, s), 1.45 (9H, s), 1.35 - 1.30 (4H, m).

5

Description 6: methyl 4-(1-aminocyclopropyl)benzoate (D6)



To the solution of methyl 4-cyanobenzoate (100 g, 620 mmol) in diethyl ether (3 L) was added titanium (IV) isopropoxide (194 g, 682 mmol), followed by dropwise addition of ethylmagnesium bromide 3M solution in diethylether (450ml, 1.36 mol) at -70°C . The mixture was stirred for 1 h, and then boron trifluoride etherate (157ml, 1.24 mol) was added at once. After 2 hours, aqueous HCl (5%) was added until the pH showed acidic, then the mixture was filtered. The solid was washed with ethylacetate. The aqueous phase was separated and the organic layer was washed with water. All aqueous layers were collected together, basified with 1M NaOH and extracted with ethylacetate. The organic layer was dried (Na_2SO_4) and concentrated to afford the title compound **(D6)** (32.0 g).


10

15

^1H NMR (400MHz, CHLOROFORM- d) δ (ppm): 7.97-7.98 (2H, m), 7.31-7.34 (2H, m), 3.90 (3H, s), 1.15-1.18 (2H, m), 1.04-1.07 (2H, m).

20

Description 7: methyl 4-(1-aminocyclopropyl)benzoate hydrochloride (D7)



methyl 4-(1-aminocyclopropyl)benzoate hydrochloride (D7) was prepared according to two different procedures reported below:

25

Procedure A:

To a cooled solution of methyl 4-((tert-butoxycarbonyl)amino)cyclopropyl)benzoate (D5) (7.4 g, 25.4 mmol) in ethyl acetate (10ml) HCl(g)/ethyl acetate (4N, 50ml) was added the mixture was stirred

at room temperature overnight. Evaporated the solvent, the residue was washed with petroleum ether to afford the title compound (**D7**) (5.3 g) as a white solid.


Procedure B

To a cooled solution of methyl 4-(1-aminocyclopropyl)benzoate (D6) (100 g, 524 mmol) in ethyl acetate (500ml) 4N HCl(g)/ethyl acetate solution (300ml) was added and the resulting mixture was stirred at room temperature for 2 hours. Evaporated the solvent, the residue was recrystallized with petroleum ether/EtOAc to afford the title compound (**D7**) (68.7 g) as a white solid.

LCMS: (ES/+) m/z: 192 [MH⁺] C₁₁H₁₃NO₂ requires 191.09

¹H NMR (400MHz, CHLOROFORM-d) δ (ppm): 9.14 (3H, brs), 7.97 (2H, d, *J* = 8.4 Hz), 7.53 (2H, d, *J* = 8.4 Hz), 3.87 (3H, s), 1.53 - 1.49 (2H, m), 1.28 - 1.31 (2H, m).


Description 8: 5-bromopicolinamide (D8)



5-bromopicolinic acid (50 g, 0.247 mol) was added to thionyl chloride (100ml) and the reaction mixture was heated to reflux for 3 hours. The resulting solution was cooled to room temperature and then concentrated in vacuo to afford a white solid. The white solid was dissolved in THF (200ml) and the solution was added dropwise into a mixture of ice/ammonia/water (500ml). The solid was filtered, washed with water and dried in vacuo. The crude was purified by recrystallization in ethyl acetate to afford the title compound (**D8**) (43.0 g) as a white solid.

¹H NMR (400 MHz, DMSO-d₆) δ (ppm): 7.73 (s, 1H), 7.97 (d, *J* = 8.0 Hz, 1H), 8.14 (s, 1H), 8.24 (dd, *J* = 6.0, 2.4 Hz, 1H), 8.76 (d, *J* = 2.0 Hz, 1H).

25 Description 9: 5-bromopicolinonitrile (D9)




Phosphorus oxychloride (111 g, 0.720 mol) was added to a mixture of 5-bromopicolinamide (D8) (58 g, 0.288 mol) in dry toluene (300ml). The mixture was heated to reflux for 2 hours. The mixture was poured into ice/water, and basified to pH=12 with 2N NaOH. The resulting mixture was extracted with ethyl acetate and

the organic phase was washed with brine, dried over Na_2SO_4 , and concentrated in vacuo. The residue was purified by column chromatography on silica gel eluting with a mixture petroleum ether/ethyl acetate 10:1. Collected fractions, after solvent evaporation afforded the title compound (**D9**) (43.6 g) as a yellow solid.

5 ^1H NMR (400 MHz, CHCl_3 -d) δ (ppm): 7.60 (d, $J = 8.4$ Hz, 1H), 8.00 (dd, $J = 6.0, 2.0$ Hz, 1H), 8.79 (d, $J = 2.0$ Hz, 1H).


Description 10: 1-(5-bromopyridin-2-yl)cyclopropanamine (D10)



10 5-bromopicolinonitrile (D9) (43.6 g, 0.238 mol) was suspended in diethyl ether (1.3L) and the resulting mixture was cooled to -78°C . Titanium (IV) isopropoxide (74.4 g, 0.262 mol) was added dropwise and the reaction mixture was stirred for 5 min. Ethylmagnesium bromide 1M in diethyl ether (525ml, 0.525 mol) was added dropwise and the resulting reaction mixture was stirred for 30 mins at -78°C . The
15 reaction mixture was allowed to warm to room temperature for 1 hour then boron trifluoride etherate (107ml) was added dropwise. After stirred at room temperature for 2 hours, the reaction was quenched with 1M HCl (1.5L). The aqueous layer was washed with diethyl ether (1L) and then basified (pH= 9) with 2N NaOH (1.25L). The resulting mixture was extracted with ethyl acetate. The organic layer
20 was dried over Na_2SO_4 and evaporated in vacuo. The residue was purified by column chromatography eluting with a mixture petroleum ether/ethyl acetate 1:1. Collected fractions after solvent evaporation afforded the title compound (**D10**) (15.7 g) as a grey solid.

25 ^1H NMR (400 MHz, CHCl_3 -d) δ (ppm): 1.13-1.20 (m, 2H), 1.26-1.29 (m, 2H), 7.30 (d, $J = 8.0$ Hz, 1H), 7.71 (dd, $J = 6.0, 2.4$ Hz, 1H), 8.51 (d, $J = 2.4$ Hz, 1H).


Description 11: tert-butyl (1-(5-bromopyridin-2-yl)cyclopropyl)carbamate (D11)



To a solution of 1-(5-bromopyridin-2-yl)cyclopropanamine (D10) (15.7 g, 66.6 mmol) in methanol (350ml) and water (110ml) NaHCO₃ (16.8 g, 200 mmol) was added followed by addition of and di-tert-buthyl dicarbonate (17.5 g, 79.9 mmol). The reaction mixture was stirred at room temperature overnight. The mixture was concentrated in vacuo and the residue was poured into water (200ml). The aqueous layer was extracted with ethyl acetate; the organic layer was washed with brine, dried over Na₂SO₄, and concentrated in vacuo. The residue was purified by column chromatography eluting with a mixture petroleum ether/ethyl acetate (10:1). Collected fractions after solvent evaporation afforded the title compound (D11) (18 g) as a yellow solid.


¹HNMR (400 MHz, CHLOROFORM-d) δ (ppm): 1.22-1.26 (m, 2H), 1.37-1.46 (m, 9H), 1.57-1.60 (m, 2H), 7.28 (s, 1H), 7.70 (dd, J = 6.0, 2.4 Hz, 1H), 8.47 (d, J = 2.0 Hz, 1H).

Description **12:** **methyl** **6-(1-((tert-butoxycarbonyl)amino)cyclopropyl)nicotinate (D12)**



To a solution of tert-butyl (1-(5-bromopyridin-2-yl)cyclopropyl)carbamate (D11) (18.0 g, 57.5 mmol) in *N,N*-dimethylformamide (80ml) and methanol (90ml) 1,3-bis(diphenylphosphino)-propane (7.1 g, 17.2 mmol), palladium (II) acetate (3 g, 13.4 mmol) and triethylamine (40ml, 285 mmol) were added. The resulting mixture was stirred at 100°C for 3 days under carbon monoxide atmosphere (5.0 MPa). After cooling to room temperature, the mixture was diluted with ethyl acetate and washed with brine. The organic layer was dried over Na₂SO₄ and concentrated in vacuo. The residue was purified by column chromatography eluting with a mixture petroleum ether/ethyl acetate (4:1). Collected fractions after solvent evaporation afforded the title compound (D12) (15.3 g) as a white solid.


¹HNMR (400 MHz, CHLOROFORM-d) δ (ppm): 1.26-1.48 (m, 13H), 3.92 (s, 3H), 7.44 (d, J = 8.0 Hz, 1H), 8.20 (dd, J = 6.4, 2.0 Hz, 1H), 9.03 (d, J = 1.2 Hz, 1H).

Description 13: methyl 6-(1-aminocyclopropyl)nicotinate hydrochloride (D13)

To the cooled solution of methyl 6-(1-((tert-butoxycarbonyl)amino)cyclopropyl)nicotinate (D12) (1 g, 3.42 mmol) in ethyl acetate (10ml) 4N HCl/ ethyl acetate solution (20ml) was added and the resulting mixture was stirred at room temperature for 1 hour. The mixture was filtered and washed with ethyl acetate to afford the title compound (**D13**) (800 mg) as a white solid.

¹H NMR (400 MHz, DMSO-*d*₆) δ (ppm): 1.48-1.52 (t, 2H), 1.65-1.68 (t, 2H), 3.89 (s, 3H), 7.52 (d, *J* = 8.4 Hz, 1H), 8.31 (dd, *J* = 6.4, 2.0 Hz, 1H), 9.02 (d, *J* = 1.2 Hz, 1H), 9.29 (s, 3H).


LCMS: (ES/+) *m/z*: 193 [MH⁺] C₁₀H₁₂N₂O₂ requires 192.09

Description 14: 4-(1-aminocyclopropyl)benzonitrile (D14)

To a solution of terephthalonitrile (3.30 g, 25.8 mmol.) in dichloromethane (130ml), Titanium (IV) isopropoxide (7.6ml, 25.8 mmol) was added at room temperature followed by dropwise addition of ethyl magnesium bromide 1M in diethyl ether (47.0 ml). The mixture was stirred at room temperature for 45 min, then boron trifluoride etherate (5ml) was added at once. After 2 hours, HCl aqueous solution (5%) was added to quench the reaction. The aqueous phase was separated, basified with aqueous 1M NaOH and extracted with ethylacetate. The organic phase was dried over Na₂SO₄ and concentrated under vacuo. The residue was purified by column chromatography eluting with a mixture petroleum ether/ethyl acetate (5:1). Collected fractions after solvent evaporation afforded the title compound (**D14**) (500 mg) as a white solid.

¹H NMR (400 MHz, DMSO-*d*₆) δ (ppm): 1.01-1.10 (4H, m), 1.23 (2H, bs), 7.47 (2H, d, *J* = 8.4 Hz), 7.72 (2H, d, *J* = 8.4 Hz).


Description 15: tert-butyl (1-(4-cyanophenyl)cyclopropyl)carbamate (D15)



To a solution of 4-(1-aminocyclopropyl)benzonitrile (D14) (2 g, 12.6 mmol.) in MeOH (30ml) NaHCO₃ (30ml, 10% aq) was added followed by di-tert-butyl dicarbonate (4.3 g, 19.7 mmol). The mixture was stirred at room temperature overnight. Water was added into the mixture and the mixture was extracted with ethylacetate (200ml). The organic layer was separated, dried over Na₂SO₄, filtered and concentrated to give a residue which was purified by column chromatography eluting with a mixture petroleum ether/ethyl acetate (10:1). Collected fractions after solvent evaporation afforded the title compound **(D15)** (1.8 g).

¹H NMR (400 MHz, CHLOROFORM-d) δ (ppm): 1.17-1.38 (13H, m), 5.21 (2H, bs), 7.18 (2H, d, *J* = 8.0 Hz), 7.50 (2H, d, *J* = 8.0 Hz).


Description 16: tert-butyl (1-(4-(1H-tetrazol-5-yl)phenyl)cyclopropyl)carbamate (D16)



To a solution of tert-butyl (1-(4-cyanophenyl)cyclopropyl)carbamate (D15) (1.5 g, 5.81 mmol) in dimethylformamide (15ml), NH₄Cl (530 mg, 9.90 mmol) was added under nitrogen atmosphere, followed by addition of sodium azide (650 mg, 9.9 mmol). The reaction mixture was heated to 100°C overnight, then cooled to room temperature with ice-water bath. Water and ethylacetate (100ml) was added. The organic layer was separated and the solvent was removed. The residue was purified by column chromatography eluting with a mixture petroleum ether/ethyl acetate (1:1). Collected fractions after solvent evaporation afforded the title compound **(D16)** (830 mg) as a yellow solid.

¹H NMR (400 MHz, DMSO-*d*₆) δ (ppm): 1.21-1.40 (13H, m), 7.18 (2H, d, *J* = 8.0 Hz), 7.77 (2H, bs), 7.95 (2H, d, *J* = 8.0 Hz).

Description 17: 1-(4-(1H-tetrazol-5-yl)phenyl)cyclopropanamine hydrochloride (D17)




To the solution of tert-butyl (1-(4-(1H-tetrazol-5-yl)phenyl)cyclopropyl)carbamate (D16) (800 mg, 2.65 mmol) in ethylacetate (10ml), 4N HCl/ethyl acetate solution (20ml) was added and the mixture was stirred at room temperature for 1 hour, then cooled to 0 °C. The solid was filtered and washed with ethylacetate to afford the title compound (**D17**) (510 mg) as a yellow solid.

¹H NMR (400 MHz, DMSO-*d*₆) δ (ppm): 1.23-1.42 (4H, m), 7.62 (2H, d, *J* = 7.2 Hz), 8.10 (2H, d, *J* = 8.0 Hz), 8.99 (3H, bs).

LCMS: (ES/+) *m/z*: 202 [MH⁺] C₁₀H₁₁N₅ requires 201.10

10

Description 18: tert-butyl 4-(3-hydroxyphenyl)piperazine-1-carboxylate (D18)




To a cooled (0 °C) solution of 1-(3-Hydroxyphenyl) piperazine (300mg, 1.683 mmol, available from Aldrich #651672) and triethylamine (0.47ml, 3.36 mmol) in tetrahydrofuran/water (3ml/3ml) Di-tert-butyl dicarbonate (440.6 mg, 2.019 mmol) was added and the reaction mixture was stirred 1h at room temperature. The solution was diluted with ethylacetate (5ml) and acidified to pH 5 by addition of 6N HCl. The phases were separated and the aqueous layer was extracted with ethylacetate (2x10ml). Collected organics after solvent evaporation afforded a residue that was purified by SPE-Si cartridge (10g) eluting with cyclohexane/ethylacetate from 100 to 60/40. Collected fractions after solvent evaporation afforded the title compound (**D18**) (400 mg)

MS: (ES/+) *m/z*: 279.3 [MH⁺] C₁₅H₂₂N₂O₃ requires 278.16

¹H NMR (400MHz, CHLOROFORM-*d*) δ = 7.14 (t, *J* = 8.1 Hz, 1 H), 6.52 (d, *J* = 8.3 Hz, 1 H), 6.43 (t, *J* = 2.4 Hz, 1 H), 6.37 (dd, *J* = 2.4, 7.8 Hz, 1 H), 5.05 - 4.98 (m, 1 H), 3.65 - 3.54 (m, 4 H), 3.19 - 3.09 (m, 4 H), 1.51 (s, 9 H)

25


Description 19: 1-benzhydrylazetid-3-yl methanesulfonate (D19)



To a cooled solution of 1-Benzhydrylazetidin-3-ol (3.5 g, 14.624 mmol, available from Manchester #A10473) and triethylamine (4.07ml, 29.25 mmol) in toluene (21ml) Methanesulfonyl chloride (1.13ml, 14.62 mmol) was added dropwise
 5 keeping the temperature at 0°C. The reaction mixture was stirred 1h at 0°C then the solid was filtered off and washed with toluene (2x5ml). The yellow filtrate was evaporated in vacuo to afford the title compound **(D19)** (5 g).


¹H NMR (400MHz, CHLOROFORM-d) δ (ppm): 7.42 (d, *J* = 7.3 Hz, 4 H), 7.34 - 7.28 (m, 4 H), 7.24 - 7.17 (m, 2 H), 5.13 (quin, *J* = 5.9 Hz, 1 H), 4.43 (s, 1 H), 3.71
 10 - 3.58 (m, 2 H), 3.27 - 3.19 (m, 2 H), 3.00 (s, 3 H)

Description 20: 1-benzhydryl-3-phenoxyazetidine (D20)



Phenol (2.2 g, 23.4 mmol) was added to a suspension of sodium hydride (60% dispersion in mineral oil, 937 mg, 23.4 mmol) in toluene (40ml) and the mixture
 15 was heated at 60°C for 2 hours. The temperature was then increased to 80°C and a solution of 1-benzhydrylazetidin-3-yl methanesulfonate (D19) (4.78 g, 14.6 mmol) in toluene (80 ml) was added dropwise. After stirred at 80°C for 2 hours, the resulting mixture was cooled to room temperature, then washed with water
 20 (100ml) and brine (100ml), dried over Na₂SO₄, filtered and evaporated in vacuo. The crude residue was purified by flash chromatography on silica gel eluting with a mixture petroleum ether/ethyl acetate from 30:1 to 20:1. Collected fractions after solvent evaporation were further purified by preparative HPLC to afford the title compound **(D20)** (1.84 g) as a white solid.


¹H NMR (400MHz, CHLOROFORM-d) δ (ppm): 7.42 (4H, d, *J* = 7.6 Hz), 7.30 - 7.28 (3H, m), 7.23 - 7.18 (5H, m), 6.93 (1H, t, *J* = 7.6 Hz), 6.75 (2H, d, *J* = 8.4 Hz), 4.84 - 4.78 (1H, m), 4.44 (1H, s), 3.75 - 3.71 (2H, m), 3.14 - 3.11 (2H, m).

Description 21: 1-benzhydryl-3-(4-fluorophenoxy)azetidine (D21)

To a stirred solution of 4-fluorophenol (0.80 g, 7.16 mmol) in acetonitrile (15ml) potassium carbonate (1.3 g, 9.30 mmol) was added followed by the addition of 1-benzhydrylazetidin-3-yl methanesulfonate (D19) (2.5 g, 7.87 mmol) and the mixture was stirred under microwave irradiation at 100°C for 5 mins. The reaction mixture was evaporated in vacuo and the residue was taken up in a mixture diethylether/water (10ml/10ml). The aqueous layer was extracted with diethylether (2x10ml). The organics after solvent evaporation were loaded on SPE-Si (25g) cartridge eluting with a mixture cyclohexane/ethylacetate (from 100/0 to 85/15. Collected fractions gave, after evaporation, the title compound **(D21)** (1.8g).

MS: (ES/+) m/z: 334 [MH⁺] C₂₂H₂₀FNO requires 333.15


¹H NMR (400MHz, CHLOROFORM-d) δ ppm: 7.44 (d, *J* = 7.3 Hz, 4 H), 7.34 - 7.27 (m, 4 H), 7.26 - 7.15 (m, 2 H), 6.88 (t, *J* = 8.8 Hz, 2 H), 6.48 (dd, *J* = 4.4, 8.8 Hz, 2 H), 4.41 (br. s., 1 H), 4.09 (d, *J* = 4.9 Hz, 1 H), 3.86 (br. s., 1 H), 3.68 (t, *J* = 6.4 Hz, 2 H), 2.90 (br. s., 2 H)

Description 22: 1-benzhydryl-3-(3-fluorophenoxy)azetidine (D22)

The title compound **(D22)** (1.93 g) was prepared according to the experimental procedure described in Description 21 starting from 1-benzhydrylazetidin-3-yl methanesulfonate (D19) (2.5g, 7.87 mmol) and 3-fluorophenol (0.642 ml, 7.16 mmol).

MS: (ES/+) m/z: 334.2 [MH⁺] C₂₂H₂₀FNO requires 333.40


¹H NMR (400MHz, CHLOROFORM-d) δ (ppm): 7.45 (d, *J* = 7.3 Hz, 4 H), 7.40 - 7.16 (m, 8 H), 6.67 (dt, *J* = 2.2, 8.2 Hz, 1 H), 6.56 (dd, *J* = 2.0, 8.3 Hz, 1 H), 6.53 - 6.46 (m, 1 H), 4.81 (t, *J* = 5.9 Hz, 1 H), 4.46 (s, 1 H), 3.80 - 3.70 (m, 2 H), 3.22 - 3.10 (m, 2 H)

Description 23 : 2-((1-benzhydrylazetidin-3-yl)oxy)-5-fluoropyrimidine (D23)

To an ice cooled suspension of 1-Benzhydrylazetidin-3-ol (1.2 g, 5.01 mmol) in dry
 5 tetrahydrofuran (40 ml) potassium tert-butoxide (562 mg, 5.01 mmol) was added
 and the reaction mixture was stirred for 10 min, then 2-chloro-5-fluoropyrimidine
 (0.619ml, 5.01 mmol) is added and the reaction is left to warm to room
 temperature and stirred for 3.5h. Solvents were evaporated in vacuo and the crude
 was taken in dichloromethane (40ml) and water (50ml). The aqueous layer was
 10 extracted with dichloromethane (2x30ml). The organics after solvent evaporation
 were purified by Biotage SNAP-Si cartridge (25g) eluting with a mixture
 cyclohexane/ethylacetate from 95/5 to 60/40. Collected fractions after solvent
 evaporation afforded the title compound **(D23)** (1.10 g)

MS: (ES/+) m/z: 202.2 [MH⁺] C₂₀H₁₈FN₃O requires 335.14

15 ¹H NMR (400MHz, CHLOROFORM-d) δ (ppm): 8.34 (s, 2 H), 7.44 (d, *J* = 7.8 Hz, 4
 H), 7.36 - 7.25 (m, 4 H, under chloroform peak), 7.25 - 7.15 (m, 2 H), 5.24 (t, *J* =
 5.9 Hz, 1 H), 4.45 (s, 1 H), 3.81 - 3.70 (m, 2 H), 3.22 - 3.11 (m, 2 H).

Description 24: 1-benzhydryl-N-(4-fluorophenyl)azetidin-3-amine (D24)

20


To a solution of 4-fluoro aniline (0.412ml, 4.296 mmol) in acetonitrile (10ml)
 potassium carbonate (771 mg, 5.584 mmol) was added followed by addition of 1-
 benzhydrylazetidin-3-yl methanesulfonate (D19) (1.5 g, 4.72 mmol). The reaction
 mixture was stirred at 100°C for 5 minutes under microwave irradiation. Solvents
 25 were evaporated under vacuo and the residue was taken in with diethylether
 (50ml) then water (50ml) was added. The aqueous layer was extracted with
 diethylether (2x30ml). The organics after solvent evaporation were purified by

Biotage SNAP-Si cartridge (25g) eluting with cyclohexane/ethylacetate from 100-0 to 85/15. Collected fractions, after solvent evaporation afforded the title **(D24)** (0.5 g)

MS: (ES/+) m/z:333.2 [MH⁺] C₂₂H₂₁FN₂ requires 332.17

5 ¹H NMR (400MHz, CHLOROFORM-d) δ (ppm): 7.44 (d, J=7.34 Hz, 4 H) 7.27 - 7.34 (m, 4 H, under chloroform peak) 7.15 - 7.26 (m, 2 H) 6.88 (t, J=8.80 Hz, 2 H) 6.48 (dd, J=8.80, 4.40 Hz, 2 H) 4.41 (br. s., 1 H) 4.09 (d, J=4.89 Hz, 1 H) 3.86 (br. s., 1 H) 3.68 (t, J=6.36 Hz, 2 H) 2.90 (br. s., 2 H)

10 **Description 25: 1-(tert-butoxycarbonyl)azetidine-3-carboxylic acid (D25)**




The title compound **(D25)** (9.9 g) was prepared according to the experimental procedure described in Description 18 starting from 3-azetidine carboxylic acid (5 g, 49.45 mmol, available from Aldrich #391131) (1.5g, 4.72 mmol). Reaction time:

15 17 h

MS: (ES/+) m/z:202.2 [MH⁺] C₉H₁₅NO₄ requires 201.10

¹H NMR (400MHz, CHLOROFORM-d) δ ppm: 4.15 (d, J = 7.3 Hz, 4 H), 3.41 (t, J = 7.3 Hz, 1 H), 1.49 - 1.44 (m, 9 H)

20 **Description 26: tert-butyl 3-(methoxy(methyl)carbamoyl)azetidine-1-carboxylate (D26)**




A mixture of 1-(tert-butoxycarbonyl)azetidine-3-carboxylic acid (D25) (5g, 24.85 mmol), 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (14.39g, 75.55 mmol), 1-hydroxybenzotriazole hydrate (0.38g, 2.48 mmol) and N,N-diisopropylethylamine (34.6 ml, 198 mmol) in dimethylformamide (80ml) was stirred overnight at room temperature. The reaction mixture was then concentrated to half volume in vacuo, poured into water (60ml) and extracted with ethylacetate (3x60ml). The combined organic phases were washed with saturated aqueous

NH₄Cl (100ml), saturated aqueous NaHCO₃ (100 ml), water and brine (100ml), dried with Na₂SO₄ anhydrous (50 g) and concentrated under reduced atmosphere. Collected organics after solvent evaporation afforded the title compound **(D26)** (5.33 g)

5 MS: (ES/+) m/z: 245 [MH⁺] C₁₁H₂₀N₂O₄ requires 244.14

¹H NMR (400MHz, CHLOROFORM-d) δ = 4.25 - 4.11 (m, 2 H), 4.11 - 4.01 (m, 2 H), 3.68 (s, 3 H), 3.67 - 3.58 (m, 1 H), 3.22 (s, 3 H), 1.46 (s, 9 H)

Description 27: tert-butyl 3-(3-fluorobenzoyl)azetidine-1-carboxylate (D27)



10

To an ice cooled solution of tert-butyl 3-(methoxy(methyl)carbamoyl)azetidine-1-carboxylate (D26) (61.8 mg, 0.25 mmol) in dry tetrahydrofuran (2 ml), 3-Fluorophenylmagnesiumbromide (1M in tetrahydrofuran) (0.506ml, 0.506 mmol) was added dropwise the under stirring under N₂ atmosphere. The reaction mixture was stirred at room temperature for 1h then NH₄Cl sat. sol. (10ml) was added and the mixture was extracted with ethylacetate (3x20ml). The organic layers were collected, dried with Na₂SO₄ and filtrated. The solvent was evaporated in vacuo to afford the title compound **(D27)** (69 mg).

15


MS: (ES/+) m/z: 280 [MH⁺] C₁₅H₁₈FO₃ requires 279.13

20

¹H NMR (400MHz, CHLOROFORM-d) δ = 7.63 - 7.54 (m, 2 H), 7.49 (dt, J = 5.6, 7.9 Hz, 1 H), 7.35 - 7.29 (m, 1 H), 4.31 - 4.18 (m, 4 H), 4.13 (q, J = 7.7 Hz, 1 H), 1.49 - 1.44 (m, 9 H).

Description 28: tert-butyl 3-(3-fluorophenyl)-3-hydroxyazetidine-1-carboxylate (D28)

25




1-Boc-3-azetidinone (500 mg, 2.77 mmol, available from Aldrich #696315) was dissolved in dry tetrahydrofuran (20 ml) under N₂ atmosphere. The solution obtained was cooled at 0°C and 3-Fluorophenylmagnesiumbromide (1M in THF)

(3.33 ml, 3.33 mmol) was added dropwise under stirring. The reaction was warmed to room temperature and stirred overnight. The reaction mixture was diluted with NH₄Cl sat. sol. (50 ml) and the organics were extracted with ethylacetate (3x50 ml). Collected organics after solvent evaporation afforded the
 5 title compound **(D28)** (783 mg)

MS: (ES/+) m/z: 268 [MH⁺] C₁₄H₁₈FNO₃ requires 267.13

¹H NMR (400MHz, CHLOROFORM-d) δ = 7.43 - 7.36 (m, 1 H), 7.34 - 7.29 (m, 1 H), 7.26 (td, *J* = 2.3, 10.0 Hz, 1 H), 7.04 (ddt, *J* = 1.0, 2.4, 8.3 Hz, 1 H), 4.25 (d, *J* = 9.8 Hz, 2 H), 4.19 (d, *J* = 9.3 Hz, 2 H), 1.49 (s, 9 H)

Description 29: tert-butyl 3-(4-fluorophenyl)-3-hydroxyazetidine-1-carboxylate (D29)




The title compound **(D29)** (819.5 mg) was prepared according to the experimental
 15 procedure described in Description 28 starting from 1-Boc-3-azetidinone (500 mg, 2.77 mmol) and 4-Fluorophenylmagnesiumbromide (2M in diethylether) (1.67 ml, 3.33 mmol)).

MS: (ES/+) m/z: 268 [MH⁺] C₁₄H₁₈FNO₃ requires 267.13

¹H NMR (400MHz, CHLOROFORM-d) δ ppm: 7.53 - 7.47 (m, 2 H), 7.14 - 7.07 (m, 2 H), 4.26 (d, *J* = 9.3 Hz, 2 H), 4.18 (d, *J* = 9.3 Hz, 2 H), 1.49 (s, 9 H)

Description 30: tert-butyl 3-((4-fluoro-2-methylphenyl)amino)azetidine-1-carboxylate (D30)




25 A solution of 1-Boc-3-azetidinone (800 mg, 4.67 mmol), 4-fluoro aniline (0.519 ml, 4.67 mmol), acetic acid (0.535 ml, 9.34 mmol) and sodium(triacetoxy)borohydride (1.98 g, 9.34 mmol) in 1,2-dichloroethane (20ml) was stirred under N₂ atmosphere at room temperature for 1 day. Sat. solution of NaHCO₃ (25ml) was added. After phase separation, the aqueous layer was extracted with dichloromethane

(2x35ml). The collected organics after solvent evaporation were purified by Biotage SNAP-Si cartridge (25g) eluting with cyclohexane/ethylacetate from 90/10 to 80/20. Collected fractions after solvent evaporation afforded the title compound **(D30)** (880 mg)

5 MS: (ES/+) m/z: 225.2 [MH-56⁺] C₁₅H₂₁FN₂O₂ requires 280.16

¹H NMR (400MHz, CHLOROFORM-d) δ = 6.90 - 6.77 (m, 2 H), 6.30 (br. s., 1 H), 4.36 - 4.30 (m, 2 H), 4.24 - 4.16 (m, 1 H), 3.79 (br. s., 2 H), 2.20 (s, 3 H), 1.47 (s, 9 H)

10 **Description 31: tert-butyl 3-((2,4-difluorophenyl)amino)azetidine-1-carboxylate (D31)**




The title compound **(D31)** (90 mg) was prepared according to the experimental procedure described in Description 30 starting from 1-Boc-3-azetidinone (300 mg, 1.75 mmol) and 2,4-difluoroaniline (0.178 ml, 1.75 mmol). Reaction time: 1 week.

15 MS: (ES/+) m/z: 229.1 [MH-56⁺] C₁₄H₁₈F₂N₂O₂ requires 284.13

¹H NMR (400MHz, CHLOROFORM-d) δ ppm: 7.53 - 7.47 (m, 2 H), 7.14 - 7.07 (m, 2 H), 4.26 (d, J = 9.3 Hz, 2 H), 4.18 (d, J = 9.3 Hz, 2 H), 1.49 (s, 9 H)

20 **Description 32: tert-butyl 3-((2-methyl-4-(trifluoromethyl)phenyl)amino)azetidine-1-carboxylate (D32)**




The title compound **(D32)** (330 mg) was prepared according to the experimental procedure described in Description 30 starting from 1-Boc-3-azetidinone (800 mg, 4.67 mmol) and 4-Amino-3-methylbenzotrifluoride (818.4 mg, 4.67 mmol).

25 MS: (ES/+) m/z: 275.2 [MH-56⁺] C₁₆H₂₁F₃N₂O₂ requires 330.13

¹H NMR (400MHz ,CHLOROFORM-d) δ ppm: 7.41 - 7.31 (m, 2 H), 6.36 (d, J = 8.3 Hz, 1 H), 4.41 - 4.33 (m, 2 H), 4.32 - 4.23 (m, 1 H), 3.79 (dd, J = 4.4, 8.8 Hz, 2 H), 2.22 (s, 3 H), 1.50 - 1.42 (m, 9 H)

5 **Description** **33:** **tert-butyl** **3-((4-fluoro-2-methylphenyl)(methylamino)azetidine-1-carboxylate (D33)**




A solution of tert-butyl 3-((4-fluoro-2-methylphenyl)amino)azetidine-1-carboxylate (D30) (240 mg, 0.856 mmol), acetic acid (0.49ml, 8.56 mmol), Formaldehyde 36%
10 wt. in water (0.066 ml, 0.856 mmol) and sodium(triacetoxy)borohydride (725 mg, 3.424 mmol) in 1,2-dichloroethane (7ml) was stirred under N₂ atmosphere at room temperature for 1 day. NaHCO₃ sat. solution (25ml) was added. After phase separation, the aqueous layer was extracted with dichloromethane (2x35ml). The organics after solvent evaporation were purified by Biotage SNAP-Si cartridge
15 (10g) eluting with cyclohexane/ethylacetate from 90/10 up to 80/20. Collected fractions after solvent evaporation afforded the title compound **(D33)** (170 mg)

MS: (ES/+) m/z: 295.2 [MH-56⁺] C₁₆H₂₃FN₂O₂ requires 294.17

¹H NMR (400MHz ,CHLOROFORM-d) δ ppm: 6.94 (d, J = 9.3 Hz, 1 H), 6.89 - 6.80 (m, 2 H), 4.04 - 3.89 (m, 3 H), 3.78 (d, J = 3.9 Hz, 2 H), 2.58 (s, 3 H), 2.39 (s,
20 3 H), 1.48 - 1.41 (m, 9 H)

Description **34:** **tert-butyl** **3-(4-(trifluoromethyl)phenoxy)pyrrolidine-1-carboxylate (D34)**




25 To a stirred solution of 1-Boc-3-pyrrolidinol (1g, 5.34 mmol; available from Sigma-Aldrich #706620) and 4-(Trifluoromethyl)phenol (0.86 g, 5.34 mmol) in dry tetrahydrofuran (10 ml), Triphenylphosphine (1.54 g, 5.87 mmol) and diisopropyl azodicarboxylate (1.15 ml, 5.87 mmol) were added. The reaction mixture was stirred at room temperature for 2 days. Solvents were evaporated in vacuo and the

residue was loaded on SPE-Si (25 g) cartridge and purified eluting with a mixture petroleum ether/ethylacetate (from 100/0 to 80/20). Collected fractions gave, after evaporation, the title compound **(D34)** (1.8g).

MS: (ES/+) m/z: 332.1 [MH⁺] C₁₆H₂₀F₃NO₃ requires 331.14

5


Description 35: tert-butyl 3-(3-(trifluoromethyl)phenoxy)pyrrolidine-1-carboxylate (D35)



The title compound **(D35)** (1.5 g) was prepared according to the experimental procedure described in Description 34 starting from 1-Boc-3-pyrrolidinol (1g, 5.34 mmol) and 3-(Trifluoromethyl)phenol (0.640 ml, 5.34 mmol)

MS: (ES/+) m/z: 332.1 [MH⁺] C₁₆H₂₀F₃NO₃ requires 331.14

Description 36: tert-butyl 3-(4-fluorophenoxy)pyrrolidine-1-carboxylate (D36)




15

The title compound **(D36)** (1.43 g) was prepared according to the experimental procedure described in Description 34 starting from 1-Boc-3-pyrrolidinol (1g, 5.34 mmol) and 4-Fluorophenol (598 mg, 5.34 mmol).

MS: (ES/+) m/z: 282.2 [MH⁺] C₁₅H₂₀FNO₃ requires 281,14

20


Description 37: tert-butyl 3-(3-fluorophenoxy)pyrrolidine-1-carboxylate (D37)



The title compound **(D37)** (1.26 g) was prepared according to the experimental procedure described in Description 34 starting from 1-Boc-3-pyrrolidinol (1g, 5.34 mmol) and 3-Fluorophenol (0.478 ml, 5.34 mmol).

MS: (ES/+) m/z: 282.2 [MH⁺] C₁₅H₂₀FNO₃ requires 281,14


Description 38: tert-butyl 3-(m-tolyloxy)pyrrolidine-1-carboxylate (D38)



The title compound (**D38**) (1.59 g) was prepared according to the experimental procedure described in Description 34 starting from 1-Boc-3-pyrrolidinol (1g, 5.34 mmol) and 3-Methylphenol (0.558 ml, 5.34 mmol).

5 MS: (ES/+) m/z: 278.2 [MH⁺] C₁₆H₂₃NO₃ requires 277,36

Description 39: tert-butyl 3-(hydroxymethyl)pyrrolidine-1-carboxylate (D39)




To an ice cooled solution of 1-Boc-pyrrolidine-3-carboxylic acid (1 g, 4.64 mmol) in
 10 dry tetrahydrofuran (6 ml) Borane-methyl sulfide complex (2M in tetrahydrofuran)
 (3.48ml, 6.96 mmol) was added dropwise the under N₂ atmosphere The reaction
 mixture was stirred overnight at room temperature. NaHCO₃ sat. sol. (20ml) was
 added and the resulting mixture was stirred for 30 min. The mixture was extracted
 with ethylacetate (3x20 ml). Collected organics after solvent evaporation afforded
 15 the title compound (**D39**) (1.02 g)

MS: (ES/+) m/z: 146.1 [M-56H⁺] C₁₀H₁₉NO₃ requires 201.14

¹H NMR (400MHz ,CHLOROFORM-d) δ ppm: 3.64 (br. s., 2 H), 3.57 - 3.27 (m, 3
 H), 3.20 - 3.06 (m, 1 H), 2.43 (br. s., 1 H), 1.99 (br. s., 1 H), 1.69 (br. s., 1 H), 1.48
 (s, 9 H).

20

Description 40: tert-butyl 3-((3-fluorophenoxy)methyl)pyrrolidine-1-carboxylate (D40)




To a solution of tert-butyl 3-(hydroxymethyl)pyrrolidine-1-carboxylate (D39) (200
 25 mg, 0.993 mmol) in dry tetrahydrofuran (4ml) 3-Fluorophenol (0.089ml, 0.993
 mmol) was added under N₂ atmosphere followed by addition of Diisopropyl
 azodicarboxylate (0.215ml, 1.093 mmol) and Triphenylphosphine (286.7 mg, 1.093
 mmol). The solution was stirred overnight at room tempearture. The solvent was
 evaporated under vacuo and the resulting residue was purified by ISOLUTE SPE-

Si cartridge (10g) eluting with cyclohexane/ethylacetate from 95:5 to 80:20. Collected fractions, after solvent evaporation afforded the title compound **(D40)** (218.5 mg)

MS: (ES/+) m/z: 240.2 [M-56H⁺] C₁₆H₂₂FNO₃ requires 295.16

5 ¹H NMR (400MHz, CHLOROFORM-d) δ ppm: 7.26 - 7.16 (m, 1 H), 6.73 - 6.60 (m, 3 H), 4.02 - 3.83 (m, 2 H), 3.62 (dd, *J* = 7.6, 11.0 Hz, 1 H), 3.57 - 3.45 (m, 1 H), 3.45 - 3.33 (m, 1 H), 3.22 (dd, *J* = 7.1, 11.0 Hz, 1 H), 2.78 - 2.60 (m, 1 H), 2.10 (dd, *J* = 5.4, 12.2 Hz, 1 H), 1.81 (dd, *J* = 8.1, 12.5 Hz, 1 H), 1.49 (s, 9 H).

10 **Description 41: (R)-tert-butyl 2-(hydroxymethyl)pyrrolidine-1-carboxylate (D41)**




To an ice cooled solution of (R)-(-)-2-(Hydroxymethyl)pyrrolidin (1 g, 9.88 mmol, available at Aldrich#281697) in THF/H₂O (21/21ml) di-tert-butyl dicarbonate (2.58 g, 11.86 mmol) was added portionwise followed by addition of triethylamine (2.96ml, 21.25 mmol). After completed addition (10 min), the reaction mixture was stirred for 17 h at room temperature. The solution was diluted with ethylacetate (21ml) and acidified to pH 5 by addition of 2N HCl (10ml). The phases were separated and the aqueous phase was extracted with ethylacetate (2x40ml).
 15 The combined organic phases were dried over Na₂SO₄ anhydrous, filtrated and the solvent was evaporated under vacuo to afford the title compound **(D41)** (2.38 g).

The product isolated was denominated 0021/037/1 (white solid).

MS: (ES/+) m/z: 146.1 [M-56H⁺] C₁₀H₁₉NO₃ requires 201.14

25 ¹H NMR (400MHz, CHLOROFORM-d) δ ppm: 4.72 (br. s., 1 H), 3.99 (br. s., 1 H), 3.72 - 3.55 (m, 2 H), 3.55 - 3.42 (m, 1 H), 3.33 (td, *J* = 6.8, 10.9 Hz, 1 H), 2.08 - 1.98 (m, 1 H), 1.84 (tdd, *J* = 6.2, 12.8, 19.3 Hz, 2 H), 1.50 (s, 9 H).

30 **Description 42: (R)-tert-butyl 2-((3-fluorophenoxy)methyl)pyrrolidine-1-carboxylate (D42)**




The title compound **(D42) (0021/047/1)** (252.3 mg) was prepared according to the experimental procedure described in Description 40 starting from (R)-tert-butyl 2-(hydroxymethyl)pyrrolidine-1-carboxylate (D41) (200mg, 0.993 mmol) and 3-Fluorophenol (0.089 ml, 0.993 mmol).

MS: (ES/+) m/z: 240.2 [M-56H⁺] C₁₆H₂₂FNO₃ requires 295.16

¹H NMR (400MHz, CHLOROFORM-d) δ ppm: = 7.27 - 7.17 (m, 1 H), 6.78 - 6.61 (m, 3 H), 4.14 (d, J = 7.3 Hz, 2 H), 3.89 (br. s., 1 H), 3.41 (br. s., 2 H), 2.13 - 1.83 (m, 4 H), 1.50 (s, 9 H).

10

Description 43: (S)-tert-butyl 2-(hydroxymethyl)pyrrolidine-1-carboxylate (D43)




The title compound **(D43)** (2.43 g mg) was prepared according to the experimental procedure described in Description 41 starting from (S)-(+)-2-(Hydroxymethyl)pyrrolidin (1 g, 9.88 mmol, available at Aldrich#186511).

MS: (ES/+) m/z: 146.1 [M-56H⁺] C₁₀H₁₉NO₃ requires 201.14

¹H NMR (400MHz, CHLOROFORM-d) δ ppm: 4.72 (br. s., 1 H), 3.98 (br. s., 1 H), 3.72 - 3.55 (m, 2 H), 3.55 - 3.41 (m, 1 H), 3.33 (td, J = 6.8, 10.9 Hz, 1 H), 2.10 - 1.97 (m, 1 H), 1.92 - 1.74 (m, 2 H), 1.50 (s, 9 H).

20

Description 44: (S)-tert-butyl 2-((3-fluorophenoxy)methyl)pyrrolidine-1-carboxylate (D44)




The title compound (**D44**) (239.7 mg) was prepared according to the experimental procedure described in Description 40 starting from (S)-tert-butyl 2-(hydroxymethyl)pyrrolidine-1-carboxylate (D43) (200mg, 0.993 mmol) and 3-Fluorophenol (0.089 ml, 0.993 mmol).

MS: (ES/+) m/z: 240.2 [M-56H⁺] C₁₆H₂₂FNO₃ requires 295.16

¹H NMR (400MHz, CHLOROFORM-d) δ ppm: = 7.26 - 7.17 (m, 1 H), 6.80 - 6.59 (m, 3 H), 4.14 (d, J = 6.8 Hz, 2 H), 3.88 (br. s., 1 H), 3.41 (br. s., 2 H), 2.12 - 1.82 (m, 4 H), 1.50 (s, 9 H).

10

Description 45: tert-butyl 3-((3-fluorophenoxy)methyl)piperidine-1-carboxylate (D45)




The title compound (**D45**) (244.9 mg) was prepared according to the experimental procedure described in Description 40 starting from tert-butyl 3-(hydroxymethyl)piperidine-1-carboxylate (200 mg, 0.929 mmol, available at Aldrich#681318) and 3-Fluorophenol (0.083 ml, 0.929 mmol).

MS: (ES/+) m/z: 254.2 [M-56H⁺] C₁₇H₂₄FNO₃ requires 309.17

¹H NMR (400MHz, CHLOROFORM-d) δ ppm: = 7.27 - 7.18 (m, 1 H), 6.73 - 6.58 (m, 3 H), 4.08 (d, J = 12.7 Hz, 1 H), 3.94 - 3.85 (m, 1 H), 3.85 - 3.77 (m, 2 H), 2.93 (t, J = 10.8 Hz, 1 H), 2.82 (t, J = 11.2 Hz, 1 H), 2.09 - 1.96 (m, 1 H), 1.95 - 1.85 (m, 1 H), 1.71 (td, J = 4.0, 13.1 Hz, 1 H), 1.50 - 1.35 (m, 11 H).

Description 46: (S)-tert-butyl 3-(3-fluorophenoxy)pyrrolidine-1-carboxylate (D46)




The title compound (**D46**) (294.6 mg) was prepared according to the experimental procedure described in Description 40 starting from (R)-tert-butyl 3-hydroxypyrrolidine-1-carboxylate (200mg, 1.068 mmol, available at Aldrich#532169) and 3-Fluorophenol (0.096 ml, 1.068 mmol).

5 MS: (ES/+) m/z: 226.1 [M-56H⁺] C₁₅H₂₀FNO₃ requires 281.14

¹H NMR (400MHz, CHLOROFORM-d) δ ppm: = 7.27 - 7.17 (m, 1 H), 6.74 - 6.56 (m, 3 H), 4.88 (br. s., 1 H), 3.71 - 3.43 (m, 4 H), 2.25 - 2.05 (m, 2 H), 1.49 (s, 9 H).

Description 47: (R)-tert-butyl 3-(3-fluorophenoxy)pyrrolidine-1-carboxylate (D47)




The title compound (**D47**) (294.6 mg) was prepared according to the experimental procedure described in Description 40 starting from (S)-tert-butyl 3-hydroxypyrrolidine-1-carboxylate (200mg, 1.068 mmol, available at Aldrich#634786) and 3-Fluorophenol (0.096 ml, 1.068 mmol).

15 MS: (ES/+) m/z: 226.1 [M-56H⁺] C₁₅H₂₀FNO₃ requires 281.14


¹H NMR (400MHz, CHLOROFORM-d) δ ppm: = 7.27 - 7.21 (m, 1 H), 6.73 - 6.64 (m, 2 H), 6.64 - 6.57 (m, 1 H), 4.88 (br. s., 1 H), 3.70 - 3.46 (m, 4 H), 2.25 - 2.06 (m, 2 H), 1.49 (s, 9 H).

Description 48: 3-phenoxyazetidine (D48)



1-benzhydryl-3-phenoxyazetidine (D20) (2.28 g, 7.23 mmol) was dissolved in ethanol (50 ml) and Pd/C (400 mg, w/w 10%) was added. The mixture was heated at 70°C under hydrogen atmosphere (50 psi) for 18 hours then filtered off. The filtrate was concentrated to obtain a residue which was recrystallized from diethylether to provide the title compound (**D48**) (400 mg) as a white solid.


¹H NMR (400MHz, CHLOROFORM-d) δ ppm: δ 7.29 - 7.28 (2H, m), 6.96 (1H, t, J= 7.6 Hz), 6.75 (2H, d, J= 8.0 Hz), 5.01 (1H, s), 4.00 - 3.93 (2H, m), 1.77 (3H, br s).

Description 49: 3-(4-fluorophenoxy)azetidine (D49)

1-chloroethyl chloroformate (0.87ml, 8.09 mmol) was added to an ice-cooled solution of 1-benzhydryl-3-(4-fluorophenoxy)azetidine (D21) (1.8 g, 5.39 mmol) in 1,2 dichloroethane (18ml) and the resulting mixture was heated under reflux for 3 hours. The reaction mixture was evaporated in vacuo and the residue was re-dissolved in methanol (10ml). This solution was heated under reflux overnight then cooled at room temperature and evaporated in vacuo. The obtained residue was loaded on SPE-SCX (20g) cartridge. The ammonia fractions, after evaporation in vacuo, were loaded on by SPE-Si (5g) cartridge eluting with a mixture dichloromethane/dichloromethane:NH₃ (2M solution in MeOH) (from 100/0 to 80/20). Collected fractions after solvent evaporation afforded the title compound **(D49)** (0.9 g)

MS: (ES/+) m/z: 168.4 [MH⁺] C₉H₁₀FNO requires 167.18

¹H NMR (400MHz, METHANOL-d₄) δ (ppm): 7.07 (t, *J* = 8.8 Hz, 2 H), 6.95 - 6.83 (m, 2 H), 5.20 - 5.09 (m, 1 H), 4.57 (dd, *J* = 6.4, 11.7 Hz, 2 H), 4.16 (dd, *J* = 4.4, 11.7 Hz, 2 H)


Description 50: 3-(3-fluorophenoxy)azetidine (D50)

The title compound **(D50)** (0.95 g) was prepared according to the experimental procedure described in Description 49 starting from 1-benzhydryl-3-(3-fluorophenoxy)azetidine (D22) (1.9 g, 5.698 mmol).

MS: (ES/+) m/z: 168.5 [MH⁺] C₉H₁₀FNO requires 167.18

¹H NMR (400MHz, METHANOL-d₄) δ (ppm): 7.43 - 7.26 (m, 1 H), 6.80 (dt, *J* = 2.0, 8.3 Hz, 1 H), 6.73 - 6.63 (m, 2 H), 5.25 - 5.11 (m, 1 H), 4.59 (dd, *J* = 6.4, 12.2 Hz, 2 H), 4.16 (dd, *J* = 4.4, 12.2 Hz, 2 H)


Description 51: 2-(azetidin-3-yloxy)-5-fluoropyrimidine (D51)



The title compound (**D51**) (0.57 g) was prepared according to the experimental procedure described in Description 49 starting from 2-((1-benzhydrylazetidin-3-yl)oxy)-5-fluoropyrimidine (D23) (1.1 g, 3.279 mmol).

- 5 ¹H NMR (400MHz, CHLOROFORM-d) δ (ppm): 8.38 (s, 2 H), 5.44 (t, J = 6.4 Hz, 1 H), 4.00 - 3.93 (m, 2 H), 3.85 (dd, J = 5.9, 9.8 Hz, 2 H).


Description 52: 3-(4-(trifluoromethyl)phenoxy)azetidine (D52)



- 10 To a solution of 1-Boc-3-hydroxyazetidine (1 g, 5.77 mmol, available from Aldrich #694347) and 4-(Trifluoromethyl)phenol (0.94 g, 5.77 mmol) in dry tetrahydrofuran (10 ml), Triphenylphosphine (1.66 g, 6.35 mmol) and diisopropyl azodicarboxylate (1.25 ml, 6.35 mmol) were added. The mixture was stirred at room temperature for 2 days. Solvents were evaporated in vacuo and the residue was loaded on SPE-Si
- 15 (25 g) cartridge and purified eluting with a mixture petroleum ether/ethylacetate (from 100/0 to 80/20). Collected fractions gave, after evaporation, a residue that was treated with a mixture dichloromethane/ trifluoroacetic acid (0.5ml/2ml). The reaction mixture was stirred 1h at room temperature then solvents were evaporated in vacuo. The residue was loaded on SPE-SCX (25g) cartridge.
- 20 Collected ammonia fractions gave, after evaporation, the title compound (**D52**) (300 mg).


MS: (ES/+) m/z : 218.1 [MH^+] C₁₀H₁₀F₃NO requires 217,19

Description 53: 3-(3-(trifluoromethyl)phenoxy)azetidine (D53)




25 The title compound (**D53**) (100 mg) was prepared according to the experimental procedure described in Description 52 starting from 1-Boc-3-hydroxyazetidine (1 g, 5.77 mmol) and 3-(Trifluoromethyl)phenol (0.69 ml, 5.77 mmol).

MS: (ES/+) m/z : 218.1 [MH^+] C₁₀H₁₀F₃NO requires 217,19

Description 54: N-(4-fluorophenyl)azetidin-3-amine (D54)

The title compound **(D54)** (60 mg) was prepared according to the experimental procedure described in Description 49 starting from 1-benzhydryl-N-(4-fluorophenyl)azetidin-3-amine (D24) (0.5 g, 1.5 mmol).


MS: (ES/+) m/z: 167.0 [MH⁺] C₉H₁₁FN₂ requires 166.22

Description 55: N-(4-fluoro-2-methylphenyl)azetidin-3-amine (D55)

To an ice cooled solution of tert-butyl 3-((4-fluoro-2-methylphenyl)amino)azetidine-1-carboxylate (D30) (300 mg, 1.07 mmol) in dichloromethane (2ml), a mixture of trifluoroacetic acid/dichloromethane (4.5ml/1.5ml) was added and the mixture stirred at room temperature for 1h. Solvents were evaporated in vacuo and the resulting residue was purified by SPE-SCX cartridge (10g). Collected ammonia fractions, after solvent evaporation afforded the title compound **(D55)** (0022/107/1) (190 mg)

MS: (ES/+) m/z: 181.1 [MH⁺] C₁₀H₁₃FN₂ requires 180.11

¹H NMR (400MHz, CHLOROFORM-d) δ (ppm): 6.91 - 6.74 (m, 2 H), 6.32 (dd, J = 4.6, 8.6 Hz, 1 H), 4.43 - 4.26 (m, 1 H), 4.09 - 3.92 (m, 2 H), 3.75 - 3.61 (m, 1 H), 3.61 - 3.47 (m, 2 H), 2.18 (s, 3 H)

Description 56: N-(4-fluoro-2-methylphenyl)-N-methylazetidin-3-amine (D56)


To an ice cooled solution of tert-butyl 3-((4-fluoro-2-methylphenyl)(methyl)amino)azetidine-1-carboxylate (D33) 8170 mg, 0.577 mmol) in dichloromethane (1ml) trifluoroacetic acid/ dichloromethane (3/1ml) was added and the resulting mixture was stirred at room temperature for 1h. Solvents were evaporated under vacuo and the residue was purified by SPE-SCX cartridge (10g)

eluting with methanol and 2N ammonia in methanol. Ammonia fractions were evaporated in vacuo to afford the title compound (**D56**) (110mg)

MS: (ES/+) m/z: 195.1 [MH⁺] C₁₁H₁₅FN₂ requires 194.12

¹H NMR (400MHz, CHLOROFORM-d) δ (ppm): 6.92 (dd, *J* = 2.9, 9.3 Hz, 1 H),
 5 6.85 - 6.77 (m, 2 H), 4.15 (t, *J* = 6.8 Hz, 1 H), 3.78 (t, *J* = 7.6 Hz, 2 H), 3.68 - 3.61
 (m, 2 H), 2.51 (s, 3 H), 2.35 (s, 3 H).

Description 57: 3-(4-(trifluoromethyl)phenoxy)pyrrolidine (**D57**)




10 To an ice cooled solution of tert-butyl 3-(4-(trifluoromethyl)phenoxy)pyrrolidine-1-carboxylate (**D34**) (1.86 g, 5.613 mmol) in dichloromethane (2 ml), a mixture of trifluoroacetic acid/dichloromethane (4.5ml/1.5ml) was added and the mixture stirred at room temperature for 3h. Solvents were evaporated in vacuo and the resulting residue was purified by SPE-SCX cartridge (10g). Collected ammonia
 15 fractions, after solvent evaporation afforded the title compound (**D57**) (844 mg)

MS: (ES/+) m/z: 232 [MH⁺] C₁₁H₁₂F₃NO requires 231.21

¹H NMR (400MHz, CHLOROFORM-d) δ (ppm): 7.66 - 7.47 (m, *J* = 8.8 Hz, 2 H),
 7.68 - 7.45 (m, 2 H), 7.04 - 6.85 (m, *J* = 8.8 Hz, 2 H), 7.06 - 6.80 (m, 2 H), 4.97 -
 4.80 (m, 1 H), 5.00 - 4.76 (m, 1 H), 3.29 - 3.16 (m, 2 H), 3.14 - 3.05 (m, 1 H), 2.97
 20 (ddd, *J* = 5.4, 8.3, 11.2 Hz, 1 H), 2.23 - 2.08 (m, 1 H), 2.07 - 1.86 (m, 1 H)


Description 58: 3-(3-(trifluoromethyl)phenoxy)pyrrolidine (**D58**)



The title compound (**D58**) (843 mg) was prepared according to the experimental
 25 procedure described in Description 57 starting from tert-butyl 3-(3-(trifluoromethyl)phenoxy)pyrrolidine-1-carboxylate (**D35**) (1.5 g, 4.52 mmol).

MS: (ES/+) m/z: 232 [MH⁺] C₁₁H₁₂F₃NO requires 231.21


¹H NMR (400MHz, CHLOROFORM-d) δ (ppm): 7.40 (t, *J* = 8.1 Hz, 1 H), 7.22 (d, *J* = 7.8 Hz, 1 H), 7.11 (s, 1 H), 7.05 (dd, *J* = 2.0, 8.3 Hz, 1 H), 4.94 - 4.85 (m, 1 H),
 30 3.29 - 3.17 (m, 2 H), 3.09 (dd, *J* = 4.6, 12.5 Hz, 1 H), 2.97 (ddd, *J* = 5.4, 8.8, 11.2 Hz, 1 H), 2.22 - 2.08 (m, 1 H), 2.04 - 1.97 (m, 1 H)

Description 59: 3-(4-fluorophenoxy)pyrrolidine (D59)

The title compound (**D59**) (585 mg) was prepared according to the experimental procedure described in Description 57 starting from tert-butyl 3-(4-fluorophenoxy)pyrrolidine-1-carboxylate (D36) (1.43 g, 5.08 mmol).

MS: (ES/+) m/z: 182.5 [MH⁺] C₁₀H₁₂FNO requires 181.21


¹H NMR (400MHz, CHLOROFORM-d) δ (ppm): 7.07 - 6.93 (m, 2 H), 6.86 - 6.73 (m, 2 H), 4.84 - 4.75 (m, 1 H), 3.27 - 3.15 (m, 2 H), 3.05 (dd, *J* = 4.6, 12.5 Hz, 1 H), 2.96 (ddd, *J* = 5.4, 8.3, 11.2 Hz, 1 H), 2.15 - 2.03 (m, 1 H), 2.03 - 1.98 (m, 1 H)

Description 60: 3-(3-fluorophenoxy)pyrrolidine (D60)

The title compound (**D60**) (643 mg) was prepared according to the experimental procedure described in Description 57 starting from tert-butyl 3-(3-fluorophenoxy)pyrrolidine-1-carboxylate (D37) (1.26 g, 4.47 mmol).

MS: (ES/+) m/z: 182.5 [MH⁺] C₁₀H₁₂FNO requires 181.21

¹H NMR (400MHz, CHLOROFORM-d) δ (ppm): 7.23 (dt, *J* = 6.8, 8.3 Hz, 1 H), 6.72 - 6.63 (m, 2 H), 6.63 - 6.53 (m, 1 H), 4.84 (dd, *J* = 4.6, 6.1 Hz, 1 H), 3.28 - 3.17 (m, 2 H), 3.09 (dd, *J* = 4.9, 12.7 Hz, 1 H), 2.98 (ddd, *J* = 5.4, 8.3, 11.2 Hz, 1 H), 2.20 - 2.08 (m, 1 H), 2.01 (d, *J* = 7.3 Hz, 1 H)

Description 61: 3-(m-tolyloxy)pyrrolidine (D61)


The title compound (**D61**) (693 mg) was prepared according to the experimental procedure described in Description 57 starting from 3-(m-tolyloxy)pyrrolidine-1-carboxylate (D38) (1.5 g, 5.73 mmol).

MS: (ES/+) m/z: 178.5 [MH⁺] C₁₀H₁₂FNO requires 177.24

¹H NMR (400MHz, CHLOROFORM-d) δ (ppm): 7.18 (t, *J* = 7.8 Hz, 1 H), 6.78 (d, *J* = 7.3 Hz, 1 H), 6.73 - 6.63 (m, 2 H), 4.90 - 4.77 (m, 1 H), 3.27 - 3.14 (m, 2 H), 3.04

(dd, $J = 4.6, 12.5$ Hz, 1 H), 2.94 (ddd, $J = 5.6, 8.4, 11.4$ Hz, 1 H), 2.34 (s, 3 H), 2.16 - 2.05 (m, 1 H), 2.04 - 2.00 (m, 1 H)

Description 62: methyl 5-chloro-2-(3-hydroxyazetidin-1-yl)nicotinate (D62)



5

methyl 5-chloro-2-(3-hydroxyazetidin-1-yl)nicotinate (D62) was prepared according to two different procedures described below:

Procedure A

To a solution of azetidin-3-ol hydrochloride (637 mg, 5.82 mmol, commercially available from Matrix Scientific #011272) and triethylamine (1.69ml, 12.11 mmol) in methanol (10ml), methyl 2-chloropyridine-3-carboxylate (1g, 4.84 mmol) was added and the mixture stirred at 150°C under microwave irradiation 10 min (2 cycles of 5 min each). The residue obtained after solvent evaporation was purified by SPE-Si cartridge (10g) eluting with a mixture cyclohexane/ethylacetate from 90/10 to 60/40. Collected fractions after solvent evaporation afforded the title compound (**D62**) (0004/099/1) (800 mg)

MS: (ES/+) m/z : 242.6 $[MH^+]$ $C_{10}H_{11}ClN_2O_3$ requires 242.04

^1H NMR (400MHz, CHLOROFORM- d) δ (ppm): 8.25 (d, $J = 2.4$ Hz, 1 H), 7.98 (d, $J = 2.4$ Hz, 1 H), 4.74 (br. s., 1 H), 4.37 (dd, $J = 6.8, 10.3$ Hz, 2 H), 3.95 (dd, $J = 3.9, 10.3$ Hz, 2 H), 3.90 (s, 3 H)

Procedure B

To a mixture of 3-Hydroxyazetidine hydrochloride (37.17g, 0.339 mol) and triethylamine (70.93 ml, 0.508 mol) in tetrahydrofuran/methanol (840/280 ml) Methyl 2,5-dichloronicotinate (70g, 0.339 mol) was added and the resulting mixture was heated at 75°C for 4 hours then at 62°C overnight. 3-Hydroxyazetidine hydrochloride (3.7g, 0.03mol) and triethylamine (23.60ml, 0.16 mol) were added and the reaction mixture was further heated at 80°C for 28h. Solvents were evaporated in vacuo. The residue was taken in dichloromethane (400ml) and water (500ml). The formed solid was filtered, washed with water


(500ml) and dried in vacuum to afford a first batch of the title compound (**D62**) (63g).

The two layer filtrate was separated and the aqueous layer was extracted with dichloromethane (1x300ml). The two organic layers obtained were collected
5 together and reduced to 1/4 of volume. The formed precipitate was filtered off, washed with cyclohexane then treated with water (200ml) and filtered off to afford a second batch of title compound (**D62**) (15g) (by ¹H NMR spectra 0.56%mol of TEA HCl 6%

MS: (ES/+) m/z: 242.6 [MH⁺] C₁₀H₁₁ClN₂O₃ requires 242.04

10 ¹H NMR (400MHz, DMSO-d₆) δ (ppm): 8.30 (dd, J = 1.2, 2.7 Hz, 1 H), 7.91 (dd, J = 1.2, 2.7 Hz, 1 H), 5.64 (d, J = 6.4 Hz, 1 H), 4.57 - 4.41 (m, 1 H), 4.16 (dd, J = 6.8, 9.8 Hz, 2 H), 3.86 - 3.77 (m, 3 H), 3.72 (dd, J = 4.4, 9.8 Hz, 2 H).

15 **Description 63: methyl 5-chloro-2-(3-((methylsulfonyl)oxy)azetidin-1-yl)nicotinate (D63)**



methyl 5-chloro-2-(3-((methylsulfonyl)oxy)azetidin-1-yl)nicotinate (D63) was prepared according to two different procedures described below

Procedure A

20 To a stirred solution of methyl 5-chloro-2-(3-hydroxyazetidin-1-yl)nicotinate (D62) (50 mg, 0.206 mmol) and triethylamine (0.057 ml, 0.412 mmol) in dimethylformamide (0.26ml) cooled at 0°C, methansulfonyl chloride (0.016ml, 0.206 mmole) was added dropwise and the reaction mixture stirred at the same temperature for 1h. After solvent evaporation the obtained residue was purified by
25 SPE-Si (5g) eluting with a mixture petroleum ether/ethyl acetate from 90/10 to 70/30. Collected fractions, after solvent evaporation, afforded the title compound (**D63**) (53 mg)

MS: (ES/+) m/z: 321.1 [MH⁺] C₁₁H₁₃ClN₂O₅S requires 320.02


¹H NMR (400 MHz, CHLOROFORM-d) δ (ppm): 8.25 (d, J=2.45 Hz, 1 H) 8.01 (d, J=2.45 Hz, 1 H) 5.41 - 5.24 (m, 1 H) 4.47 (ddd, J=11.00, 6.72, 0.86 Hz, 2 H) 4.29 - 4.13 (m, 2 H) 3.88 (s, 3 H) 3.08 (s, 3 H)

Procedure B

5 To an ice cooled stirred solution of methyl 5-chloro-2-(3-hydroxyazetidin-1-yl)nicotinate (D62) (66 g, 0.27 mol) and triethylamine (56.86 ml, 0.40 mol) in dimethylformamide (500 ml) methanesulfonylchloride (23.15 ml, 0.29 mol) was added dropwise maintaining the temperature at 0°C. The reaction mixture was stirred at 0°C for 3,5h then methanesulfonyl chloride (6.3ml, 0.037 mol) and
10 triethylamine (18.9ml, 0.135 mol) were added and the reaction mixture was stirred for 3h at 0°C. After this time the formed solid was filtered off. Water (700ml) was added to the filtrate. The formed solid was filtered off, washed with water (400ml) and dried under vacuo to afford the title compound (**D63**) (80g).

¹H NMR (400 MHz, DMSO-d₆) δ (ppm): 8.37 (d, J = 2.4 Hz, 1 H), 8.01 (d, J = 2.4 Hz, 1 H), 5.46 - 5.19 (m, 1 H), 4.44 - 4.31 (m, 2 H), 4.10 (td, J = 1.7, 10.8 Hz, 2 H),
15 3.83 (s, 3 H), 3.27 (s, 3 H)

Description 64: 1-(5-chloro-3-(methoxycarbonyl)pyridin-2-yl)azetidine-3-carboxylic acid (D64)




20

To a mixture 3-Azetidinecarboxylic acid (411 mg, 4.06 mmol) and triethylamine (1.17ml, 8.47 mmol) in methanol (3ml), methyl 2-chloropyridine-3-carboxylate (700 mg, 3.38 mmol) was added and the mixture was heated at 150°C under microwave irradiation 10 min (2 cycles of 5 min each).Solvents were evaporated
25 in vacuo and the residue was taken in water (5ml) and 1M HCl (5ml) and extracted with ethylacetate (3x5ml). Collected organics after solvent evaporation afforded the title compound (**D64**) (880 mg)

MS: (ES/+) m/z: 270.8 [MH⁺] C₁₁H₁₁ClN₂O₄ requires 270.04

¹H NMR (400 MHz, CHLOROFORM-*d*) δ ppm 8.23 - 8.32 (m, 1 H) 7.90 - 8.06 (m, 1 H) 4.31 - 4.45 (m, 2 H) 4.17 - 4.30 (m, 2 H) 3.84 - 3.95 (m, 3 H) 3.58 (tt, *J*=8.93, 6.11 Hz, 1 H).

5 **Description 65: methyl 5-chloro-2-(3-(hydroxymethyl)azetidin-1-yl)nicotinate (D65)**




To a cooled solution of (D64) (340 mg, 1.25 mmol) and N-Methylmorpholine (0.207ml, 1.88 mmol) in dry tetrahydrofuran (30ml), isobutyl chloroformate (0.244ml, 1.88 mmol) was added dropwise and the resulting mixture was stirred 2h
10 at 0°C. Sodium borohydride (261 mg, 6.90 mmol) was added slowly and the solution stirred 10 min at 0°C then 30 min at room temperature. The reaction mixture was cooled again to 0°C then methanol (20ml) was added and the reaction allowed to reach room temperature. The residue obtained after solvent
15 evaporation was purified by SPE-Si cartridge (10g) eluting with a mixture dichloromethane/methanol from 100/0 to 98/2. Collected fractions after solvent evaporation afforded the title compound **(D65)** (0021/004/1)(215.2 mg).

MS: (ES/+) *m/z*: 257.2 [MH⁺] C₁₁H₁₃ClN₂O₃ requires 256.06

¹H NMR (400MHz, METHANOL-*d*₄) δ = 8.20 (d, *J* = 2.4 Hz, 1 H), 7.95 (d, *J* = 2.9
20 Hz, 1 H), 4.11 (t, *J* = 9.0 Hz, 2 H), 3.88 (s, 3 H), 3.82 (dd, *J* = 5.4, 9.8 Hz, 2 H), 3.72 (d, *J* = 6.4 Hz, 2 H), 2.87 - 2.76 (m, 1 H)

Description 66: methyl 2-chloro-5-(trifluoromethyl)nicotinate (D66)




25 A solution of 2-chloro-5-(trifluoromethyl)nicotinic acid (500 mg, 2.21 mmole, available from Apollo #PC9219) in a mixture diethyl ether/methanol (5ml)/(15ml) was cooled to -20°C then trimethylsilyldiazomethane (2M solution in diethyl ether) (2.15ml, 4.43 mmol) was added dropwise. The reaction mixture was stirred at -20°C for 1h then allowed to warm to room temperature. After solvent evaporation,

the obtained residue was loaded on SPE-Si cartridge (10g) eluting with a mixture cyclohexane/dichloromethane from 80/20 to 60/40. Collected fractions, after solvent evaporation, afforded the title compound **(D66)** (300 mg)

MS: (ES/+) m/z: 240.1 [MH⁺] C₈H₅ClF₃NO₂ requires 239.00

5 ¹H NMR (400 MHz, CHLOROFORM-d) δ (ppm): 8.80 (s, 1 H) 8.43 (s, 1 H) 4.03 (s, 3 H)

Description 67: methyl 2-(3-hydroxyazetidin-1-yl)-5-(trifluoromethyl)nicotinate (D67)




10

The title compound **(D67)** (4.0g) was prepared according to the experimental procedure described in Description 62 starting from azetidin-3-ol hydrochloride (2.3g, 21.03 mmol) and methyl 2-chloro-5-(trifluoromethyl)nicotinate (D66) (4.2 g, 17.53 mmol).

15 MS: (ES/+) m/z: 277 [MH⁺] C₁₁H₁₁F₃N₂O₃ requires 276.07

¹H NMR (400 MHz, CHLOROFORM-d) δ (ppm): 8.64 - 8.41 (m, 1 H) 8.18 (d, J=2.45 Hz, 1 H) 4.75 (dd, J=7.09, 3.18 Hz, 1 H) 4.44 (dd, J=11.00, 6.60 Hz, 2 H) 4.04 (dd, J=11.13, 4.03 Hz, 2 H) 3.91 (s, 3 H) 2.15 - 2.49 (m, 1 H)

20 **Description 68: methyl 2-((methylsulfonyl)oxy)azetidin-1-yl)-5-(trifluoromethyl)nicotinate (D68)**




The title compound **(D53)** (4.85g) was prepared according to the experimental procedure described in Description 63 starting from methyl 2-(3-hydroxyazetidin-1-yl)-5-(trifluoromethyl)nicotinate (D67) (3.9 g, 14.11 mmol)

25

MS: (ES/+) m/z: 355 [MH⁺] C₁₂H₁₃F₃N₂O₅S requires 354.05

^1H NMR (400 MHz, CHLOROFORM- d) δ (ppm): 8.53 (d, $J=1.96$ Hz, 1 H) 8.26 (d, $J=2.45$ Hz, 1 H) 5.47 - 5.22 (m, 1 H) 4.58 (dd, $J=11.98, 6.60$ Hz, 2 H) 4.36 (dd, $J=11.74, 3.67$ Hz, 2 H) 3.92 (s, 3 H) 3.11 (s, 3 H).

5 **Description 69: methyl 2-chloro-5-fluoronicotinate (D69)**




The title compound (**D69**) (0022/105/1) (1.8 g) was prepared according to the experimental procedure described in Description 66 starting from 2-Chloro-5-fluoronicotinic acid (2 g, 11.39 mmol) and trimethylsilyldiazomethane (2M solution
10 in diethyl ether) (17 ml, 34.18 mmol)

MS: (ES/+) m/z : 190.1 [MH^+] $\text{C}_7\text{H}_5\text{ClFNO}_2$ requires 189.00

^1H NMR (400 MHz, CHLOROFORM- d) δ (ppm): 8.41 (d, $J = 2.9$ Hz, 1 H), 7.93 (dd, $J = 3.2, 7.6$ Hz, 1 H), 3.98 (s, 3 H)

15 **Description 70: methyl 5-fluoro-2-(3-hydroxyazetidin-1-yl)nicotinate (D70)**




The title compound (**D70**) (75 mg) was prepared according to the experimental procedure described in Description 62 starting from azetidin-3-ol hydrochloride (208 mg, 1.89 mmol) and methyl 2-chloro-5-fluoronicotinate (300 mg, 1.58 mmol,
20 commercially available from Adesis#2-482).

MS: (ES/+) m/z : 227.2 [MH^+] $\text{C}_{10}\text{H}_{11}\text{FN}_2\text{O}_3$ requires 226.08

^1H NMR (400 MHz, CHLOROFORM- d) δ (ppm): 8.23 (br. s., 1 H) 7.92 - 7.66 (m, 1 H) 4.74 (br. s., 1 H) 4.36 (br. s., 2 H) 4.05 - 3.70 (m, 4 H)

25 **Description 71: methyl 5-fluoro-2-(3-((methylsulfonyl)oxy)azetidin-1-yl)nicotinate (D71)**




The title compound (**D71**) (90 mg) was prepared according to the experimental procedure described in Description 63 starting from methyl 5-fluoro-2-(3-hydroxyazetidin-1-yl)nicotinate (D70) (73 mg, 0.322mmol)

MS: (ES/+) m/z: 305.6 [MH⁺] C₁₁H₁₃FN₂O₅S requires 304.05

- 5 ¹H NMR (400 MHz, CHLOROFORM-d) δ (ppm): 8.24 (d, J=3.18 Hz, 1 H) 7.85 (dd, J=8.44, 3.06 Hz, 1 H) 5.36 (tt, J=6.60, 4.16 Hz, 1 H) 4.49 (dd, J=11.74, 6.60 Hz, 2 H) 4.24 (dd, J=11.74, 4.16 Hz, 2 H) 3.91 (s, 3 H) 3.10 (s, 3 H).

Description 72: methyl 5-chloro-2-(2-phenylpyrrolidin-1-yl)nicotinate (D72)




10

To a solution of Methyl 2,5-dichloronicotinate (120 mg, 0.58 mmol,) in isopropanol (10ml), 2-phenylpyrrolidine (86 mg, 0.58 mmol, available from Matrix Scientific # 018619) and N,N-Diisopropylethylamine (90 mg, 0.70 mmol) were added. The mixture was heated under reflux overnight. After cooling to room temperature, the mixture was evaporated and the residue was dissolved in ethyl acetate (10ml), washed with water (10ml) and brine (10ml), dried over Na₂SO₄ and evaporated in vacuo. The crude residue was purified by flash chromatography on silica gel eluting with a mixture petroleum ether/ethyl acetate 20:1 to afford the title compound (**D72**) (167 mg) as colorless oil.

15

- 20 ¹H NMR (400MHz ,CHLOROFORM-d) δ (ppm): 8.10 (1H, d, J= 2.4 Hz), 7.79 (1H, d, J= 2.4 Hz), 7.28 - 7.18 (5H, m), 5.36 - 5.32 (1H, m), 3.95 - 3.89 (1H, m), 3.85 (3H, s), 3.33 - 3.28 (1H, m), 2.52 - 2.47 (1H, m), 2.07 - 2.04 (1H, m), 1.92 - 1.89 (2H, m).


25 **Description 73: methyl 5-chloro-2-(3-phenylpyrrolidin-1-yl)nicotinate (D73)**



The title compound (**D35**) (316 mg) was prepared according to the experimental procedure described in Description 72 starting from methyl 2,5-dichloronicotinate (206 mg, 1.00 mmol) and 3-phenylpyrrolidine (147 mg, 1.00 mmol)

¹H NMR (400MHz, CHLOROFORM-d) δ (ppm): 8.23 (1H, d, J = 2.4 Hz), 7.90 (1H, d, J = 2.4 Hz), 7.38 - 7.26 (5H, m), 3.90 (3H, s), 3.74 - 3.43 (5H, m), 2.39 - 2.35 (1H, m), 2.15 - 2.10 (1H, m).

Description 74: methyl 2-(2-benzylpyrrolidin-1-yl)-5-chloronicotinate (D74)




The title compound (**D74**) (80 mg) was prepared according to the experimental procedure described in Description 62 starting from Methyl 2-chloropyridine-3-carboxylate (106.62 mg, 0.516 mmol, available from Matrix #037174) and 2-benzylpyrrolidine (100 mg, 0.602 mmol, commercially available from Apollo#OR12512)

MS: (ES/+) m/z : 331.0 [MH^+] $C_{18}H_{19}ClN_2O_2$ requires 330.81

¹H NMR (400MHz, CHLOROFORM-d) δ (ppm): 8.28 (d, J = 2.9 Hz, 1 H), 7.91 (d, J = 2.4 Hz, 1 H), 7.35 - 7.18 (m, 5 H), 4.67 - 4.53 (m, 1 H), 3.90 (s, 2 H), 3.54 - 3.43 (m, 1 H), 3.36 - 3.25 (m, 1 H), 2.94 - 2.83 (m, 1 H), 2.76 (d, J = 8.3 Hz, 1 H), 2.03 - 1.92 (m, 1 H), 1.91 - 1.81 (m, 1 H), 1.79 - 1.61 (m, 1 H)

Description 75: methyl 5-chloro-2-(3-phenoxyazetidin-1-yl)nicotinate (D75)



To a solution of methyl 2,5-dichloronicotinate (217 mg, 1.05 mmol) in tetrahydrofuran (5ml), 3-phenoxyazetidine (D48) (149 mg, 1.05 mmol) and triethylamine (117 mg, 1.16 mmol) were added and the mixture was heated at reflux for 18 hours. The resulting mixture was cooled to room temperature, the precipitates were filtered off and the filtrate was concentrated under vacuo. The


residue was dissolved in ethyl acetate (5ml), washed with water (5ml) and brine (5ml), dried over Na₂SO₄, filtered and concentrated. The crude residue was purified by flash chromatography on silica gel eluting with a mixture petroleum ether/ethyl acetate from 30:1 to 20:1. Collected fractions after solvent evaporation

5 afforded the title compound (**D75**) (250 mg) as a white solid.

¹H NMR (400 MHz, CHLOROFORM-d) δ (ppm): 8.24 (1H, d, *J* = 2.8 Hz), 7.98 (1H, d, *J* = 2.4 Hz), 7.31 - 7.27 (2H, m), 6.99 (1H, t, *J* = 7.2 Hz), 6.77 (2H, d, *J* = 7.6 Hz), 5.04-5.01 (1H, m), 4.52 (2H, dd, *J* = 10.4, 6.4 Hz), 4.11 (2H, dd, *J* = 10.0, 4.0 Hz), 3.88 (3H, s).

10

Description 76: methyl 5-chloro-2-(3-(4-fluorophenoxy)azetidin-1-yl)nicotinate (D76)



To a mixture of (D49) (243 mg, 1.454 mmol) and triethylamine (0.253ml, 1.817 mmol) in methanol (3ml), methyl 2-chloropyridine-3-carboxylate (250mg, 1.2118 mmol) was added and the resulting mixture was heated 10 min (2 cycles of 5 min each) at 150°C under microwave irradiation. Solvents were evaporated in vacuo and the residue was purified by SPE-Si cartridge (25g) eluting with cyclohexane/ethylacetate from 95/5 to 85/15. Collected fractions after solvent


20 evaporation afforded the title compound (**D76**) (270 mg)

MS: (ES/+) *m/z*: 337.1 [MH⁺] C₁₆H₁₄ClFN₂O₃ requires 336.07

¹H NMR (400 MHz, CHLOROFORM-d) δ (ppm): 8.27 (d, *J* = 2.4 Hz, 1 H), 8.02 (d, *J* = 2.4 Hz, 1 H), 7.06 - 6.97 (m, 2 H), 6.78 - 6.69 (m, 2 H), 4.99 (ddd, *J* = 2.2, 4.2, 6.4 Hz, 1 H), 4.53 (ddd, *J* = 1.0, 6.4, 10.3 Hz, 2 H), 4.13 (dd, *J* = 3.9, 11.2 Hz, 2 H), 3.90 (s, 3 H)

25

Description 77: methyl 5-chloro-2-(3-(3-fluorophenoxy)azetidin-1-yl)nicotinate (D77)



methyl 5-chloro-2-(3-(3-fluorophenoxy)azetidin-1-yl)nicotinate (D77) was prepared according to three different procedures reported below

Procedure A

- 5 The title compound (**D77**) (295 mg) was prepared according to the experimental procedure described in Description 76 starting from methyl 2-chloropyridine-3-carboxylate (250mg, 1.2118 mmol) and (D50) (243 mg, 1.454 mmol).

Procedure B

- To a solution of 3-Fluorophenol (0.005 ml, 0.056 mmole) in acetonitrile (1ml),
 10 potassium carbonate (10 mg, 0.0728 mmol) were added followed by the addition of methyl 5-chloro-2-(3-((methylsulfonyl)oxy)azetidin-1-yl)nicotinate (D63) (20 mg, 0.062 mmol). The reaction mixture was heated at 150°C under microwave irradiation for 10 min (2 cycle of 5 min each) then at 180°C for 5 min. After solvent evaporation the obtained residue was purified by SPE-Si (10g) eluting with mixture
 15 cyclohexane/ethyl acetate from 95/5 to 90/10. Collected fractions, after solvent evaporation, afforded the title compound **D77** (10 mg)

MS: (ES/+) m/z: 337.1 [MH⁺] C₁₆H₁₄ClFN₂O₃ requires 336.07


- Procedure C To a solution of 3-Fluorophenol (0.139 ml, 1.417 mmole) in acetonitrile (3 ml), potassium carbonate (254.6 mg, 1.842 mmol) were added
 20 followed by the addition of methyl 5-chloro-2-(3-((methylsulfonyl)oxy)azetidin-1-yl)nicotinate (D63) (500 mg, 1.558 mmol). The reaction mixture was heated at 160°C under microwave irradiation for 20 min. After solvent evaporation the obtained residue was diluted in 1M HCl (10 ml) and extracted with ethyl acetate (3x20 ml). Collected organics, after solvent evaporation, afforded a residue that
 25 was first purified eluting with a mixture cyclohexane/ethy/acetate/methanol from 95/5/0 to 90/10/0 to 90/10/20. Collected fractions, after solvent evaporation, afforded a residue (350 mg) that was further purified by SPE-SCX (20g) cartridge. The ammonia fractions, after evaporation afforded the title compound (**D77**) (290 mg).

- 30 MS: (ES/+) m/z: 337.1 [MH⁺] C₁₆H₁₄ClFN₂O₃ requires 336.07

¹H NMR (400 MHz, CHLOROFORM-d) δ (ppm): 8.27 (d, J=2.45 Hz, 1 H) 8.02 (d, J=2.93 Hz, 1 H) 7.28 - 7.18 (m, 1 H) 6.72 (td, J=8.31, 2.45 Hz, 1 H) 6.58 (dd, J=8.31, 1.96 Hz, 1 H) 6.51 (dt, J=10.64, 2.26 Hz, 1 H) 5.10 - 4.90 (m, 1 H) 4.55 (dd, J=10.76, 6.36 Hz, 2 H) 4.14 (dd, J=10.51, 4.16 Hz, 2 H) 3.91 (s, 3 H).

5


Description 78: methyl 5-chloro-2-(3-(4-(trifluoromethyl)phenoxy)azetidin-1-yl)nicotinate (D78)



The title compound (**D78**) (200 mg) was prepared according to the experimental procedure described in Description 62 starting from Methyl 2,5-dichloronicotinate (160 mg, 0.775 mmol) and 3-(4-(trifluoromethyl)phenoxy)azetidine (D52) (202.13 mg, 0.903 mmol).

MS: (ES/+) m/z: 387.5 [MH⁺] C₁₇H₁₄ClF₃N₂O₃ requires 386.06


15 **Description 79: methyl 5-chloro-2-(3-(3-(trifluoromethyl)phenoxy)azetidin-1-yl)nicotinate (D79)**



The title compound (**D79**) (110 mg) was prepared according to the experimental procedure described in Description 62 starting from Methyl 2,5-dichloronicotinate (87 mg, 0.422 mmol) and 3-(3-(trifluoromethyl)phenoxy)azetidine (D53) (110 mg, 0.506 mmol).

MS: (ES/+) m/z: 387.5 [MH⁺] C₁₇H₁₄ClF₃N₂O₃ requires 386.06

25 **Description 80: methyl 5-chloro-2-(3-(3-fluorophenyl)-3-hydroxyazetidin-1-yl)nicotinate (D80)**




To a cooled (0°C) solution of tert-butyl 3-(3-fluorophenyl)-3-hydroxyazetidine-1-carboxylate (D28) (100 mg, 0.374 mmol) in dichloromethane (0.5 ml), a mixture 3:1 of trifluoroacetic acid/dichloromethane (1ml) was added and the mixture was stirred 30 min at room temperature. The residue obtained after solvent evaporation was dissolved in a mixture 3:1 of tetrahydrofuran/methanol (1ml) and triethylamine (0.156 ml, 1.122 mmol) was added followed by addition of methyl 2,5-dichloronicotinate (77.32 mg, 0.374 mmol). The resulting mixture was heated 15h at 60°C. After solvent evaporation the residue was taken in NH₄Cl sat. sol. (10ml) and the resulting mixture was extracted with ethylacetate (2x10ml). The residue obtained after solvent evaporation was purified by SPE-Si cartridge (5g) eluting with a mixture cyclohexane/ethylacetate from 100/0 to 90:10. Collected fractions, after solvent evaporation afforded the title compound (**D80**) (71.4 mg)

MS: (ES/+) m/z: 337.2 [MH⁺] C₁₆H₁₄ClFN₂O₃ requires 336.75

¹H NMR (400MHz, CHLOROFORM-d) δ = 8.29 (d, *J* = 2.9 Hz, 1 H), 8.04 (d, *J* = 2.4 Hz, 1 H), 7.43 - 7.30 (m, 3 H), 7.07 - 7.00 (m, 1 H), 4.47 (d, *J* = 9.8 Hz, 2 H), 4.33 (d, *J* = 9.8 Hz, 2 H), 3.91 - 3.88 (m, 3 H).


Description 81: methyl 5-chloro-2-(3-(4-fluorophenyl)-3-hydroxyazetidin-1-yl)nicotinate (D81)



The title compound (**D81**) (0021/074/1) (75.9 mg) was prepared according to the experimental procedure described in Description 80 starting from tert-butyl 3-(4-fluorophenyl)-3-hydroxyazetidine-1-carboxylate (D29) (100 mg, 0.374 mmol) and methyl 2,5-dichloronicotinate (77.32 mg, 0.374 mmol).

MS: (ES/+) m/z: 337.2 [MH⁺] C₁₆H₁₄ClFN₂O₃ requires 336.75

Description 82: methyl 5-chloro-2-(3-((4-fluorophenoxy)methyl)azetidin-1-yl)nicotinate (D82)




To a solution of methyl 5-chloro-2-(3-(hydroxymethyl)azetidin-1-yl)nicotinate (D65) (59 mg, 0.229 mmol) in dry tetrahydrofuran (1.6ml) 4-Fluorophenol (25.8 mg, 0.229 mmol) Diisopropyl azodicarboxylate (50 μ l, 0.253 mmol) and the triphenylphosphine (66.3 mg, 0.258 mmol) were added. The resulting solution was stirred overnight at room temperature. The residue obtained after solvent evaporation was purified by ISOLUTE SPE-Si cartridge (10g) eluting with a mixture cyclohexane/ethylacetate from 100/0 to 90/10. Collected fractions, after solvent evaporation afforded the title compound (**D82**) (53.1 mg)

MS: (ES/+) m/z: 351.3 [MH⁺] C₁₇H₁₆ClFN₂O₃ requires 350.08

¹H NMR (400MHz, CHLOROFORM-d) δ = 8.25 (d, J = 2.4 Hz, 1 H), 7.97 (d, J = 2.9 Hz, 1 H), 7.03 - 6.92 (m, 2 H), 6.88 - 6.76 (m, 2 H), 4.26 (t, J = 9.0 Hz, 2 H), 4.13 (d, J = 6.8 Hz, 2 H), 3.96 (dd, J = 5.4, 9.8 Hz, 2 H), 3.90 (s, 3 H), 3.18 - 3.08 (m, 1 H).


Description 83: methyl 5-chloro-2-(3-((3-fluorophenoxy)methyl)azetidin-1-yl)nicotinate (D83)



The title compound (**D83**) (0021/006/3) (66.2 mg) was prepared according to the experimental procedure described in Description 82 starting from methyl 5-chloro-2-(3-(hydroxymethyl)azetidin-1-yl)nicotinate (D65) (37 mg, 0.143 mmol) and 3-Fluorophenol (13 μ l, 0.143 mmol).

MS: (ES/+) m/z: 351.3 [MH⁺] C₁₇H₁₆ClFN₂O₃ requires 350.08

Description 84: methyl 5-chloro-2-(3-((4-fluorophenyl)amino)azetidin-1-yl)nicotinate (D84)




The title compound (**D84**) (79 mg) was prepared according to the experimental procedure described in Description 62 starting from Methyl 2,5-dichloronicotinate (62.06 mg, 0.3 mmol) and N-(4-fluorophenyl)azetidin-3-amine (D54) (60 mg, 0.361 mmol).

MS: (ES/+) m/z: 336.1 [MH⁺] C₁₆H₁₅ClFN₃O₂ requires 335.07

¹H NMR (400MHz, CHLOROFORM-d) δ (ppm): 8.26 (d, *J* = 2.4 Hz, 1 H), 8.00 (d, *J* = 2.4 Hz, 1 H), 6.94 (t, *J* = 8.8 Hz, 2 H), 6.61 - 6.41 (m, 2 H), 4.49 (dd, *J* = 7.6, 9.0 Hz, 2 H), 4.31 (s, 1 H), 3.96 - 3.84 (m, 5 H)

Description 85: methyl 5-chloro-2-(3-((2,4-difluorophenyl)amino)azetidin-1-yl)nicotinate (D85)




To a cooled (0°C) solution of tert-butyl 3-((2,4-difluorophenyl)amino)azetidine-1-carboxylate (D31) (90 mg, 0.316 mmol) in dichloromethane, a mixture of trifluoroacetic acid/dichloromethane (3ml/1ml) was added and the reaction mixture was stirred 1h. The solvents were evaporated in vacuo and the residue was dissolved in tetrahydrofuran/methanol (3/1ml) triethylamine (0.132 ml, 0.95 mmol) was added followed by the addition of methyl 2,5-dichloronicotinate (52.33 mg, 0.253 mmol) and the resulting mixture was stirred 12h at 75°C. The residue obtained after solvent evaporation was purified by Biotage SNAP-Si column eluting with cyclohexane/ethyl acetate from 100/0 to 90/10. Collected fractions afforded the title compound (**D85**) (0022/086/5) (38 mg).

MS: (ES/+) m/z: 354.1 [MH⁺] C₁₆H₁₄ClF₂N₃O₂ requires 353.07.

¹H NMR (400MHz, CHLOROFORM-d) δ = 8.26 (d, *J* = 2.4 Hz, 1 H), 8.00 (d, *J* = 2.4 Hz, 1 H), 6.89 - 6.71 (m, 2 H), 6.47 (dt, *J* = 5.1, 9.2 Hz, 1 H), 4.50 (dd, *J* = 7.3, 9.3 Hz, 2 H), 4.33 (br. s., 1 H), 4.12 (br. s., 1 H), 3.98 - 3.85 (m, 5 H)

Description **86:** **methyl** **5-chloro-2-(3-((2-methyl-4-**
(trifluoromethyl)phenyl)amino)azetidin-1-yl)nicotinate (D86)




The title compound **(D86)** (44 mg) was prepared according to the experimental
 5 procedure described in Description 85 starting from tert-butyl 3-((2-methyl-4-
 (trifluoromethyl)phenyl)amino)azetidine-1-carboxylate (D32) (150 mg, 0.454 mmol)
 and methyl 2,5-dichloronicotinate (74.92 mg, 0.363 mmol)

MS: (ES/+) m/z: 400.2 [MH⁺] C₁₈H₁₇ClF₃N₃O₂ requires 399.15

¹H NMR (400MHz, CHLOROFORM-d) δ (ppm): 8.27 (d, J = 2.4 Hz, 1 H), 8.01 (d, J
 10 = 2.4 Hz, 1 H), 7.39 (d, J = 8.8 Hz, 1 H), 7.34 (s, 1 H), 6.42 (d, J = 8.3 Hz, 1 H),
 4.55 (dd, J = 7.6, 9.0 Hz, 2 H), 4.41 (br. s., 1 H), 4.19 (br. s., 1 H), 3.95 (dd, J =
 4.4, 9.8 Hz, 2 H), 3.90 (s, 3 H), 2.22 (s, 3 H)

Description **87:** **methyl** **5-chloro-2-(3-((4-fluoro-2-**
 15 **methylphenyl)(methyl)amino)azetidin-1-yl)nicotinate (D87)**




To mixture of N-methyl-N-(2-methyl-4-fluoro-phenyl)azetidin-3-amine (D56) (110
 mg, 0.566 mmol) and triethylamine (0.18 ml, 0.849 mmol) in
 tetrahydrofuran/methanol (3/1ml) Methyl 2,5-dichloronicotinate (116.82 mg, 0.566
 20 mmol) was added and the mixture was heated at 75 °C for 12 hours. Solvents were
 evaporated and the residue was purified by SNAP-Si cartridge (10g) eluting with
 cyclohexane/ethyl acetate from 100/0 to 90/10. Collected fractions after solvent
 evaporation afforded the title compound **(D87)** (170 mg)

MS: (ES/+) m/z: 363.8 [MH⁺] C₁₈H₁₉ClFN₃O₂ requires 363.81

¹H NMR (400MHz, CHLOROFORM-d) δ (ppm): 8.25 (br. s, 1 H), 8.02 (br. s., 1 H),
 25 6.99 - 6.79 (m, 3 H), 4.40 - 4.21 (m, J = 6.4 Hz, 2 H), 4.21 - 4.09 (m, J = 6.8 Hz, 1
 H), 3.97 - 3.90 (m, 2 H), 3.86 (s, 3 H), 2.61 (br. s., 3 H), 2.35 (s, 3 H)

Description 88: methyl 2-(3-((5-methylisoxazol-3-yl)oxy)azetidin-1-yl)-5-(trifluoromethyl)nicotinate (D88)




To a solution of 5-methylisoxazol-3-ol (33.48mg, 0.34 mmol) in acetonitrile (0.7ml)
 5 potassium carbonate (60.85 mg, 0.44 mmol) was added followed by addition of
 methyl 2-(3-((methylsulfonyl)oxy)azetidin-1-yl)-5-(trifluoromethyl)nicotinate (D68)
 (120mg, 0.34 mmol). The reaction mixture was heated at 180°C under microwave
 irradiation for 25 min. After solvent evaporation the residue was purified by Biotage
 SNAP-Si column (10g) eluting with cyclohexane/ethyl acetate from 95/05 to 70/30.
 10 Collected fractions were evaporated in vacuo tot afford the title compound **(D88)**
 (20 mg)

MS: (ES/+) m/z: 358.2 [MH⁺] C₁₅H₁₄F₃N₃O₄ requires 357.09

¹H NMR (400MHz ,CHLOROFORM-d) δ (ppm): 8.62 - 8.42 (m, 1 H), 8.21 (d, *J* =
 2.0 Hz, 1 H), 5.67 (d, *J* = 0.7 Hz, 1 H), 5.29 (ddd, *J* = 2.6, 3.9, 6.5 Hz, 1 H), 4.56
 15 (ddd, *J* = 0.9, 6.5, 11.2 Hz, 2 H), 4.25 (dd, *J* = 2.7, 11.2 Hz, 2 H), 3.91 (s, 3 H),
 2.36 (d, *J* = 0.7 Hz, 3 H)

Description 89: methyl 5-(trifluoromethyl)-2-(3-((6-(trifluoromethyl)pyridin-2-yl)oxy)azetidin-1-yl)nicotinate (D89)



20


The title compound **(D89)** (25 mg) was prepared according to the experimental
 procedure described in Description 88 starting from methyl 2-(3-
 ((methylsulfonyl)oxy)azetidin-1-yl)-5-(trifluoromethyl)nicotinate (D68) (120mg, 0.34
 mmol) and 2-Hydroxy-6-(trifluoromethyl)pyridine (55.12mg, 0.34 mmol,
 25 commercially available from Fluorochem#032990).

MS: (ES/+) m/z: 358.2 [MH⁺] C₁₇H₁₃F₆N₃O₃ requires 421.09

¹H NMR (400MHz ,CHLOROFORM-d) δ (ppm): 8.52 (d, *J* = 1.7 Hz, 1 H), 8.21 (d, *J* =
 2.2 Hz, 1 H), 7.78 (t, *J* = 7.9 Hz, 1 H), 7.33 (d, *J* = 7.3 Hz, 1 H), 7.00 (d, *J* = 8.3

Hz, 1 H), 5.65 - 5.34 (m, 1 H), 4.63 (dd, $J = 6.6, 11.0$ Hz, 2 H), 4.25 (dd, $J = 3.9, 11.2$ Hz, 2 H), 3.92 (s, 3 H)

Description 90: methyl 5-fluoro-2-(3-((4-fluoro-2-methylphenyl)amino)azetidin-1-yl)nicotinate (D90)




A mixture of methyl 2-chloro-5-fluoronicotinate (D69) (199.85 mg, 1.054 mmol) and potassium carbonate (291 mg, 2.108 mmol) in tetrahydrofuran (2ml) was stirred under N₂ nitrogen 15 min at room temperature. N-(4-fluoro-2-methylphenyl)azetidin-3-amine (D55) (190 mg, 1.054 mmol) was added and the resulting mixture was stirred 1 day at room temperature. The residue obtained after solvent evaporation was purified by Biotage SNAP-Si column eluting with a mixture cyclohexane/ethyl acetate from 100/0 to 80/20. Collected fractions after solvent evaporation afforded the title compound (**D90**)(155 mg)

MS: (ES/+) m/z : 334.6 [MH^+] C₁₇H₁₇F₂N₃O₂ requires 333.33

¹H NMR (400MHz, CHLOROFORM-d) δ = 8.24 (d, $J = 2.9$ Hz, 1 H), 7.80 (dd, $J = 2.9, 8.3$ Hz, 1 H), 6.91 - 6.75 (m, 2 H), 6.32 (dd, $J = 4.9, 8.3$ Hz, 1 H), 4.50 (dd, $J = 7.3, 9.3$ Hz, 2 H), 4.40 - 4.27 (m, 1 H), 3.97 - 3.81 (m, 5 H), 3.72 (d, $J = 6.4$ Hz, 1 H), 2.18 (s, 3 H)


Description 91: methyl 5-chloro-2-(3-(4-(trifluoromethyl)phenoxy)pyrrolidin-1-yl)nicotinate (D91)



The title compound (**D91**) (230 mg) was prepared according to the experimental procedure described in Description 62 starting methyl 2,5-dichloronicotinate (180 mg, 0.87 mmol) and 3-(4-(trifluoromethyl)phenoxy)pyrrolidine (D57) (242 mg, 1.05 mmol).

MS: (ES/+) m/z: 401.5 [MH⁺] C₁₈H₁₆ClF₃N₂O₃ requires 400.08

Description 92: methyl 5-chloro-2-(3-(3-(trifluoromethyl)phenoxy)pyrrolidin-1-yl)nicotinate (D92)




5

The title compound (**D92**) (270 mg) was prepared according to the experimental procedure described in Description 62 starting methyl 2,5-dichloronicotinate (241.37 mg, 1.17 mmol) and from 3-(3-(trifluoromethyl)phenoxy)pyrrolidine (D58) (323 mg, 1.39 mmol).

10 MS: (ES/+) m/z: 401.5 [MH⁺] C₁₈H₁₆ClF₃N₂O₃ requires 400.08

Description 93: methyl 5-chloro-2-(3-(4-fluorophenoxy)pyrrolidin-1-yl)nicotinate (D93)




15 The title compound (**D93**) (235 mg) was prepared according to the experimental procedure described in Description 62 starting from methyl 2,5-dichloronicotinate (241.37 mg, 1.17 mmol) and 3-(4-fluorophenoxy)pyrrolidine (D59) (253 mg, 1.39 mmol).

MS: (ES/+) m/z: 351 [MH⁺] C₁₇H₁₆ClFN₂O₃ requires 350.08

20

Description 94: methyl 5-chloro-2-(3-phenoxy)pyrrolidin-1-yl)nicotinate (D94)




To a solution of methyl 2,5-dichloronicotinate (303 mg, 1.47 mmol) in tetrahydrofuran (10 ml) 3-phenoxy)pyrrolidine (240 mg, 1.47 mmol, available from
25 Tigersci #P67164) and triethylamine (163 mg, 1.62 mmol) were added and the

mixture was refluxed 18 hours. After cooling to room temperature, the precipitates were filtered off and the filtrate was concentrated under reduced pressure. The residue was dissolved in ethyl acetate (10 ml), washed with water (10 ml) and brine (10 ml), dried over Na₂SO₄ and concentrated. The residue was purified by
 5 flash chromatography on silica gel eluting with a mixture: petroleum ether/ethyl acetate from 30:1 to 20:1. Collected fractions, after solvent evaporation afforded the title compound (**D94**) (234 mg) as a colorless oil.

¹H NMR (400MHz, CHLOROFORM-d) δ (ppm): 8.22 (1H, d, *J* = 2.8 Hz), 7.90 (1H, d, *J* = 2.4 Hz), 7.31 (2H, dd, *J* = 8.4, 7.6 Hz), 6.99 (1H, t, *J* = 7.6 Hz), 6.91 - 6.89
 10 (2H, m), 5.03 - 5.01 (1H, m), 3.95 - 3.94 (1H, m), 3.92 (3H, s), 3.86 - 3.79 (1H, m), 3.53 - 3.48 (1H, m), 3.41-3.40 (1H, m), 2.36 - 2.30 (1H, m), 2.24 - 2.17 (1H, m).

Description 95: methyl 5-chloro-2-(3-(3-fluorophenoxy)pyrrolidin-1-yl)nicotinate (D95)




15

The title compound (**D95**) (250 mg) was prepared according to the experimental procedure described in Description 62 starting from methyl 2,5-dichloronicotinate (241.37 mg, 1.17 mmol) and 3-(3-fluorophenoxy)pyrrolidine (D60) (253 mg, 1.39 mmol).

20 MS: (ES/+) *m/z*: 351 [MH⁺] C₁₇H₁₆ClFN₂O₃ requires 350.08

Description 96: methyl 5-chloro-2-(3-(*m*-tolylloxy)pyrrolidin-1-yl)nicotinate (D96)




25 The title compound (**D96**) (200 mg) was prepared according to the experimental procedure described in Description 62 starting from methyl 2,5-dichloronicotinate

(241.37 mg, 1.17 mmol) and 3-(m-tolyloxy)pyrrolidine (D61) (247.7 mg, 1.39 mmol).

MS: (ES/+) m/z: 347 [MH⁺] C₁₈H₁₉ClN₂O₃ requires 346.11

5 **Description 97: methyl 4-(1-(2,5-dichloronicotinamido)cyclopropyl)benzoate (D97)**




To a solution of 2,5-dichloronicotinic acid (1.84g, 7.06 mmol) in dry dimethylformamide (15ml) 1-Hydroxybenzotriazole hydrate (1.08 g, 7.06 mmol) and 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (2.03g, 10.58 mmol), a solution of methyl 4-(1-aminocyclopropyl)benzoate hydrochloride (D7) (1.67g, 7.06 mmol) and triethylamine (0.98ml, 7.06 mmol) in dry dimethylformamide (15ml) was added and the resulting mixture was stirred 1h at room temperature. NH₄Cl saturated solution (50ml) was added the mixture was extracted with ethylacetate (3x50ml). Collected organics, after solvent evaporation, was purified by Biotage column SNAP-Si (50g) eluting with a mixture dichloromethane/ ethylacetate from 100/0 to 95:5. Collected organics after solvent evaporation afforded the title compound **(D97)** (1.03 mg)

MS: (ES/+) m/z: 365.1 [MH⁺] C₁₇H₁₄Cl₂N₂O₃ requires 364.4

20 ¹H NMR (400MHz, CHLOROFORM-d) δ = 8.46 (d, *J* = 2.4 Hz, 1 H), 8.14 (d, *J* = 2.4 Hz, 1 H), 8.05 - 7.99 (m, 2 H), 7.41 - 7.35 (m, 2 H), 7.17 (s, 1 H), 3.93 (s, 3 H), 1.50 (s, 4 H).

Description 98: 5-chloro-2-(2-phenylpyrrolidin-1-yl)nicotinic acid (D98)




25

To an ice cooled solution of methyl 5-chloro-2-(2-phenylpyrrolidin-1-yl)nicotinate (D72) (165 mg, 0.520 mmol) in methanol (10ml), 10N NaOH (10ml) was added. The mixture was heated under reflux overnight. After cooled to room temperature,

the mixture was concentrated in vacuo. The residue was diluted with water (10ml), acidified with 2.5N HCl (pH 1-2), and the resulting mixture was extracted with ethyl acetate (2x10ml). The organic solution was washed with brine (20 ml), dried over Na₂SO₄ and evaporated in vacuo to afford the title compound (**D98**) (170 mg) as a red solid.


Description 99: 5-chloro-2-(3-phenylpyrrolidin-1-yl)nicotinic acid (D99)



The title compound (**D99**) (270 mg) was prepared according to the experimental procedure described in Description 60 starting from methyl 5-chloro-2-(3-phenylpyrrolidin-1-yl)nicotinate (D73) (310mg, 1.00 mmol)


¹H NMR (400MHz, CHLOROFORM-d) δ (ppm): 8.36 (1H, d, *J* = 2.4 Hz), 8.20 (1H, d, *J* = 2.4 Hz), 7.40 - 7.27 (5H, m), 3.78 - 3.52 (5H, m), 2.47 - 2.42 (1H, m), 2.21 - 2.10 (1H, m).

Description 100: 2-(2-benzylpyrrolidin-1-yl)-5-chloronicotinic acid (D100)




To methyl 2-(2-benzylpyrrolidin-1-yl)-5-chloronicotinate (D74) (75 mg, 0.226 mmol) in a mixture 1,4-dioxane/water (3ml/1ml), lithium hydroxide monohydrate (14.3 mg, 0.34 mmol) was added and the resulting mixture was stirred at 150°C under microwave irradiation for 10 min (2 cycles of 5 min each). Solvents were evaporated in vacuo. The obtained residue was diluted with water/1M HCl (5ml/15ml) and extracted with ethyl acetate (3x30ml). Collected fractions after solvent evaporation afforded the title compound (**D100**) (70 mg).

MS: (ES/+) *m/z*: 317 [MH⁺] C₁₇H₁₇ClN₂O₂ requires 316.10

Description 101: 5-chloro-2-(3-phenoxyazetidin-1-yl)nicotinic acid (D101)

Methyl 5-chloro-2-(3-phenoxyazetidin-1-yl)nicotinate (D75) (305 mg, 0.96 mmol) was dissolved in methanol/tetrahydrofuran (10 ml/10 ml), 5N NaOH (10ml) was added at 0 °C. The resulting reaction mixture was heated to 35 °C for 18 hours then cooled to room temperature and concentrated. Water added (10ml) and the mixture was acidified with 2.5N HCl (pH1-2). The white solid was collected, washed with water and dried to provide compound **(D101)** (280 mg) as a white solid.

¹H NMR (400 MHz, DMSO-*d*₆): δ (ppm): 8.33 (1H, d, *J* = 2.8 Hz), 7.97 (1H, d, *J* = 2.8 Hz), 7.33 (2H, dd, *J* = 8.4, 7.6 Hz), 6.99 (1H, t, *J* = 7.2 Hz), 6.87 (2H, d, *J* = 7.6 Hz), 5.11 - 5.07 (1H, m), 4.45 (2H, dd, *J* = 10.4, 6.4 Hz), 3.97 (2H, dd, *J* = 6.4, 3.6 Hz).


Description 102: 5-chloro-2-(3-(4-fluorophenoxy)azetidin-1-yl)nicotinic acid (D102)

The title compound **(D102)** (240 mg) was prepared according to the experimental procedure described in Description 100 starting from methyl 5-chloro-2-(3-(4-fluorophenoxy)azetidin-1-yl)nicotinate (D76) (270 mg, 0.801 mmol)

MS: (ES/+) *m/z*: 323.1 [MH⁺] C₁₅H₁₂ClFN₂O₃ requires 322.05

¹H NMR (400MHz, DMSO-*d*₆) δ (ppm): 13.16 (br. s., 1 H), 8.32 (d, *J* = 2.9 Hz, 1 H), 8.00 - 7.93 (m, 1 H), 7.20 - 7.10 (m, 2 H), 6.94 - 6.83 (m, 2 H), 5.13 - 4.99 (m, 1 H), 4.44 (dd, *J* = 5.9, 10.8 Hz, 2 H), 3.96 (dd, *J* = 3.4, 10.3 Hz, 2 H)

Description 103: 5-chloro-2-(3-(3-fluorophenoxy)azetidin-1-yl)nicotinic acid (D103)



5-chloro-2-(3-(3-fluorophenoxy)azetidin-1-yl)nicotinic acid (D103) was prepared according to three different procedures reported below

Procedure A

5 To a solution of 3-Fluorophenol (0.139 ml, 1.417 mmole) in acetonitrile (3ml), potassium carbonate (254.6 mg, 1.842 mmol) were added followed by the addition of methyl 5-chloro-2-(3-((methylsulfonyl)oxy)azetidin-1-yl)nicotinate (D63) (500 mg, 1.558 mmol). The reaction mixture was heated at 160°C under microwave irradiation for 25 min. Solvents were evaporated in vacuo and the residue was
10 diluted with 1M sol HCl (20ml) and extracted with ethyl acetate (3x20ml). The organics after solvent evaporation were loaded on SPE-SCX cartridge (20g). Collected ammonia fractions were evaporated in vacuo and the residue was dissolved in 1,4-dioxane/water (3ml/1ml) and heated at 150°C under microwave irradiation for 10 min in the presence of LiOH (59.4mg, 1.417mmol). The mixture
15 was evaporated in vacuo, diluted with water/1M HCl (10ml/20ml) and extracted with ethyl acetate (3x40ml). Collected organics, after solvent evaporation, afforded the title compound (**D103**) (420 mg)

Procedure B

The title compound (**D103**) (250 mg) was prepared according to the experimental
20 procedure described in Description 100 starting from methyl 5-chloro-2-(3-(3-fluorophenoxy)azetidin-1-yl)nicotinate (D77) (290 mg, 0.861 mmol)

MS: (ES/+) m/z: 323.5 [MH⁺] C₁₅H₁₂ClFN₂O₃ requires 322.05

¹H NMR (400MHz, DMSO-d₆) δ (ppm): 13.20 (s, 1 H), 8.33 (d, *J* = 2.4 Hz, 1 H), 7.97 (d, *J* = 2.7 Hz, 1 H), 7.35 (q, *J* = 8.1 Hz, 1 H), 6.99 - 6.30 (m, 3 H), 5.11 (tt, *J* = 3.5, 6.4 Hz, 1 H), 4.46 (dd, *J* = 6.4, 10.5 Hz, 2 H), 3.97 (dd, *J* = 3.3, 10.4 Hz, 2 H)
25

Procedure C


To a solution of 3-fluorophenol (24.6ml, 0.274 mol) in dimethylformamide (400ml) anhydrous potassium carbonate (37.87g, 0.274 mol) was added and the mixture
30 was heated at 80°C for 4 hours. A solution of 5-chloro-2-(3-

((methylsulfonyl)oxy)azetidin-1-yl)nicotinic acid (D63) (80g, 0.249 mol) in dimethylformamide (160ml) was added dropwise and the reaction mixture was stirred at 120°C for 24 hours. The resulting mixture was cooled to room temperature, then 1M NaOH (548ml) was added and the mixture was left stirring
 5 12 hours at 120°C. The reaction mixture was extracted with diethylether (1L). The resulting mixture was acidified to pH1 by addition of 2N HCl. A precipitate formed and was filtered off and was washed with water (500ml). After drying title compound (**D103**) (60g) was isolated

MS: (ES/+) m/z: 323.5 [MH⁺] C₁₅H₁₂ClFN₂O₃ requires 322.05

10 ¹H NMR (400MHz, DMSO-d₆) δ (ppm): 13.18 (br. s., 1 H), 8.32 (d, *J* = 2.4 Hz, 1 H), 7.97 (d, *J* = 2.4 Hz, 1 H), 7.39 - 7.30 (m, 1 H), 6.86 - 6.62 (m, 3 H), 5.11 (tt, *J* = 3.3, 6.5 Hz, 1 H), 4.46 (dd, *J* = 6.4, 10.3 Hz, 2 H), 3.97 (dd, *J* = 3.4, 10.8 Hz, 2 H).


Description 104: 5-chloro-2-(3-(4-(trifluoromethyl)phenoxy)azetidin-1-yl)nicotinic acid (D104)
 15



The title compound (**D104**) (200 mg) was prepared according to the experimental procedure described in 100 starting from methyl 5-chloro-2-(3-(4-(trifluoromethyl)phenoxy)azetidin-1-yl)nicotinate (D78) (110 mg, 0.284 mmol)

20 MS: (ES/+) m/z: 373.1 [MH⁺] C₁₆H₁₂ClF₃N₂O₃ requires 372.05


Description 105: 5-chloro-2-(3-(3-(trifluoromethyl)phenoxy)azetidin-1-yl)nicotinic acid (D105)



25 The title compound (**D105**) (180 mg) was prepared according to the experimental procedure described in 100 starting from methyl 5-chloro-2-(3-(3-(trifluoromethyl)phenoxy)azetidin-1-yl)nicotinate (D79) (110 mg, 0.284 mmol)

MS: (ES/+) m/z: 373.1 [MH⁺] C₁₆H₁₂ClF₃N₂O₃ requires 372.05

Description 106: 5-chloro-2-(3-(4-fluoro-3-(trifluoromethyl)phenoxy)azetidin-1-yl)nicotinic (D106)




5 The title compound **(D106)** (117 mg) was prepared according to the experimental procedure described in Description 103A *vero* starting from methyl 5-chloro-2-(3-((methylsulfonyl)oxy)azetidin-1-yl)nicotinate (D63) (100 mg, 0.311 mmol) and 4-Fluoro-3-(trifluoromethyl)phenol (51.04 mg, 0.284 mmol).

MS: (ES/+) m/z: 391.2 [MH⁺] C₁₆H₁₁ClF₄N₂O₃ requires 390.04

10 ¹H NMR (400 MHz, DMSO-d₆) δ (ppm): 8.32 (d, J=2.45 Hz, 1 H) 7.97 (d, J=2.69 Hz, 1 H) 7.55 - 7.45 (m, 1 H) 7.30 - 7.23 (m, 1 H) 7.15 - 7.22 (m, 1 H) 5.26 - 5.12 (m, 1 H) 4.46 (dd, J=10.39, 6.72 Hz, 2 H) 3.98 (dd, J=10.39, 3.06 Hz, 2 H)

Description 107: 5-chloro-2-(3-(3-(trifluoromethoxy)phenoxy)azetidin-1-yl)nicotinic acid (D107)




The title compound **(D107)** (112 mg) was prepared according to the experimental procedure described in Description 103A starting from methyl 5-chloro-2-(3-((methylsulfonyl)oxy)azetidin-1-yl)nicotinate (D63) (100 mg, 0.311 mmol) and 3-20 (trifluoromethoxy)phenol (0.036 ml, 0.284 mmol).

MS: (ES/+) m/z: 389.2 [MH⁺] C₁₆H₁₂ClF₃N₂O₄ requires 388.04

¹H NMR (400MHz, DMSO-d₆) δ (ppm): 13.22 (br. s., 1 H), 8.33 (d, J = 2.7 Hz, 1 H), 7.97 (d, J = 2.7 Hz, 1 H), 7.45 (t, J = 8.3 Hz, 1 H), 6.99 (d, J = 8.6 Hz, 1 H), 6.96 - 6.83 (m, 2 H), 5.24 - 4.99 (m, 1 H), 4.46 (dd, J = 6.2, 10.6 Hz, 2 H), 3.98 (dd, J = 25 3.4, 10.3 Hz, 2 H)

Description 108: 5-chloro-2-(3-(2,4-difluorophenoxy)azetidin-1-yl)nicotinic acid (D108)




The title compound (**D108**) (84 mg) was prepared according to the experimental procedure described in Description 103A starting from methyl 5-chloro-2-(3-((methylsulfonyl)oxy)azetidin-1-yl)nicotinate (D63) (100 mg, 0.311 mmol) and 2,4-
5 Difluorophenol (0.027 ml, 0.284 mmol).

MS: (ES/+) m/z: 341.1 [MH⁺] C₁₅H₁₁ClF₂N₂O₃ requires 340.04

¹H NMR (400MHz, DMSO-d₆) δ (ppm): 13.21 (br. s., 1 H), 8.33 (d, *J* = 2.4 Hz, 1 H), 7.98 (d, *J* = 2.4 Hz, 1 H), 7.60 - 7.21 (m, 1 H), 7.20 - 6.77 (m, 2 H), 5.12 (td, *J* = 2.9, 6.4 Hz, 1 H), 4.44 (dd, *J* = 6.6, 10.5 Hz, 2 H), 4.00 (dd, *J* = 3.4, 10.5 Hz, 2 H)

10

Description 109: 5-chloro-2-(3-(3,4-difluorophenoxy)azetidin-1-yl)nicotinic acid (D109)



The title compound (**D109**) (87 mg) was prepared according to the experimental procedure described in Description 103A starting from methyl 5-chloro-2-(3-((methylsulfonyl)oxy)azetidin-1-yl)nicotinate (D63) (100 mg, 0.311 mmol) and 3,4-
15 Difluorophenol (36.87 mg, 0.284 mmol).


MS: (ES/+) m/z: 341.1 [MH⁺] C₁₅H₁₁ClF₂N₂O₃ requires 340.04

¹H NMR (400MHz, DMSO-d₆) δ (ppm): 9.25 (s, 1 H), 8.22 (d, *J* = 2.4 Hz, 1 H), 7.85 (d, *J* = 8.6 Hz, 2 H), 7.77 (d, *J* = 2.4 Hz, 1 H), 7.39 - 7.25 (m, 3 H), 6.90 (d, *J* = 7.3 Hz, 1 H), 6.81 (br. s., 1 H), 6.77 - 6.67 (m, 2 H), 4.27 (d, *J* = 6.1 Hz, 3 H), 3.84 (s, 3 H), 3.69 (d, *J* = 5.6 Hz, 2 H), 1.45 - 1.24 (m, 4 H)

20

Description 110: 2-(3-(3-(4-(tert-butoxycarbonyl)piperazin-1-yl)phenoxy)azetidin-1-yl)-5-chloronicotinic acid (D110)

25




To a solution of tert-butyl 4-(3-hydroxyphenyl)piperazine-1-carboxylate (D18) (143.18 mg, 0.514 mmol) in dimethylformamide (2ml), potassium carbonate (71 mg, 0.514 mmol) and the reaction mixture was heated 2h at 80°C. methyl 5-chloro-2-(3-((methylsulfonyl)oxy)azetidin-1-yl)nicotinate (D63) (150 mg, 0.467 mmol) in dimethylformamide (2ml) was added dropwise and the resulting mixture stirred 21h at 120°C. After cooling at room temperature, 1M NaOH (0.935ml) was added and the mixture stirred 1h at 120°C. After cooling the reaction mixture was extracted with diethylether (2x10ml) and the aqueous was evaporated in vacuo. The residue was purified by SPE-Si cartridge (5g) eluting with a mixture dichloromethane/methanol from 100/0 to 80/20. Collected fractions, after solvent evaporation afforde the title compound (**D110**) (155 mg)

MS: (ES/+) m/z: 489.4 [MH⁺] C₂₄H₂₉ClN₄O₅ requires 488.18

¹H NMR (400MHz, DMSO-d₆) δ (ppm): 8.28 (br. s., 1 H), 7.91 (br. s., 1 H), 7.14 (t, J = 8.1 Hz, 1 H), 6.59 (d, J = 8.3 Hz, 1 H), 6.41 (s, 1 H), 6.28 (d, J = 8.3 Hz, 1 H), 5.06 (br. s., 1 H), 4.43 (dd, J = 6.4, 10.3 Hz, 2 H), 3.94 (dd, J = 3.4, 10.3 Hz, 2 H), 3.44 (d, J = 4.9 Hz, 4 H), 3.15 - 3.03 (m, 4 H), 1.43 (s, 9 H).

Description 111: 5-chloro-2-(3-(3-fluorophenyl)-3-hydroxyazetidin-1-yl)nicotinic acid (D111)




To a solution of methyl 5-chloro-2-(3-(3-fluorophenyl)-3-hydroxyazetidin-1-yl)nicotinate (D80) (70 mg, 0.207 mmol) in a mixture 3:1 1,4-dioxane/water (2ml), lithium hydroxide monohydrate (133 mg, 0.312 mmol) was added and the resulting mixture was stirred 4 h at 70°C. After solvent evaporation the residue was taken in a mixture water/1M HCl (10ml/10ml) and extracted with ethylacetate (2x30ml).

Collected organics after solvent evaporation afforded the title compound (**D111**) (64.6 mg).

MS: (ES/+) m/z: 323.1 [MH⁺] C₁₅H₁₂ClFN₂O₃ requires 322.05

¹H NMR (400MHz, DMSO-d₆) δ (ppm): 8.35 (d, J = 2.4 Hz, 1 H), 7.98 (d, J = 2.9 Hz, 1 H), 7.48 - 7.40 (m, 1 H), 7.38 - 7.27 (m, 2 H), 7.12 (dt, J = 2.0, 8.3 Hz, 1 H), 6.42 (s, 1 H), 4.26 - 4.14 (m, 4 H).

Description 112: 5-chloro-2-(3-(4-fluorophenyl)-3-hydroxyazetidin-1-yl)nicotinic acid (D112)




The title compound (**D112**) (65.5 mg) was prepared according to the experimental procedure described in Description 111 starting from methyl 5-chloro-2-(3-(4-fluorophenyl)-3-hydroxyazetidin-1-yl)nicotinate (D81) (74 mg, 0.22 mmol).

MS: (ES/+) m/z: 323.1 [MH⁺] C₁₅H₁₂ClFN₂O₃ requires 322.05

¹H NMR (400MHz, DMSO-d₆) δ (ppm): 8.34 (d, J = 2.9 Hz, 1 H), 7.98 (d, J = 2.4 Hz, 1 H), 7.55 (dd, J = 5.6, 8.6 Hz, 2 H), 7.20 (t, J = 8.8 Hz, 2 H), 6.34 (s, 1 H), 4.25 - 4.14 (m, 4 H).

Description 113: 5-chloro-2-(3-((4-fluorophenoxy)methyl)azetidin-1-yl)nicotinic acid (D113)




To a solution of methyl 5-chloro-2-(3-((4-fluorophenoxy)methyl)azetidin-1-yl)nicotinate (D82) (52.1 mg, 0.148 mmol) in a mixture (3:1) 1,4-dioxane/water (1.6ml), lithium hydroxide monohydrate (9.3 mg, 0.22 mmol) was added and the resulting mixture was heated under microwave irradiation 6 min at 140°C. After

solvent evaporation the residue was taken in a mixture water/ 1M HCl (20ml/5ml) and extracted with ethylacetate (3x20ml). Collected organics after solvent evaporation afforded the title compound (**D113**) (55.4 mg).

MS: (ES/+) m/z: 337.2 [MH⁺] C₁₆H₁₄ClFN₂O₃ requires 336.07

- 5 ¹H NMR (400MHz ,DMSO-d₆) δ (ppm): 8.29 (d, J = 2.9 Hz, 1 H), 7.91 (d, J = 2.9 Hz, 1 H), 7.14 - 7.08 (m, 2 H), 6.98 - 6.93 (m, 2 H), 4.17 - 4.09 (m, 4 H), 3.83 (dd, J = 5.4, 8.8 Hz, 2 H), 3.11 - 3.03 (m, 1 H).

- 10 **Description 114: 5-chloro-2-(3-((3-fluorophenoxy)methyl)azetidin-1-yl)nicotinic acid (D114)**




The title compound (**D114**) (66.3 mg) was prepared according to the experimental procedure described in Description 113 starting from methyl 5-chloro-2-(3-(3-fluorophenyl)-3-hydroxyazetidin-1-yl)nicotinate (D83) (66.2 mg, 0.188 mmol).

- 15 MS: (ES/+) m/z: 337.2 [MH⁺] C₁₆H₁₄ClFN₂O₃ requires 336.07

¹H NMR (400MHz ,DMSO-d₆) δ (ppm): 8.29 (d, J = 2.4 Hz, 1 H), 7.91 (d, J = 2.4 Hz, 1 H), 7.35 - 7.26 (m, 1 H), 6.85 - 6.73 (m, 3 H), 4.22 - 4.10 (m, 4 H), 3.83 (dd, J = 5.4, 9.3 Hz, 2 H), 3.13 - 3.03 (m, 1 H).

- 20 **Description 115: 5-chloro-2-(3-((3-(trifluoromethyl)phenyl)amino)azetidin-1-yl)nicotinic acid (D115)**




- 25 To a solution of 3-(Trifluoromethyl)aniline (0.047 ml, 0.374 mmol) in acetonitrile (0.5ml), potassium carbonate (67.21 mg , 0.486 mmol) was added followed by the addition of methyl 5-chloro-2-(3-((methylsulfonyl)oxy)azetidin-1-yl)nicotinate (D63)(120 mg, 0.374 mmol). The reaction mixture was heated at 160°C under microwave irradiation for 25 min. Lithium hydroxide monohydrate (23.54 mg, 0.561

mmol) was added and the resulting reaction mixture was heated at 150°C under microwave irradiation for 5 min. Solvents were evaporated in vacuo and the residue was diluted with water (5ml) and HCl 1M (15ml) and extracted with ethyl acetate (3x20ml). Collected organics, after solvent evaporation, afforded the title compound **(D115)** (50 mg)

MS: (ES/+) m/z: 372.1 [MH⁺] C₁₆H₁₃ClF₃N₃O₂ requires 371.06

Description 116: 5-chloro-2-(3-((3-fluorophenyl)amino)azetidin-1-yl)nicotinic acid (D116)




The title compound **(D116)** (40 mg) was prepared according to the experimental procedure described in Description 115 starting from methyl 5-chloro-2-(3-((methylsulfonyl)oxy)azetidin-1-yl)nicotinate (D63) (120 mg, 0.374 mmol) and 3-Fluoroaniline (0.036 ml, 0.374 mmole).

MS: (ES/+) m/z: 322.1 [MH⁺] C₁₅H₁₃ClFN₃O₂ requires 321.07

¹H NMR (400MHz, DMSO-d₆) δ (ppm): 8.30 (d, *J* = 2.7 Hz, 1 H), 7.93 (d, *J* = 2.7 Hz, 1 H), 7.11 (d, *J* = 7.3 Hz, 1 H), 6.42 - 6.24 (m, 3 H), 4.42 - 4.31 (m, 2 H), 4.30 - 4.21 (m, 1 H), 3.79 (dd, *J* = 4.5, 9.4 Hz, 2 H)


Description 117: 5-chloro-2-(3-((4-fluorophenyl)amino)azetidin-1-yl)nicotinic acid (D117)



The title compound **(D117)** (70 mg) was prepared according to the experimental procedure described in Description 100 starting from methyl 5-chloro-2-(3-((4-fluorophenyl)amino)azetidin-1-yl)nicotinate (D84) (76 mg, 0.226 mmol)

MS: (ES/+) m/z: 322.1 [MH⁺] C₁₅H₁₃ClFN₃O₂ requires 321.05

Description 118: 5-chloro-2-(3-((2,4-difluorophenyl)amino)azetidin-1-yl)nicotinic acid (D118)




To a solution of methyl 5-chloro-2-(3-((2,4-difluorophenyl)amino)azetidin-1-yl)nicotinate (D85) (37 mg, 0.104 mmol) in a mixture 3:1 1,4-dioxane/water (4 ml), 1M NaOH (0.157 ml) was added and the resulting mixture was stirred 12 h at 60°C. After cooling the reaction mixture was acidified to pH 1 by addition of 1M HCl. The resulting precipitate was collected by filtration and afforded the title compound (**D118**) (35 mg).

10 MS: (ES/+) m/z: 340.1 [MH⁺] C₁₅H₁₂ClF₂N₃O₂ requires 339.06

¹H NMR (400MHz, DMSO-d₆) δ (ppm): 8.29 (d, *J* = 2.9 Hz, 1 H), 7.92 (d, *J* = 2.4 Hz, 1 H), 7.17 - 7.03 (m, 1 H), 6.93 - 6.82 (m, 1 H), 6.65 - 6.54 (m, 1 H), 4.40 - 4.32 (m, 2 H), 4.28 (d, *J* = 5.9 Hz, 1 H), 3.87 (dd, *J* = 4.4, 9.3 Hz, 2 H)

15 **Description 119: 5-chloro-2-(3-((2-methyl-4-(trifluoromethyl)phenyl)amino)azetidin-1-yl)nicotinic acid (D119)**




The title compound (**D119**) (40 mg) was prepared according to the experimental procedure described in Description 118 starting from methyl 5-chloro-2-(3-((2-methyl-4-(trifluoromethyl)phenyl)amino)azetidin-1-yl)nicotinate (D86) (44 mg, 0.110 mmol)

MS: (ES/+) m/z: 386.2 [MH⁺] C₁₇H₁₅ClF₃N₃O₂ requires 385.08

¹H NMR (400MHz, DMSO-d₆) δ (ppm): 8.31 (d, *J* = 2.9 Hz, 1 H), 7.93 (d, *J* = 2.4 Hz, 1 H), 7.36 - 7.30 (m, 2 H), 6.49 (d, *J* = 8.3 Hz, 1 H), 6.17 - 5.90 (m, 1 H), 4.44 - 4.34 (m, 3 H), 3.95 (dd, *J* = 3.4, 8.8 Hz, 2 H), 2.18 (s, 3 H)

Description 120: 5-chloro-2-(3-((4-fluoro-2-methylphenyl)(methyl)amino)azetidin-1-yl)nicotinic acid (D120)




To a solution of methyl 5-chloro-2-(3-(methyl(2-methyl-4-fluorophenyl)amino)azetidin-1-yl)nicotinate (D87) (170 mg, 0.467 mmol) in 1,4 dioxane (3ml) and water (1ml) 1M NaOH (0.7 ml) was added. The mixture was stirred at 60°C for 2h. Organic solvent was evaporated and remaining aqueous were acidified 2N HCl and extracted with ethylacetate (3x5ml). The combined organic phases after solvent evaporation afforded the title compound (**D120**) (156 mg)

MS: (ES/+) m/z: 350.1 [MH⁺] C₁₇H₁₇ClFN₃O₂ requires 349.79

¹H NMR (400MHz, DMSO-d₆) δ (ppm): 13.06 (s, 1 H), 8.27 (d, J = 2.4 Hz, 1 H), 7.91 (d, J = 2.4 Hz, 1 H), 7.05 (d, J = 9.8 Hz, 1 H), 6.99 - 6.90 (m, 2 H), 4.17 - 4.03 (m, 3 H), 3.66 (dd, J = 3.4, 8.3 Hz, 2 H), 2.49 (s, 3 H), 2.26 (s, 3 H)

Description 121: 2-(3-(3-fluorophenoxy)azetidin-1-yl)-5-(trifluoromethyl)nicotinic acid (D121)




To a mixture of 3-(3-fluorophenoxy)azetidine (D50) (106.73 mg, 0.638 mmol) and triethylamine (0.11ml, 0.798 mmol) in methanol (3ml), 2-Chloro-5-(trifluoromethyl)nicotinic acid (120 mg, 0.532 mmol) was added and the mixture was heated 10 min (2 cycles of 5 min each) under microwave irradiation at 150°C. After solvent evaporation the residue was purified by SPE-Si cartridge (25g) eluting with a mixture dichloromethane/methanol from 100/0 to 50/50. Collected fraction after solvent evaporation afforded the title compound (**D121**) (83 mg)

MS: (ES/+) m/z: 357.1 [MH⁺] C₁₆H₁₂F₄N₂O₃ requires 356.08

¹H NMR (400MHz, CHLOROFORM-d) δ (ppm): 8.58 (d, J = 1.5 Hz, 1 H), 8.37 (d, J = 2.0 Hz, 1 H), 7.28 - 7.23 (m, 1 H), 6.74 (dt, J = 1.5, 8.3 Hz, 2 H), 6.58 (dd, J = 2.2, 8.1 Hz, 1 H), 6.53 (td, J = 2.3, 10.6 Hz, 1 H), 5.13 - 4.97 (m, 1 H), 4.67 (dd, J = 6.4, 10.8 Hz, 2 H), 4.30 (dd, J = 3.9, 10.8 Hz, 2 H)

Description 122: 2-(3-(4-fluorophenoxy)azetidin-1-yl)-5-(trifluoromethyl)nicotinic acid (D122)




The title compound (**D122**) (180 mg) was prepared according to the experimental procedure described in Description 121 starting from 3-(4-fluorophenoxy)azetidine) (D49) (177.89 mg, 1.064 mmol) and 2-chloro-5-(trifluoromethyl)nicotinic acid (200 mg, 0.886 mmol)

MS: (ES/+) m/z: 357.1 [MH⁺] C₁₆H₁₂F₄N₂O₃ requires 356.08

¹H NMR (400MHz, CHLOROFORM-d) δ (ppm): 8.57 (d, J = 2.0 Hz, 1 H), 8.36 (d, J = 2.4 Hz, 1 H), 7.09 - 6.92 (m, 2 H), 6.83 - 6.57 (m, 2 H), 5.08 - 4.96 (m, 1 H), 4.64 (dd, J = 6.4, 10.8 Hz, 2 H), 4.28 (dd, J = 3.9, 11.2 Hz, 2 H)

Description 123: 2-(3-(4-chlorophenoxy)azetidin-1-yl)-5-(trifluoromethyl)nicotinic acid (D123)




The title compound (**D123**) (125 mg) was prepared according to the experimental procedure described in Description 103A vero starting from methyl 2-(3-((methylsulfonyl)oxy)azetidin-1-yl)-5-(trifluoromethyl)nicotinate (D68) (100 mg, 0.258 mmol) and 4-Chlorophenol (0.033 ml, 0.338 mmol).

MS: (ES/+) m/z: 373.2 [MH⁺] C₁₆H₁₂ClF₃N₂O₃ requires 372.05

¹H NMR (400MHz, DMSO-d₆) δ (ppm): 9.71 (s, 1 H), 8.61 (s, 1 H), 8.16 (d, J = 2.4 Hz, 1 H), 7.37 (d, J = 8.8 Hz, 2 H), 6.92 (d, J = 8.8 Hz, 1 H), 5.11 (br. s., 1 H), 4.63 - 4.38 (m, 2 H), 4.16 - 3.95 (m, 2 H)

Description 124: 2-(3-(3-chlorophenoxy)azetidin-1-yl)-5-(trifluoromethyl)nicotinic acid (D124)




The title compound (**D124**) (85 mg) was prepared according to the experimental procedure described in Description 103A starting from methyl 2-(3-((methylsulfonyl)oxy)azetidin-1-yl)-5-(trifluoromethyl)nicotinate (D68) (100 mg, 0.258 mmol) and 3-Chlorophenol (0.035 ml, 0.338 mmol).

5 MS: (ES/+) m/z: 373.2 [MH⁺] C₁₆H₁₂ClF₃N₂O₃ requires 372.05

¹H NMR (400MHz, DMSO-d₆) δ (ppm): 8.61 (d, *J* = 1.7 Hz, 1 H), 8.16 (d, *J* = 2.2 Hz, 1 H), 7.40 - 7.32 (m, 1 H), 7.06 (d, *J* = 8.1 Hz, 1 H), 6.98 (t, *J* = 2.0 Hz, 1 H), 6.91 - 6.85 (m, 1 H), 5.15 (qd, *J* = 3.0, 6.1 Hz, 1 H), 4.56 (dd, *J* = 6.5, 10.6 Hz, 2 H), 4.15 - 4.05 (m, 2 H)

10

Description 125: 2-(3-(4-fluoro-3-(trifluoromethyl)phenoxy)azetidin-1-yl)-5-(trifluoromethyl)nicotinic acid (D125)




15 The title compound (**D125**) (108 mg) was prepared according to the experimental procedure described in Description 103A starting from methyl 2-(3-((methylsulfonyl)oxy)azetidin-1-yl)-5-(trifluoromethyl)nicotinate (D68) (100 mg, 0.258 mmol) and 4-Fluoro-3-(trifluoromethyl)phenol (60.98 mg, 0.338 mmol).

MS: (ES/+) m/z: 425 [MH⁺] C₁₇H₁₁F₇N₂O₃ requires 424.07

20 ¹H NMR (400MHz, DMSO-d₆) δ (ppm): 8.61 (d, *J* = 1.5 Hz, 1 H), 8.16 (d, *J* = 2.4 Hz, 1 H), 7.53 - 7.45 (m, 1 H), 7.31 - 7.17 (m, 2 H), 5.21 (dd, *J* = 3.3, 6.2 Hz, 1 H), 4.57 (dd, *J* = 6.5, 10.1 Hz, 2 H), 4.15 - 4.05 (m, 2 H)

Description 126: 2-(3-(3-(trifluoromethoxy)phenoxy)azetidin-1-yl)-5-(trifluoromethyl)nicotinic acid (D126)



25


The title compound (**D126**) (110 mg) was prepared according to the experimental procedure described in Description 103A starting from methyl 2-(3-

((methylsulfonyl)oxy)azetidin-1-yl)-5-(trifluoromethyl)nicotinate (D68) (100 mg, 0.258 mmol) and 3-(trifluoromethoxy)phenol (0.043 ml, 0.338 mmol).

MS: (ES/+) m/z: 423 [MH⁺] C₁₇H₁₂F₆N₂O₄ requires 422.07

¹H NMR (400MHz, DMSO-d₆) δ (ppm): 13.32 (br. s., 1 H), 8.62 (d, *J* = 2.0 Hz, 1 H), 8.16 (d, *J* = 2.2 Hz, 1 H), 7.46 (t, *J* = 8.2 Hz, 1 H), 7.00 (d, *J* = 8.3 Hz, 1 H), 6.94 (dd, *J* = 2.2, 8.3 Hz, 1 H), 6.91 (s, 1 H), 5.17 (td, *J* = 3.0, 6.4 Hz, 1 H), 4.57 (dd, *J* = 6.2, 10.6 Hz, 2 H), 4.09 (dd, *J* = 3.2, 10.8 Hz, 2 H)

Description 127: 2-(3-(2,4-difluorophenoxy)azetidin-1-yl)-5-(trifluoromethyl)nicotinic acid (D127)




The title compound (**D127**) (95 mg) was prepared according to the experimental procedure described in Description 103A starting from methyl 2-(3-((methylsulfonyl)oxy)azetidin-1-yl)-5-(trifluoromethyl)nicotinate (D68) (100 mg, 0.258 mmol) and 2,4-Difluorophenol (0.032 ml, 0.338 mmol).

MS: (ES/+) m/z: 375 [MH⁺] C₁₆H₁₁F₅N₂O₃ requires 374.07

¹H NMR (400MHz, DMSO-d₆) δ (ppm): 13.32 (br. s., 1 H), 8.62 (d, *J* = 1.7 Hz, 1 H), 8.16 (d, *J* = 2.4 Hz, 1 H), 7.44 - 7.28 (m, 1 H), 7.12 - 6.92 (m, 2 H), 5.15 (td, *J* = 3.1, 6.5 Hz, 1 H), 4.55 (dd, *J* = 6.1, 11.0 Hz, 2 H), 4.11 (dd, *J* = 3.3, 10.9 Hz, 2 H).

20

Description 128: 2-(3-(3,4-difluorophenoxy)azetidin-1-yl)-5-(trifluoromethyl)nicotinic acid (D128)




The title compound (**D128**) (100 mg) was prepared according to the experimental procedure described in Description 103A starting from methyl 2-(3-((methylsulfonyl)oxy)azetidin-1-yl)-5-(trifluoromethyl)nicotinate (D68) (100 mg, 0.258 mmol) and 3,4-Difluorophenol (44.06 mg, 0.338 mmol).

MS: (ES/+) m/z: 375 [MH⁺] C₁₆H₁₁F₅N₂O₃ requires 374.07

¹H NMR (400MHz ,DMSO-d₆) δ (ppm): 13.30 (br. s., 1 H), 8.63 - 8.58 (m, 1 H), 8.61 (d, *J* = 1.7 Hz, 1 H), 8.16 (d, *J* = 2.4 Hz, 1 H), 7.46 - 7.31 (m, 1 H), 7.06 (ddd, *J* = 2.9, 6.7, 12.4 Hz, 1 H), 6.79 - 6.62 (m, 1 H), 5.11 (tt, *J* = 3.4, 6.4 Hz, 1 H), 4.55 (dd, *J* = 6.5, 10.9 Hz, 2 H), 4.06 (dd, *J* = 3.1, 11.4 Hz, 2 H)

5

Description 129: 2-(3-((5-methylisoxazol-3-yl)oxy)azetidin-1-yl)-5-(trifluoromethyl)nicotinic acid (D129)




To a solution of methyl 2-(3-((5-methylisoxazol-3-yl)oxy)azetidin-1-yl)-5-(trifluoromethyl)nicotinate (D88) (20mg, 0.056 mmol) in 1,4-dioxane/water (3ml/1ml), lithium hydroxide monohydrate (3.52mg, 0.084 mmol) and the resulting mixture was heated at 130°C under microwave irradiation 10 min (2 cycles of 5 min each). Solvents were evaporated in vacuo and the residue was taken in a mixture water/1M HCl (5ml/15ml) and extracted with ethyl acetate (3x20ml).
Collected organics, after solvent evaporation, afforded the title compound (**D129**) (19 mg)

MS: (ES/+) *m/z*: 344.2 [MH⁺] C₁₄H₁₂F₃N₃O₄ requires 343.08

¹H NMR (400MHz ,DMSO-d₆) δ (ppm): 13.32 (br. s., 1 H), 8.61 (d, *J* = 1.5 Hz, 1 H), 8.16 (d, *J* = 2.2 Hz, 1 H), 6.06 (d, *J* = 1.0 Hz, 1 H), 5.21 (br. s., 1 H), 4.47 (dd, *J* = 6.5, 11.1 Hz, 2 H), 4.12 (dd, *J* = 2.3, 11.1 Hz, 2 H), 2.34 (d, *J* = 0.5 Hz, 3 H)

Description 130: 5-(trifluoromethyl)-2-(3-((6-(trifluoromethyl)pyridin-2-yl)oxy)azetidin-1-yl)nicotinic acid (D130)




The title compound (**D130**) (77 mg) was prepared according to the experimental procedure described in Description 129 starting methyl 5-(trifluoromethyl)-2-(3-((6-(trifluoromethyl)pyridin-2-yl)oxy)azetidin-1-yl)nicotinate (D89) (80mg, 0.19 mmol) and 2-Hydroxy-6-(trifluoromethyl)pyridine (55.12mg, 0.34 mmol).

MS: (ES/+) m/z: 408.6 [MH⁺] C₁₆H₁₁F₆N₃O₃ requires 407.07

¹H NMR (400MHz, DMSO-d₆) δ (ppm): 13.71 - 12.69 (m, 1 H), 8.66 - 8.49 (m, 1 H), 8.20 - 8.11 (m, 1 H), 8.10 - 7.96 (m, 1 H), 7.61 - 7.49 (m, 1 H), 7.33 - 7.18 (m, 1 H), 5.53 - 5.32 (m, 1 H), 4.62 - 4.43 (m, 2 H), 4.22 - 4.05 (m, 2 H)

5

Description 131: 2-(3-((5-fluoropyrimidin-2-yl)oxy)azetidin-1-yl)-5-(trifluoromethyl)nicotinic acid (D131)




To a mixture of 2-(azetidin-3-yloxy)-5-fluoropyrimidine (D51) (108 mg, 0.638 mmol) and triethylamine (0.11ml, 0.798 mmol) in methanol (1ml) and tetrahydrofuran (2ml), 2-chloro-5-(trifluoromethyl)nicotinic acid (120 mg, 0.532 mmol) was added and the mixture was heated 2h at 80 °C. After solvent evaporation the residue was purified by SPE-Si cartridge (25g) eluting with a mixture dichloromethane/methanol from 95/5 to 80/20. Collected fraction after solvent evaporation afforded the title compound (**D131**) (44 mg)

MS: (ES/+) m/z: 359.3 [MH⁺] C₁₄H₁₀F₄N₄O₃ requires 358.07

¹H NMR (400MHz, CHLOROFORM-d) δ (ppm): 8.74 (s, 2 H), 8.59 (d, J = 2.0 Hz, 1 H), 8.13 (d, J = 2.4 Hz, 1 H), 5.38 (s, 1 H), 4.52 (dd, J = 6.4, 11.2 Hz, 2 H), 4.14 (dd, J = 3.4, 11.2 Hz, 2 H)

20

Description 132: 5-fluoro-2-(3-(3-fluorophenoxy)azetidin-1-yl)nicotinic acid (D132)




The title compound (**D132**) (108 mg) was prepared according to the experimental procedure described in Description 115 starting from methyl 5-fluoro-2-(3-((methylsulfonyl)oxy)azetidin-1-yl)nicotinate (D71) (90 mg, 0.295 mmol) and 3-Fluorophenol (0.029 ml, 0.295 mmol).

MS: (ES/+) m/z: 307.2 [MH⁺] C₁₅H₁₂F₂N₂O₃ requires 306.08

¹H NMR (400MHz ,DMSO-d₆) δ (ppm): 13.18 (br. s., 1 H), 8.35 (d, *J* = 3.2 Hz, 1 H), 7.93 - 7.81 (m, 1 H), 7.35 (q, *J* = 8.1 Hz, 1 H), 6.82 (dt, *J* = 2.4, 8.6 Hz, 1 H), 6.79 - 6.68 (m, 2 H), 5.11 (tt, *J* = 3.4, 6.4 Hz, 1 H), 4.43 (dd, *J* = 6.4, 10.0 Hz, 2 H), 3.94 (dd, *J* = 3.3, 9.9 Hz, 2 H)

5

Description 133: 2-(3-(3-chlorophenoxy)azetidin-1-yl)-5-fluoronicotinic acid (133)




To a solution of 3-chlorophenol (0.035ml, 0.328 mmol) in dimethylformamide (1ml),
 10 potassium carbonate (45.42 mg, 0.328 mmol) and the reaction mixture was stirred
 2h at 80°C. Methyl 5-fluoro-2-(3-((methylsulfonyl)oxy)azetidin-1-yl)nicotinate (D71)
 (100 mg, 0.328 mmol).was added and the resulting reaction mixture was heated
 12 h at 160°C. After cooling at room temperature 1N NaOH (0.656ml, 0.656 mmol)
 was added and the reaction mixture heated 2 h at 120°C. Solvents were
 15 evaporated in vacuo and the residue was loaded on SPE-SCX cartridge (5g).
 Ammonia fractions after solvent evaporation afforded a residue that was further
 purified by Biotage column SNAP-C18 (30g) eluting with water/acetic acid
 (0.1%)/acetonitrile-acetic acid (0.1%) from 70/30 to 0/100.

Collected fractions, after solvent evaporation, afforded the title compound (**D133**)
 20 (14 mg)

MS: (ES/+) *m/z*: 323.1 [MH⁺] C₁₅H₁₂ClFN₂O₃ requires 322.05

¹H NMR (400MHz ,DMSO-d₆) δ (ppm) 13.19 (br. s., 1 H), 8.34 (d, *J* = 2.9 Hz, 1 H),
 7.85 (dd, *J* = 2.9, 8.8 Hz, 1 H), 7.40 - 7.29 (m, 1 H), 7.08 - 7.01 (m, 1 H), 6.96 (t, *J*
 = 2.2 Hz, 1 H), 6.91 - 6.83 (m, 1 H), 5.17 - 5.08 (m, 1 H), 4.43 (dd, *J* = 6.4, 9.8 Hz,
 25 2 H), 3.93 (dd, *J* = 3.4, 10.3 Hz, 2 H))

Description 134: 5-fluoro-2-(3-(3-(trifluoromethoxy)phenoxy)azetidin-1-yl)nicotinic acid (D134)




The title compound (**D134**) (27 mg) was prepared according to the experimental procedure described in Description 133 starting from Methyl 5-fluoro-2-(3-((methylsulfonyl)oxy)azetidin-1-yl)nicotinate (D71) (100 mg, 0.328 mmol) and 3-(trifluoromethoxy)phenol (0.042ml, 0.328 mmol).

MS: (ES/+) m/z: 372.6 [MH⁺] C₁₆H₁₂F₄N₂O₄ requires 372.7

¹H NMR (400MHz, DMSO-d₆) δ (ppm): 13.17 (br. s., 1 H), 8.34 (d, *J* = 2.9 Hz, 1 H), 7.86 (dd, *J* = 2.9, 8.8 Hz, 1 H), 7.45 (t, *J* = 8.3 Hz, 1 H), 6.99 (d, *J* = 7.3 Hz, 1 H), 6.93 (dd, *J* = 2.4, 8.3 Hz, 1 H), 6.88 (s, 1 H), 5.19 - 4.99 (m, 1 H), 4.44 (dd, *J* = 6.4, 9.8 Hz, 2 H), 3.95 (dd, *J* = 3.4, 10.3 Hz, 2 H)

Description 135: 5-fluoro-2-(3-((4-fluoro-2-methylphenyl)amino)azetidin-1-yl)nicotinic acid (D135)




To a solution of methyl 5-fluoro-2-(3-((4-fluoro-2-methylphenyl)amino)azetidin-1-yl)nicotinate (D90) (150 mg, 0.450 mmol) in 1,4-dioxane/water (3ml/1ml), 1M NaOH (0.675 ml, 0.657 mmol) was added and the resulting mixture was stirred 2 h at 60°C. Organic solvent was evaporated. The remaining aqueous were washed with dichloromethane (5ml) then acidified to pH2 by addition of 2M HCl and extracted with ethylacetate (3x20ml). Collected organics, after solvent evaporation afforded the title compound (**D135**) (140 mg).

MS: (ES/+) m/z: 321.1 [MH⁺] C₁₆H₁₅F₂N₃O₂ requires 319.11

¹H NMR (400MHz, DMSO-d₆) δ (ppm): 8.32 (d, *J* = 2.9 Hz, 1 H), 7.82 (dd, *J* = 2.9, 8.8 Hz, 1 H), 6.93 - 6.78 (m, 2 H), 6.34 (dd, *J* = 5.1, 8.6 Hz, 1 H), 4.39 - 4.31 (m, 2 H), 4.27 - 4.19 (m, 1 H), 3.83 (dd, *J* = 4.9, 9.3 Hz, 2 H), 2.13 (s, 3 H).


Description 136: lithium 5-chloro-2-(3-(4-(trifluoromethyl)phenoxy)pyrrolidin-1-yl)nicotinate (D136)



To a mixture of methyl 5-chloro-2-(3-(4-(trifluoromethyl)phenoxy)pyrrolidin-1-yl)nicotinate (D91) (220 mg, 0.548 mmol) in a mixture 1,4-dioxane/water (2ml/1ml), lithium hydroxide monohydrate (34.55 mg, 0.823 mmol) was added and the resulting mixture was stirred at 150°C under microwave irradiation for 10 min (2 cycles of 5 min each). Solvents were evaporated in vacuo to afford the title compound **(D136)** 265 mg

MS: (ES/+) m/z: 387.4 [MH⁺] (free acid) C₁₇H₁₄ClF₃N₂O₃ requires 386.07


10 **Description 137: 5-chloro-2-(3-(3-(trifluoromethyl)phenoxy)pyrrolidin-1-yl)nicotinic acid (D137)**



The title compound **(D137)** (240 mg) was prepared according to the experimental procedure described in Description 100 starting from methyl 5-chloro-2-(3-(3-(trifluoromethyl)phenoxy)pyrrolidin-1-yl)nicotinate (D92) (270 mg, 0.673 mmol)

15 MS: (ES/+) m/z: 387 [MH⁺] C₁₇H₁₄ClF₃N₂O₃ requires 386.06


Description 138: 5-chloro-2-(3-(4-fluorophenoxy)pyrrolidin-1-yl)nicotinic acid (D138)



20 The title compound **(D138)** (220 mg) was prepared according to the experimental procedure described in Description 100 starting from methyl 5-chloro-2-(3-(4-fluorophenoxy)pyrrolidin-1-yl)nicotinate (D93) (235 mg, 0.669 mmol)


MS: (ES/+) m/z: 337 [MH⁺] C₁₆H₁₄ClFN₂O₃ requires 336.06

25

Description 139: 5-chloro-2-(3-phenoxypyrrolidin-1-yl)nicotinic acid (D139)


Methyl 5-chloro-2-(3-phenoxypyrrolidin-1-yl)nicotinate (D94) (230 mg, 0.69 mmol) was dissolved in methanol (10ml), 10N NaOH (10ml) was added at 0°C. The reaction mixture was heated to reflux for 18 hours. After cooling to room temperature, methanol was evaporated then water (10ml) was added and the mixture was acidified to pH1-2 by addition of 2.5N HCl at 0°C. The mixture was stirred at 0°C for 30 min. The white solid was collected by filtration, washed with water, dried to provide compound **(D139)** (210 mg) as a white solid.

¹H NMR (400 MHz, DMSO-*d*₆): δ (ppm): 13.23 (1H, br s), 8.26 (1H, d, *J* = 2.4 Hz), 7.88 (1H, d, *J* = 2.0 Hz), 7.32 - 7.28 (2H, m), 6.97 - 6.94 (3H, m), 5.13 (1H, s), 3.87 - 3.82 (1H, m), 3.70 - 3.63 (1H, m), 3.34 - 3.31 (2H, m), 2.24 - 2.14 (2H, m).

Description 140: 5-chloro-2-(3-(3-fluorophenoxy)pyrrolidin-1-yl)nicotinic acid (D140)

The title compound **(D140)** (228 mg) was prepared according to the experimental procedure described in Description 100 starting from methyl 5-chloro-2-(3-(3-fluorophenoxy)pyrrolidin-1-yl)nicotinate (D95)) (250 mg, 0.712 mmol)

MS: (ES/+) *m/z*: 337 [MH⁺] C₁₆H₁₄ClFN₂O₃ requires 336.06


Description 141: 5-chloro-2-(3-(*m*-tolylloxy)pyrrolidin-1-yl)nicotinic acid (D141)

The title compound (**D141**) (180 mg) was prepared according to the experimental procedure described in Description 100 starting from methyl 5-chloro-2-(3-(m-tolyloxy)pyrrolidin-1-yl)nicotinate (D96) (250 mg, 0.712 mmol)

MS: (ES/+) m/z: 333 [MH⁺] C₁₇H₁₇ClN₂O₃ requires 332.09

5


Description 142: methyl 4-(1-(5-chloro-2-(2-phenylpyrrolidin-1-yl)nicotinamido)cyclopropyl)benzoate (D142)



A solution of 5-chloro-2-(2-phenylpyrrolidin-1-yl)nicotinic acid (D98) (150 mg, 0.5 mmol), methyl 4-(1-aminocyclopropyl)benzoate hydrochloride (D7) (114 mg, 0.5 mmol) and N,N-Diisopropylethylamine (194 mg, 1.5 mmol) in dimethylformamide (10ml) was stirred 1h at room temperature, then benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate (PyBOP) (312 mg, 0.6 mmol) was added. The mixture was stirred at room temperature overnight, then poured into ice-water (20ml) and extracted with ethyl acetate (2x20ml). The organic solution was washed with brine (40ml), dried over Na₂SO₄ and concentrated to obtain a residue which was purified by flash chromatography on silica gel eluting with a mixture petroleum ether/ethyl acetate (4:1). Collected fractions after solvent evaporation afforded the title compound (**D142**) (189 mg) as a yellow solid.

¹H NMR (400MHz, CHLOROFORM-d) δ (ppm): 8.10 (1H, d, *J* = 2.4 Hz) 8.03 - 8.00 (2H, m) 7.74 (1H, d, *J* = 2.4 Hz) 7.67 (1H, s) 7.41 (2H, d, *J* = 8.0 Hz) 7.28 - 7.18 (5H, m) 5.36 - 5.32 (1H, m) 3.91 (3H, s) 3.69 - 3.63 (1H, m) 3.16 - 3.11 (1H, m) 2.43 - 2.37 (1H, m) 1.97 - 1.87 (3H, m) 1.49 - 1.39 (4H, m)


Description 143: methyl 4-(1-(5-chloro-2-(3-phenylpyrrolidin-1-yl)nicotinamido)cyclopropyl)benzoate (D143)



The title compound (**D143**) (210 mg) was prepared according to the experimental procedure described in Description 142 starting from 5-chloro-2-(3-phenylpyrrolidin-1-yl)nicotinic acid (D99) (260 mg, 0.860 mmol) and methyl 4-(1-aminocyclopropyl)benzoate hydrochloride (D7) (195 mg, 0.86 mmol).

¹H NMR (400MHz, CHLOROFORM-d) δ (ppm): 8.20 (1H, d, *J* = 2.4 Hz) 7.90 (1H, d, *J* = 8.0 Hz) 7.65 (1H, d, *J* = 2.4 Hz) 7.40 - 7.20 (7H, m) 6.81 (1H, s) 3.93 (3H, s) 3.70 - 3.37 (5H, m) 2.34 - 2.27 (1H, m) 2.08 - 2.01 (1H, m) 1.45 - 1.37 (4H, m)

10 **Description 144: methyl 4-(1-(2-(2-benzylpyrrolidin-1-yl)-5-chloronicotinamido)cyclopropyl)benzoate (D144)**




A mixture of 2-(2-benzylpyrrolidin-1-yl)-5-chloronicotinic acid (D100) (70 mg, 0.22 mmol), methyl 4-(1-aminocyclopropyl)benzoate (D7) (50.31 mg, 0.22 mmol) and N,N-Diisopropylethylamine (0.115ml, 0.66 mmol) in dimethylformamide (5ml) was stirred at room temperature for 1h. (Benzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate (PyBOP) (137.9 mg, 0.265 mmol) was added and the resulting mixture was stirred overnight at room temperature. The reaction mixture was poured into ice-water and extracted with diethyl ether (3x15ml). The combined organic layers were washed with brine (2x10ml), dried over Na₂SO₄, filtered and concentrated. The crude residue was purified by Biotage column (10g) eluting with a mixture dichloromethane/ethylacetate from 100/0 to 90/10. Collected fractions, after solvent evaporation, afforded the title compound (**D144**) (66 mg)

25 MS: (ES/+) m/z: 490.2 [MH⁺] C₂₈H₂₈ClN₃O₃ requires 489.18

¹H NMR (400MHz ,CHLOROFORM-d) δ (ppm): 8.32 - 8.24 (m, 1 H), 8.03 - 7.96 (m, 2 H), 7.94 - 7.85 (m, 1 H), 7.27 - 7.21 (m, 3 H), 7.20 - 7.07 (m, 3 H), 7.03 - 6.96 (m, 1 H), 4.64 - 4.52 (m, 1 H), 3.95 - 3.90 (m, 3 H), 3.04 - 2.96 (m, 2 H), 2.91 - 2.81 (m, 1 H), 2.12 - 1.99 (m, 1 H), 1.88 - 1.60 (m, 4 H), 1.48 - 1.39 (m, 1 H),
5 1.39 - 1.27 (m, 2 H), 1.04 - 0.94 (m, 1 H)


Description 145: methyl 4-(1-(5-chloro-2-(3-phenoxyazetidin-1-yl)nicotinamido)cyclopropyl)benzoate (D145)



10 The title compound **(D145)** (225 mg) was prepared according to the experimental procedure described in Description 142 starting from 5-chloro-2-(3-phenoxyazetidin-1-yl)nicotinic acid (D101) (140 mg, 0.46 mmol) and methyl 4-(1-aminocyclopropyl)benzoate hydrochloride (D7) (104 mg, 0.40 mmol).

¹H NMR (400MHz ,CHLOROFORM-d) δ (ppm): 8.23 (1H, d, *J* = 2.4 Hz) 7.96 (2H, d, *J* = 8.0 Hz) 7.77 (1H, d, *J* = 2.4 Hz) 7.41 (2H, d, *J* = 8.0 Hz) 7.32 (2H, t, *J* = 7.6 Hz) 7.07 (1H, s) 7.03 (1H, t, *J* = 7.6 Hz) 6.71 (2H, d, *J* = 8.0 Hz) 4.95 - 4.92 (1H, m) 4.35 (2H, dd, *J* = 10.0, 2.4Hz) 4.00 (2H, dd, *J* = 10.0, 4.0Hz) 3.94 (3H, s), 1.43 - 1.41 (4H, m)

20 **Description 146: (S)-methyl 4-(1-(5-chloro-2-(3-(4-fluorophenoxy)azetidin-1-yl)nicotinamido)ethyl)benzoate (D146)**




A mixture of 5-chloro-2-(3-(4-fluorophenoxy)azetidin-1-yl)nicotinic acid (D102) (75 mg, 0.232 mmol) 1-Hydroxybenzotriazole hydrate (31.34 mg, 0.232 mmol) and 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (66.8 mg, 0.35 mmol)
25

in dichloromethane (3ml) was stirred 1h at room temperature. A solution (S)-methyl 4-(1-aminoethyl)benzoate (D3) (50mg, 0.232 mmol) and triethylamine (0.03ml, 0.232 mmol) in dichloromethane (1ml) was added and the resulting mixture was stirred overnight at room temperature. NaHCO₃ sat. sol. (5ml) was added and the mixture was extracted with dichloromethane (3x10ml). Collected organics, after solvent evaporation were purified by SPE-Si (10g) eluting with a mixture Cyclohexane/ethylacetate from 95/05 to 60/40. Collected fractions, after solvent evaporation, afforded the title compound (**D146**) (100 mg).

MS: (ES/+) m/z: 484 [MH⁺] C₂₅H₂₃ClFN₃O₄ requires 483.14

¹H NMR (400MHz, CHLOROFORM-d) δ (ppm): 8.22 (d, *J* = 2.4 Hz, 1 H), 8.04 - 8.00 (m, *J* = 8.3 Hz, 2 H), 7.76 (d, *J* = 2.4 Hz, 1 H), 7.48 - 7.43 (m, *J* = 8.3 Hz, 2 H), 7.03 - 6.95 (m, 2 H), 6.65 - 6.58 (m, 3 H), 5.37 (quin, *J* = 7.2 Hz, 1 H), 4.87 - 4.78 (m, 1 H), 4.29 (ddd, *J* = 6.6, 9.8, 16.4 Hz, 2 H), 4.01 (dd, *J* = 4.2, 9.5 Hz, 1 H), 3.95 (s, 3 H), 3.91 (dd, *J* = 3.9, 9.8 Hz, 1 H), 1.61 (d, *J* = 6.8 Hz, 3 H)

Description 147: (S)-methyl 4-(1-(5-chloro-2-(3-(3-fluorophenoxy)azetidin-1-yl)nicotinamido)ethyl)benzoate (D147)




The title compound (**D147**) (90 mg) was prepared according to the experimental procedure described in Description 146 starting from 5-chloro-2-(3-(3-fluorophenoxy)azetidin-1-yl)nicotinic acid (D103) (75 mg, 0.232 mmol) and (S)-methyl 4-(1-aminoethyl)benzoate (D3) (50 mg, 0.232 mmol).

MS: (ES/+) m/z: 484 [MH⁺] C₂₅H₂₃ClFN₃O₄ requires 483.14

¹H NMR (400MHz, CHLOROFORM-d) δ (ppm): 8.22 (d, *J* = 2.4 Hz, 1 H), 8.05 - 8.00 (m, *J* = 7.8 Hz, 2 H), 7.77 (d, *J* = 2.4 Hz, 1 H), 7.48 - 7.43 (m, *J* = 8.3 Hz, 2 H), 7.28 - 7.15 (m, 1 H), 6.79 - 6.68 (m, 1 H), 6.68 - 6.58 (m, 1 H), 6.50 - 6.34 (m, 2 H), 5.47 - 5.31 (m, 1 H), 4.94 - 4.80 (m, 1 H), 4.45 - 4.24 (m, 2 H), 4.10 - 3.98 (m, 1 H), 3.94 (s, 4 H), 1.61 (d, *J* = 6.8 Hz, 3 H)

Description **148:** **methyl** **4-(1-(5-chloro-2-(3-(4-(trifluoromethyl)phenoxy)azetidin-1-yl)nicotinamido)cyclopropyl)benzoate**
(D148)




- 5 To a mixture of 5-chloro-2-(3-(4-(trifluoromethyl)phenoxy)azetidin-1-yl)nicotinic acid (D104) (200 mg, 0.53 mmol), methyl 4-(1-aminocyclopropyl)benzoate (D7) (144.31 mg, 0.634 mmol) and N,N-diisopropylethylamine (0.291 ml, 1.674 mmol) in dichloromethane (8 ml), ®T3P (1-Propanephosphonic acid cyclic anhydride) (403 mg, 0.633 mmol) was added and the mixture stirred under microwave
 10 irradiation at 110°C for 10 min (2 cycle of 5 min each). 1M NaOH (5ml) was added and the mixture extracted with dichloromethane (3x20ml). Collected organics, after solvent evaporation, afforded a crude material that was purified by SPE-Si cartridge (10g) eluting with a mixture cyclohexane/ ethyl acetate from 100/0 to 60/40. Collected fractions, after solvent evaporation, afforded the title compound
 15 **(D148)** (140 mg)

MS: (ES/+) m/z: 546.2 [MH⁺] C₂₇H₂₃ClF₃N₃O₄ requires 545.13

- ¹H NMR (400MHz ,CHLOROFORM-d) δ (ppm): 8.23 (d, *J* = 2.4 Hz, 1 H), 7.99 (d, *J* = 8.3 Hz, 2 H), 7.75 (d, *J* = 2.4 Hz, 1 H), 7.63 - 7.55 (m, *J* = 8.3 Hz, 2 H), 7.50 - 7.40 (m, *J* = 8.3 Hz, 2 H), 7.05 - 6.95 (m, 1 H), 6.76 (d, *J* = 8.8 Hz, 2 H), 5.04 -
 20 4.89 (m, 1 H), 4.43 - 4.29 (m, 2 H), 4.07 - 3.97 (m, 2 H), 3.94 (s, 3 H), 1.42 (d, *J* = 8.8 Hz, 4 H)


- Description** **149:** **methyl** **4-(1-(5-chloro-2-(3-(3-(trifluoromethyl)phenoxy)azetidin-1-yl)nicotinamido)cyclopropyl)benzoate**
 25 **(D149)**



The title compound (**D149**) (20 mg) was prepared according to the experimental procedure described in Description 148 starting from 5-chloro-2-(3-(3-(trifluoromethyl)phenoxy)azetidin-1-yl)nicotinic acid (D105) (160 mg, 0.423 mmol) and methyl 4-(1-aminocyclopropyl)benzoate (D7) (115.45 mg, 0.507 mmol). The residue obtained from SPE-Si cartridge purification (38 mg) dissolved in a mixture of chloroform/ethanol/n-hexane (70/15/15) (1ml) was separated by chiral HPLC [Phenomenex Lux1 column (250x20mm, 5 μ m particle size). Mobile phase: isocratic premixed mixture of (hexane 75%, ethanol 25%) containing 0.1% of diethylamine. Flow rate=10 ml/min. UV detection: 235 nm]. Collected fractions, after solvent evaporation afforded the title compound (**D149**) (20 mg)

MS: (ES/+) m/z: 546.3 [MH⁺] C₂₇H₂₃ClF₃N₃O₄ requires 545.13

Description 150: methyl 4-(1-(5-chloro-2-(3-(4-fluorophenoxy)azetidin-1-yl)nicotinamido)cyclopropyl)benzoate (D150)




The title compound (**D150**) (75 mg) was prepared according to the experimental procedure described in Description 146 starting from 5-chloro-2-(3-(4-fluorophenoxy)azetidin-1-yl)nicotinic acid (D102) (70 mg, 0.216 mmol) and solution methyl 4-(1-aminocyclopropyl)benzoate (D7) (49.18 mg, 0.216 mmol).

MS: (ES/+) m/z: 496.2 [MH⁺] C₂₆H₂₃ClFN₃O₄ requires 495.14

¹H NMR (400MHz, CHLOROFORM-d) δ (ppm): 8.28 - 8.19 (m, 1 H), 7.98 - 7.91 (m, 2 H), 7.78 - 7.71 (m, 1 H), 7.46 - 7.39 (m, 2 H), 7.07 - 6.94 (m, 3 H), 6.69 - 6.59 (m, 2 H), 4.91 - 4.81 (m, 1 H), 4.36 - 4.27 (m, 2 H), 3.94 (s, 5 H), 1.46 - 1.37 (m, 4 H)

Description 151: methyl 4-(1-(5-chloro-2-(3-(3-fluorophenoxy)azetidin-1-yl)nicotinamido)cyclopropyl)benzoate (D151)



5 methyl 4-(1-(5-chloro-2-(3-(3-fluorophenoxy)azetidin-1-yl)nicotinamido)cyclopropyl)benzoate (D151) was prepared according to two different procedures reported below

Procedure A

The title compound (**D151**) (56 mg) was prepared according to the experimental
10 procedure described in Description 146 starting from 5-chloro-2-(3-(3-fluorophenoxy)azetidin-1-yl)nicotinic acid (D103) (70 mg, 0.216 mmol) and methyl 4-(1-aminocyclopropyl)benzoate (D7) (49.18 mg, 0.216 mmol).

MS: (ES/+) m/z: 496.2 [MH⁺] C₂₆H₂₃ClFN₃O₄ requires 495.14

¹H NMR (400MHz ,CHLOROFORM-d) δ (ppm): 8.23 (d, *J* = 2.4 Hz, 1 H), 8.00 -
15 7.91 (m, *J* = 8.8 Hz, 2 H), 7.76 (d, *J* = 2.4 Hz, 1 H), 7.49 - 7.38 (m, *J* = 8.3 Hz, 2 H), 7.28 - 7.17 (m, 1 H), 7.02 (s, 1 H), 6.81 - 6.65 (m, 1 H), 6.47 (d, *J* = 5.9 Hz, 2 H), 5.01 - 4.80 (m, 1 H), 4.34 (d, *J* = 5.9 Hz, 2 H), 4.04 - 3.96 (m, 2 H), 3.93 (s, 3 H), 1.42 (d, *J* = 7.3 Hz, 4 H)


Procedure B

20 A mixture of 5-chloro-2-(3-(3-fluorophenoxy)azetidin-1-yl)nicotinic acid (D103) (30 g, 0.0929 mol), 1-Hydroxybenzotriazole hydrate (14.2 g, 0.0929 mol) 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (26.7 g, 0.1394 mol) in dimethylformamide (230ml) was stirred 40 min at room temperature. A solution of methyl 4-(1-aminocyclopropyl)benzoate (D7) (21.16 g, 0.0929 mol) and
25 triethylamine (12.94 ml, 0.0929 mol) in dimethylformamide (75 ml) was added and the resulting mixture was stirred 3 hours at room temperature. Water (500 ml) was added and the formed precipitate was filtered off and washed with water. After drying it afforde the title compound (**D151**) (41g)

¹H NMR (400MHz ,DMSO-d₆) δ (ppm): 9.26 (s, 1 H), 8.23 (d, *J* = 2.4 Hz, 1 H), 7.84 (d, *J* = 8.3 Hz, 2 H), 7.79 (d, *J* = 2.4 Hz, 1 H), 7.38 - 7.27 (m, 3 H), 6.88 - 6.77 (m, 1 H), 6.77 - 6.64 (m, 2 H), 5.09 (td, *J* = 3.0, 6.2 Hz, 1 H), 4.35 (dd, *J* = 6.4, 9.8 Hz, 2 H), 3.90 - 3.72 (m, 5 H), 1.33 (d, *J* = 7.8 Hz, 4 H)

5

Description 152: methyl 4-(1-(5-chloro-2-(3-(4-fluoro-3-(trifluoromethyl)phenoxy)azetidin-1-yl)nicotinamido)cyclopropyl)benzoate (D152)




10 The title compound (**D152**) (28 mg) was prepared according to the experimental procedure described in Description 144 starting from 5-chloro-2-(3-(4-fluoro-3-(trifluoromethyl)phenoxy)azetidin-1-yl)nicotinic (D106) (115 mg, 0.295 mmol) and methyl 4-(1-aminocyclopropyl)benzoate (D7) (67.01 mg, 0.295 mmol).

MS: (ES/+) *m/z*: 564.4 [MH⁺] C₂₆H₂₃ClFN₃O₄ requires 563.12

15 ¹H NMR (400MHz ,CHLOROFORM-d) δ (ppm): 8.23 (d, *J* = 2.4 Hz, 1 H), 7.96 (d, *J* = 8.3 Hz, 2 H), 7.75 (d, *J* = 2.4 Hz, 1 H), 7.42 (d, *J* = 8.3 Hz, 2 H), 7.15 (t, *J* = 9.2 Hz, 1 H), 7.04 - 6.91 (m, 2 H), 6.88 - 6.66 (m, 1 H), 5.05 - 4.74 (m, 1 H), 4.36 (dd, *J* = 6.2, 9.9 Hz, 2 H), 3.98 (dd, *J* = 4.0, 9.9 Hz, 2 H), 3.93 (s, 3 H), 1.42 (d, *J* = 10.0 Hz, 4 H)

20

Description 153: methyl 4-(1-(5-chloro-2-(3-(3-(trifluoromethoxy)phenoxy)azetidin-1-yl)nicotinamido)cyclopropyl)benzoate (D153)




The title compound (**D153**) (120 mg) was prepared according to the experimental procedure described in Description 144 starting from 5-chloro-2-(3-(3-(trifluoromethoxy)phenoxy)azetidin-1-yl)nicotinic acid (D107) (110 mg, 0.282 mmol) and methyl 4-(1-aminocyclopropyl)benzoate (D7) (64.43 mg, 0.282 mmol).

5 MS: (ES/+) m/z: 562.4 [MH⁺] C₂₇H₂₃ClF₃N₃O₅ requires 561.13

¹H NMR (400MHz, CHLOROFORM-d) δ (ppm): 8.23 (d, *J* = 2.7 Hz, 1 H), 7.96 (d, *J* = 8.6 Hz, 2 H), 7.76 (d, *J* = 2.4 Hz, 1 H), 7.41 (d, *J* = 8.3 Hz, 2 H), 7.32 (t, *J* = 8.3 Hz, 1 H), 7.02 (s, 1 H), 6.89 (d, *J* = 8.1 Hz, 1 H), 6.64 (s, 1 H), 6.60 (d, *J* = 8.1 Hz, 1 H), 5.04 - 4.83 (m, 1 H), 4.36 (dd, *J* = 6.2, 9.9 Hz, 2 H), 4.00 (dd, *J* = 4.0, 9.9 Hz, 2 H), 3.92 (s, 3 H), 1.50 - 1.31 (m, 4 H)

10

Description 154: methyl 4-(1-(5-chloro-2-(3-(2,4-difluorophenoxy)azetidin-1-yl)nicotinamido)cyclopropyl)benzoate (D154)




15 The title compound (**D154**) (55 mg) was prepared according to the experimental procedure described in Description 144 starting from 5-chloro-2-(3-(2,4-difluorophenoxy)azetidin-1-yl)nicotinic acid (D108) (82 mg, 0.240 mmol) and methyl 4-(1-aminocyclopropyl)benzoate (D7) (54.79 mg, 0.240 mmol).

MS: (ES/+) m/z: 514.13 [MH⁺] C₂₆H₂₂ClF₂N₃O₄ requires 513.13

20 ¹H NMR (400MHz, CHLOROFORM-d) δ (ppm): 8.23 (d, *J* = 2.4 Hz, 1 H), 7.96 (d, *J* = 8.3 Hz, 2 H), 7.75 (d, *J* = 2.4 Hz, 1 H), 7.43 (d, *J* = 8.3 Hz, 2 H), 7.02 (s, 1 H), 6.91 (ddd, *J* = 2.9, 8.3, 11.1 Hz, 1 H), 6.79 (t, *J* = 8.3 Hz, 1 H), 6.58 (dt, *J* = 5.0, 9.1 Hz, 1 H), 5.03 - 4.80 (m, 1 H), 4.31 (dd, *J* = 6.2, 9.9 Hz, 2 H), 4.02 (dd, *J* = 3.8, 9.9 Hz, 2 H), 3.94 (s, 3 H), 1.50 - 1.35 (m, 4 H)

25

Description 155: methyl 4-(1-(5-chloro-2-(3-(3,4-difluorophenoxy)azetidin-1-yl)nicotinamido)cyclopropyl)benzoate (D155)




The title compound (**D155**) (50 mg) was prepared according to the experimental procedure described in Description 144 starting from 5-chloro-2-(3-(3,4-difluorophenoxy)azetidin-1-yl)nicotinic acid (D109) (87 mg, 0.255 mmol) and methyl 4-(1-aminocyclopropyl)benzoate (D7) (58.14 mg, 0.255 mmol).

MS: (ES/+) m/z: 514.13 [MH⁺] C₂₆H₂₂ClF₂N₃O₄ requires 513.13

¹H NMR (400MHz, CHLOROFORM-d) δ (ppm): 8.23 (br. s., 1 H), 7.95 (br. s., 2 H), 7.74 (br. s., 1 H), 7.44 (br. s., 2 H), 7.09 (d, *J* = 8.6 Hz, 1 H), 6.98 (br. s., 1 H), 6.56 (br. s., 1 H), 6.36 (br. s., 1 H), 4.85 (br. s., 1 H), 4.32 (br. s., 2 H), 3.97 (br. s., 5 H), 1.42 (d, *J* = 8.3 Hz, 4 H)

Description 156: methyl 4-(1-(5-chloro-2-(3-(3-(piperazin-1-yl)phenoxy)azetidin-1-yl)nicotinamido)cyclopropyl)benzoate (D156)



A suspension of 2-(3-(3-(4-(tert-butoxycarbonyl)piperazin-1-yl)phenoxy)azetidin-1-yl)-5-chloronicotinic acid (D110) (150 mg, 0.306 mmol), 1-Hydroxybenzotriazole hydrate (47 mg, 0.306 mmol) and 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (88 mg, 0.46 mmol) in dimethylformamide (2ml) was stirred 40 min at room temperature. A solution of methyl 4-(1-aminocyclopropyl)benzoate (D7) (68.9 mg, 0.306 mmol) and triethylamine (0.042ml, 0.306 mmol) in dimethylformamide (2ml) was added and the resulting mixture was stirred 40 min at room temperature. Water (2ml) was added and the resulting precipitate was collected by filtration and purified by Biotage column (10g) eluting with a mixture dichloromethane/ethylacetate from 100 /0 to 80/20. Collected fractions, after

solvent evaporation, afforded tert-butyl 4-(3-((1-(5-chloro-3-((1-(4-(methoxycarbonyl)phenyl)cyclopropyl)carbamoyl)pyridin-2-yl)azetidin-3-yl)oxy)phenyl)piperazine-1-carboxylate (135 mg)

MS: (ES/+) m/z: 662.5 [MH⁺] C₃₅H₄₀ClN₅O₆ requires 661.27


- 5 ¹H NMR (400MHz, DMSO-d₆) δ = 9.25 (s, 1 H), 8.23 (d, J = 2.4 Hz, 1 H), 7.85 (d, J = 8.3 Hz, 2 H), 7.79 (d, J = 2.4 Hz, 1 H), 7.33 (d, J = 8.8 Hz, 2 H), 7.13 (t, J = 8.3 Hz, 1 H), 6.59 (d, J = 7.8 Hz, 1 H), 6.38 (s, 1 H), 6.20 (d, J = 5.9 Hz, 1 H), 5.04 (br. s., 1 H), 4.32 (dd, J = 6.4, 9.8 Hz, 2 H), 3.86 (s, 3 H), 3.80 (dd, J = 3.7, 10.0 Hz, 2 H), 3.43 (d, J = 4.9 Hz, 4 H), 3.14 - 3.04 (m, 4 H), 1.42 (s, 9 H), 1.33 (d, J = 2.9 Hz, 4 H)
- 10 4 H)

- To a cooled solution of tert-butyl 4-(3-((1-(5-chloro-3-((1-(4-(methoxycarbonyl)phenyl)cyclopropyl)carbamoyl)pyridin-2-yl)azetidin-3-yl)oxy)phenyl)piperazine-1-carboxylate (130 mg, 0.196 mmol) in dichloromethane (1ml) a mixture trifluoroacetic acid/dichloromethane (3ml/1ml) was added and the
- 15 resulting mixture stirred for 15 min. Solvents were evaporated in vacuo to afford a residue that was loaded on SPE-SCX (5g) cartridge. Ammonia fractions after solvent evaporation afforded the title compound **(D156)** (105 mg)

MS: (ES/+) m/z: 562.4 [MH⁺] C₃₀H₃₂ClN₅O₄ requires 561.21

- ¹H NMR (400MHz, DMSO-d₆) δ = 9.25 (s, 1 H), 8.23 (d, J = 2.4 Hz, 1 H), 7.89 - 7.81 (m, J = 8.3 Hz, 2 H), 7.79 (d, J = 2.4 Hz, 1 H), 7.39 - 7.29 (m, J = 8.3 Hz, 2 H), 7.11 (t, J = 8.3 Hz, 1 H), 6.56 (d, J = 8.8 Hz, 1 H), 6.33 (s, 1 H), 6.17 (d, J = 8.3 Hz, 1 H), 5.03 (br. s., 1 H), 4.32 (dd, J = 6.4, 9.8 Hz, 2 H), 3.86 (s, 3 H), 3.80 (dd, J = 3.2, 10.0 Hz, 2 H), 3.10 - 2.99 (m, 4 H), 2.88 - 2.78 (m, 4 H), 1.33 (s, 4 H)
- 20 4 H)

- 25 **Description 157 methyl 4-((5-chloro-2-(3-(3-fluorophenoxy)azetidin-1-yl)nicotinamido)methyl)benzoate (D157)**




The title compound **(D157)** (55 mg) was prepared according to the experimental procedure described in Description 144 starting from 5-chloro-2-(3-(3-

fluorophenoxy)azetidin-1-yl)nicotinic acid (D103) (50 mg, 0.154 mmol) and Methyl 4-(aminomethyl)benzoate hydrochloride (31.24 mg, 0.154 mmol, available at Aldrich#328383).

MS: (ES/+) m/z: 470.3 [MH⁺] C₂₄H₂₁ClFN₃O₄ requires 469.12

5 ¹H NMR (400MHz, CHLOROFORM-d) δ (ppm): 8.23 (br. s., 1 H), 8.02 (d, *J* = 7.8 Hz, 2 H), 7.83 (br. s., 1 H), 7.43 (d, *J* = 7.3 Hz, 2 H), 7.32 - 7.16 (m, 7 H), 6.74 (d, *J* = 7.8 Hz, 2 H), 6.53 - 6.35 (m, 2 H), 4.91 (br. s., 1 H), 4.69 (br. s., 2 H), 4.39 (br. s., 2 H), 4.09 - 3.99 (m, 2 H), 3.95 (br. s., 3 H)

10 **Description 158: ethyl 6-((5-chloro-2-(3-(3-fluorophenoxy)azetidin-1-yl)nicotinamido)methyl)nicotinate (D158)**




The title compound (**D158**) (59 mg) was prepared according to the experimental procedure described in Description 144 starting from 5-chloro-2-(3-(3-fluorophenoxy)azetidin-1-yl)nicotinic acid (D103) (50 mg, 0.154 mmol) and ethyl 6-(aminomethyl)nicotinate hydrochloride (33.56 mg, 0.154 mmol, commercially available at Chemimpex#23882).

MS: (ES/+) m/z: 485.3 [MH⁺] C₂₄H₂₂ClFN₄O₄ requires 484.13

20 ¹H NMR (400MHz, CHLOROFORM-d) δ (ppm): 9.18 (d, *J* = 1.7 Hz, 1 H), 8.38 (d, *J* = 8.1 Hz, 1 H), 8.24 (d, *J* = 2.4 Hz, 1 H), 7.88 (d, *J* = 2.4 Hz, 1 H), 7.83 - 7.66 (m, 1 H), 7.49 (d, *J* = 8.1 Hz, 1 H), 7.27 - 7.14 (m, 1 H), 6.70 (d, *J* = 2.2 Hz, 1 H), 6.52 (dd, *J* = 2.2, 8.3 Hz, 1 H), 6.47 (td, *J* = 2.3, 10.6 Hz, 1 H), 5.07 - 4.93 (m, 1 H), 4.85 (d, *J* = 4.6 Hz, 2 H), 4.56 - 4.37 (m, 4 H), 4.13 (dd, *J* = 4.4, 10.3 Hz, 2 H), 1.50 - 1.37 (m, 3 H)

25

Description 159: methyl 6-(1-(5-chloro-2-(3-(3-fluorophenoxy)azetidin-1-yl)nicotinamido)cyclopropyl)nicotinate (D159)




The title compound (**D159**) (22.4 mg) was prepared according to the experimental procedure described in *Description 146* starting from 5-chloro-2-(3-(3-fluorophenoxy)azetidin-1-yl)nicotinic acid (**D103**) (60 mg, 0.186 mmol) and methyl 6-(1-aminocyclopropyl)nicotinate hydrochloride (**D12**) (28.5 mg, 0.186 mmol).

MS: (ES/+) m/z: 497.2 [MH⁺] C₂₅H₂₂ClFN₄O₄ requires 496.13

¹H NMR (400MHz, CHLOROFORM-d) δ (ppm): 9.32 (s, 1 H), 8.94 (d, J = 2.0 Hz, 1 H), 8.26 (d, J = 2.4 Hz, 1 H), 8.13 (dd, J = 2.0, 8.3 Hz, 1 H), 7.89 (d, J = 2.4 Hz, 1 H), 7.57 (d, J = 8.8 Hz, 1 H), 7.34 (d, J = 6.8 Hz, 1 H), 6.83 (s, 1 H), 6.78 - 6.70 (m, 2 H), 5.15 - 5.09 (m, 1 H), 4.41 (dd, J = 6.1, 10.0 Hz, 2 H), 3.92 - 3.85 (m, 5 H), 1.62 - 1.57 (m, 2 H), 1.38 - 1.34 (m, 2 H).

Description 160: methyl 4-(1-(5-chloro-2-(3-(3-fluorobenzoyl)azetidin-1-yl)nicotinamido)cyclopropyl)benzoate (D160)




A solution of tert-butyl 3-(3-fluorobenzoyl)azetidine-1-carboxylate (**D27**) (100 mg, 0.358 mmol) in a 3:1 mixture of trifluoroacetic acid/dichloromethane (0.5ml) was stirred 30 min at room temperature. After solvent evaporation the residue was dissolved in tetrahydrofuran/methanol 3:1 (1ml) then triethylamine (0.15ml, 1.074 mmol) and methyl 4-(1-(2,5-dichloronicotinamido)cyclopropyl)benzoate (**D97**) (130.8 mg, 0.358 mmol) were added and the resulting mixture was heated at 75°C for 5 h, then overnight at 80°C. The reaction mixture was loaded on SPE-SCX cartridge (2g). Collected ammonia fractions afforded, after solvent evaporation, a residue that was washed with a mixture dichloromethane/methanol and filtered off to afford the title compound (**D160**) (40.5 mg)

MS: (ES/+) m/z: 508.4 [MH⁺] C₂₇H₂₃ClFN₃O₄ requires 507.14

¹H NMR (400MHz ,CHLOROFORM-d) δ (ppm):.

Description 161: methyl 4-(1-(5-chloro-2-(3-(3-fluorophenyl)-3-hydroxyazetidin-1-yl)nicotinamido)cyclopropyl)benzoate (D161)



5

The title compound (**D161**) (64.7 mg) was prepared according to the experimental procedure described in Description 146 (reaction time 1h) starting from 5-chloro-2-(3-(3-fluorophenyl)-3-hydroxyazetidin-1-yl)nicotinic acid (**D111**) (63 mg, 0.195 mmol) and methyl 4-(1-aminocyclopropyl)benzoate hydrochloride (**D7**) (44.4 mg, 0.195 mmol).


10

MS: (ES/+) m/z: 496.2 [MH⁺] C₂₆H₂₃ClFN₃O₄ requires 495.14

¹H NMR (400MHz ,CHLOROFORM-d) δ (ppm): 8.25 (d, J = 2.4 Hz, 1 H), 7.95 (d, J = 8.3 Hz, 2 H), 7.80 (d, J = 2.4 Hz, 1 H), 7.43 - 7.35 (m, 3 H), 7.27 - 7.18 (m, 2 H), 7.16 (s, 1 H), 7.06 (dt, J = 2.4, 8.3 Hz, 1 H), 4.25 - 4.20 (m, 2 H), 4.15 (d, J = 8.8 Hz, 2 H), 3.92 (s, 3 H), 1.43 - 1.33 (m, 4 H).

15

Description 162: methyl 4-(1-(5-chloro-2-(3-(4-fluorophenyl)-3-hydroxyazetidin-1-yl)nicotinamido)cyclopropyl)benzoate (D162)



20

The title compound (**D162**) (76.7 mg) was prepared according to the experimental procedure described in Description 146 (reaction time 1h) starting from 5-chloro-2-(3-(4-fluorophenyl)-3-hydroxyazetidin-1-yl)nicotinic acid (**D112**) (64 mg, 0.198 mmol) and methyl 4-(1-aminocyclopropyl)benzoate hydrochloride (**D7**) (45 mg, 0.198 mmol).


25

MS: (ES/+) m/z: 496.2 [MH⁺] C₂₆H₂₃ClFN₃O₄ requires 495.14

¹H NMR (400MHz ,CHLOROFORM-d) δ (ppm): = 8.25 (d, *J* = 2.4 Hz, 1 H), 7.99 - 7.94 (m, *J* = 8.3 Hz, 2 H), 7.79 (d, *J* = 2.4 Hz, 1 H), 7.44 (dd, *J* = 5.1, 8.6 Hz, 2 H), 7.41 - 7.36 (m, *J* = 8.3 Hz, 2 H), 7.15 (s, 1 H), 7.11 (t, *J* = 8.8 Hz, 2 H), 4.24 (d, *J* = 9.3 Hz, 2 H), 4.15 (d, *J* = 9.3 Hz, 2 H), 3.92 (s, 2 H), 1.44 - 1.33 (m, 4 H).

5

Description 163: methyl 4-(1-(5-chloro-2-(3-((4-fluorophenoxy)methyl)azetidin-1-yl)nicotinamido)cyclopropyl)benzoate (D163)




10 A mixture of 5-chloro-2-(3-((4-fluorophenoxy)methyl)azetidin-1-yl)nicotinic acid (D113) (55.4 mg, 0.161 mmol), O-(6-Chlorobenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HCTU) (66.8 mg, 0.161 mmol) and N,N-disopropylethylamine (0.072ml, 0.403 mmol) was stirred 30 min at room temperature. Methyl 4-(1-aminocyclopropyl)benzoate hydrochloride (D7) (37.8 mg, 15 0.161 mmol) was added and the reaction mixture stirred overnight at room temperature. NH₄Cl saturated solution (20ml) was added and the mixture was extracted with ethylacetate (3x10ml). The residue obtained after solvent evaporation was purified by SPE-Si cartridge (10g) eluting dichloromethane. Collected fractions, after solvent evaporation, afforded the title compound (**D163**) 20 (52.6 mg).

MS: (ES/+) m/z: 510.4 [MH⁺] C₂₇H₂₅ClFN₃O₄ requires 509.97

¹H NMR (400MHz ,CHLOROFORM-d) δ = 8.23 (d, *J* = 2.4 Hz, 1 H), 8.00 - 7.96 (m, 2 H), 7.78 (d, *J* = 2.4 Hz, 1 H), 7.42 - 7.37 (m, 2 H), 7.07 (s, 1 H), 7.03 - 6.97 (m, 2 H), 6.87 - 6.81 (m, 2 H), 4.14 - 4.04 (m, 4 H), 3.92 (s, 3 H), 3.82 (dd, *J* = 5.4, 8.8 25 Hz, 2 H), 3.07 - 3.01 (m, 1 H), 1.42 (s, 4 H).

Description 164: methyl 4-(1-(5-chloro-2-(3-(3-fluorophenyl)-3-hydroxyazetidin-1-yl)nicotinamido)cyclopropyl)benzoate (D164)




The title compound (**D164**) (62 mg) was prepared according to the experimental procedure described in Description 163 starting from 5-chloro-2-((3-((3-fluorophenoxy)methyl)azetidin-1-yl)nicotinic acid (D114) (65 mg, 0.193 mmol) and methyl 4-(1-aminocyclopropyl)benzoate hydrochloride (D7) (44 mg, 0.193 mmol).

MS: (ES/+) m/z: 510.4 [MH⁺] C₂₇H₂₅ClFN₃O₄ requires 509.97

¹H NMR (400MHz, CHLOROFORM-d) δ (ppm): 8.23 (d, *J* = 2.4 Hz, 1 H), 8.01 - 7.95 (m, 2 H), 7.78 (d, *J* = 2.9 Hz, 1 H), 7.42 - 7.38 (m, 2 H), 7.27 - 7.22 (m, 1 H), 7.07 (s, 1 H), 6.74 - 6.66 (m, 2 H), 6.62 (td, *J* = 2.4, 10.8 Hz, 1 H), 4.14 - 4.06 (m, 4 H), 3.92 (s, 3 H), 3.82 (dd, *J* = 5.4, 8.8 Hz, 2 H), 3.09 - 3.00 (m, 1 H), 1.42 (s, 4 H)

Description 165: methyl 4-(1-(5-chloro-2-(3-((3-(trifluoromethyl)phenyl)amino)azetidin-1-yl)nicotinamido)cyclopropyl)benzoate (D165)




The title compound (**D165**) (17 mg) was prepared according to the experimental procedure described in Description 144 starting from 5-chloro-2-((3-((3-(trifluoromethyl)phenyl)amino)azetidin-1-yl)nicotinic acid (D115) (50 mg, 0.135 mmol) and methyl 4-(1-aminocyclopropyl)benzoate (D7) (30.62 mg, 0.135 mmol).

MS: (ES/+) m/z: 545.3 [MH⁺] C₂₇H₂₄ClF₃N₄O₃ requires 544.15

¹H NMR (400MHz, DMSO-d₆) δ (ppm): 9.25 (s, 1 H), 8.22 (d, *J* = 2.4 Hz, 1 H), 7.85 (d, *J* = 8.6 Hz, 2 H), 7.77 (d, *J* = 2.4 Hz, 1 H), 7.39 - 7.25 (m, 3 H), 6.90 (d, *J* = 7.3 Hz, 1 H), 6.81 (br. s., 1 H), 6.77 - 6.67 (m, 2 H), 4.27 (d, *J* = 6.1 Hz, 3 H), 3.84 (s, 3 H), 3.69 (d, *J* = 5.6 Hz, 2 H), 1.45 - 1.24 (m, 4 H)

Description 166: methyl 4-(1-(5-chloro-2-(3-((3-fluorophenyl)amino)azetidin-1-yl)nicotinamido)cyclopropyl)benzoate (D166)




The title compound (**D166**) (17 mg) was prepared according to the experimental procedure described in Description 144 starting from 5-chloro-2-(3-((3-fluorophenyl)amino)azetidin-1-yl)nicotinic acid (D116) (40 mg, 0.124 mmol) and methyl 4-(1-aminocyclopropyl)benzoate (D7) (28.3 mg, 0.124 mmol).

MS: (ES/+) m/z: 495.2 [MH⁺] C₂₆H₂₄ClFN₄O₃ requires 494.15

¹H NMR (400MHz, CHLOROFORM-d) δ (ppm): 8.18 (d, *J* = 2.2 Hz, 1 H), 7.97 (d, *J* = 8.3 Hz, 2 H), 7.73 (d, *J* = 2.4 Hz, 1 H), 7.43 (d, *J* = 8.3 Hz, 2 H), 7.21 - 7.08 (m, 1 H), 6.62 - 6.36 (m, 1 H), 6.33 - 6.10 (m, 2 H), 4.48 - 4.27 (m, 2 H), 3.92 (s, 3 H), 3.86 - 3.73 (m, 2 H), 1.41 (d, *J* = 7.8 Hz, 4 H), 1.28 (s, 1 H).

Description 167: methyl 4-(1-(5-chloro-2-(3-((4-fluorophenyl)amino)azetidin-1-yl)nicotinamido)cyclopropyl)benzoate (D167)




The title compound (**D167**) (43 mg) was prepared according to the experimental procedure described in Description 146 starting from 5-chloro-2-(3-((4-fluorophenyl)amino)azetidin-1-yl)nicotinic acid (D117) (70 mg, 0.217 mmol) and methyl 4-(1-aminocyclopropyl)benzoate (D7) (50 mg, 0.217 mmol).

MS: (ES/+) m/z: 495.3 [MH⁺] C₂₆H₂₄ClFN₄O₃ requires 494.15

¹H NMR (400MHz, DMSO-d₆) δ (ppm): 9.25 (s, 1 H), 8.21 (d, *J* = 2.4 Hz, 1 H), 7.91 - 7.82 (m, 2 H), 7.75 (d, *J* = 2.4 Hz, 1 H), 7.39 - 7.27 (m, 2 H), 6.94 (t, *J* = 9.0 Hz, 2 H), 6.45 (dd, *J* = 4.4, 8.8 Hz, 2 H), 6.23 (d, *J* = 5.9 Hz, 1 H), 4.27 - 4.08 (m, 3 H), 3.88 - 3.77 (m, 3 H), 3.65 (dd, *J* = 4.2, 8.6 Hz, 2 H), 1.41 - 1.28 (m, 3 H)

Description 168: methyl 4-(1-(5-chloro-2-(3-((4-fluoro-2-methylphenyl)amino)azetidin-1-yl)nicotinamido)cyclopropyl)benzoate (D168)




5 To a solution of N-(4-fluoro-2-methylphenyl)azetidin-3-amine (D55) and triethylamine (0.14ml, 1.04 mmol) in tetrahydrofuran/methanol (3ml/1ml) methyl 4-(1-(2,5-dichloronicotinamido)cyclopropyl)benzoate (D97) (253 mg, 0.693 mmol) was added and the resulting mixture was heated 24 h at 75°C. The residue obtained after solvent evaporation, was purified by Biotage SNAP-Si (10g) 10 cartridge eluting with eluting with a mixture dichloromethane/ethylacetate from 95/5 to 80/20. Collected fractions, after solvent evaporation afforded the title compound (**D168**) (105 mg).

MS: (ES/+) m/z: 509.3 [MH⁺] C₂₇H₂₆ClFN₄O₃ requires 508.17

¹H NMR (400MHz, DMSO-d₆) δ = 9.23 (s, 1 H), 8.21 (d, J = 2.4 Hz, 1 H), 7.93 - 7.82 (m, J = 8.3 Hz, 2 H), 7.74 (d, J = 2.4 Hz, 1 H), 7.41 - 7.24 (m, J = 8.3 Hz, 2 H), 6.89 (dd, J = 2.9, 9.8 Hz, 1 H), 6.85 - 6.68 (m, 1 H), 6.22 (dd, J = 4.9, 8.8 Hz, 1 H), 5.34 (d, J = 5.9 Hz, 1 H), 4.31 - 4.12 (m, 3 H), 3.86 (s, 3 H), 3.76 (dd, J = 4.2, 8.6 Hz, 2 H), 2.13 (s, 3 H), 1.34 (d, J = 8.3 Hz, 4 H)

20 **Description 169: methyl 4-(1-(5-chloro-2-(3-((2,4-difluorophenyl)amino)azetidin-1-yl)nicotinamido)cyclopropyl)benzoate (D169)**




A mixture of 5-chloro-2-(3-((2,4-difluorophenyl)amino)azetidin-1-yl)nicotinic acid 25 (D118) (40 mg, 0.118 mmol), 1-Hydroxybenzotriazole hydrate (18 mg, 0.118

mmol) and 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (34 mg, 0.177 mmol) in dimethylformamide (5ml) was stirred 10 min at room temperature. A solution of methyl 4-(1-aminocyclopropyl)benzoate hydrochloride (D7) (32.2 mg, 0.141 mmol) and triethylamine (0.02ml, 0.141 mmol) in dry dimethylformamide
 5 (2ml) was added and the mixture was stirred 24h at room temperature. After solvent evaporation, water (10ml) was added and the formed precipitate was filtered off and purified by Biotage SNAP-Si (10g) cartridge eluting with a mixture dichloromethane/methanol from 100/0 to 80/20. Collected fractions, after solvent evaporation afforded the title compound (**D169**) (105 mg).

10 MS: (ES/+) m/z: 513.2 [MH⁺] C₂₆H₂₃ClF₂N₄O₃ requires 512.14

¹H NMR (400MHz, DMSO-d₆) δ = 9.23 (s, 1 H), 8.21 (d, J = 2.4 Hz, 1 H), 7.91 - 7.80 (m, J = 8.3 Hz, 2 H), 7.74 (d, J = 2.4 Hz, 1 H), 7.40 - 7.29 (m, J = 8.3 Hz, 2 H), 7.18 - 7.06 (m, 1 H), 6.85 (t, J = 8.6 Hz, 1 H), 6.48 (d, J = 5.4 Hz, 1 H), 6.03 (br. s., 1 H), 4.22 (d, J = 3.9 Hz, 3 H), 3.86 (s, 3 H), 3.76 (d, J = 4.9 Hz, 2 H), 1.34
 15 (d, J = 9.3 Hz, 4 H)

Description 170: methyl 4-(1-(5-chloro-2-(3-((2-methyl-4-(trifluoromethyl)phenyl)amino)azetidin-1-yl)nicotinamido)cyclopropyl)benzoate (D170)



20


The title compound (**D170**) (43 mg) was prepared according to the experimental procedure described in Description 169 starting from 5-chloro-2-(3-((2-methyl-4-(trifluoromethyl)phenyl)amino)azetidin-1-yl)nicotinic acid (D119) (40 mg, 0.103 mmol) and methyl 4-(1-aminocyclopropyl)benzoate (D7) (23.6 mg, 0.103 mmol).

25 MS: (ES/+) m/z: 559.3 [MH⁺] C₂₈H₂₆ClF₃N₄O₃ requires 558.16

¹H NMR (400MHz, DMSO-d₆) δ (ppm): = 9.26 (s, 1 H), 8.22 (d, J = 2.4 Hz, 1 H), 7.90 (d, J = 8.8 Hz, 2 H), 7.76 (d, J = 2.4 Hz, 1 H), 7.40 - 7.25 (m, 4 H), 6.38 (d, J

= 8.3 Hz, 1 H), 6.05 (d, $J = 4.4$ Hz, 1 H), 4.37 - 4.17 (m, 3 H), 3.85 (s, 5 H), 2.18 (s, 3 H), 1.34 (d, $J = 9.8$ Hz, 4 H)

Description 171: methyl 4-(1-(5-chloro-2-(3-((4-fluoro-2-methylphenyl)(methyl)amino)azetidin-1-yl)nicotinamido)cyclopropyl)benzoate (D171)




The title compound (**D171**) (58 mg) was prepared according to the experimental procedure described in Description 169 (reaction time 2h) starting from 5-chloro-2-(3-((4-fluoro-2-methylphenyl)(methyl)amino)azetidin-1-yl)nicotinic acid (**D120**) (55 mg, 0.157 mmol) and methyl 4-(1-aminocyclopropyl)benzoate (**D7**) (35.8 mg, 0.157 mmol).

MS: (ES/+) m/z : 523.3 [MH^+] $C_{28}H_{28}ClFN_4O_3$ requires 522.18

^1H NMR (400MHz, DMSO- d_6) δ (ppm): 9.20 (s, 1 H), 8.18 (d, $J = 2.4$ Hz, 1 H), 7.82 (d, $J = 8.8$ Hz, 2 H), 7.71 (d, $J = 2.4$ Hz, 1 H), 7.30 (d, $J = 8.3$ Hz, 2 H), 7.04 (d, $J = 9.3$ Hz, 1 H), 6.91 (d, $J = 6.8$ Hz, 2 H), 4.09 - 4.03 (m, 1 H), 4.02 - 3.94 (m, 2 H), 3.86 (s, 3 H), 3.52 (dd, $J = 4.4, 8.8$ Hz, 2 H), 2.43 (s, 3 H), 2.26 (s, 3 H), 1.28 (s, 4 H)

Description 172: methyl 4-(1-(2-(3-(3-fluorophenoxy)azetidin-1-yl)-5-(trifluoromethyl)nicotinamido)cyclopropyl)benzoate (D172)




The title compound (**D172**) (60 mg) was prepared according to the experimental procedure described in Description 146 starting from 2-(3-(3-

fluorophenoxy)azetidin-1-yl)-5-(trifluoromethyl)nicotinic acid (D121) (50 mg, 0.14 mmol) and methyl 4-(1-aminocyclopropyl)benzoate (D7) (31.95 mg, 0.14 mmol).

MS: (ES/+) m/z: 530.2 [MH⁺] C₂₇H₂₃F₄N₃O₄ requires 529.16

¹H NMR (400MHz, CHLOROFORM-d) δ (ppm): 8.48 (s, 1 H), 8.04 (s, 2 H), 8.01 - 7.93 (m, *J* = 8.3 Hz, 2 H), 7.81 (d, *J* = 2.0 Hz, 1 H), 7.49 - 7.40 (m, *J* = 8.3 Hz, 2 H), 6.79 (s, 1 H), 6.78 - 6.71 (m, 1 H), 6.46 (d, *J* = 7.8 Hz, 2 H), 5.00 - 4.87 (m, 1 H), 4.43 (br. s., 2 H), 4.08 (d, *J* = 3.9 Hz, 2 H), 3.93 (s, 3 H), 1.43 (d, *J* = 3.4 Hz, 3 H)

Description 173: methyl 4-(1-(2-(3-(4-fluorophenoxy)azetidin-1-yl)-5-(trifluoromethyl)nicotinamido)cyclopropyl)benzoate (D173)




The title compound (**D173**) (80 mg) was prepared according to the experimental procedure described in Description 146 starting from 2-(3-(4-fluorophenoxy)azetidin-1-yl)-5-(trifluoromethyl)nicotinic acid (D122) (90 mg, 0.252 mmol) and methyl 4-(1-aminocyclopropyl)benzoate (D7) (57.51 mg, 0.252 mmol).

MS: (ES/+) m/z: 530.2 [MH⁺] C₂₇H₂₃F₄N₃O₄ requires 529.16

¹H NMR (400MHz, CHLOROFORM-d) δ (ppm): 8.50 - 8.46 (m, 1 H), 7.99 - 7.93 (m, *J* = 8.3 Hz, 2 H), 7.80 (d, *J* = 2.4 Hz, 1 H), 7.47 - 7.41 (m, *J* = 8.3 Hz, 2 H), 7.00 (t, *J* = 8.6 Hz, 2 H), 6.72 (s, 1 H), 6.67 - 6.60 (m, 2 H), 4.88 (s, 1 H), 4.40 (dd, *J* = 5.9, 10.3 Hz, 2 H), 4.04 (dd, *J* = 3.9, 10.3 Hz, 2 H), 3.95 (s, 3 H), 1.43 (d, *J* = 2.9 Hz, 4 H)

Description 174: methyl 4-(1-(2-(3-(4-chlorophenoxy)azetidin-1-yl)-5-(trifluoromethyl)nicotinamido)cyclopropyl)benzoate (D174)




The title compound (**D174**) (25 mg) was prepared according to the experimental procedure described in Description 144 starting from 2-(3-(4-chlorophenoxy)azetidin-1-yl)-5-(trifluoromethyl)nicotinic acid (D123) (125 mg, 0.335 mmol) and methyl 4-(1-aminocyclopropyl)benzoate (D7) (76.35 mg, 0.335 mmol).

MS: (ES/+) m/z: 546.3 [MH⁺] C₂₇H₂₃ClF₃N₃O₄ requires 545.13

¹H NMR (400MHz, CHLOROFORM-d) δ (ppm): 8.47 (s, 1 H), 7.99 (d, *J* = 8.3 Hz, 2 H), 7.80 (s, 1 H), 7.45 (d, *J* = 8.3 Hz, 2 H), 7.26 (m, 2 H), 6.73 (br. s., 1 H), 6.61 (d, *J* = 8.8 Hz, 2 H), 5.00 - 4.78 (m, 1 H), 4.42 (dd, *J* = 6.4, 10.0 Hz, 2 H), 4.06 (dd, *J* = 3.3, 10.1 Hz, 2 H), 3.96 (s, 3 H), 1.43 (d, *J* = 4.9 Hz, 4 H)

Description 175: methyl 4-(1-(2-(3-(3-chlorophenoxy)azetidin-1-yl)-5-(trifluoromethyl)nicotinamido)cyclopropyl)benzoate (D175)




The title compound (**D175**) (14 mg) was prepared according to the experimental procedure described in Description 144 starting from 2-(3-(3-chlorophenoxy)azetidin-1-yl)-5-(trifluoromethyl)nicotinic acid (D124) (85 mg, 0.228 mmol) and methyl 4-(1-aminocyclopropyl)benzoate (D7) (51.92 mg, 0.228 mmol).

MS: (ES/+) m/z: 546.3 [MH⁺] C₂₇H₂₃ClF₃N₃O₄ requires 545.14

¹H NMR (400MHz, CHLOROFORM-d) δ (ppm): 8.48 (s, 1 H), 7.97 (d, *J* = 8.3 Hz, 2 H), 7.82 (d, *J* = 2.2 Hz, 1 H), 7.43 (d, *J* = 8.3 Hz, 2 H), 7.27 - 7.17 (m, 1 H), 7.02 (d, *J* = 6.1 Hz, 1 H), 6.74 (t, *J* = 2.2 Hz, 2 H), 6.57 (dd, *J* = 2.6, 8.2 Hz, 1 H), 4.93 (br. s., 1 H), 4.62 - 4.31 (m, 2 H), 4.08 (d, *J* = 7.6 Hz, 2 H), 3.93 (s, 3 H), 1.44 (d, *J* = 4.9 Hz, 4 H)

Description 176: methyl 4-(1-(2-(3-(4-fluoro-3-(trifluoromethyl)phenoxy)azetidin-1-yl)-5-(trifluoromethyl)nicotinamido)cyclopropyl)benzoate (D176)



5

The title compound (**D176**) (52 mg) was prepared according to the experimental procedure described in Description 144 starting from 2-(3-(4-fluoro-3-(trifluoromethyl)phenoxy)azetidin-1-yl)-5-(trifluoromethyl)nicotinic acid (D125) (108 mg, 0.254 mmol) and methyl 4-(1-aminocyclopropyl)benzoate (D7) (57.95 mg, 0.254 mmol).


10

MS: (ES/+) m/z: 598.4 [MH⁺] C₂₈H₂₂F₇N₃O₄ requires 597.15

¹H NMR (400MHz, CHLOROFORM-d) δ (ppm): 8.48 (s, 1 H), 7.97 (d, *J* = 8.6 Hz, 2 H), 7.81 (d, *J* = 2.2 Hz, 1 H), 7.44 (d, *J* = 8.3 Hz, 2 H), 7.16 (t, *J* = 9.4 Hz, 1 H), 6.97 (dd, *J* = 3.2, 5.6 Hz, 1 H), 6.79 (d, *J* = 9.0 Hz, 1 H), 6.72 (s, 1 H), 4.93 (s, 1 H), 4.46 (dd, *J* = 6.4, 10.5 Hz, 2 H), 4.07 (dd, *J* = 3.5, 10.4 Hz, 2 H), 3.93 (s, 3 H), 1.44 (d, *J* = 6.4 Hz, 4 H)

15

Description 177: methyl 4-(1-(2-(3-(3-(trifluoromethoxy)phenoxy)azetidin-1-yl)-5-(trifluoromethyl)nicotinamido)cyclopropyl)benzoate (D177)



20


The title compound (**D177**) (113 mg) was prepared according to the experimental procedure described in Description 144 starting from 2-(3-(3-(trifluoromethoxy)phenoxy)azetidin-1-yl)-5-(trifluoromethyl)nicotinic acid (D126) (110 mg, 0.26 mmol) and methyl 4-(1-aminocyclopropyl)benzoate (D7) (59.31 mg, 0.26 mmol).

25

MS: (ES/+) m/z: 596.4 [MH⁺] C₂₈H₂₃F₆N₃O₅ requires 595.15

¹H NMR (400MHz, CHLOROFORM-d) δ (ppm): 8.48 (s, 1 H), 7.97 (d, *J* = 8.3 Hz, 2 H), 7.82 (d, *J* = 2.2 Hz, 1 H), 7.43 (d, *J* = 8.3 Hz, 2 H), 7.33 (t, *J* = 8.4 Hz, 1 H), 6.90 (d, *J* = 8.1 Hz, 1 H), 6.74 (s, 1 H), 6.67 - 6.62 (m, 1 H), 6.61 - 6.54 (m, 1 H), 5.05 - 4.85 (m, 1 H), 4.46 (dd, *J* = 6.5, 10.4 Hz, 2 H), 4.08 (dd, *J* = 3.9, 10.3 Hz, 2 H), 3.96 - 3.86 (m, 3 H), 1.48 - 1.36 (m, 4 H)

Description 178: methyl 4-(1-(2-(3-(2,4-difluorophenoxy)azetidin-1-yl)-5-(trifluoromethyl)nicotinamido)cyclopropyl)benzoate (D178)




The title compound (**D178**) (106 mg) was prepared according to the experimental procedure described in Description 144 starting from 2-(3-(2,4-difluorophenoxy)azetidin-1-yl)-5-(trifluoromethyl)nicotinic acid (D127) (95 mg, 0.253 mmol) and methyl 4-(1-aminocyclopropyl)benzoate (D7) (57.79 mg, 0.253 mmol).

MS: (ES/+) m/z: 548.4 [MH⁺] C₂₈H₂₃F₆N₃O₅ requires 547.14

¹H NMR (400MHz, CHLOROFORM-d) δ (ppm): 8.48 (s, 1 H), 7.98 (s, 2 H), 7.81 (d, *J* = 2.2 Hz, 1 H), 7.45 (d, *J* = 8.3 Hz, 2 H), 6.92 (ddd, *J* = 2.9, 8.4, 11.2 Hz, 1 H), 6.86 - 6.76 (m, 1 H), 6.75 (s, 1 H), 6.59 (dt, *J* = 5.0, 9.1 Hz, 1 H), 5.00 - 4.75 (m, 1 H), 4.41 (dd, *J* = 6.4, 10.3 Hz, 2 H), 4.11 (dd, *J* = 3.8, 10.4 Hz, 2 H), 3.94 (s, 3 H), 1.43 (s, 4 H)

Description 179: methyl 4-(1-(2-(3-(3,4-difluorophenoxy)azetidin-1-yl)-5-(trifluoromethyl)nicotinamido)cyclopropyl)benzoate (D179)




The title compound (**D179**) (80 mg) was prepared according to the experimental procedure described in Description 144 starting from 2-(3-(3,4-difluorophenoxy)azetidin-1-yl)-5-(trifluoromethyl)nicotinic acid (D128) (100 mg, 0.267 mmol) and methyl 4-(1-aminocyclopropyl)benzoate (D7) (60.83 mg, 0.267 mmol).

MS: (ES/+) m/z: 548.4 [MH⁺] C₂₈H₂₃F₆N₃O₅ requires 547.15

¹H NMR (400MHz, CHLOROFORM-d) δ (ppm): 8.48 (s, 1 H), 7.98 (s, 2 H), 7.81 (d, *J* = 2.2 Hz, 1 H), 7.45 (d, *J* = 8.3 Hz, 2 H), 6.92 (ddd, *J* = 2.9, 8.4, 11.2 Hz, 1 H), 6.86 - 6.76 (m, 1 H), 6.75 (s, 1 H), 6.59 (dt, *J* = 5.0, 9.1 Hz, 1 H), 5.00 - 4.75 (m, 1 H), 4.41 (dd, *J* = 6.4, 10.3 Hz, 2 H), 4.11 (dd, *J* = 3.8, 10.4 Hz, 2 H), 3.94 (s, 3 H), 1.43 (s, 4 H)

Description 180: methyl 4-(1-(2-(3-((5-methylisoxazol-3-yl)oxy)azetidin-1-yl)-5-(trifluoromethyl)nicotinamido)cyclopropyl)benzoate (D180)




The title compound (**D180**) (20 mg) was prepared according to the experimental procedure described in Description 144 starting from 2-(3-((5-methylisoxazol-3-yl)oxy)azetidin-1-yl)-5-(trifluoromethyl)nicotinic acid (D129) (19 mg, 0.055 mmol) and methyl 4-(1-aminocyclopropyl)benzoate hydrochloride (D7) (12.6 mg, 0.055 mmol).

MS: (ES/+) m/z: 517.4 [MH⁺] C₂₅H₂₃F₃N₄O₅ requires 516.16

¹H NMR (400MHz, CHLOROFORM-d) δ (ppm): 8.46 (s, 1 H), 8.00 (d, *J* = 8.3 Hz, 2 H), 7.83 (d, *J* = 2.2 Hz, 1 H), 7.43 (d, *J* = 8.6 Hz, 2 H), 6.83 (br. s., 1 H), 5.65 (d, *J* = 1.0 Hz, 1 H), 5.21 (t, *J* = 3.8 Hz, 1 H), 4.44 (dd, *J* = 6.1, 10.5 Hz, 2 H), 4.13 (dd, *J* = 3.3, 10.9 Hz, 2 H), 3.93 (s, 3 H), 2.38 (d, *J* = 0.7 Hz, 3 H), 1.44 (s, 4 H)

Description 181: methyl 4-(1-(5-(trifluoromethyl)-2-(3-((6-(trifluoromethyl)pyridin-2-yl)oxy)azetidin-1-yl)nicotinamido)cyclopropyl)benzoate (D181)




The title compound (**D181**) (75 mg) was prepared according to the experimental procedure described in Description 144 starting from 5-(trifluoromethyl)-2-(3-((6-(trifluoromethyl)pyridin-2-yl)oxy)azetidin-1-yl)nicotinic acid (D130) (77 mg, 0.189 mmol) and methyl 4-(1-aminocyclopropyl)benzoate hydrochloride (D7) (43.04 mg, 0.189 mmol).

MS: (ES/+) m/z: 581.04 [MH⁺] C₂₇H₂₂F₆N₄O₄ requires 580.15

¹H NMR (400MHz, CHLOROFORM-d) δ (ppm): 8.48 (d, *J* = 1.5 Hz, 1 H), 8.02 - 7.93 (m, 2 H), 7.85 (d, *J* = 2.0 Hz, 1 H), 7.79 (t, *J* = 7.9 Hz, 1 H), 7.39 (d, *J* = 8.8 Hz, 2 H), 7.36 - 7.31 (m, 1 H), 6.99 (d, *J* = 8.3 Hz, 1 H), 6.77 (s, 1 H), 5.54 - 5.34 (m, 1 H), 4.52 (dd, *J* = 7.1, 10.5 Hz, 2 H), 4.21 - 4.06 (m, 2 H), 3.92 (s, 3 H), 1.44 (d, *J* = 2.7 Hz, 4 H)

Description 182: methyl 4-(1-(2-(3-((5-fluoropyrimidin-2-yl)oxy)azetidin-1-yl)-5-(trifluoromethyl)nicotinamido)cyclopropyl)benzoate (D182)




The title compound (**D182**) (36 mg) was prepared according to the experimental procedure described in Description (D169) starting from 2-(3-((5-fluoropyrimidin-2-yl)oxy)azetidin-1-yl)-5-(trifluoromethyl)nicotinic acid (D131) (42 mg, 0.117 mmol) and methyl 4-(1-aminocyclopropyl)benzoate hydrochloride (D7) (27 mg, 0.117 mmol).

MS: (ES/+) m/z: 532.04 [MH⁺] C₂₅H₂₁F₄N₅O₄ requires 531.15

¹H NMR (400MHz, CHLOROFORM-d) δ (ppm): 9.34 (s, 1 H), 8.70 (s, 2 H), 8.52 (s, 1 H), 7.94 (d, *J* = 2.0 Hz, 1 H), 7.85 - 7.80 (m, *J* = 8.8 Hz, 2 H), 7.39 - 7.33 (m,

$J = 8.3$ Hz, 2 H), 5.39 - 5.27 (m, 1 H), 4.40 (dd, $J = 6.4, 10.8$ Hz, 2 H), 3.96 (dd, $J = 3.4, 10.3$ Hz, 2 H), 3.86 (s, 3 H), 1.34 (d, $J = 12.7$ Hz, 4 H)

Description 183: methyl 4-(1-(2-(3-((3-fluorophenyl)amino)azetidin-1-yl)-5-(trifluoromethyl)nicotinamido)cyclopropyl)benzoate (D183)




To a solution of 3-Fluoroaniline (0.032ml, 0.34 mmol) in acetonitrile (0.5ml), potassium carbonate (61 mg, 0.044 mmol) was added followed by the addition of methyl 2-(3-((methylsulfonyl)oxy)azetidin-1-yl)-5-(trifluoromethyl)nicotinate (D68) (120 mg, 0.374 mmol). The reaction mixture was stirred under microwave irradiation for 50 min at 200°C (2 cycles of 25 min each). Lithium hydroxide monohydrate (14.26 mg, 0.34 mmol) and a mixture 1,4-dioxane/water (3/1ml) was added and the mixture was stirred under microwave irradiation for 5 min at 150°C. The mixture was evaporated in vacuo, diluted with water (5ml)/1M HCl (15ml) and extracted with ethylacetate (3x20ml). After solvent evaporation, the residue was dissolved in dimethylformamide (2.5ml) then (Benzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate (PyBOP) (307.55mg, 0.59 mmol) and N,N-Disopropylethylamine (0.27ml, 1.57mmol) were added and the mixture stirred at room temperature for 1h. Methyl 4-(1-aminocyclopropyl)benzoate hydrochloride (D7) (89.7 mg, 0.394 mmol) was added and the resulting mixture was stirred at room temperature overnight then poured into ice-water and extracted with diethylether (3x20ml). The combined organic layers were washed with brine, dried over Na₂SO₄, filtered and concentrated. The crude residue obtained after solvent evaporation was loaded on SNAP-Si cartridge (10g) and eluted with a mixture cyclohexane/dichloromethane from 30/70 to 0/100 then dichloromethane/ethylacetate from 100/0 to 80/20. Collected fractions, after solvent evaporation afforded the title compound (**D183**) (16 mg)

MS: (ES/+) m/z: 529.4 [MH⁺] C₂₇H₂₄F₄N₄O₃ requires 528.18

¹H NMR (400MHz ,CHLOROFORM-d) δ (ppm): 8.45 (s, 1 H), 7.97 (d, *J* = 8.8 Hz, 2 H), 7.77 (d, *J* = 2.0 Hz, 1 H), 7.41 (d, *J* = 8.3 Hz, 2 H), 7.20 - 7.11 (m, 1 H), 6.82 (s, 1 H), 6.49 (dt, *J* = 2.2, 8.4 Hz, 1 H), 6.23 (dd, *J* = 1.7, 8.1 Hz, 1 H), 6.20 - 6.08 (m, 1 H), 4.38 (dd, *J* = 7.6, 9.0 Hz, 2 H), 4.28 - 4.18 (m, 1 H), 3.94 - 3.89 (m, 3 H), 3.82 (dd, *J* = 4.6, 9.5 Hz, 2 H), 1.41 (d, *J* = 3.9 Hz, 4 H)

Description 184: methyl 4-(1-(2-(3-((4-fluorophenyl)amino)azetidin-1-yl)-5-(trifluoromethyl)nicotinamido)cyclopropyl)benzoate (D184)




The title compound (**D184**) (35 mg) was prepared according to the experimental procedure described in Description 183 starting from methyl 2-(3-((methylsulfonyl)oxy)azetidin-1-yl)-5-(trifluoromethyl)nicotinate (D68) (120 mg, 0.374 mmol) and 4-Fluoroaniline (0.032 ml, 0.34 mmol)

MS: (ES/+) *m/z*: 529.4 [MH⁺] C₂₇H₂₄F₄N₄O₃ requires 528.18

¹H NMR (400MHz ,CHLOROFORM-d) δ (ppm): 8.43 (s, 1 H), 8.01 - 7.93 (m, 2 H), 7.78 (d, *J* = 2.2 Hz, 1 H), 7.44 (d, *J* = 8.3 Hz, 2 H), 6.95 (t, *J* = 8.7 Hz, 2 H), 6.50 (br. s., 2 H), 4.43 - 4.31 (m, 2 H), 4.26 - 4.16 (m, 1 H), 3.97 - 3.87 (m, 5 H), 1.38 (br. s., 4 H)

Description 185: ethyl 4-(1-(2-(3-((4-fluoro-2-methylphenyl)amino)azetidin-1-yl)-5-(trifluoromethyl)nicotinamido)cyclopropyl)benzoate (D185)




The title compound (**D185**) (20 mg) was prepared according to the experimental procedure described in Description 183 starting from methyl 2-(3-

((methylsulfonyl)oxy)azetidin-1-yl)-5-(trifluoromethyl)nicotinate (D68) (120 mg, 0.374 mmol) and 4-Fluoro-2-methylaniline (0.037 ml, 0.34 mmol)

MS: (ES/+) m/z: 543.5 [MH⁺] C₂₈H₂₆F₄N₄O₃ requires 542.19

¹H NMR (400MHz, CHLOROFORM-d) δ (ppm): 8.45 (s, 1 H), 7.97 (d, *J* = 8.6 Hz, 2 H), 7.77 (d, *J* = 2.2 Hz, 1 H), 7.45 (d, *J* = 8.3 Hz, 2 H), 6.91 - 6.85 (m, 1 H), 6.84 - 6.79 (m, 1 H), 6.27 - 6.09 (m, 1 H), 4.47 - 4.37 (m, 2 H), 4.26 - 4.19 (m, 1 H), 3.99 - 3.86 (m, 5 H), 2.18 (s, 3 H), 1.46 (br. s., 4 H)

Description 186: methyl 4-(1-(2-(3-((2,4-difluorophenyl)amino)azetidin-1-yl)-5-(trifluoromethyl)nicotinamido)cyclopropyl)benzoate (D186)




The title compound (**D186**) (9 mg) was prepared according to the experimental procedure described in Description 183 starting from methyl 2-(3-((methylsulfonyl)oxy)azetidin-1-yl)-5-(trifluoromethyl)nicotinate (D68) (120 mg, 0.374 mmol) and 2,4-Difluoroaniline (0.032 ml, 0.34 mmol)

MS: (ES/+) m/z: 547.4 [MH⁺] C₂₇H₂₃F₅N₄O₃ requires 546.17

¹H NMR (400MHz, CHLOROFORM-d) δ (ppm): 8.46 (s, 1 H), 7.98 (s, 2 H), 7.77 (d, *J* = 2.0 Hz, 1 H), 7.44 (d, *J* = 8.3 Hz, 2 H), 6.84 (ddd, *J* = 2.7, 8.4, 11.4 Hz, 1 H), 6.80 - 6.72 (m, 2 H), 6.27 (dt, *J* = 5.4, 9.0 Hz, 1 H), 4.38 (dd, *J* = 7.3, 9.3 Hz, 2 H), 4.22 (t, *J* = 5.6 Hz, 1 H), 3.92 (s, 3 H), 3.84 (dd, *J* = 4.6, 9.5 Hz, 2 H), 1.42 (d, *J* = 3.4 Hz, 4 H)

Description 187: methyl 4-(1-(5-fluoro-2-(3-(3-fluorophenoxy)azetidin-1-yl)nicotinamido)cyclopropyl)benzoate (D187)




The title compound (**D187**) (45 mg) was prepared according to the experimental procedure described in Description 144 starting from 5-fluoro-2-(3-(3-fluorophenoxy)azetidin-1-yl)nicotinic acid (D132) (50 mg, 0.228 mmol) and methyl 4-(1-aminocyclopropyl)benzoate (D7) (52.04 mg, 0.228 mmol).

5 MS: (ES/+) m/z: 480.3 [MH⁺] C₂₆H₂₃F₂N₃O₄ requires 479.17

¹H NMR (400MHz, CHLOROFORM-d) δ (ppm): 8.19 (d, *J* = 2.7 Hz, 1 H), 7.96 (d, *J* = 8.3 Hz, 2 H), 7.72 (dd, *J* = 2.9, 8.1 Hz, 1 H), 7.52 (s, 1 H), 7.42 (d, *J* = 8.3 Hz, 2 H), 7.27 - 7.19 (m, 1 H), 6.81 - 6.66 (m, 1 H), 6.53 - 6.40 (m, 2 H), 4.96 - 4.81 (m, 1 H), 4.31 (dd, *J* = 6.2, 9.7 Hz, 2 H), 3.98 (dd, *J* = 4.2, 9.8 Hz, 2 H), 3.93 (s, 3 H),
10 1.42 (d, *J* = 7.3 Hz, 4 H)

Description 188: methyl 4-(1-(2-(3-(3-chlorophenoxy)azetidin-1-yl)-5-fluoronicotinamido)cyclopropyl)benzoate (D188)




15 The title compound (**D188**) (12 mg) was prepared according to the experimental procedure described in Description 169 starting from 2-(3-(3-chlorophenoxy)azetidin-1-yl)-5-fluoronicotinic acid (D133) (14 mg, 0.043 mmol) and methyl 4-(1-aminocyclopropyl)benzoate hydrochloride (D7) (9.85 mg, 0.043 mmol).

20 MS: (ES/+) m/z: 496.2 [MH⁺] C₂₆H₂₃ClFN₃O₄ requires 495.14

¹H NMR (400MHz, CHLOROFORM-d) δ (ppm): 9.23 (s, 1 H), 8.24 (d, *J* = 2.9 Hz, 1 H), 7.84 (d, *J* = 8.3 Hz, 2 H), 7.72 (dd, *J* = 2.9, 8.3 Hz, 1 H), 7.37 - 7.27 (m, 3 H), 7.05 (d, *J* = 7.3 Hz, 1 H), 6.91 (t, *J* = 2.2 Hz, 1 H), 6.81 (dd, *J* = 2.4, 8.3 Hz, 1 H), 5.10 (br. s., 1 H), 4.32 (dd, *J* = 6.4, 9.8 Hz, 2 H), 3.85 (s, 3 H), 3.79 (dd, *J* = 3.4, 9.8 Hz, 2 H), 1.34 (d, *J* = 2.0 Hz, 4 H)
25

Description 189: methyl 4-(1-(5-fluoro-2-(3-(3-(trifluoromethoxy)phenoxy)azetidin-1-yl)nicotinamido)cyclopropyl)benzoate (D189)




The title compound (**D189**) (39 mg) was prepared according to the experimental procedure described in Description 169 starting from 5-fluoro-2-(3-(3-(trifluoromethoxy)phenoxy)azetidin-1-yl)nicotinic acid (D134) (27 mg, 0.072 mmol) and methyl 4-(1-aminocyclopropyl)benzoate hydrochloride (D7) (16.5 mg, 0.072 mmol).

MS: (ES/+) m/z: 546.2 [MH⁺] C₂₇H₂₃F₄N₃O₅ requires 545.16

¹H NMR (400MHz, CHLOROFORM-d) δ (ppm): 9.23 (s, 1 H), 8.24 (d, *J* = 2.9 Hz, 1 H), 7.88 - 7.81 (m, *J* = 8.3 Hz, 2 H), 7.73 (dd, *J* = 2.9, 8.8 Hz, 1 H), 7.43 (t, *J* = 8.1 Hz, 1 H), 7.37 - 7.29 (m, *J* = 8.3 Hz, 2 H), 6.99 (d, *J* = 8.8 Hz, 1 H), 6.90 - 6.83 (m, 2 H), 5.23 - 5.03 (m, 1 H), 4.33 (dd, *J* = 6.1, 9.5 Hz, 2 H), 3.85 (s, 3 H), 3.80 (dd, *J* = 3.4, 9.8 Hz, 2 H), 1.33 (s, 4 H)

Description 190: methyl 4-(1-(5-fluoro-2-(3-((4-fluoro-2-methylphenyl)amino)azetidin-1-yl)nicotinamido)cyclopropyl)benzoate (**D190**)




The title compound (**D190**) (26 mg) was prepared according to the experimental procedure described in Description 169 starting from 5-fluoro-2-(3-((4-fluoro-2-methylphenyl)amino)azetidin-1-yl)nicotinic acid (D135) (70 mg, 0.219 mmol) and methyl 4-(1-aminocyclopropyl)benzoate hydrochloride (D7) (50 mg, 0.219 mmol).

MS: (ES/+) m/z: 493.3 [MH⁺] C₂₇H₂₆F₂N₄O₃ requires 492.2

¹H NMR (400MHz, CHLOROFORM-d) δ (ppm): 9.20 (s, 1 H), 8.21 (d, *J* = 2.9 Hz, 1 H), 7.90 - 7.82 (m, *J* = 8.3 Hz, 2 H), 7.67 (dd, *J* = 2.9, 8.8 Hz, 1 H), 7.38 - 7.30 (m, *J* = 8.3 Hz, 2 H), 6.89 (dd, *J* = 2.9, 9.8 Hz, 1 H), 6.86 - 6.73 (m, 1 H), 6.22 (dd, *J* =


4.9, 8.8 Hz, 1 H), 5.31 (d, $J = 5.4$ Hz, 1 H), 4.27 - 4.12 (m, 3 H), 3.86 (s, 3 H), 3.78 - 3.67 (m, 2 H), 2.13 (s, 3 H), 1.34 (d, $J = 3.9$ Hz, 4 H)

Description **191:** **methyl** **4-((1S)-1-(5-chloro-2-(3-(4-**
(trifluoromethyl)phenoxy)pyrrolidin-1-yl)nicotinamido)ethyl)benzoate (D191)



The title compound (**D191**) (50 mg) was prepared according to the experimental procedure described in Description 148 starting from lithium 5-chloro-2-(3-(4-(trifluoromethyl)phenoxy)pyrrolidin-1-yl)nicotinate (D136) (130 mg, 0.331 mmol) and (S)-methyl 4-(1-aminoethyl)benzoate (D3) (71.19 mg, 0.331 mmol)
 MS: (ES/+) m/z : 548.3 [MH^+] $C_{27}H_{25}ClF_3N_3O_4$ requires 547.15


Description **192:** **methyl** **4-((1S)-1-(5-chloro-2-(3-(3-**
(trifluoromethyl)phenoxy)pyrrolidin-1-yl)nicotinamido)ethyl)benzoate (D192)



The title compound (**D192**) (64 mg) was prepared according to the experimental procedure described in Description 146 starting from 5-chloro-2-(3-(3-(trifluoromethyl)phenoxy)pyrrolidin-1-yl)nicotinic acid (D137) (120 mg, 0.305 mmol) and (S)-methyl 4-(1-aminoethyl)benzoate (D3) (65.7 mg, 0.305 mmol)
 MS: (ES/+) m/z : 548.2 [MH^+] $C_{27}H_{25}ClF_3N_3O_4$ requires 547.15


^1H NMR (400MHz, CHLOROFORM- d) δ (ppm): 8.20 (d, $J = 2.9$ Hz, 1 H), 8.03 (d, $J = 8.3$ Hz, 2 H), 7.71 (s, 1 H), 7.49 (s, 3 H), 7.27 - 7.22 (m, 1 H), 7.10 - 7.05 (m, 1 H), 7.03 - 6.96 (m, 1 H), 6.79 - 6.71 (m, 1 H), 5.42 - 5.29 (m, 1 H), 4.97 - 4.91 (m, 1 H), 3.92 (d, $J = 5.9$ Hz, 3 H), 3.84 - 3.77 (m, 1 H), 3.76 - 3.49 (m, 2 H), 3.47 - 3.38 (m, 1 H), 2.26 - 2.08 (m, 2 H), 1.61 (dd, $J = 7.1, 19.3$ Hz, 3 H)

Description 193: methyl 4-((1S)-1-(5-chloro-2-(3-(4-fluorophenoxy)pyrrolidin-1-yl)nicotinamido)ethyl)benzoate (D193)



The title compound (**D193**) (64 mg) was prepared according to the experimental procedure described in Description 146 starting from 5-chloro-2-(3-(4-fluorophenoxy)pyrrolidin-1-yl)nicotinic acid (D138) (110 mg, 0.320 mmol), and (S)-methyl 4-(1-aminoethyl)benzoate (D3) (68.82 mg, 0.320 mmol) MS: (ES/+) m/z: 499.2 [MH⁺] C₂₆H₂₅ClFN₃O₄ requires 497.15


Description 194: methyl 4-(1-(5-chloro-2-(3-phenoxy)pyrrolidin-1-yl)nicotinamido)cyclopropyl)benzoate (D194)



The title compound (**D194**) (100 mg) was prepared according to the experimental procedure described in Description 144 starting from 5-chloro-2-(3-phenoxy)pyrrolidin-1-yl)nicotinic acid (D139) (127 mg, 0.40 mmol), and methyl 4-(1-aminocyclopropyl)benzoate hydrochloride (D7) (91 mg, 0.40 mmol) (column eluting system: dichloromethane/methanol from 100/1 to 50/1)

¹H NMR (400MHz, CHLOROFORM-d) δ (ppm): 8.17 (1H, d, *J* = 2.0 Hz), 7.96 (2H, d, *J* = 8.4 Hz), 7.70 (1H, d, *J* = 2.0 Hz), 7.39 (2H, d, *J* = 8.4 Hz), 7.30 - 7.28 (2H, m), 7.20 - 7.18 (1H, m), 6.97 (1H, t, *J* = 7.2 Hz), 6.81 (2H, d, *J* = 8.0 Hz), 4.90 (1H, s), 3.89 (3H, s), 3.72 (1H, dd, *J* = 12.0, 4.4 Hz), 3.60 (1H, dd, *J* = 17.2, 9.6 Hz), 3.43 - 3.37 (2H, m), 2.18 - 2.12 (2H, m), 1.45 - 1.34 (4H, m).


Description 195: methyl 4-(1-(5-chloro-2-(3-(3-(trifluoromethyl)phenoxy)pyrrolidin-1-yl)nicotinamido)cyclopropyl)benzoate (D195)



The title compound (**D195**) (150 mg) was prepared according to the experimental procedure described in Description 146 starting from 5-chloro-2-(3-(3-(trifluoromethyl)phenoxy)pyrrolidin-1-yl)nicotinic acid (D137) (120 mg, 0.305 mmol) and methyl 4-(1-aminocyclopropyl)benzoate (D7) (65.57 mg, 0.305 mmol).

MS: (ES/+) m/z: 560.2 [MH⁺] C₂₈H₂₅ClF₃N₃O₄ requires 559.15


Description 196: methyl 4-(1-(5-chloro-2-(3-(4-fluorophenoxy)pyrrolidin-1-yl)nicotinamido)cyclopropyl)benzoate (D196)



The title compound (**D196**) (50 mg) was prepared according to the experimental procedure described in Description 146 starting from 5-chloro-2-(3-(4-fluorophenoxy)pyrrolidin-1-yl)nicotinic acid (D138) (110 mg, 0.320 mmol) and methyl 4-(1-aminocyclopropyl)benzoate (D7) (72.86 mg, 0.320 mmol).

MS: (ES/+) m/z: 510.2 [MH⁺] C₂₇H₂₅ClFN₃O₄ requires 509.15

Description 197: methyl 4-(1-(5-chloro-2-(3-(3-fluorophenoxy)pyrrolidin-1-yl)nicotinamido)cyclopropyl)benzoate (D197)




The title compound (**D197**) (180 mg) was prepared according to the experimental procedure described in Description 146 starting from 5-chloro-2-(3-(3-fluorophenoxy)pyrrolidin-1-yl)nicotinic acid (D140) (225 mg, 0.656 mmol) and methyl 4-(1-aminocyclopropyl)benzoate (D7) (149.36 mg, 0.656 mmol).

MS: (ES/+) m/z: 510.2 [MH⁺] C₂₇H₂₅ClFN₃O₄ requires 509.15

¹H NMR (400MHz, CHLOROFORM-d) δ (ppm): 8.20 (d, J = 2.4 Hz, 1 H), 8.03 - 7.95 (m, J = 8.3 Hz, 2 H), 7.72 (d, J = 2.4 Hz, 1 H), 7.48 - 7.41 (m, J = 8.3 Hz, 2 H), 7.24 (d, J = 6.8 Hz, 1 H), 7.17 (s, 1 H), 6.73 - 6.65 (m, 1 H), 6.63 - 6.51 (m, 2 H), 4.95 - 4.81 (m, 1 H), 3.91 (s, 3 H), 3.78 - 3.70 (m, 1 H), 3.65 - 3.54 (m, 1 H),
 5 3.41 (d, J = 12.2 Hz, 2 H), 2.18 (br. s., 2 H), 1.49 - 1.37 (m, 4 H)


Description 198: methyl 4-(1-(5-chloro-2-(3-(m-tolyloxy)pyrrolidin-1-yl)nicotinamido)cyclopropyl)benzoate (D198)



10 The title compound (**D198**) (12 mg) was prepared according to the experimental procedure described in Description 146 starting from 5-chloro-2-(3-(m-tolyloxy)pyrrolidin-1-yl)nicotinic acid (D141) (160 mg, 0.472 mmol) and methyl 4-(1-aminocyclopropyl)benzoate (D7) (107.46 mg, 0.472 mmol). The residue (50 mg) obtained from SPE-Si cartridge purification (50 mg) dissolved in a mixture of
 15 chloroform/ethanol (1/1) (1ml) was separated by chiral HPLC [Phenomenex Lux1 column (250x20mm, 5 μ m particle size). Mobile phase: isocratic premixed mixture of (hexane 80%, ethanol 20%) containing 0.1% of diethylamine. Flow rate=10 ml/min. UV detection: 245 nm]. Collected fractions, after solvent evaporation, afforded the title compound (**D198**) (12 mg)

20 MS: (ES/+) m/z : 506.3 [MH^+] C₂₈H₂₈ClN₃O₄ requires 505.18


Description 199: methyl 4-(1-(5-chloro-2-(3-(4-(trifluoromethyl)phenoxy)pyrrolidin-1-yl)nicotinamido)cyclopropyl)benzoate (D199)



The title compound (**D199**) (24 mg) was prepared according to the experimental procedure described in Description 148 starting from lithium 5-chloro-2-(3-(4-(trifluoromethyl)phenoxy)pyrrolidin-1-yl)nicotinate (D136) (130 mg, 0.331 mmol) and methyl 4-(1-aminocyclopropyl)benzoate (D7) (75.36 mg, 0.331 mmol).

5 MS: (ES/+) m/z: 560.3 [MH⁺] C₂₈H₂₅ClF₃N₃O₄ requires 559.15

Description 200: methyl 4-(1-(5-chloro-2-(3-((3-fluorophenoxy)methyl)pyrrolidin-1-yl)nicotinamido)cyclopropyl)benzoate (D200)




10 The title compound (**D200**) (38 mg) was prepared according to the experimental procedure described in Description 160 starting from tert-butyl 3-((3-fluorophenoxy)methyl)pyrrolidine-1-carboxylate (D40) (100 mg, 0.338 mmol) and reacting in the second step with methyl 4-(1-(2,5-dichloronicotinamido)cyclopropyl)benzoate (D97) (61.8 mg, 0.169 mmol).

15 MS: (ES/+) m/z: 524.4 [MH⁺] C₂₈H₂₇ClF₃N₃O₄ requires 523.17


¹H NMR (400MHz, CHLOROFORM-d) δ (ppm): 8.18 (d, J = 2.4 Hz, 1 H), 8.01 - 7.97 (m, J = 8.3 Hz, 2 H), 7.65 (d, J = 2.4 Hz, 1 H), 7.46 - 7.42 (m, J = 8.3 Hz, 2 H), 7.25 - 7.20 (m, 1 H), 6.74 - 6.64 (m, 2 H), 6.59 (td, J = 2.4, 10.9 Hz, 1 H), 3.96 - 3.91 (m, 1 H), 3.90 (s, 3 H), 3.88 - 3.81 (m, 1 H), 3.53 (dd, J = 7.3, 10.8 Hz, 1 H), 3.45 (t, J = 6.8 Hz, 2 H), 3.31 (dd, J = 7.3, 10.8 Hz, 1 H), 2.75 - 2.65 (m, 1 H), 2.12 (dd, J = 6.4, 12.2 Hz, 1 H), 1.80 (dd, J = 7.8, 12.2 Hz, 1 H), 1.45 - 1.38 (m, 4 H).

Description 201: (R)-methyl 4-(1-(5-chloro-2-(2-((3-fluorophenoxy)methyl)pyrrolidin-1-yl)nicotinamido)cyclopropyl)benzoate (D201)




The title compound (**D201**) (80 mg) was prepared according to the experimental procedure described in Description 160 starting from (R)-tert-butyl 2-((3-fluorophenoxy)methyl)pyrrolidine-1-carboxylate (D42) (100 mg, 0.338 mmol) and
 5 reacting in the second step with methyl 4-(1-(2,5-dichloronicotinamido)cyclopropyl)benzoate (D97) (61.8 mg, 0.169 mmol).
 MS: (ES/+) m/z: 524.4 [MH⁺] C₂₈H₂₇ClFN₃O₄ requires 523.17

Description 202: (S)-methyl 4-(1-(5-chloro-2-(2-((3-fluorophenoxy)methyl)pyrrolidin-1-yl)nicotinamido)cyclopropyl)benzoate (D202)



The title compound (**D202**) (89 mg) was prepared according to the experimental procedure described in Description 160 starting from (S)-tert-butyl 2-((3-fluorophenoxy)methyl)pyrrolidine-1-carboxylate (D44) (100 mg, 0.338 mmol) and
 15 reacting in the second step with methyl 4-(1-(2,5-dichloronicotinamido)cyclopropyl)benzoate (D97) (61.8 mg, 0.169 mmol).
 MS: (ES/+) m/z: 524.4 [MH⁺] C₂₈H₂₇ClFN₃O₄ requires 523.17


Description 203: methyl 4-(1-(5-chloro-2-(3-((3-fluorophenoxy)methyl)piperidin-1-yl)nicotinamido)cyclopropyl)benzoate (D203)



The title compound (**D203**) (97 mg) was prepared according to the experimental procedure described in Description 160 starting from tert-butyl 3-((3-fluorophenoxy)methyl)piperidine-1-carboxylate (D45) (100 mg, 0.323 mmol) and
 5 reacting in the second step with methyl 4-(1-(2,5-dichloronicotinamido)cyclopropyl)benzoate (D97) (59 mg, 0.161 mmol).

MS: (ES/+) m/z: 538.4 [MH⁺] C₂₉H₂₉ClFN₃O₄ requires 537.18

Description 204: (S)-methyl 4-(1-(5-chloro-2-(3-(3-fluorophenoxy)pyrrolidin-1-yl)nicotinamido)cyclopropyl)benzoate (D204)
 10




The title compound (**D204**) (101 mg) was prepared according to the experimental procedure described in Description 160 starting from (S)-tert-butyl 3-(3-fluorophenoxy)pyrrolidine-1-carboxylate (D46) (100 mg, 0.355 mmol) and reacting
 15 in the second step with methyl 4-(1-(2,5-dichloronicotinamido)cyclopropyl)benzoate (D) (0021/056/3) (65 mg, 0.177 mmol).

MS: (ES/+) m/z: 510.4 [MH⁺] C₂₇H₂₅ClFN₃O₄ requires 509.9

¹H NMR (400MHz, CHLOROFORM-d) δ (ppm): 8.24 - 8.17 (m, 1 H), 8.01 - 7.94 (m, 2 H), 7.75 - 7.68 (m, 1 H), 7.47 - 7.41 (m, 2 H), 7.27 - 7.21 (m, 2 H), 6.75 -
 20 6.66 (m, 1 H), 6.64 - 6.52 (m, 2 H), 4.91 - 4.82 (m, 1 H), 3.91 (s, 3 H), 3.79 - 3.69 (m, 1 H), 3.66 - 3.55 (m, 1 H), 3.50 - 3.35 (m, 2 H), 2.23 - 2.13 (m, 2 H), 1.45 - 1.35 (m, J = 7.3, 7.3 Hz, 4 H)

Description 205: (R)-methyl 4-(1-(5-chloro-2-(3-(3-fluorophenoxy)pyrrolidin-1-yl)nicotinamido)cyclopropyl)benzoate (D205)



The title compound (**D205**) (96 mg) was prepared according to the experimental procedure described in Description 160 starting from (R)-tert-butyl 3-(3-fluorophenoxy)pyrrolidine-1-carboxylate (D47) (100 mg, 0.355 mmol) and reacting in the second step with methyl 4-(1-(2,5-dichloronicotinamido)cyclopropyl)benzoate (D97) (0021/056/3) (65 mg, 0.177 mmol).

MS: (ES/+) m/z: 510.4 [MH⁺] C₂₇H₂₅ClFN₃O₄ requires 509.9

¹H NMR (400MHz, CHLOROFORM-d) δ (ppm): 8.20 (d, J = 2.4 Hz, 1 H), 8.00 - 7.94 (m, J = 8.3 Hz, 2 H), 7.72 (d, J = 2.4 Hz, 1 H), 7.45 - 7.39 (m, J = 8.8 Hz, 2 H), 7.27 - 7.20 (m, 2 H), 6.74 - 6.65 (m, 1 H), 6.63 - 6.53 (m, 2 H), 4.91 - 4.86 (m, 1 H), 3.91 (s, 3 H), 3.78 - 3.70 (m, 0 H), 3.64 - 3.54 (m, 0 H), 3.43 (s, 2 H), 2.40 - 2.23 (m, 2 H), 1.40 - 1.34 (m, 4 H)

EXAMPLES


In the following Examples the relative stereochemistry is derived from the stereochemistry of the previous intermediates from which the compounds were synthesised.

Examples 1, 2 and 3:

4-(1-(5-chloro-2-(2-phenylpyrrolidin-1-yl)nicotinamido)cyclopropyl)benzoic acid (racemic mixture) (E1)

4-(1-(5-chloro-2-(2-phenylpyrrolidin-1-yl)nicotinamido)cyclopropyl)benzoic acid (enantiomer 1) (E2)

4-(1-(5-chloro-2-(2-phenylpyrrolidin-1-yl)nicotinamido)cyclopropyl)benzoic acid (enantiomer 2) (E3)



To an ice cooled solution of methyl 4-(1-(5-chloro-2-(2-phenylpyrrolidin-1-yl)nicotinamido)cyclopropyl)benzoate (D142) (189 mg, 0.40 mmol) in a mixture methanol /tetrahydrofuran (10ml/10ml), 2N NaOH (10ml) was added. The reaction mixture was heated to 40°C for 2 hours then cooled to 0°C, acidified with 2.5N HCl (pH=1-2) and stirred at 0°C for 10 min. The formed solid was collected by filtration and dried to provide title compound **(E1)** (112 mg).

MS: (ES/+) m/z: 462 [MH⁺] C₂₆H₂₄ClN₃O₃ requires 461.15

¹H NMR (400MHz, DMSO-d₆) δ (ppm): 9.35 (1H, s), 7.99 (1H, d, *J* = 2.8 Hz), 7.90 (2H, d, *J* = 8.8 Hz), 7.40 (2H, d, *J* = 8.0 Hz), 7.30 (1H, d, *J* = 2.8 Hz), 7.24 - 7.13 (5H, m), 5.35 (1H, t, *J* = 7.2 Hz), 3.61 - 3.56 (1H, m), 3.14 - 3.11 (1H, m), 2.36 - 2.34 (1H, m), 1.83 - 1.65 (3H, m), 1.36 - 1.32 (4H, m)

(E1) (14 mg) dissolved in ethanol (1.5ml) was separated by chiral HPLC [Daicel Chiralpack IC column (2x25 cm, 5μm particle size). Mobile phase: isocratic premixed mixture of hexane 80%, ethanol 20% containing 0.2% of trifluoroacetic acid. Flow rate=10 ml/min. UV detection: 270 nm]. Collected fractions after solvent evaporation of the separated peaks, gave the title compounds **(E2)** (8 mg) and **(E3)** (8 mg) as single enantiomers.

(E2): (single enantiomer 1)

MS: (ES/+) m/z: 462 [MH⁺] C₂₆H₂₄ClN₃O₃ requires 461.15

¹H NMR (400MHz, DMSO-d₆) δ (ppm): 9.31 (s, 1 H), 7.98 (d, *J* = 2.4 Hz, 1 H), 7.93 - 7.85 (m, *J* = 8.3 Hz, 2 H), 7.71 (d, *J* = 2.4 Hz, 1 H), 7.45 - 7.35 (m, *J* = 8.3 Hz, 2 H), 7.27 - 7.16 (m, 4 H), 7.14 (d, *J* = 6.4 Hz, 1 H), 5.35 (t, *J* = 7.1 Hz, 1 H), 3.57 (d, *J* = 9.8 Hz, 1 H), 3.23 - 3.05 (m, 1 H), 2.40 - 2.29 (m, 1 H), 1.90 - 1.75 (m, 2 H), 1.66 (dd, *J* = 7.6, 12.0 Hz, 1 H), 1.44 - 1.29 (m, 4 H).

(E3): (single enantiomer 2)

MS: (ES/+) m/z: 462 [MH⁺] C₂₆H₂₄ClN₃O₃ requires 461.15

¹H NMR (400MHz, DMSO-d₆) δ (ppm): 9.31 (s, 1 H), 7.98 (d, *J* = 2.4 Hz, 1 H), 7.93 - 7.84 (m, *J* = 8.3 Hz, 2 H), 7.71 (d, *J* = 2.4 Hz, 1 H), 7.46 - 7.36 (m, *J* = 8.3


Hz, 2 H), 7.26 - 7.16 (m, 4 H), 7.16 - 7.09 (m, 1 H), 5.35 (t, $J = 7.1$ Hz, 1 H), 3.60 - 3.54 (m, 1 H), 3.13 (d, $J = 4.4$ Hz, 1 H), 2.37 - 2.30 (m, 1 H), 1.90 - 1.75 (m, 2 H), 1.66 (dd, $J = 7.3, 11.7$ Hz, 1 H), 1.35 (d, $J = 7.3$ Hz, 4 H)

5 **Examples 4, 5 and 6:**

4-(1-(5-chloro-2-(3-phenylpyrrolidin-1-yl)nicotinamido)cyclopropyl)benzoic acid (E4)

4-(1-(5-chloro-2-(3-phenylpyrrolidin-1-yl)nicotinamido)cyclopropyl)benzoic acid (E5) (enantiomer 1)

10 **4-(1-(5-chloro-2-(3-phenylpyrrolidin-1-yl)nicotinamido)cyclopropyl)benzoic acid (E6) (enantiomer 2)**



The title compound (**E4**) (53 mg) was prepared according to the experimental procedure described in Example 1 starting from methyl 4-(1-(5-chloro-2-(3-phenylpyrrolidin-1-yl)nicotinamido)cyclopropyl)benzoate (D143) (210 mg, 0.440 mmol)

MS: (ES/+) m/z: 462 [MH⁺] C₂₆H₂₄ClN₃O₃ requires 461.15

¹H NMR (400MHz, DMSO-d₆) δ (ppm): 9.31 (1H, s), 8.20 (1H, d, $J = 2.4$ Hz), 7.79 (1H, d, $J = 8.0$ Hz), 7.72 (1H, d, $J = 2.4$ Hz), 7.34 - 7.22 (7H, m), 3.63 - 2.51 (5H, m), 2.29 - 2.25 (1H, m), 2.01 - 1.96 (1H, m), 1.36 - 1.24 (4H, m)

(**E4**) (25mg) dissolved in ethanol/chloroform (7.5ml/0.5ml) was separated by chiral HPLC [Daicel Chiralpack AD-H column (2x25 cm, 5μm particle size). Mobile phase: isocratic premixed mixture of heptane 70%, ethanol 30% containing 0.1% of trifluoroacetic acid. Flow rate=10 ml/min. UV detection: 270 nm]. Collected fractions after solvent evaporation of the separated peaks, gave the title compounds (**E5**) (3 mg) and (**E6**) (3 mg) as single enantiomers.

MS: (ES/+) m/z: 462 [MH⁺] C₂₆H₂₄ClN₃O₃ requires 461.15

(**E5**): (single enantiomer 1)

MS: (ES/+) m/z: 462 [MH⁺] C₂₆H₂₄ClN₃O₃ requires 461.15


(E6): (single enantiomer 2)

Examples 7, 8 and 9:

5 **4-(1-(2-(2-benzylpyrrolidin-1-yl)-5-chloronicotinamido)cyclopropyl)benzoic acid (racemic mixture) (E7)**

4-(1-(2-(2-benzylpyrrolidin-1-yl)-5-chloronicotinamido)cyclopropyl)benzoic acid (enantiomer 1) (E8)

4-(1-(2-(2-benzylpyrrolidin-1-yl)-5-chloronicotinamido)cyclopropyl)benzoic acid (enantiomer 2) (E9)



10

To a solution of methyl 4-(1-(2-(2-benzylpyrrolidin-1-yl)-5-chloronicotinamido)cyclopropyl)benzoate (D144) (60 mg, 0.122 mmol) in 1,4-dioxane (3ml) and water (1ml) lithium hydroxide monohydrate (7.7 mg, 0.18 mmol) was added and the resulting mixture was stirred at 150°C under microwave irradiation for 10 min (2 cycles of 5 min each). Solvents were evaporated in vacuo, and the residue was diluted with water (5ml) and 1M HCl (15ml) and extracted with ethylacetate (3x20ml). Collected organics, after solvent evaporation, afforded the title compound **(E7)** (racemic mixture) (47 mg).

15

MS: (ES/+) m/z: 476.2 [MH⁺] C₂₇H₂₆ClN₃O₃ requires 475.17

20

¹H NMR (400MHz ,DMSO-d₆) δ (ppm): 12.79 (br. s., 1 H) 9.24 (s, 1 H) 8.26 (d, J=2.45 Hz, 1 H) 7.88 (d, J=8.31 Hz, 2 H) 7.71 (d, J=2.93 Hz, 1 H) 7.38 (d, J=8.31 Hz, 2 H) 7.09 - 7.33 (m, 5 H) 4.43 (d, J=5.87 Hz, 1 H) 3.17 - 3.30 (m, 1 H) 3.11 (dd, J=12.72, 2.93 Hz, 1 H) 2.89 - 3.04 (m, 1 H) 2.54 - 2.61 (m, 1 H) 1.75 (d, J=5.38 Hz, 2 H) 1.52 - 1.70 (m, 2 H) 1.32 (s, 4 H)

25

(E7) (20.5mg) dissolved in ethanol (1.5ml) was separated by chiral HPLC [Daicel Chiralpack AD-H column (2x25 cm, 5μm particle size). Mobile phase: isocratic premixed mixture of heptane 70%, ethanol 20% containing 0.1% of trifluoroacetic acid. Flow rate=10 ml/min. UV detection: 275 nm]. Collected fractions after solvent

evaporation of the separated peaks, gave the title compounds **(E8)** (13 mg) (0022/057/1) and **(E9)** (14 mg) (0022/057/2) as single enantiomers.

(E8): (single enantiomer 1)

MS: (ES/+) m/z: 476.2 [MH⁺] C₂₇H₂₆ClN₃O₃ requires 475.17


5 ¹H NMR (400MHz, DMSO-d₆) δ (ppm): 9.23 (s, 1 H), 8.26 (d, *J* = 2.4 Hz, 1 H), 7.91 - 7.84 (m, *J* = 8.3 Hz, 2 H), 7.71 (d, *J* = 2.4 Hz, 1 H), 7.42 - 7.35 (m, *J* = 8.8 Hz, 2 H), 7.31 - 7.14 (m, 5 H), 4.43 (br. s., 1 H), 3.29 - 3.18 (m, 1 H), 3.10 (dd, *J* = 3.4, 12.7 Hz, 1 H), 2.99 (d, *J* = 6.4 Hz, 1 H), 2.61 - 2.54 (m, 1 H), 1.75 (d, *J* = 5.4 Hz, 2 H), 1.69 - 1.55 (m, 2 H), 1.32 (s, 4 H)

10 **(E9)**: (single enantiomer 2)

MS: (ES/+) m/z: 476.2 [MH⁺] C₂₇H₂₆ClN₃O₃ requires 475.17

¹H NMR (400MHz, DMSO-d₆) δ (ppm): 9.23 (s, 1 H), 8.26 (d, *J* = 2.4 Hz, 1 H), 7.92 - 7.83 (m, *J* = 8.8 Hz, 2 H), 7.71 (d, *J* = 2.9 Hz, 1 H), 7.42 - 7.34 (m, *J* = 8.3 Hz, 2 H), 7.31 - 7.13 (m, 5 H), 4.43 (d, *J* = 5.9 Hz, 1 H), 3.31 - 3.18 (m, 1 H), 3.10 (dd, *J* = 3.2, 13.0 Hz, 1 H), 2.99 (d, *J* = 5.9 Hz, 1 H), 2.61 - 2.54 (m, 1 H), 1.75 (d, *J* = 4.9 Hz, 2 H), 1.69 - 1.54 (m, 2 H), 1.32 (s, 4 H)

Example 10: 4-(1-(5-chloro-2-(3-phenoxyazetidin-1-yl)nicotinamido)cyclopropyl)benzoic acid (E10)




20

The title compound **(E10)** (160 mg) was prepared according to the experimental procedure described in Example 1 starting from methyl 4-(1-(5-chloro-2-(3-phenoxyazetidin-1-yl)nicotinamido)cyclopropyl) benzoate (D145) (220 mg, 0.46 mmol)

25 MS: (ES/+) m/z: 464 [MH⁺] C₂₅H₂₂ClN₃O₄ requires 463.13

¹H NMR (400MHz, DMSO-d₆) δ (ppm): 9.31 (1H, s), 8.23 (1H, d, *J* = 2.8 Hz), 7.85 (2H, d, *J* = 8.4 Hz), 7.80 (1H, d, *J* = 2.8 Hz), 7.34 - 7.30 (4H, m), 6.98 (1H, t, *J* = 7.2 Hz), 6.80 (2H, d, *J* = 8.0 Hz), 5.09 - 5.04 (1H, m), 4.35 - 4.31 (2H, m), 3.83 - 3.80 (2H, m), 1.33 - 1.25 (4H, m)

Example 11: (S)-4-(1-(5-chloro-2-(3-(4-fluorophenoxy)azetidin-1-yl)nicotinamido)ethyl)benzoic acid (E11)




5 The title compound **(E11)** (88 mg) was prepared according to the experimental procedure described in Example 7 starting from (S)-methyl 4-(1-(5-chloro-2-(3-(4-fluorophenoxy)azetidin-1-yl)nicotinamido)ethyl)benzoate (D146) (100 mg, 0.206 mmol).

MS: (ES/+) m/z: 470.2 [MH⁺] C₂₄H₂₁ClFN₃O₄ requires 469.12

10 ¹H NMR (400MHz, DMSO-d₆) δ (ppm): 12.88 (br. s., 1 H), 9.04 (d, *J* = 7.8 Hz, 1 H), 8.21 (d, *J* = 2.4 Hz, 1 H), 7.90 (d, *J* = 8.3 Hz, 2 H), 7.70 (d, *J* = 2.4 Hz, 1 H), 7.48 (d, *J* = 8.3 Hz, 2 H), 7.21 - 7.02 (m, 2 H), 6.86 - 6.65 (m, 2 H), 5.07 (t, *J* = 7.3 Hz, 1 H), 4.97 (td, *J* = 3.0, 6.2 Hz, 1 H), 4.27 (dd, *J* = 6.4, 9.8 Hz, 1 H), 4.14 (dd, *J* = 5.9, 9.8 Hz, 1 H), 3.81 - 3.60 (m, 2 H), 1.44 (d, *J* = 6.8 Hz, 3 H)

15

Example 12: (S)-4-(1-(5-chloro-2-(3-(3-fluorophenoxy)azetidin-1-yl)nicotinamido)ethyl)benzoic acid (E12)




20 The title compound **(E12)** (80 mg) was prepared according to the experimental procedure described in Example 7 starting from (S)-methyl 4-(1-(5-chloro-2-(3-(3-fluorophenoxy)azetidin-1-yl)nicotinamido)ethyl)benzoate (D147) (90 mg, 0.186 mmol).

MS: (ES/+) m/z: 470.2 [MH⁺] C₂₄H₂₁ClFN₃O₄ requires 469.12

25 ¹H NMR (400MHz, DMSO-d₆) δ (ppm): 12.83 (br. s., 1 H), 9.03 (d, *J* = 7.8 Hz, 1 H), 8.27 - 8.16 (m, 1 H), 7.95 - 7.83 (m, 2 H), 7.69 (d, *J* = 2.4 Hz, 1 H), 7.52 - 7.43

(m, 2 H), 7.39 - 7.21 (m, 1 H), 6.80 (dt, $J = 2.2, 8.4$ Hz, 1 H), 6.68 (td, $J = 2.3, 11.1$ Hz, 1 H), 6.58 (dd, $J = 2.0, 8.3$ Hz, 1 H), 5.19 - 4.89 (m, 2 H), 4.30 (dd, $J = 6.4, 9.8$ Hz, 1 H), 4.22 (dd, $J = 6.1, 10.0$ Hz, 1 H), 3.83 - 3.62 (m, 2 H), 1.50 - 1.34 (m, 3 H)

5 Example 13: 4-(1-(5-chloro-2-(3-(4-(trifluoromethyl)phenoxy)azetidin-1-yl)nicotinamido)cyclopropyl)benzoic acid (E13)




The title compound (**E13**) (133 mg) was prepared according to the experimental procedure described in Example 7 starting from methyl 4-(1-(5-chloro-2-(3-(4-(trifluoromethyl)phenoxy)azetidin-1-yl)nicotinamido)cyclopropyl)benzoate (D148) (140 mg, 0.25 mmol).

MS: (ES/+) m/z : 532.2 [MH^+] $C_{26}H_{21}ClF_3N_3O_4$ requires 531.12

^1H NMR (400MHz, DMSO- d_6) δ (ppm): 12.83 (br. s., 1 H), 9.29 (s, 1 H), 8.24 (d, $J = 2.4$ Hz, 1 H), 7.88 (d, $J = 8.8$ Hz, 2 H), 7.81 (d, $J = 2.4$ Hz, 1 H), 7.68 (d, $J = 8.8$ Hz, 2 H), 7.38 - 7.28 (m, 2 H), 7.02 (d, $J = 8.3$ Hz, 2 H), 5.16 (td, $J = 2.8, 5.7$ Hz, 1 H), 4.36 (dd, $J = 6.4, 9.8$ Hz, 2 H), 3.84 (dd, $J = 3.2, 10.0$ Hz, 2 H), 1.39 - 1.25 (m, 4 H)

20 Example 14: 4-(1-(5-chloro-2-(3-(3-(trifluoromethyl)phenoxy)azetidin-1-yl)nicotinamido)cyclopropyl)benzoic acid (E14)




The title compound (**E14**) (12 mg) was prepared according to the experimental procedure described in Example 7 starting from methyl 4-(1-(5-chloro-2-(3-(3-(trifluoromethyl)phenoxy)pyrrolidin-1-yl)nicotinamido)cyclopropyl)benzoate (D149) (20 mg, 0.036 mmol)

MS: (ES/+) m/z: 532.2 [MH⁺] C₂₆H₂₁ClF₃N₃O₄ requires 531.12

¹H NMR (400MHz, DMSO-d₆) δ (ppm): 12.78 (br. s., 1 H), 9.27 (s, 1 H), 8.24 (d, *J* = 2.4 Hz, 1 H), 7.93 - 7.72 (m, 3 H), 7.62 - 7.47 (m, 1 H), 7.41 - 7.24 (m, 3 H), 7.22 - 7.02 (m, 2 H), 5.28 - 5.08 (m, 1 H), 4.37 (dd, *J* = 6.1, 10.0 Hz, 2 H), 3.84 (dd, *J* = 2.9, 9.8 Hz, 2 H), 1.32 (s, 4 H)

Example 15: 4-(1-(5-chloro-2-(3-(4-fluorophenoxy)azetidin-1-yl)nicotinamido)cyclopropyl)benzoic acid (E15)




10 The title compound (**E15**) (50 mg) was prepared according to the experimental procedure described in Example 7 starting from methyl 4-(1-(5-chloro-2-(3-(4-fluorophenoxy)azetidin-1-yl)nicotinamido)cyclopropyl)benzoate (D150) (75 mg, 0.151 mmol).

MS: (ES/+) m/z: 482.2 [MH⁺] C₂₅H₂₁ClFN₃O₄ requires 481.12

15 ¹H NMR (400MHz, DMSO-d₆) δ (ppm): 12.83 (br. s., 1 H), 9.27 (s, 1 H), 8.23 (d, *J* = 2.4 Hz, 1 H), 7.86 (d, *J* = 8.3 Hz, 2 H), 7.79 (d, *J* = 2.4 Hz, 1 H), 7.32 (d, *J* = 8.3 Hz, 2 H), 7.13 (t, *J* = 8.8 Hz, 2 H), 6.89 - 6.75 (m, 2 H), 5.11 - 4.94 (m, 1 H), 4.31 (dd, *J* = 6.4, 9.8 Hz, 2 H), 3.80 (dd, *J* = 3.4, 10.3 Hz, 2 H), 1.32 (d, *J* = 4.9 Hz, 4 H)

20 **Example 16: 4-(1-(5-chloro-2-(3-(3-fluorophenoxy)azetidin-1-yl)nicotinamido)cyclopropyl)benzoic acid (E16)**



4-(1-(5-chloro-2-(3-(3-fluorophenoxy)azetidin-1-yl)nicotinamido)cyclopropyl)benzoic acid (E16) was prepared according to two
25 different experimental procedures described below

Procedure A

The title compound (**E16**) (47 mg) was prepared according to the experimental procedure described in Example 7 starting from methyl 4-(1-(5-chloro-2-(3-(3-fluorophenoxy)azetidin-1-yl)nicotinamido)cyclopropyl)benzoate (D151) (56 mg, 0.113 mmol).

¹H NMR (400MHz, DMSO-d₆) δ (ppm): 12.77 (br. s., 1 H) 9.26 (s, 1 H) 8.23 (d, J=2.45 Hz, 1 H) 7.84 (d, J=8.80 Hz, 2 H) 7.80 (d, J=2.45 Hz, 1 H) 7.19 - 7.47 (m, 3 H) 6.81 (td, J=8.56, 1.96 Hz, 1 H) 6.73 (dt, J=11.13, 2.26 Hz, 1 H) 6.66 (dd, J=8.07, 2.20 Hz, 1 H) 5.09 (dt, J=6.24, 3.00 Hz, 1 H) 4.35 (dd, J=9.78, 6.36 Hz, 2 H) 3.82 (dd, J=10.03, 3.18 Hz, 2 H) 1.32 (d, J=3.91 Hz, 4 H)


Procedure B

To an ice cooled solution of methyl 4-(1-(5-chloro-2-(3-(3-fluorophenoxy)azetidin-1-yl)nicotinamido)cyclopropyl)benzoate (D151) (3g, 6.049 mmol) in a mixture 1,4-dioxane/water (30ml/10ml), 1N NaOH (9.07ml) was added. The reaction mixture was heated to 60°C for 12 hours then cooled to 0°C, acidified with 1N HCl (pH=1) and stirred at 0°C for 10 min. The formed solid was collected by filtration and dried to provide title compound (**E16**) (2.46 g).

MS: (ES/+) m/z: 482.2 [MH⁺] C₂₅H₂₁ClFN₃O₄ requires 481.12

¹H NMR (400MHz, DMSO-d₆) δ (ppm): 12.76 (br. s., 1 H), 9.25 (s, 1 H), 8.23 (d, J = 2.4 Hz, 1 H), 7.91 - 7.72 (m, 3 H), 7.44 - 7.31 (m, 3 H), 6.89 - 6.60 (m, 3 H), 5.09 (br. s., 1 H), 4.35 (dd, J = 6.1, 10 Hz, 2 H), 3.82 (dd, J = 3.2, 10.0 Hz, 2 H), 1.32 (d, J = 3.9 Hz, 4 H)

Example 17: 4-(1-(5-chloro-2-(3-(4-fluoro-3-(trifluoromethyl)phenoxy)azetidin-1-yl)nicotinamido)cyclopropyl)benzoic acid (E17)




The title compound (**E17**) (24 mg) was prepared according to the experimental procedure described in Example 7 starting from methyl 4-(1-(5-chloro-2-(3-(4-

fluoro-3-(trifluoromethyl)phenoxy)azetidin-1-yl)nicotinamido)cyclopropyl)benzoate (D152) (25 mg, 0.044 mmol).

MS: (ES/+) m/z: 550.3 [MH⁺] C₂₆H₂₀ClF₄N₃O₄ requires 549.11

¹H NMR (400MHz, DMSO-d₆) δ (ppm): 9.48 (s, 1 H), 8.45 (d, *J* = 2.4 Hz, 1 H),
 5 8.11 - 7.96 (m, 3 H), 7.67 (t, *J* = 10.0 Hz, 1 H), 7.52 (d, *J* = 8.3 Hz, 2 H), 7.45 -
 7.34 (m, 2 H), 5.37 (d, *J* = 3.4 Hz, 1 H), 4.56 (dd, *J* = 6.5, 9.9 Hz, 2 H), 4.04 (dd, *J*
 = 3.1, 9.9 Hz, 2 H), 1.53 (br. s., 4 H)

Example 18: 4-(1-(5-chloro-2-(3-(3-(trifluoromethoxy)phenoxy)azetidin-1-yl)nicotinamido)cyclopropyl)benzoic acid (E18)




The title compound (**E18**) (107 mg) was prepared according to the experimental procedure described in Example 7 starting from methyl 4-(1-(5-chloro-2-(3-(3-(trifluoromethoxy)phenoxy)azetidin-1-yl)nicotinamido)cyclopropyl)benzoate (D153)
 15 (115 mg, 0.204 mmol).

MS: (ES/+) m/z: 548.3 [MH⁺] C₂₆H₂₁ClF₃N₃O₅ requires 547.11

¹H NMR (400MHz, DMSO-d₆) δ (ppm): 12.77 (br. s., 1 H), 9.26 (s, 1 H), 8.24 (d, *J*
 = 2.4 Hz, 1 H), 7.84 (d, *J* = 8.3 Hz, 2 H), 7.81 (d, *J* = 2.4 Hz, 1 H), 7.48 - 7.38 (m, 1
 H), 7.31 (d, *J* = 8.3 Hz, 2 H), 6.98 (d, *J* = 8.3 Hz, 1 H), 6.90 - 6.83 (m, 2 H), 5.19 -
 20 5.03 (m, 1 H), 4.35 (dd, *J* = 6.4, 10.0 Hz, 2 H), 3.83 (dd, *J* = 3.3, 9.9 Hz, 2 H), 1.32
 (s, 4 H)

Example 19: 4-(1-(5-chloro-2-(3-(2,4-difluorophenoxy)azetidin-1-yl)nicotinamido)cyclopropyl)benzoic acid (E19)




The title compound (**E19**) (48 mg) was prepared according to the experimental procedure described in Example 7 starting from methyl 4-(1-(5-chloro-2-(3-(2,4-difluorophenoxy)azetidin-1-yl)nicotinamido)cyclopropyl)benzoate (D154) (50 mg, 0.097 mmol).

5 MS: (ES/+) m/z: 500.3 [MH⁺] C₂₅H₂₀ClF₂N₃O₄ requires 499.11

¹H NMR (400MHz, DMSO-d₆) δ (ppm): 12.82 (br. s., 1 H), 9.28 (s, 1 H), 8.24 (s, 1 H), 7.85 (d, *J* = 8.1 Hz, 2 H), 7.80 (s, 1 H), 7.38 - 7.28 (m, 3 H), 7.05 - 6.86 (m, 2 H), 5.10 (br. s., 1 H), 4.38 - 4.27 (m, 2 H), 3.84 (dd, *J* = 2.8, 10.4 Hz, 2 H), 1.32 (d, *J* = 6.1 Hz, 4 H)

10

Example 20: 4-(1-(5-chloro-2-(3-(3,4-difluorophenoxy)azetidin-1-yl)nicotinamido)cyclopropyl)benzoic acid (E20)



The title compound (**E20**) (28 mg) was prepared according to the experimental procedure described in Example 7 starting from methyl 4-(1-(5-chloro-2-(3-(3,4-difluorophenoxy)azetidin-1-yl)nicotinamido)cyclopropyl)benzoate (D155) (48 mg, 0.093 mmol).

15


MS: (ES/+) m/z: 500.3 [MH⁺] C₂₅H₂₀ClF₂N₃O₄ requires 499.11

¹H NMR (400MHz, DMSO-d₆) δ (ppm): 9.26 (s, 1 H), 8.23 (s, 1 H), 7.83 (d, *J* = 7.8 Hz, 2 H), 7.80 (s, 1 H), 7.42 - 7.26 (m, 3 H), 6.65 (d, *J* = 8.6 Hz, 1 H), 5.06 (br. s., 1 H), 4.33 (dd, *J* = 6.1, 10.0 Hz, 2 H), 3.80 (dd, *J* = 2.8, 9.9 Hz, 2 H), 1.33 (br. s., 4 H)

20

Example 21: 4-(1-(5-chloro-2-(3-(3-(piperazin-1-yl)phenoxy)azetidin-1-yl)nicotinamido)cyclopropyl)benzoic acid (E21)

25




To a solution of methyl 4-(1-(5-chloro-2-(3-(3-(piperazin-1-yl)phenoxy)azetidin-1-yl)nicotinamido)cyclopropyl)benzoate (D156) (105 mg, 0.186 mmol) in a mixture 1-4dioxane/water (3ml/1ml), 1N NaOH (0.28ml) was added. The reaction mixture was heated to 60°C overnight. After cooling at room temperature, the reaction mixture was acidified with 1N HCl (pH=1) and the solvents were evaporated in vacuo. The residue was loaded on Porapak RXN RP cartridge (5g) eluting with water + 0.1% acetic acid /acetonitrile + 0.1% acetic acid from 90/10 to 0/100. Collected fractions after solvent evaporation afforded the title compound (**E21**) (79 mg).

MS: (ES/+) m/z: 548.3 [MH⁺] C₂₉H₃₀ClN₅O₄ requires 547.20

¹H NMR (400MHz, DMSO-d₆) δ (ppm): 9.25 (s, 1 H), 8.23 (d, *J* = 2.4 Hz, 1 H), 7.88 - 7.81 (m, *J* = 8.8 Hz, 2 H), 7.78 (d, *J* = 2.4 Hz, 1 H), 7.33 - 7.23 (m, *J* = 8.3 Hz, 2 H), 7.15 (t, *J* = 8.3 Hz, 1 H), 6.60 (d, *J* = 8.8 Hz, 1 H), 6.35 (s, 1 H), 6.26 (dd, *J* = 1.7, 8.1 Hz, 1 H), 5.07 (br. s., 1 H), 4.30 (dd, *J* = 6.4, 9.8 Hz, 2 H), 3.80 (dd, *J* = 2.7, 10.0 Hz, 2 H), 3.31 - 3.20 (m, 4 H), 3.17 - 3.08 (m, 4 H), 1.31 (d, *J* = 7.3 Hz, 4 H)

Example 22: 4-((5-chloro-2-(3-(3-fluorophenoxy)azetidin-1-yl) nicotinamido) methyl)benzoic acid (E22)




The title compound (**E22**) (46 mg) was prepared according to the experimental procedure described in Example 7 starting from methyl 4-((5-chloro-2-(3-(3-fluorophenoxy)azetidin-1-yl)nicotinamido)methyl)benzoate (D157) (47 mg, 0.1 mmol).

MS: (ES/+) m/z: 456.3 [MH⁺] C₂₃H₁₉ClFN₃O₄ requires 455.10

¹H NMR (400MHz, DMSO-d₆) δ (ppm): 9.08 (br. s., 1 H), 8.22 (d, *J* = 2.2 Hz, 1 H), 7.89 (d, *J* = 7.8 Hz, 2 H), 7.72 (s, 1 H), 7.44 (d, *J* = 8.1 Hz, 2 H), 7.34 (d, *J* = 7.8 Hz, 1 H), 6.81 (t, *J* = 8.8 Hz, 1 H), 6.72 (d, *J* = 10.5 Hz, 1 H), 6.65 (d, *J* = 8.1 Hz, 1 H), 5.08 (br. s., 1 H), 4.47 (d, *J* = 5.9 Hz, 2 H), 4.34 (dd, *J* = 6.5, 9.9 Hz, 2 H), 3.82 (dd, *J* = 3.1, 10.1 Hz, 2 H)

Example 23: 6-((5-chloro-2-(3-(3-fluorophenoxy)azetidin-1-yl)nicotinamido)methyl)nicotinic acid (E23)




The title compound (**E23**) (46 mg) was prepared according to the experimental procedure described in Example 7 starting from ethyl 6-((5-chloro-2-(3-(3-fluorophenoxy)azetidin-1-yl)nicotinamido)methyl)nicotinate (D158) (59 mg, 0.121 mmol).

MS: (ES/+) m/z: 457.3 [MH⁺] C₂₂H₁₈ClFN₄O₄ requires 456.10

¹H NMR (400MHz, DMSO-d₆) δ (ppm): 12.43 - 13.66 (m, 1 H) 9.15 (t, *J*=5.87 Hz, 1 H) 8.94 (d, *J*=1.96 Hz, 1 H) 8.07 - 8.29 (m, 2 H) 7.76 (d, *J*=2.45 Hz, 1 H) 7.50 (d, *J*=8.31 Hz, 1 H) 7.16 - 7.42 (m, 1 H) 6.80 (td, *J*=8.44, 2.20 Hz, 1 H) 6.67 - 6.75 (m, 1 H) 6.55 - 6.67 (m, 1 H) 5.09 (dt, *J*=6.24, 3.00 Hz, 1 H) 4.56 (d, *J*=5.87 Hz, 2 H) 4.36 (dd, *J*=10.27, 6.36 Hz, 2 H) 3.85 (dd, *J*=10.27, 3.42 Hz, 2 H)

Example 24: 6-((5-chloro-2-(3-(3-fluorophenoxy)azetidin-1-yl)nicotinamido)methyl)nicotinic acid (E24)




To a solution of methyl 6-((5-chloro-2-(3-(3-fluorophenoxy)azetidin-1-yl)nicotinamido)methyl)nicotinate (D159) (22 mg, 0.045 mmol) in a mixture 1-

4dioxane/water (1.5ml/0.5ml), lithium hydroxide hydrate (2.8 mg, 0.067 mmol) was added. The reaction mixture was heated to 70°C for 1 h. After solvent evaporation the residue was taken in water (10ml) and 1M HCl (10ml) and extracted with ethylacetate (2x20ml). Collected aorganics after solvent evaporation afforded the
 5 title compound **(E24)** (19 mg)

MS: (ES/+) m/z: 483.2 [MH⁺] C₂₄H₂₀ClFN₄O₄ requires 482.12

¹H NMR (400MHz ,DMSO-d₆) δ (ppm): 9.32 (s, 1 H), 8.92 (d, J = 2.4 Hz, 1 H), 8.25 (d, J = 2.4 Hz, 1 H), 8.13 (dd, J = 2.4, 8.3 Hz, 1 H), 7.89 (d, J = 2.4 Hz, 1 H), 7.55 (d, J = 7.8 Hz, 1 H), 7.38 - 7.31 (m, 1 H), 6.84 - 6.70 (m, 3 H), 5.12 (d, J = 2.4 Hz,
 10 1 H), 4.41 (dd, J = 6.6, 10.0 Hz, 2 H), 3.88 (dd, J = 2.9, 10.3 Hz, 2 H), 1.62 - 1.57 (m, 2 H), 1.36 - 1.32 (m, 2 H).

Example 25: 4-(1-(5-chloro-2-(3-(3-fluorobenzoyl)azetidin-1-yl)nicotinamido)cyclopropyl)benzoic acid (E25)



15


To a solution of methyl 6-((5-chloro-2-(3-(3-fluorophenoxy)azetidin-1-yl)nicotinamido)methyl)nicotinate (D160) (40.5 mg, 0.079 mmol) in a mixture 1-4dioxane/water (1.5ml/0.5ml), lithium hydroxide hydrate (10 mg, 0.24 mmol) was added. The reaction mixture was heated to 70°C under mixcrowev irradiation for
 20 20 min (4 cycles of 5 min each). After solvent evaporation the residue was taken in water (5ml) and 1M HCl (5ml) and extracted with ethylacetate (3x10ml). Collected organics after solvent evaporation afforded the title compound **(E25)** (29 mg)

MS: (ES/+) m/z: 494.2 [MH⁺] C₂₆H₂₁ClFN₃O₄ requires 493.12

¹H NMR (400MHz ,DMSO-d₆) δ (ppm): 9.22 (s, 1 H), 8.22 (d, J = 2.4 Hz, 1 H), 7.79 (d, J = 8.3 Hz, 2 H), 7.76 (d, J = 2.9 Hz, 1 H), 7.74 - 7.60 (m, 3 H), 7.55 - 7.49 (m, 1 H), 7.25 (d, J = 8.3 Hz, 2 H), 4.56 - 4.47 (m, 1 H), 4.22 (t, J = 8.8 Hz, 2 H), 4.03 (dd, J = 6.1, 8.6 Hz, 2 H), 1.30 (d, J = 6.4 Hz, 4 H).

25

Example 26: 4-(1-(5-chloro-2-(3-(3-fluorophenyl)(methoxyimino)methyl)azetidin-1-yl)nicotinamido)cyclopropyl)benzoic acid (isomers mixture) (E26)




5 4-(1-(5-chloro-2-(3-(3-fluorobenzoyl)azetidin-1-yl)nicotinamido)cyclopropyl)benzoic acid (E25) (12.6 mg, 0.025 mmol) was dissolved in dry pyridine (1.2ml) then O-methylhydroxylamine hydrochloride (4.3 mg, 0.051 mmol) was added and the resulting mixture was stirred at room temperature for 60 h. Solvents were evaporated in vacuo, and the residue was diluted with water (5ml) and extracted
10 with ethylacetate (3x20ml). Collected organics, after solvent evaporation, afforded a residue that was washed with methanol and dried in vacuo to afford the title compound **(E26)** (0021/092/2) (3 mg).

MS: (ES/+) m/z: 523.3 [MH⁺] C₂₇H₂₄ClFN₄O₄ requires 522.15

¹H NMR (400MHz, DMSO-d₆) δ (ppm): 9.20 - 9.14 (m, 1 H), 8.20 - 8.15 (m, 1 H),
15 7.87 - 7.78 (m, 2 H), 7.73 (d, J = 2.4 Hz, 1 H), 7.50 - 7.42 (m, 1 H), 7.31 - 7.18 (m, 5 H), 4.28 - 4.10 (m, 3 H), 3.89 - 3.81 (m, 3 H), 3.72 (t, J = 7.8 Hz, 2 H), 1.32 - 1.23 (m, 4 H).

Example 27: 4-(1-(5-chloro-2-(3-(3-fluorophenyl)-3-hydroxyazetidin-1-yl)nicotinamido)cyclopropyl)benzoic acid (E27)




The title compound **(E27)** (55 mg) was prepared according to the experimental procedure described in Example 24 starting from methyl 4-(1-(5-chloro-2-(3-(3-fluorophenyl)-3-hydroxyazetidin-1-yl)nicotinamido)cyclopropyl)benzoate (D161)
25 (63 mg, 0.127 mmol).

MS: (ES/+) m/z: 482.2 [MH⁺] C₂₅H₂₁ClFN₃O₄ requires 481.12

¹H NMR (400MHz ,DMSO-d₆) δ (ppm): 12.76 (br. s., 1 H), 9.28 (s, 1 H), 8.25 (d, J = 2.4 Hz, 1 H), 7.84 - 7.80 (m, 3 H), 7.47 - 7.40 (m, 1 H), 7.32 (d, J = 8.3 Hz, 3 H), 7.26 (d, J = 10.3 Hz, 1 H), 7.15 - 7.09 (m, 1 H), 6.40 (s, 1 H), 4.12 - 4.00 (m, 3 H), 1.31 (s, 4 H).

5

Example 28: 4-(1-(5-chloro-2-(3-(4-fluorophenyl)-3-hydroxyazetidin-1-yl)nicotinamido)cyclopropyl)benzoic acid (E28)




The title compound (**E28**) (62 mg) was prepared according to the experimental procedure described in Example 24 starting from methyl 4-(1-(5-chloro-2-(3-(4-fluorophenyl)-3-hydroxyazetidin-1-yl)nicotinamido)cyclopropyl)benzoate) (D162) (75 mg, 0.151 mmol).

MS: (ES/+) m/z: 482.2 [MH⁺] C₂₅H₂₁ClFN₃O₄ requires 481.12

¹H NMR (400MHz ,DMSO-d₆) δ (ppm): 12.75 (br. s., 1 H), 9.27 (s, 1 H), 8.24 (d, J = 2.4 Hz, 1 H), 7.86 - 7.81 (m, J = 8.3 Hz, 2 H), 7.80 (d, J = 2.4 Hz, 1 H), 7.49 (dd, J = 5.4, 8.8 Hz, 2 H), 7.35 - 7.31 (m, J = 8.3 Hz, 2 H), 7.20 (t, J = 8.8 Hz, 2 H), 6.31 (s, 1 H), 4.05 (s, 4 H), 1.31 (s, 4 H).

Example 29: 4-(1-(5-chloro-2-(3-((4-fluorophenoxy)methyl)azetidin-1-yl)nicotinamido)cyclopropyl)benzoic acid (E29)




To a solution of 4-(1-(5-chloro-2-(3-((4-fluorophenoxy)methyl)azetidin-1-yl)nicotinamido)cyclopropyl)benzoic acid (D163) (51.6 mg, 0.101 mmol) in 3:1 mixture 1,4-dioxane/ water (2ml), lithium hydroxide monohydrate (6.4 mg, 0.151 mmol) was added. The mixture was stirred at 120°C under microwaves irradiation (2 cycles of 6 min each) then 6 min at 140°C. Lithium hydroxide monohydrate (2.1

mg, 0.05 mmol) was added and the mixture was stirred at 140°C for 3 min under microwaves irradiation. After solvent evaporation the organics were diluted with water (20ml) and 1M HCl (5ml) and extracted with ethylacetate (3x20ml). Collected organics, after solvent evaporation afforded the title compound (**E29**) (42 mg).

MS: (ES/+) m/z: 496.4 [MH⁺] C₂₆H₂₃ClFN₃O₄ requires 495.14

¹H NMR (400MHz, DMSO-d₆) δ (ppm): 9.21 (s, 1 H), 8.20 (d, *J* = 2.4 Hz, 1 H), 7.90 - 7.83 (m, *J* = 8.3 Hz, 2 H), 7.74 (d, *J* = 2.4 Hz, 1 H), 7.36 - 7.29 (m, *J* = 8.8 Hz, 2 H), 7.15 - 7.06 (m, 2 H), 7.00 - 6.92 (m, 2 H), 4.11 (d, *J* = 6.8 Hz, 2 H), 4.00 (t, *J* = 8.6 Hz, 2 H), 3.71 (dd, *J* = 5.4, 8.8 Hz, 2 H), 3.04 (d, *J* = 5.9 Hz, 1 H), 1.32 (s, 4 H).

Example 30: 4-(1-(5-chloro-2-(3-((4-fluorophenoxy)methyl)azetidin-1-yl)nicotinamido)cyclopropyl)benzoic acid (E30)




The title compound (**E30**) (57 mg) was prepared according to the experimental procedure described in Example 29 starting from methyl 4-(1-(5-chloro-2-(3-(3-fluorophenyl)-3-hydroxyazetidin-1-yl)nicotinamido)cyclopropyl)benzoate) (D164) (61 mg, 0.119 mmol).

MS: (ES/+) m/z: 496.4 [MH⁺] C₂₆H₂₃ClFN₃O₄ requires 495.14

¹H NMR (400MHz, DMSO-d₆) δ (ppm): 9.21 (s, 1 H), 8.20 (d, *J* = 2.4 Hz, 1 H), 7.86 (d, *J* = 8.3 Hz, 2 H), 7.74 (d, *J* = 2.4 Hz, 1 H), 7.36 - 7.26 (m, 3 H), 6.86 - 6.73 (m, 3 H), 4.15 (d, *J* = 6.8 Hz, 2 H), 4.00 (t, *J* = 8.6 Hz, 2 H), 3.71 (dd, *J* = 5.4, 8.8 Hz, 2 H), 3.09 - 3.00 (m, 1 H), 1.32 (s, 4 H).

Example 31: 4-(1-(5-chloro-2-(3-((3-(trifluoromethyl)phenyl)amino)azetidin-1-yl)nicotinamido)cyclopropyl)benzoic acid (E31)




The title compound (**E31**) (15 mg) was prepared according to the experimental procedure described in Example 7 starting from methyl 4-(1-(5-chloro-2-(3-((3-(trifluoromethyl)phenyl)amino)azetidin-1-yl)nicotinamido)cyclopropyl)benzoate

5 (D165) (16 mg, 0.029 mmol).

MS: (ES/+) m/z: 531.2 [MH⁺] C₂₆H₂₂ClF₃N₄O₃ requires 530.13

¹H NMR (400MHz, DMSO-d₆) δ (ppm): 9.25 (s, 1 H), 8.22 (s, 1 H), 7.85 (d, *J* = 7.8 Hz, 2 H), 7.80 - 7.79 (m, 1 H), 7.77 (s, 1 H), 7.38 - 7.26 (m, 3 H), 6.88 (d, *J* = 8.1 Hz, 1 H), 6.82 (br. s., 1 H), 6.76 (s, 1 H), 6.71 (d, *J* = 8.1 Hz, 1 H), 4.33 - 4.18 (m, 3 H), 3.70 (d, *J* = 4.6 Hz, 2 H), 3.37 (br. s., 1 H), 1.32 (s, 4 H)

Example 32: 4-(1-(5-chloro-2-(3-((3-fluorophenyl)amino)azetidin-1-yl)nicotinamido)cyclopropyl)benzoic acid (E32)




15 The title compound (**E32**) (15 mg) was prepared according to the experimental procedure described in Example 7 starting from methyl 4-(1-(5-chloro-2-(3-((3-fluorophenyl)amino)azetidin-1-yl)nicotinamido)cyclopropyl)benzoate (D166) (16 mg, 0.032 mmol).

MS: (ES/+) m/z: 481.2 [MH⁺] C₂₅H₂₂ClFN₄O₃ requires 480.14

20 ¹H NMR (400MHz, DMSO-d₆) δ (ppm): 12.76 (br. s., 1 H), 9.25 (s, 1 H), 8.21 (s, 1 H), 7.85 (d, *J* = 7.3 Hz, 2 H), 7.80 - 7.71 (m, 1 H), 7.31 (d, *J* = 8.1 Hz, 2 H), 7.16 - 7.04 (m, 1 H), 6.63 (d, *J* = 4.6 Hz, 1 H), 6.40 - 6.31 (m, 1 H), 6.31 - 6.21 (m, 2 H), 4.31 - 4.17 (m, 3 H), 3.69 (d, *J* = 5.1 Hz, 2 H), 1.33 (s, 4 H)

25 **Example 33: 4-(1-(5-chloro-2-(3-((4-fluorophenyl)amino)azetidin-1-yl)nicotinamido)cyclopropyl)benzoic acid (E33)**




The title compound (**E33**) (37 mg) was prepared according to the experimental procedure described in Example 7 starting from methyl 4-(1-(5-chloro-2-(3-((4-fluorophenyl)amino)azetidin-1-yl)nicotinamido)cyclopropyl)benzoate (D167) (42 mg, 0.092 mmol).

MS: (ES/+) m/z: 481.3 [MH⁺] C₂₅H₂₂ClFN₄O₃ requires 480.14

¹H NMR (400MHz, DMSO-d₆) δ (ppm): 12.82 (br. s., 1 H), 9.25 (s, 1 H), 8.20 (d, *J* = 2.4 Hz, 1 H), 7.87 (s, 2 H), 7.75 (d, *J* = 2.4 Hz, 1 H), 7.32 (d, *J* = 8.8 Hz, 2 H), 6.95 (t, *J* = 8.8 Hz, 2 H), 6.54 - 6.40 (m, 2 H), 6.23 (br. s., 1 H), 4.33 - 4.06 (m, 3 H), 3.66 (dd, *J* = 3.9, 8.8 Hz, 2 H), 1.41 - 1.24 (m, 4 H)

Example 34: 4-(1-(5-chloro-2-(3-((4-fluoro-2-methylphenyl)amino)azetidin-1-yl)nicotinamido)cyclopropyl)benzoic acid (E34)




To a solution of methyl 4-(1-(5-chloro-2-(3-((4-fluoro-2-methylphenyl)amino)azetidin-1-yl)nicotinamido)cyclopropyl) benzoate (D168) (105 mg, 0.206 mmol) in a mixture 1,4 dioxane/water (3ml/1ml), 1N NaOH (0.309 ml) was added. The reaction mixture was stirred at room temperature overnight. Organic solvent was evaporated in vacuo and the reaction mixture was acidified with 2N HCl (pH=5-6). The solid obtained was filtered off and dried to afford the title (**E34**) (65 mg)

MS: (ES/+) m/z: 495.3 [MH⁺] C₂₆H₂₄ClFN₄O₃ requires 494.15

¹H NMR (400MHz, DMSO-d₆) δ (ppm): 12.81 (br. s., 1 H), 9.23 (s, 1 H), 8.20 (d, *J* = 2.4 Hz, 1 H), 7.90 - 7.83 (m, *J* = 8.3 Hz, 2 H), 7.74 (d, *J* = 2.4 Hz, 1 H), 7.37 - 7.27 (m, *J* = 8.3 Hz, 2 H), 6.92 - 6.78 (m, 2 H), 6.21 (dd, *J* = 4.9, 8.8 Hz, 1 H), 5.34

(d, $J = 5.9$ Hz, 1 H), 4.29 - 4.09 (m, 3 H), 3.77 (dd, $J = 4.2, 8.6$ Hz, 2 H), 2.13 (s, 3 H), 1.37 - 1.29 (m, 4 H).

Example 35: 4-(1-(5-chloro-2-(3-((2,4-difluorophenyl)amino)azetidin-1-yl)nicotinamido)cyclopropyl)benzoic acid (E35)




To a solution of methyl 4-(1-(5-chloro-2-(3-((2,4-difluorophenyl)amino)azetidin-1-yl)nicotinamido)cyclopropyl)benzoate (D169) (12 mg, 0.024 mmol) in a mixture 1,4-dioxane/water (3ml/1ml), 1N NaOH (0.036ml) was added. The reaction mixture was stirred 12 h at 60°C. Organic solvent was evaporated in vacuo and the reaction mixture was acidified with 2N HCl (pH=2) and the resulting mixture was extracted with ethylacetate (3x5ml). Combined organics were evaporated in vacuo and the residue was loaded on SNAP-C18 gold cartridge (15g) eluting with H₂O-AcOH (0.1%)/ CH₃CN-AcOH (0.1%) from 10/90 to 0/100. Collected fractions were evaporated in vacuo to afford the title **(E35)** (5 mg)

MS: (ES/+) m/z : 499.2 [MH^+] C₂₅H₂₁ClF₂N₄O₃ requires 498.13

¹H NMR (400MHz, DMSO- d_6) δ (ppm): 13.05 - 12.53 (m, 1 H), 9.23 (s, 1 H), 8.20 (d, $J = 2.4$ Hz, 1 H), 7.90 - 7.81 (m, $J = 8.3$ Hz, 2 H), 7.74 (d, $J = 2.4$ Hz, 1 H), 7.37 - 7.27 (m, $J = 7.8$ Hz, 2 H), 7.16 - 7.04 (m, 1 H), 6.88 (t, $J = 7.8$ Hz, 1 H), 6.52 - 6.41 (m, 1 H), 6.04 (br. s., 1 H), 4.21 (d, $J = 4.9$ Hz, 3 H), 3.77 (d, $J = 4.9$ Hz, 2 H), 1.38 - 1.28 (m, 4 H)

Example 36: 4-(1-(5-chloro-2-(3-((2-methyl-4-(trifluoromethyl)phenyl)amino)azetidin-1-yl)nicotinamido)cyclopropyl) benzoic acid (E36)




The title compound (**E36**) (16 mg) was prepared according to the experimental procedure described in Example 35 (reaction time=2h) starting from methyl 4-(1-(5-chloro-2-(3-((2-methyl-4-trifluoromethyl)phenyl)amino)azetidin-1-yl)nicotinamido)cyclopropyl)benzoate (D170) (27 mg, 0.048 mmol).

5 MS: (ES/+) m/z: 545.2 [MH⁺] C₂₇H₂₄ClF₃N₄O₃ requires 544.15

¹H NMR (400MHz, DMSO-d₆) δ (ppm): 12.86 - 12.65 (m, 1 H), 9.29 - 9.14 (m, 1 H), 8.28 - 8.17 (m, 1 H), 7.98 - 7.82 (m, 2 H), 7.78 - 7.67 (m, 1 H), 7.43 - 7.25 (m, 4 H), 6.46 - 6.32 (m, 1 H), 6.14 - 5.99 (m, 1 H), 4.38 - 4.18 (m, 3 H), 3.93 - 3.84 (m, 2 H), 2.25 - 2.13 (m, 3 H), 1.41 - 1.24 (m, 4 H)

10

Example 37: 4-(1-(5-chloro-2-(3-((4-fluoro-2-methylphenyl)(methyl)amino)azetidin-1-yl)nicotinamido)cyclopropyl)benzoic acid (E37)



15 To a solution of starting from methyl 4-(1-(5-chloro-2-(3-((4-fluoro-2-methylphenyl)(methyl)amino)azetidin-1-yl)nicotinamido)cyclopropyl)benzoate (D171) (56 mg, 0.107 mmol).in a mixture 1-4 dioxane/water (3ml/1ml), 1N NaOH (0.16ml) was added. The reaction mixture was stirred 2h at 60 °C. Organic solvent was evaporated in vacuo and the reaction mixture was acidified with 2N HCl


20 (pH=2) and the resulting mixture was extracted with ethylacetate (3x5ml). Combined organics were evaporated in vacuo to afford afford the title (**E37**) (53 mg).

MS: (ES/+) m/z: 509.2 [MH⁺] C₂₇H₂₆ClFN₄O₃ requires 508.17

¹H NMR (400MHz, DMSO-d₆) δ (ppm): 12.78 (br. s., 1 H), 9.20 (s, 1 H), 8.17 (d, J = 2.4 Hz, 1 H), 7.87 - 7.78 (m, J = 8.3 Hz, 2 H), 7.71 (d, J = 2.4 Hz, 1 H), 7.35 - 7.25 (m, J = 8.8 Hz, 2 H), 7.03 (dd, J = 2.9, 9.8 Hz, 1 H), 6.98 - 6.83 (m, 2 H), 4.12 - 3.92 (m, 3 H), 3.53 (dd, J = 4.4, 8.8 Hz, 2 H), 2.44 (s, 3 H), 2.25 (s, 3 H), 1.34 - 1.20 (m, 4 H)

25

Example 38: 4-(1-(2-(3-(3-fluorophenoxy)azetidin-1-yl)-5-(trifluoromethyl)nicotinamido)cyclopropyl)benzoic acid (E38)




5 The title compound (**E38**) (41 mg) was prepared according to the experimental procedure described in Example 7 starting from methyl 4-(1-(2-(3-(3-fluorophenoxy)azetidin-1-yl)-5-(trifluoromethyl)nicotinamido)cyclopropyl)benzoate (D172) (60 mg, 0.113 mmol).

MS: (ES/+) m/z: 516.2 [MH⁺] C₂₆H₂₁F₄N₃O₄ requires 515.15

10 ¹H NMR (400MHz, DMSO-d₆) δ (ppm): 12.78 (br. s., 1 H), 9.36 (s, 1 H), 8.52 (s, 1 H), 7.95 (d, J = 2.0 Hz, 1 H), 7.85 (s, 2 H), 7.41 - 7.27 (m, 3 H), 6.81 (dt, J = 2.0, 8.3 Hz, 1 H), 6.78 - 6.70 (m, 1 H), 6.66 (dd, J = 2.2, 8.1 Hz, 1 H), 5.17 - 5.05 (m, 1 H), 4.44 (dd, J = 6.1, 10.5 Hz, 2 H), 3.91 (dd, J = 3.2, 10.5 Hz, 2 H), 1.41 - 1.28 (m, 4 H)

15

Example 39: 4-(1-(2-(3-(4-fluorophenoxy)azetidin-1-yl)-5-(trifluoromethyl)nicotinamido)cyclopropyl)benzoic acid (E39)




20 The title compound (**E39**) (70 mg) was prepared according to the experimental procedure described in Example 7 starting from methyl 4-(1-(2-(3-(4-fluorophenoxy)azetidin-1-yl)-5-(trifluoromethyl)nicotinamido)cyclopropyl)benzoate (D173) (75 mg, 0.141 mmol).

MS: (ES/+) m/z: 516.2 [MH⁺] C₂₆H₂₁F₄N₃O₄ requires 515.15

25 ¹H NMR (400MHz, DMSO-d₆) δ (ppm): 12.84 (s, 1 H), 9.37 (s, 1 H), 8.52 (s, 1 H), 7.94 (d, J = 2.0 Hz, 1 H), 7.87 (d, J = 8.3 Hz, 2 H), 7.34 (d, J = 8.3 Hz, 2 H), 7.14

(t, $J = 8.8$ Hz, 2 H), 6.95 - 6.73 (m, 2 H), 5.14 - 4.89 (m, 1 H), 4.41 (dd, $J = 6.4$, 10.3 Hz, 2 H), 3.89 (dd, $J = 3.4$, 10.3 Hz, 2 H), 1.43 - 1.22 (m, 4 H)

Example 40: 4-(1-(2-(3-(4-chlorophenoxy)azetidin-1-yl)-5-(trifluoromethyl)nicotinamido)cyclopropyl)benzoic acid (E40)




The title compound (**E40**) (17 mg) was prepared according to the experimental procedure described in Example 7 starting from methyl 4-(1-(2-(3-(4-chlorophenoxy)azetidin-1-yl)-5-(trifluoromethyl)nicotinamido)cyclopropyl)benzoate (D174) (23 mg, 0.042 mmol).

MS: (ES/+) m/z : 532.3 [MH^+] $C_{26}H_{21}ClF_3N_3O_4$ requires 531.12

^1H NMR (400MHz, DMSO- d_6) δ (ppm): 12.85 (br. s., 1 H), 9.37 (s, 1 H), 8.52 (s, 1 H), 7.95 (d, $J = 2.2$ Hz, 1 H), 7.87 (s, 2 H), 7.46 - 7.26 (m, 4 H), 6.95 - 6.77 (m, 2 H), 5.16 - 4.84 (m, 1 H), 4.42 (dd, $J = 6.4$, 10.3 Hz, 2 H), 3.90 (dd, $J = 2.8$, 10.1 Hz, 2 H), 1.44 - 1.28 (m, 4 H)

Example 41: 4-(1-(2-(3-(3-chlorophenoxy)azetidin-1-yl)-5-(trifluoromethyl)nicotinamido)cyclopropyl)benzoic acid (E41)




The title compound (**E41**) (10 mg) was prepared according to the experimental procedure described in Example 7 starting from methyl 4-(1-(2-(3-(3-chlorophenoxy)azetidin-1-yl)-5-(trifluoromethyl)nicotinamido)cyclopropyl)benzoate (D175) (12 mg, 0.0219 mmol).

MS: (ES/+) m/z : 532.3 [MH^+] $C_{26}H_{21}ClF_3N_3O_4$ requires 531.12

¹H NMR (400MHz, DMSO-d₆) δ (ppm): 12.77 (br. s., 1 H), 9.36 (s, 1 H), 8.52 (s, 1 H), 7.96 (d, *J* = 2.0 Hz, 1 H), 7.85 (d, *J* = 8.3 Hz, 2 H), 7.39 - 7.24 (m, 3 H), 7.09 - 7.00 (m, 1 H), 6.93 (t, *J* = 2.2 Hz, 1 H), 6.80 (dd, *J* = 2.2, 8.1 Hz, 1 H), 5.21 - 5.02 (m, 1 H), 4.44 (dd, *J* = 6.1, 10.5 Hz, 2 H), 3.99 - 3.83 (m, 2 H), 1.42 - 1.28 (m, 4 H)

5

Example 42: 4-(1-(2-(3-(4-fluoro-3-(trifluoromethyl)phenoxy)azetidin-1-yl)-5-(trifluoromethyl)nicotinamido)cyclopropyl)benzoic acid (E42)



The title compound (**E42**) (41 mg) was prepared according to the experimental procedure described in Example 7 starting from methyl 4-(1-(2-(3-(4-fluoro-3-


(trifluoromethyl)phenoxy)azetidin-1-yl)-5-

(trifluoromethyl)nicotinamido)cyclopropyl)benzoate (D176) (50 mg, 0.083 mmol).

MS: (ES/+) *m/z*: 584.4 [MH⁺] C₂₇H₂₀F₇N₃O₄ requires 583.13

¹H NMR (400MHz, DMSO-d₆) δ (ppm): 12.80 (br. s., 1 H), 9.36 (s, 1 H), 8.52 (d, *J* = 1.5 Hz, 1 H), 7.96 (d, *J* = 2.2 Hz, 1 H), 7.84 (d, *J* = 8.6 Hz, 2 H), 7.46 (t, *J* = 10.1 Hz, 1 H), 7.33 (d, *J* = 8.6 Hz, 2 H), 7.19 (dd, *J* = 2.8, 5.7 Hz, 2 H), 5.18 (td, *J* = 2.9, 6.2 Hz, 1 H), 4.45 (dd, *J* = 6.2, 10.6 Hz, 2 H), 3.93 (dd, *J* = 3.1, 10.4 Hz, 2 H), 1.41 - 1.27 (m, 4 H)

Example 43: 4-(1-(2-(3-(3-(trifluoromethoxy)phenoxy)azetidin-1-yl)-5-(trifluoromethyl)nicotinamido)cyclopropyl)benzoic acid (E43)



The title compound (**E43**) (106 mg) was prepared according to the experimental procedure described in Example 7 starting from methyl 4-(1-(2-(3-(3-


(trifluoromethoxy)phenoxy)azetidin-1-yl)-5-

(trifluoromethyl)nicotinamido)cyclopropyl)benzoate (D177) (113 mg, 0.189 mmol).

MS: (ES/+) m/z: 582.4 [MH⁺] C₂₇H₂₁F₆N₃O₅ requires 581.14

¹H NMR (400MHz, DMSO-d₆) δ (ppm): 12.78 (br. s., 1 H), 9.36 (s, 1 H), 8.52 (d, *J* = 1.2 Hz, 1 H), 7.96 (d, *J* = 2.2 Hz, 1 H), 7.84 (d, *J* = 8.3 Hz, 2 H), 7.44 (t, *J* = 8.3 Hz, 1 H), 7.33 (d, *J* = 8.6 Hz, 2 H), 6.98 (d, *J* = 7.8 Hz, 1 H), 6.86 (s, 2 H), 5.23 - 5.02 (m, 1 H), 4.45 (dd, *J* = 6.2, 10.4 Hz, 2 H), 3.92 (dd, *J* = 2.9, 10.3 Hz, 2 H), 1.41 - 1.26 (m, 4 H)

10 **Example 44: 4-(1-(2-(3-(2,4-difluorophenoxy)azetidin-1-yl)-5-(trifluoromethyl)nicotinamido)cyclopropyl)benzoic acid (E44)**




The title compound (**E44**) (98 mg) was prepared according to the experimental procedure described in Example 7 starting from methyl 4-(1-(2-(3-(2,4-difluorophenoxy)azetidin-1-yl)-5-

(trifluoromethyl)nicotinamido)cyclopropyl)benzoate (D178) (106 mg, 0.193 mmol).

MS: (ES/+) m/z: 534.3 [MH⁺] C₂₆H₂₀F₅N₃O₄ requires 533.14

¹H NMR (400MHz, DMSO-d₆) δ (ppm): 12.82 (br. s., 1 H), 9.37 (s, 1 H), 8.53 (d, *J* = 1.5 Hz, 1 H), 7.96 (d, *J* = 2.2 Hz, 1 H), 7.86 (d, *J* = 8.6 Hz, 2 H), 7.42 - 7.29 (m, 3 H), 7.06 - 6.97 (m, 1 H), 6.97 - 6.86 (m, 1 H), 5.23 - 4.93 (m, 1 H), 4.42 (dd, *J* = 6.2, 10.6 Hz, 2 H), 3.93 (dd, *J* = 3.1, 10.6 Hz, 2 H), 1.45 - 1.27 (m, 4 H)

Example 45: 4-(1-(2-(3-(3,4-difluorophenoxy)azetidin-1-yl)-5-(trifluoromethyl)nicotinamido)cyclopropyl)benzoic acid (E45)




The title compound (**E45**) (75 mg) was prepared according to the experimental procedure described in Example 7 starting from methyl 4-(1-(2-(3-(3,4-difluorophenoxy)azetidin-1-yl)-5-

(trifluoromethyl)nicotinamido)cyclopropyl)benzoate (D179) (79 mg, 0.144 mmol).

5 MS: (ES/+) m/z: 534.3 [MH⁺] C₂₆H₂₀F₅N₃O₄ requires 533.14

¹H NMR (400MHz, DMSO-d₆) δ (ppm): 12.80 (br. s., 1 H), 9.36 (s, 1 H), 8.52 (s, 1 H), 7.95 (d, *J* = 2.2 Hz, 1 H), 7.84 (d, *J* = 8.3 Hz, 2 H), 7.43 - 7.19 (m, 3 H), 7.01 (ddd, *J* = 3.1, 6.6, 12.3 Hz, 1 H), 6.65 (d, *J* = 8.1 Hz, 1 H), 5.08 (td, *J* = 2.8, 6.1 Hz, 1 H), 4.43 (dd, *J* = 6.0, 10.4 Hz, 2 H), 3.89 (dd, *J* = 3.2, 10.5 Hz, 2 H), 1.42 - 1.26 (m, 4 H)

Example 46: 4-(1-(2-(3-((5-methylisoxazol-3-yl)oxy)azetidin-1-yl)-5-(trifluoromethyl)nicotinamido)cyclopropyl)benzoic acid (E46)




15 The title compound (**E46**) (18 mg) was prepared according to the experimental procedure described in Example 7 starting from methyl 4-(1-(5-chloro-2-(3-((5-methylisoxazol-3-yl)oxy)azetidin-1-yl)nicotinamido)cyclopropyl)benzoate (D180) (20 mg, 0.039 mmol).

MS: (ES/+) m/z: 503.3 [MH⁺] C₂₄H₂₁F₃N₄O₅ requires 502.15

20 ¹H NMR (400MHz, DMSO-d₆) δ (ppm): 12.78 (s, 1 H), 9.34 (s, 1 H), 8.52 (d, *J* = 1.5 Hz, 1 H), 7.96 (d, *J* = 2.0 Hz, 1 H), 7.84 (d, *J* = 8.6 Hz, 2 H), 7.32 (d, *J* = 8.3 Hz, 2 H), 6.04 (d, *J* = 1.0 Hz, 1 H), 5.19 (br. s., 1 H), 4.36 (dd, *J* = 6.6, 10.3 Hz, 2 H), 3.96 (dd, *J* = 2.7, 10.5 Hz, 2 H), 2.34 (d, *J* = 0.7 Hz, 3 H), 1.34 (d, *J* = 4.2 Hz, 4 H)

Example 47: 4-(1-(5-(trifluoromethyl)-2-(3-((6-(trifluoromethyl)pyridin-2-yl)oxy)azetidin-1-yl)nicotinamido)cyclopropyl)benzoic acid (E47)




The title compound (**E47**) (62 mg) was prepared according to the experimental procedure described in Example 7 starting from methyl 4-(1-(5-chloro-2-(3-((5-methylisoxazol-3-yl)oxy)azetidin-1-yl)nicotinamido)cyclopropyl)benzoate (D181)

5 (75 mg, 0.131 mmol).

MS: (ES/+) m/z: 567.3 [MH⁺] C₂₆H₂₀F₆N₄O₄ requires 566.14

¹H NMR (400MHz, DMSO-d₆) δ (ppm): 12.74 (s, 1 H), 9.34 (s, 1 H), 8.52 (d, *J* = 1.5 Hz, 1 H), 8.04 (t, *J* = 7.9 Hz, 1 H), 7.96 (d, *J* = 2.0 Hz, 1 H), 7.82 (d, *J* = 8.6 Hz, 2 H), 7.54 (d, *J* = 7.3 Hz, 1 H), 7.31 (d, *J* = 8.6 Hz, 2 H), 7.25 (d, *J* = 8.3 Hz, 1 H),
 10 5.51 - 5.30 (m, 1 H), 4.43 (dd, *J* = 6.7, 10.6 Hz, 2 H), 3.99 (dd, *J* = 3.3, 10.9 Hz, 2 H), 1.32 (s, 4 H)

Example 48: 4-(1-(2-(3-((5-fluoropyrimidin-2-yl)oxy)azetidin-1-yl)-5-(trifluoromethyl)nicotinamido)cyclopropyl)benzoic acid (E48)



15


To a solution of methyl 4-(1-(2-(3-((5-fluoropyrimidin-2-yl)oxy)azetidin-1-yl)-5-(trifluoromethyl)nicotinamido)cyclopropyl) benzoate (D182) (35 mg, 0.065 mmol) in a mixture 1-4 dioxane/water (3ml/1ml) 1M NaOH (0.098ml, 0.098 mmol) was added. The mixture stirred 24 h at room temperature. After solvent evaporation,
 20 1N HCl solution was added up to pH2. The solid precipitate was filtered off and washed with diethylether to afford the title compound (**E48**) (27 mg)

MS: (ES/+) m/z: 518.2 [MH⁺] C₂₄H₁₉F₄N₅O₄ requires 517.14

¹H NMR (400MHz, DMSO-d₆) δ (ppm): 12.82 (br. s., 1 H), 9.35 (s, 1 H), 8.70 (s, 2 H), 8.52 (s, 1 H), 7.94 (d, *J* = 2.0 Hz, 1 H), 7.85 - 7.73 (m, *J* = 8.3 Hz, 2 H), 7.39 -

7.30 (m, $J = 8.3$ Hz, 2 H), 5.34 (td, $J = 2.9, 6.5$ Hz, 1 H), 4.40 (dd, $J = 6.4, 10.8$ Hz, 2 H), 3.96 (dd, $J = 3.2, 10.5$ Hz, 2 H), 1.41 - 1.27 (m, 4 H).

Example 49: 4-(1-(2-(3-((3-fluorophenyl)amino)azetidin-1-yl)-5-(trifluoromethyl)nicotinamido)cyclopropyl)benzoic acid (E49)




The title compound (**E49**) (14.5 mg) was prepared according to the experimental procedure described in Example 7 starting from methyl 4-(1-(2-(3-((3-fluorophenyl)amino)azetidin-1-yl)-5-(trifluoromethyl) nicotinamido) cyclopropyl) benzoate (D183) (16 mg, 0.030 mmol).

MS: (ES/+) m/z : 515.14 [MH^+] $C_{26}H_{22}F_4N_4O_3$ requires 514.16

^1H NMR (400MHz, DMSO- d_6) δ (ppm): 12.78 (br. s., 1 H), 9.35 (s, 1 H), 8.50 (d, $J = 1.5$ Hz, 1 H), 7.92 (d, $J = 2.4$ Hz, 1 H), 7.86 (d, $J = 8.3$ Hz, 2 H), 7.32 (d, $J = 8.8$ Hz, 2 H), 7.17 - 7.05 (m, 1 H), 6.67 (d, $J = 5.9$ Hz, 1 H), 6.42 - 6.33 (m, 1 H), 6.32 - 6.20 (m, 2 H), 4.39 - 4.29 (m, 2 H), 4.24 (d, $J = 5.9$ Hz, 1 H), 3.78 (dd, $J = 4.2, 9.5$ Hz, 2 H), 1.34 (d, $J = 6.8$ Hz, 4 H)

Example 50: 4-(1-(2-(3-((4-fluorophenyl)amino)azetidin-1-yl)-5-(trifluoromethyl)nicotinamido)cyclopropyl)benzoic acid (E50)



20


The title compound (**E50**) (34 mg) was prepared according to the experimental procedure described in Example 7 starting from methyl 4-(1-(2-(3-((4-fluorophenyl)amino)azetidin-1-yl)-5-(trifluoromethyl) nicotinamido) cyclopropyl) benzoate (D184) (35 mg, 0.066 mmol).

25 MS: (ES/+) m/z : 515.14 [MH^+] $C_{26}H_{22}F_4N_4O_3$ requires 514.16

¹H NMR (400MHz ,DMSO-d₆) δ (ppm): 12.82 (br. s., 1 H), 9.34 (s, 1 H), 8.49 (s, 1 H), 7.94 - 7.82 (m, 3 H), 7.33 (d, *J* = 8.3 Hz, 2 H), 6.95 (t, *J* = 8.8 Hz, 2 H), 6.45 (dd, *J* = 4.4, 8.8 Hz, 2 H), 6.26 (br. s., 1 H), 4.39 - 4.25 (m, 2 H), 4.18 (br. s., 1 H), 3.74 (dd, *J* = 4.2, 9.0 Hz, 2 H), 1.42 - 1.25 (m, 4 H)

5

Example 51: 4-(1-(2-(3-((4-fluoro-2-methylphenyl)amino)azetidin-1-yl)-5-(trifluoromethyl)nicotinamido)cyclopropyl)benzoic acid (E51)




The title compound (**E51**) (19 mg) was prepared according to the experimental procedure described in Example 7 starting from methyl 4-(1-(2-(3-((4-fluoro-2-methylphenyl)amino)azetidin-1-yl)-5-(trifluoromethyl) nicotinamido) cyclopropyl) benzoate (D185) (20 mg, 0.036 mmol).

MS: (ES/+) *m/z*: 529.4 [MH⁺] C₂₇H₂₄F₄N₄O₃ requires 528.18

¹H NMR (400MHz ,DMSO-d₆) δ (ppm): 12.83 (br. s., 1 H), 9.48 - 9.20 (m, 1 H), 8.50 (s, 1 H), 7.95 - 7.82 (m, 3 H), 7.34 (d, *J* = 8.3 Hz, 2 H), 6.98 - 6.71 (m, 2 H), 6.21 (dd, *J* = 4.9, 8.8 Hz, 1 H), 5.40 (br. s., 1 H), 4.40 - 4.28 (m, 2 H), 4.21 (br. s., 1 H), 3.91 - 3.79 (m, 2 H), 2.13 (s, 3 H), 1.40 - 1.27 (m, 4 H)

Example 52: 4-(1-(2-(3-((2,4-difluorophenyl)amino)azetidin-1-yl)-5-(trifluoromethyl)nicotinamido)cyclopropyl)benzoic acid (E52)




The title compound (**E52**) (34 mg) was prepared according to the experimental procedure described in Example 7 starting from methyl 4-(1-(2-(3-((2,4-

difluorophenyl)amino)azetidin-1-yl)-5-(trifluoromethyl) nicotinamido) cyclopropyl) benzoate (D186) (9 mg, 0.016 mmol).

MS: (ES/+) m/z: 533.4 [MH⁺] C₂₆H₂₁F₅N₄O₃ requires 532.15

¹H NMR (400MHz, DMSO-d₆) δ (ppm): 12.83 (br. s., 1 H), 9.41 - 9.27 (m, 1 H),
 5 8.56 - 8.43 (m, 1 H), 7.94 - 7.81 (m, 3 H), 7.42 - 7.29 (m, 2 H), 7.11 (ddd, *J* = 2.7,
 8.9, 11.9 Hz, 1 H), 6.87 (t, *J* = 8.8 Hz, 1 H), 6.47 (dt, *J* = 5.6, 9.4 Hz, 1 H), 6.09 (br.
 s., 1 H), 4.36 - 4.28 (m, 2 H), 4.26 (br. s., 1 H), 3.86 (dd, *J* = 3.7, 9.0 Hz, 2 H), 1.41
 - 1.28 (m, 4 H)

10 **Example 53: 4-(1-(5-fluoro-2-(3-(3-fluorophenoxy)azetidin-1-yl)nicotinamido)cyclopropyl)benzoic acid (E53)**




The title compound (**E53**) (33 mg) was prepared according to the experimental procedure described in Example 7 starting from methyl 4-(1-(5-fluoro-2-(3-(3-fluorophenoxy)azetidin-1-yl)nicotinamido)cyclopropyl)benzoate (D187) (43 mg,
 15 0.089 mmol).

MS: (ES/+) m/z: 466.3 [MH⁺] C₂₅H₂₁F₂N₃O₄ requires 465.15

¹H NMR (400MHz, DMSO-d₆) δ (ppm): 12.78 (br. s., 1 H), 9.23 (s, 1 H), 8.24 (d, *J* = 2.9 Hz, 1 H), 7.84 (d, *J* = 8.3 Hz, 2 H), 7.72 (dd, *J* = 2.7, 8.6 Hz, 1 H), 7.44 - 7.21
 20 (m, 3 H), 6.85 - 6.77 (m, 1 H), 6.77 - 6.70 (m, 1 H), 6.66 (dd, *J* = 2.0, 8.3 Hz, 1 H),
 5.14 - 5.01 (m, 1 H), 4.32 (dd, *J* = 6.4, 9.8 Hz, 2 H), 3.79 (dd, *J* = 3.4, 9.8 Hz, 2 H),
 1.32 (s, 4 H)

25 **Example 54: 4-(1-(5-fluoro-2-(3-(3-chlorophenoxy)azetidin-1-yl)nicotinamido)cyclopropyl)benzoic acid (E54)**




The title compound (**E54**) (11.6 mg) was prepared according to the experimental procedure described in Example 37 starting from methyl 4-(1-(5-fluoro-2-(3-(3-chlororophenoxy)azetidin-1-yl)nicotinamido)cyclopropyl)benzoate (D188) (12 mg, 0.024 mmol).

5 MS: (ES/+) m/z: 482.2 [MH⁺] C₂₅H₂₁ClFN₃O₄ requires 481.12

¹H NMR (400MHz, DMSO-d₆) δ (ppm): 12.77 (br. s., 1 H), 9.22 (s, 1 H), 8.24 (d, *J* = 2.4 Hz, 1 H), 7.84 (d, *J* = 8.3 Hz, 2 H), 7.72 (dd, *J* = 2.9, 8.3 Hz, 1 H), 7.37 - 7.27 (m, 3 H), 7.03 (d, *J* = 7.8 Hz, 1 H), 6.92 (s, 1 H), 6.80 (dd, *J* = 2.4, 8.3 Hz, 1 H), 5.10 (d, *J* = 2.9 Hz, 1 H), 4.32 (dd, *J* = 6.1, 9.5 Hz, 2 H), 3.80 (dd, *J* = 3.4, 9.8 Hz, 2 H), 1.33 (s, 4 H)

Example 55: 4-(1-(5-fluoro-2-(3-(3-(trifluoromethoxy)phenoxy)azetidin-1-yl)nicotinamido)cyclopropyl)benzoic acid (E55)




15 The title compound (**E55**) (24 mg) was prepared according to the experimental procedure described in Example 37 starting from methyl 4-(1-(5-fluoro-2-(3-(3-(trifluoromethoxy)phenoxy)azetidin-1-yl)nicotinamido)cyclopropyl)benzoate (D189) (39 mg, 0.071 mmol).

MS: (ES/+) m/z: 532.2 [MH⁺] C₂₆H₂₁F₄N₃O₅ requires 531.14

20 ¹H NMR (400MHz, DMSO-d₆) δ (ppm): 9.23 (s, 1 H), 8.24 (d, *J* = 2.9 Hz, 1 H), 7.88 - 7.81 (m, *J* = 8.3 Hz, 2 H), 7.73 (dd, *J* = 2.9, 8.3 Hz, 1 H), 7.44 (t, *J* = 8.6 Hz, 1 H), 7.35 - 7.29 (m, *J* = 8.3 Hz, 2 H), 6.97 (d, *J* = 8.3 Hz, 1 H), 6.90 - 6.84 (m, 2 H), 5.13 (t, *J* = 3.4 Hz, 1 H), 4.33 (dd, *J* = 6.4, 9.8 Hz, 2 H), 3.81 (dd, *J* = 3.4, 9.8 Hz, 2 H), 1.32 (s, 4 H)

25

Example 56: 4-(1-(5-fluoro-2-(3-((4-fluoro-2-methylphenyl)amino)azetidin-1-yl)nicotinamido)cyclopropyl)benzoic acid (E56)




The title compound (**E56**) (18 mg) was prepared according to the experimental procedure described in Example 37 starting from methyl 4-(1-(5-fluoro-2-(3-((4-fluoro-2-methylphenyl)amino)azetidin-1-yl)nicotinamido)cyclopropyl)benzoate

5 (D190) (25 mg, 0.051 mmol)

MS: (ES/+) m/z: 479.2 [MH⁺] C₂₆H₂₄F₂N₄O₃ requires 478.18

¹H NMR (400MHz, DMSO-d₆) δ (ppm): 12.80 (br. s., 1 H), 9.20 (s, 1 H), 8.21 (d, *J* = 2.9 Hz, 1 H), 7.92 - 7.80 (m, *J* = 8.3 Hz, 2 H), 7.66 (dd, *J* = 2.9, 8.3 Hz, 1 H), 7.37 - 7.27 (m, *J* = 8.3 Hz, 2 H), 6.93 - 6.77 (m, 2 H), 6.21 (dd, *J* = 4.9, 8.8 Hz, 1 H), 5.30 (d, *J* = 5.4 Hz, 1 H), 4.27 - 4.10 (m, 3 H), 3.74 (dd, *J* = 4.2, 8.1 Hz, 2 H), 2.12 (s, 3 H), 1.33 (s, 4 H)

Example 57: 4-((1S)-1-(5-chloro-2-(3-(4-(trifluoromethyl)phenoxy)pyrrolidin-1-yl)nicotinamido)ethyl)benzoic acid (E57)



15


To a solution of methyl 4-((1S)-1-(5-chloro-2-(3-(4-(trifluoromethyl)phenoxy)pyrrolidin-1-yl)nicotinamido)ethyl)benzoate (D191) (50 mg, 0.091 mmol) in 1,4-dioxane (3ml) and water (1ml) lithium hydroxide monohydrate (5.8 mg, 0.14 mmol) was added and the resulting mixture was stirred at room temperature for 2 days. Solvents were evaporated in vacuo. The residue was diluted with water (5ml) and 1M HCl (15ml) and extracted with ethylacetate (3x20ml). Collected organics, after solvent evaporation, afforded the title compound (**E57**) (40 mg).

20

MS: (ES/+) m/z: 534.2 [MH⁺] C₂₆H₂₃ClF₃N₃O₄ requires 533.13

25

Example 58: 4-((1S)-1-(5-chloro-2-(3-(3-(trifluoromethyl)phenoxy)pyrrolidin-1-yl)nicotinamido)ethyl)benzoic acid (E58)




The title compound **(E58)** (61 mg) was prepared according to the experimental procedure described in Example 7 starting from methyl 4-((1S)-1-(5-chloro-2-(3-(3-(trifluoromethyl)phenoxy)pyrrolidin-1-yl)nicotinamido)ethyl)benzoate (D192) (110 mg, 0.2 mmol)

MS: (ES/+) m/z: 534 [MH⁺] C₂₆H₂₃ClF₃N₃O₄ requires 533.13

¹H NMR (400MHz, DMSO-d₆) δ (ppm): 12.84 (br. s., 2 H), 9.06 (dd, *J* = 4.2, 7.6 Hz, 2 H), 8.23 - 8.13 (m, 2 H), 7.91 (dd, *J* = 8.3, 10.3 Hz, 4 H), 7.61 (d, *J* = 2.4 Hz, 1 H), 7.57 - 7.44 (m, 7 H), 7.30 (d, *J* = 7.8 Hz, 2 H), 7.27 - 7.14 (m, 4 H), 5.21 (br. s., 1 H), 5.16 - 5.02 (m, 3 H), 3.77 (dd, *J* = 4.4, 12.2 Hz, 1 H), 3.66 (dd, *J* = 4.4, 12.7 Hz, 1 H), 3.58 - 3.39 (m, 4 H), 3.30 - 3.28 (m, 2 H), 2.33 - 1.90 (m, 4 H), 1.46 (d, *J* = 6.8 Hz, 3 H), 1.39 (d, *J* = 6.8 Hz, 3 H)

Example 59: 4-((1S)-1-(5-chloro-2-(3-(4-fluorophenoxy)pyrrolidin-1-yl)nicotinamido)ethyl)benzoic acid (E59)



The title compound **(E59)** (62 mg) was prepared according to the experimental procedure described in Example 7 starting from methyl 4-((1S)-1-(5-chloro-2-(3-(4-fluorophenoxy)pyrrolidin-1-yl)nicotinamido)ethyl)benzoate (D193) (64 mg, 0.128 mmol)

MS: (ES/+) m/z: 484 [MH⁺] C₂₅H₂₃ClFN₃O₄ requires 483.14

¹H NMR (400MHz, DMSO-d₆) δ (ppm): 9.07 (d, *J* = 7.8 Hz, 2 H), 8.16 (d, *J* = 2.4 Hz, 2 H), 7.99 - 7.85 (m, 4 H), 7.61 (d, *J* = 2.9 Hz, 1 H), 7.58 - 7.44 (m, 5 H), 7.10 (dt, *J* = 6.4, 8.8 Hz, 4 H), 6.97 - 6.79 (m, 4 H), 5.17 - 5.05 (m, 2 H), 5.00 (br. s., 1


H), 4.91 (br. s., 1 H), 3.69 (dd, $J = 4.4, 12.2$ Hz, 1 H), 3.62 - 3.55 (m, 1 H), 3.53 - 3.26 (m, 5 H), 3.20 (d, $J = 12.7$ Hz, 1 H), 2.22 - 1.95 (m, 4 H), 1.46 (d, $J = 6.8$ Hz, 3 H), 1.41 (d, $J = 6.8$ Hz, 3 H)

5 **Example 60, 61 and 62:**

4-(1-(5-chloro-2-(3-phenoxy pyrrolidin-1-yl)nicotinamido)cyclopropyl)benzoic acid (racemic mixture) (E60)

4-(1-(5-chloro-2-(3-phenoxy pyrrolidin-1-yl)nicotinamido)cyclopropyl)benzoic acid (enantiomer 1) (E61)

10 **4-(1-(5-chloro-2-(3-phenoxy pyrrolidin-1-yl)nicotinamido)cyclopropyl)benzoic acid (enantiomer 2) (E62)**



To an ice cooled solution of methyl 4-(1-(5-chloro-2-(3-phenoxy pyrrolidin-1-yl)nicotinamido)cyclopropyl)benzoate (D194) (100 mg, 0.20 mmol) in a mixture
15 methanol/tetrahydrofuran (10ml/10ml) 2N NaOH (10ml). The reaction mixture was heated to 40°C for 3 hours then cooled to room temperature. Methanol was evaporated and water was added (10ml). After cooling to 0°C, the mixture was acidified with 2.5N HCl (pH=1-2), then stirred at 0°C for 30min. The pale yellow solid was collected by filtration, washed with water, dried and washed with
20 DCM/MeOH (v/v, 20:1), filtered and dried to provide the title compound **(E60)** (36 mg) as a white solid.

MS: (ES/+) m/z: 478 [MH⁺] C₂₆H₂₄ClN₃O₄ requires 477.14

¹HNMR (400 MHz, METHANOL-d₄) δ (ppm): 8.13 (1H, d, $J = 2.0$ Hz), 7.99 (2H, d, $J = 8.4$ Hz), 7.63 (1H, d, $J = 2.0$ Hz), 7.47 (2H, d, $J = 8.0$ Hz), 7.29 (2H, t, $J = 7.6$ Hz), 6.96 (1H, t, $J = 7.6$ Hz), 6.86 (2H, d, $J = 8.4$ Hz), 4.99 (1H, s), 3.66 - 3.70 (2H, m), 3.50 - 3.51 (1H, m), 3.37 (1H, s), 2.18 (2H, s), 1.32 - 1.41 (4H, m).
25

(E60) (23 mg) dissolved in ethanol (4.5ml) was separated by chiral HPLC [Daicel Chiralpack IC column (2x25cm, 5μm particle size). Mobile phase: isocratic premixed mixture of heptane 70%, ethanol 30% containing 0.1% of trifluoroacetic acid. Flow rate=10 ml/min. UV detection: 270 nm]. Collected fractions after solvent
30

evaporation of the separated peaks, gave the title compounds **(E61)** (9 mg) and **(E62)** (9 mg) as single enantiomers.

(E61): (single enantiomer 1)

MS: (ES/+) m/z: 478 [MH⁺] C₂₆H₂₄ClN₃O₄ requires 477.14

5 ¹H NMR (400MHz, DMSO-d₆) δ (ppm): 9.27 (s, 1 H), 8.18 (d, *J* = 2.4 Hz, 1 H), 7.92 - 7.84 (m, 2 H), 7.69 (d, *J* = 2.9 Hz, 1 H), 7.35 (d, *J* = 8.8 Hz, 2 H), 7.32 - 7.26 (m, 2 H), 6.95 (t, *J* = 7.3 Hz, 1 H), 6.90 (d, *J* = 7.8 Hz, 2 H), 5.08 (br. s., 1 H), 3.70 (dd, *J* = 4.4, 12.2 Hz, 1 H), 3.60 - 3.51 (m, 1 H), 3.51 - 3.44 (m, 1 H), 3.31 (d, *J* = 12.2 Hz, 1 H), 2.15 (d, *J* = 12.7 Hz, 2 H), 1.36 - 1.24 (m, 4 H).

10 **(E62)**: (single enantiomer 2)

MS: (ES/+) m/z: 478 [MH⁺] C₂₆H₂₄ClN₃O₄ requires 477.14


¹H NMR (400MHz, DMSO-d₆) δ (ppm): 9.27 (s, 1 H), 8.18 (d, *J* = 2.4 Hz, 1 H), 7.92 - 7.84 (m, 2 H), 7.69 (d, *J* = 2.9 Hz, 1 H), 7.35 (d, *J* = 8.8 Hz, 2 H), 7.32 - 7.26 (m, 2 H), 6.95 (t, *J* = 7.3 Hz, 1 H), 6.90 (d, *J* = 7.8 Hz, 2 H), 5.08 (br. s., 1 H), 3.70 (dd, *J* = 4.4, 12.2 Hz, 1 H), 3.60 - 3.51 (m, 1 H), 3.51 - 3.44 (m, 1 H), 3.31 (d, *J* = 12.2 Hz, 1 H), 2.15 (d, *J* = 12.7 Hz, 2 H), 1.36 - 1.24 (m, 4 H).

Example 63, 64 and 65:

20 **4-(1-(5-chloro-2-(3-(3-(trifluoromethyl)phenoxy)pyrrolidin-1-yl)nicotinamido)cyclopropyl)benzoic acid (racemic mixture) (E63)**
(0004/052/1)

4-(1-(5-chloro-2-(3-(3-(trifluoromethyl)phenoxy)pyrrolidin-1-yl)nicotinamido)cyclopropyl)benzoic acid (enantiomer 1) (E64)

25 **4-(1-(5-chloro-2-(3-(3-(trifluoromethyl)phenoxy)pyrrolidin-1-yl)nicotinamido)cyclopropyl)benzoic acid (enantiomer 2) (E65)**



The title compound **(E63)** (88 mg) was prepared according to the experimental procedure described in Example 7 starting from methyl 4-(1-(5-chloro-2-(3-(3-(trifluoromethyl)phenoxy)pyrrolidin-1-yl)nicotinamido)cyclopropyl)benzoate (D195) (50 mg, 0.098 mmol).

MS: (ES/+) m/z: 546.2 [MH⁺] C₂₇H₂₃ClF₃N₃O₄ requires 545.13

¹H NMR (400MHz, DMSO-d₆) δ (ppm): 12.78 (br. s., 1 H), 9.29 (s, 1 H), 8.19 (d, *J* = 2.4 Hz, 1 H), 7.86 (d, *J* = 8.3 Hz, 2 H), 7.72 (d, *J* = 2.4 Hz, 1 H), 7.57 - 7.47 (m, 1 H), 7.39 - 7.29 (m, 3 H), 7.28 - 7.18 (m, 2 H), 5.24 (br. s., 1 H), 3.75 (dd, *J* = 4.2, 12.0 Hz, 1 H), 3.62 - 3.50 (m, 1 H), 3.50 - 3.41 (m, 1 H), 3.38 - 3.35 (m, 1 H), 2.28 - 2.16 (m, 2 H), 2.11 (d, *J* = 13.7 Hz, 2 H), 1.39 - 1.17 (m, 4 H)

(E63) (27.3 mg) dissolved in chloroform (150ul) ethanol (115ul) and heptane (350ul) was separated by chiral HPLC [Daicel Chiralpack IC column (2x25 cm, 5μm particle size). Mobile phase: isocratic premixed mixture of heptane 70%, ethanol 30% containing 0.1% of trifluoroacetic acid. Flow rate=10 ml/min. UV detection: 270 nm]. Collected fractions after solvent evaporation of the separated peaks, gave the title compounds **(E64)** (11 mg) and **(E65)** (7 mg) as single enantiomers.

(E64): (single enantiomer 1)

MS: (ES/+) m/z: 546.2 [MH⁺] C₂₇H₂₃ClF₃N₃O₄ requires 545.13

¹H NMR (400MHz, DMSO-d₆) δ (ppm): 13.07 - 12.43 (m, 1 H), 9.27 (s, 1 H), 8.27 - 8.10 (m, 1 H), 7.90 - 7.82 (m, *J* = 8.3 Hz, 2 H), 7.76 - 7.66 (m, 1 H), 7.59 - 7.47 (m, 1 H), 7.35 (d, *J* = 8.3 Hz, 3 H), 7.27 - 7.21 (m, 2 H), 5.30 - 5.15 (m, 1 H), 3.78 - 3.71 (m, 1 H), 3.60 - 3.50 (m, 1 H), 3.50 - 3.42 (m, 1 H), 3.38 - 3.30 (m, 1 H), 2.29 - 2.04 (m, 2 H), 1.40 - 1.20 (m, 4 H)

(E65): (single enantiomer 2)

MS: (ES/+) m/z: 546.2 [MH⁺] C₂₇H₂₃ClF₃N₃O₄ requires 545.13


¹H NMR (400MHz, DMSO-d₆) δ (ppm): 12.74 (br. s., 1 H), 9.27 (s, 1 H), 8.19 (d, *J* = 2.4 Hz, 1 H), 7.86 (d, *J* = 8.3 Hz, 2 H), 7.71 (d, *J* = 2.4 Hz, 1 H), 7.58 - 7.47 (m, 1 H), 7.40 - 7.28 (m, 3 H), 7.27 - 7.20 (m, 2 H), 5.24 (br. s., 1 H), 3.74 (dd, *J* = 3.9, 12.2 Hz, 1 H), 3.59 - 3.50 (m, 1 H), 3.50 - 3.43 (m, 1 H), 3.34 (d, *J* = 11.7 Hz, 1 H), 2.21 (dd, *J* = 4.6, 9.0 Hz, 1 H), 2.12 (br. s., 1 H), 1.39 - 1.18 (m, 4 H)

Example 66, 67 and 68:

4-(1-(5-chloro-2-(3-(4-fluorophenoxy)pyrrolidin-1-yl)nicotinamido)cyclopropyl)benzoic acid (racemic mixture) (E66)

4-(1-(5-chloro-2-(3-(4-fluorophenoxy)pyrrolidin-1-yl)nicotinamido)cyclopropyl)benzoic acid (enantiomer 1) (E67)

4-(1-(5-chloro-2-(3-(4-fluorophenoxy)pyrrolidin-1-yl)nicotinamido)cyclopropyl)benzoic acid (enantiomer 2) (E68)



5

The title compound (**E66**) (23 mg) was prepared according to the experimental procedure described in Example 7 starting from methyl 4-(1-(5-chloro-2-(3-(4-fluorophenoxy)pyrrolidin-1-yl)nicotinamido)cyclopropyl)benzoate (D196) (50 mg, 0.098 mmol).

10 MS: (ES/+) m/z: 496.2 [MH⁺] C₂₆H₂₃ClFN₃O₄ requires 495.14

¹H NMR (400MHz, DMSO-d₆) δ (ppm): 12.79 (br. s., 1 H), 9.29 (s, 1 H), 8.19 (d, J = 2.4 Hz, 1 H), 7.87 (d, J = 8.6 Hz, 2 H), 7.71 (d, J = 2.4 Hz, 1 H), 7.39 - 7.24 (m, 3 H), 6.91 - 6.69 (m, 3 H), 5.13 (br. s., 1 H), 3.72 (dd, J = 4.3, 12.1 Hz, 1 H), 3.60 - 3.40 (m, 2 H), 3.31 - 3.29 (m, 1 H), 2.27 - 2.04 (m, 2 H), 1.42 - 1.17 (m, 4 H)

15 (E66) (15 mg) dissolved in chloroform (300ul) and ethanol (2.2ml) was separated by chiral HPLC [Daicel Chiralpack IC column (2x25 cm, 5μm particle size). Mobile phase: isocratic premixed mixture of heptane 70%, ethanol 30% containing 0.1% of trifluoroacetic acid. Flow rate=10 ml/min. UV detection: 270 nm]. Collected fractions after solvent evaporation of the separated peaks, gave the title
20 compounds (**E67**) (3 mg) and (**E68**) (3 mg) as single enantiomers.

(**E67**): (single enantiomer 1)

MS: (ES/+) m/z: 496.2 [MH⁺] C₂₆H₂₃ClFN₃O₄ requires 495.14

25 ¹H NMR (400MHz, DMSO-d₆) δ (ppm): 12.78 (br. s., 1 H), 9.27 (s, 1 H), 8.18 (d, J = 2.4 Hz, 1 H), 7.87 (d, J = 8.8 Hz, 2 H), 7.70 (d, J = 2.9 Hz, 1 H), 7.35 (d, J = 8.3 Hz, 2 H), 7.16 - 7.05 (m, 2 H), 6.99 - 6.81 (m, 2 H), 5.03 (br. s., 1 H), 3.68 (dd, J = 4.4, 12.2 Hz, 1 H), 3.58 - 3.40 (m, 2 H), 3.34 - 3.26 (m, 1 H, under water peak), 2.26 - 1.98 (m, 2 H), 1.39 - 1.19 (m, 4 H)

(**E68**): (single enantiomer 2)

MS: (ES/+) m/z: 496.2 [MH⁺] C₂₆H₂₃ClFN₃O₄ requires 495.14


¹H NMR (400MHz, DMSO-d₆) δ (ppm): 12.78 (br. s., 1 H), 9.27 (s, 1 H), 8.18 (d, *J* = 2.4 Hz, 1 H), 7.90 - 7.81 (m, 2 H), 7.70 (d, *J* = 2.9 Hz, 1 H), 7.35 (d, *J* = 8.3 Hz, 2 H), 7.16 - 7.06 (m, 2 H), 6.97 - 6.88 (m, 2 H), 5.03 (br. s., 1 H), 3.68 (dd, *J* = 4.4, 12.2 Hz, 1 H), 3.53 (dt, *J* = 6.8, 10.3 Hz, 1 H), 3.49 - 3.41 (m, 1 H), 3.34 - 3.30 (m, 1 H, under water peak), 2.22 - 2.02 (m, 2 H), 1.36 - 1.22 (m, 4 H)

Example 69, 70 and 71:

4-(1-(5-chloro-2-(3-(3-fluorophenoxy)pyrrolidin-1-yl)nicotinamido)cyclopropyl)benzoic acid (racemic mixture) (E69)

4-(1-(5-chloro-2-(3-(3-fluorophenoxy)pyrrolidin-1-yl)nicotinamido)cyclopropyl)benzoic acid (enantiomer1) (E70)

4-(1-(5-chloro-2-(3-(3-fluorophenoxy)pyrrolidin-1-yl)nicotinamido)cyclopropyl)benzoic acid (enantiomer 2) (E71)



The title compound (**E69**) (166 mg) was prepared according to the experimental procedure described in Example 7 starting from methyl 4-(1-(5-chloro-2-(3-(3-fluorophenoxy)pyrrolidin-1-yl)nicotinamido)cyclopropyl)benzoate (D197) (180 mg, 0.353 mmol).

MS: (ES/+) *m/z*: 496.2 [MH⁺] C₂₆H₂₃ClFN₃O₄ requires 495.14

¹H NMR (400MHz, DMSO-d₆) δ (ppm): 12.79 (br. s., 1 H), 9.29 (s, 1 H), 8.19 (d, *J* = 2.4 Hz, 1 H), 7.87 (d, *J* = 8.6 Hz, 2 H), 7.71 (d, *J* = 2.4 Hz, 1 H), 7.39 - 7.24 (m, 3 H), 6.91 - 6.69 (m, 3 H), 5.13 (br. s., 1 H), 3.72 (dd, *J* = 4.3, 12.1 Hz, 1 H), 3.60 - 3.40 (m, 2 H), 3.31 - 3.29 (m, 1 H), 2.27 - 2.04 (m, 2 H), 1.42 - 1.17 (m, 4 H)

(**E69**) (25 mg) dissolved in and ethanol (3.7ml) was separated by chiral HPLC [Daicel Chiralpack IC column (2x25 cm, 5μm particle size). Mobile phase: isocratic premixed mixture of heptane 70%, ethanol 30% containing 0.1% of trifluoroacetic acid. Flow rate=10 ml/min. UV detection: 270 nm]. Collected fractions after solvent evaporation of the separated peaks, gave the title compounds (**E70**) (11 mg) and (**E71**) (11 mg) as single enantiomers.

(E70): (single enantiomer 1)

MS: (ES/+) m/z: 496.2 [MH⁺] C₂₆H₂₃ClFN₃O₄ requires 495.14


¹H NMR (400MHz, DMSO-d₆) δ (ppm): 9.27 (s, 1 H), 8.19 (d, *J* = 2.4 Hz, 1 H), 7.87 (d, *J* = 8.3 Hz, 2 H), 7.70 (d, *J* = 2.4 Hz, 1 H), 7.39 - 7.27 (m, 3 H), 6.91 - 6.72 (m, 3 H), 5.13 (br. s., 1 H), 3.71 (dd, *J* = 4.4, 12.2 Hz, 1 H), 3.58 - 3.39 (m, 2 H), 3.32 (d, *J* = 12.2 Hz, 1 H), 2.26 - 2.14 (m, 1 H), 2.12 (br. s., 1 H), 1.37 - 1.22 (m, 4 H)

(E71): (single enantiomer 2)

MS: (ES/+) m/z: 496.2 [MH⁺] C₂₆H₂₃ClFN₃O₄ requires 495.14

¹H NMR (400MHz, DMSO-d₆) δ (ppm): 9.27 (s, 1 H), 8.19 (d, *J* = 2.4 Hz, 1 H), 7.87 (d, *J* = 8.3 Hz, 2 H), 7.70 (d, *J* = 2.4 Hz, 1 H), 7.39 - 7.25 (m, 3 H), 6.88 - 6.71 (m, 3 H), 5.13 (br. s., 1 H), 3.72 (dd, *J* = 4.6, 12.5 Hz, 1 H), 3.60 - 3.42 (m, 2 H), 3.32 (d, *J* = 12.2 Hz, 1 H), 2.25 - 2.14 (m, 1 H), 2.11 (br. s., 1 H), 1.38 - 1.23 (m, 4 H)

Example 72: 4-(1-(5-chloro-2-(3-(*m*-tolylloxy)pyrrolidin-1-yl)nicotinamido)cyclopropyl)benzoic acid (E72)



The title compound **(E72)** (4 mg) was prepared according to the experimental procedure described in Example 7 starting from methyl 4-(1-(5-chloro-2-(3-(*m*-tolylloxy)pyrrolidin-1-yl)nicotinamido)cyclopropyl)benzoate (D198) (12 mg, 0.024 mmol)

MS: (ES/+) m/z: 492.2 [MH⁺] C₂₇H₂₆ClN₃O₄ requires 491.16

¹H NMR (400MHz, DMSO-d₆) δ (ppm): 9.28 (s, 1 H), 8.19 (d, *J* = 2.4 Hz, 1 H), 7.87 (d, *J* = 8.3 Hz, 2 H), 7.70 (d, *J* = 2.4 Hz, 1 H), 7.35 (d, *J* = 8.3 Hz, 2 H), 7.16 (s, 1 H), 6.83 - 6.63 (m, 3 H), 5.07 (br. s., 1 H), 3.70 (dd, *J* = 4.2, 12.0 Hz, 1 H), 3.61 - 3.41 (m, 2 H), 3.30 (d, *J* = 12.7 Hz, 1 H), 2.28 (s, 3 H), 2.23 - 2.04 (m, 2 H), 1.42 - 1.14 (m, 4 H)


Example 73, 74 and 75: 4-(1-(5-chloro-2-(3-(4-(trifluoromethyl)phenoxy)pyrrolidin-1-yl)nicotinamido)cyclopropyl)benzoic acid (racemic mixture) (E73)

4-(1-(5-chloro-2-(3-(4-(trifluoromethyl)phenoxy)pyrrolidin-1-

5 yl)nicotinamido)cyclopropyl)benzoic acid (Enantiomer1) (E74)

4-(1-(5-chloro-2-(3-(4-(trifluoromethyl)phenoxy)pyrrolidin-1-

yl)nicotinamido)cyclopropyl)benzoic acid (Enantiomer2) (E75)



To a solution of methyl 4-(1-(5-chloro-2-(3-(4-(trifluoromethyl)phenoxy)pyrrolidin-1-yl)nicotinamido)cyclopropyl)benzoate (D199) (24 mg, 0.428 mmol) in a mixture 1,4-dioxane and water (3ml/1ml) lithium hydroxide monohydrate (2.7 mg, 0.064 mmol) was added and the mixture was stirred 2 days at room temperature. After solvent evaporation the residue was diluted with water (5ml) and HCl 1M (15ml) and extracted with ethylacetate (3x20ml). Collected organics after solvent evaporation gave the title compound **(E73)** (15mg) as racemic mixture.

MS: (ES/+) m/z: 546.2 [MH⁺] C₂₇H₂₃ClF₃N₃O₄ requires 545.13

¹H NMR (400MHz, METHANOL-d₄) δ (ppm): 8.17 - 8.09 (m, 1 H), 8.01 - 7.94 (m, 2 H), 7.64 - 7.55 (m, 3 H), 7.50 - 7.44 (m, 2 H), 7.06 - 6.98 (m, 2 H), 5.13 - 5.06 (m, 1 H), 3.79 - 3.60 (m, 2 H), 3.55 - 3.47 (m, 1 H), 3.40 - 3.40 (m, 1 H), 2.28 - 2.10 (m, 2 H), 1.44 - 1.28 (m, 4 H)

(E73) (12 mg) dissolved in a mixture dimethylsulfoxide/ethanol/hexane (200μl/300μl/200μl) was separated by chiral HPLC [Daicel Chiralpack IC column (2x25 cm, 5μm particle size). Mobile phase: isocratic premixed mixture of hexane 80%, isopropanol 20% containing 0.2% of trifluoroacetic acid. Flow rate=10 ml/min. UV detection: 245 nm]. Collected fractions after solvent evaporation of the separated peaks, gave the title compounds **(E74)** (1 mg) and **(E75)** (1.3 mg) as single enantiomers.

(E74): (single enantiomer 1)

MS: (ES/+) m/z: 546.2 [MH⁺] C₂₇H₂₃ClF₃N₃O₄ requires 545.13


¹H NMR (400MHz ,DMSO-d₆) δ (ppm): 9.35 - 9.21 (m, 1 H), 8.23 - 8.16 (m, 1 H), 7.90 - 7.84 (m, 2 H), 7.73 - 7.69 (m, 1 H), 7.67 - 7.61 (m, 2 H), 7.38 - 7.33 (m, 2 H), 7.13 - 7.07 (m, 2 H), 5.24 - 5.19 (m, 1 H), 3.78 - 3.71 (m, 1 H), 3.59 - 3.44 (m, 2 H), 3.38 - 3.31 (m, 1 H), 2.28 - 2.08 (m, 2 H), 1.38 - 1.20 (m, 4 H)

5 **(E75):** (single enantiomer 2)

MS: (ES/+) m/z: 546.2 [MH⁺] C₂₇H₂₃ClF₃N₃O₄ requires 545.13

¹H NMR (400MHz ,DMSO-d₆) δ (ppm): 9.32 - 9.24 (m, 1 H), 8.23 - 8.12 (m, 1 H), 7.92 - 7.83 (m, 2 H), 7.75 - 7.68 (m, 1 H), 7.67 - 7.59 (m, 2 H), 7.40 - 7.30 (m, 2 H), 7.14 - 7.06 (m, 2 H), 5.27 - 5.17 (m, 1 H), 3.79 - 3.70 (m, 1 H), 3.60 - 3.44 (m, 2 H), 3.39 - 3.34 (m, 1 H), 2.26 - 2.11 (m, 2 H), 1.35 - 1.24 (m, 4 H)

Example 76: 4-(1-(5-chloro-2-(3-((3-fluorophenoxy)methyl)pyrrolidin-1-yl)nicotinamido)cyclopropyl)benzoic acid (E76)



15 To a solution of methyl 4-(1-(5-chloro-2-(3-((3-fluorophenoxy)methyl)pyrrolidin-1-yl)nicotinamido)cyclopropyl)benzoate (D200) (37 mg, 0.070 mmol) in a mixture 1,4-dioxane and water (3:1) (2ml) lithium hydroxide monohydrate (10 mg, 0.238 mmol) was added and the mixture was stirred 20 min (4 cycles of 5 min eac) under microwaves irradiation. After solvent evaporation the residue was diluted with


20 water (5ml) and 1M HCl (5ml) and extracted with ethylacetate (3x10ml). Collected organics after solvent evaporation afforded a residue that was purified by ISOLUTE Spe-Si (1g) eluting with a mixture dichloromethane/methanol 98:2. Collected fractions after solvent evapoartion afforded the title compound **(E76)** (18.2 mg)

25 MS: (ES/+) m/z: 510.3 [MH⁺] C₂₇H₂₅ClFN₃O₄ requires 509.15

¹H NMR (400MHz ,DMSO-d₆) δ (ppm): 12.77 (br. s., 1 H), 9.26 (s, 1 H), 8.17 (d, *J* = 2.4 Hz, 1 H), 7.87 (d, *J* = 8.3 Hz, 2 H), 7.68 (d, *J* = 2.4 Hz, 1 H), 7.36 (d, *J* = 8.3 Hz, 2 H), 7.33 - 7.27 (m, 1 H), 6.84 - 6.73 (m, 3 H), 4.03 (dd, *J* = 6.4, 9.8 Hz, 1 H), 3.94 - 3.87 (m, 1 H), 3.48 - 3.35 (m, 3 H), 3.23 (dd, *J* = 7.3, 10.8 Hz, 1 H), 2.70 -

2.61 (m, 1 H), 2.10 - 2.01 (m, 1 H), 1.74 (dd, $J = 8.1, 12.0$ Hz, 1 H), 1.32 (d, $J = 5.4$ Hz, 4 H).

Example 77: 4 (R)-4-(1-(5-chloro-2-(2-((3-fluorophenoxy)methyl)pyrrolidin-1-yl)nicotinamido)cyclopropyl)benzoic acid (E77)




The title compound (**E77**) (23.2 mg) was prepared according to the experimental procedure described in Example 76 starting from methyl (R)-4-(1-(5-chloro-2-(2-((3-fluorophenoxy)methyl)pyrrolidin-1-yl)nicotinamido)cyclopropyl)benzoate (D201) (78 mg, 0.149 mmol)

MS: (ES/+) m/z : 510.3 [MH^+] $C_{27}H_{25}ClFN_3O_4$ requires 509.15

^1H NMR (400MHz, DMSO- d_6) δ (ppm): 12.80 (br. s., 1 H), 9.27 (s, 1 H), 8.21 (d, $J = 2.4$ Hz, 1 H), 7.91 - 7.85 (m, $J = 8.3$ Hz, 2 H), 7.71 (d, $J = 2.4$ Hz, 1 H), 7.40 - 7.35 (m, $J = 8.3$ Hz, 2 H), 7.30 (q, $J = 7.8$ Hz, 1 H), 6.91 - 6.80 (m, 2 H), 6.78 - 6.71 (m, 1 H), 4.60 - 4.52 (m, 1 H), 4.21 (dd, $J = 3.2, 9.5$ Hz, 1 H), 3.83 (t, $J = 8.6$ Hz, 1 H), 3.36 (d, $J = 9.8$ Hz, 1 H), 3.09 - 3.01 (m, 1 H), 2.10 - 1.85 (m, 3 H), 1.78 (dd, $J = 5.6, 10.5$ Hz, 1 H), 1.35 - 1.28 (m, 4 H).

Example 78: 4 (S)-4-(1-(5-chloro-2-(2-((3-fluorophenoxy)methyl)pyrrolidin-1-yl)nicotinamido)cyclopropyl)benzoic acid (E78)




The title compound (**E78**) (28 mg) was prepared according to the experimental procedure described in Example 76 starting from methyl (S)-4-(1-(5-chloro-2-(2-((3-fluorophenoxy)methyl)pyrrolidin-1-yl)nicotinamido)cyclopropyl)benzoate (D202) (87 mg, 0.166 mmol)

MS: (ES/+) m/z: 510.3 [MH⁺] C₂₇H₂₅ClFN₃O₄ requires 509.15

¹H NMR (400MHz, DMSO-d₆) δ (ppm): 12.82 (br. s., 1 H), 9.27 (s, 1 H), 8.21 (d, J = 2.9 Hz, 1 H), 7.91 - 7.86 (m, J = 8.3 Hz, 2 H), 7.71 (d, J = 2.4 Hz, 1 H), 7.40 - 7.34 (m, J = 8.3 Hz, 2 H), 7.34 - 7.26 (m, 1 H), 6.91 - 6.79 (m, 2 H), 6.75 (dt, J = 2.0, 8.3 Hz, 1 H), 4.61 - 4.52 (m, 1 H), 4.21 (dd, J = 3.2, 9.5 Hz, 1 H), 3.83 (t, J = 8.6 Hz, 1 H), 3.40 - 3.34 (m, 1 H), 3.09 - 3.01 (m, 1 H), 2.10 - 1.86 (m, 3 H), 1.78 (dd, J = 6.1, 10.5 Hz, 1 H), 1.37 - 1.26 (m, 4 H).

Example 79: 4-(1-(5-chloro-2-(3-((3-fluorophenoxy)methyl)piperidin-1-yl)nicotinamido)cyclopropyl)benzoic acid (E79)




The title compound (**E79**) (34.4 mg) was prepared according to the experimental procedure described in Example 76 starting from methyl 4-(1-(5-chloro-2-(3-((3-fluorophenoxy)methyl)piperidin-1-yl)nicotinamido)cyclopropyl)benzoate (D203) (95 mg, 0.176 mmol)

MS: (ES/+) m/z: 524.3 [MH⁺] C₂₈H₂₇ClFN₃O₄ requires 523.17

¹H NMR (400MHz, DMSO-d₆) δ (ppm): = 9.28 (s, 1 H), 8.25 (d, J = 2.4 Hz, 1 H), 7.85 (d, J = 8.3 Hz, 2 H), 7.76 (d, J = 2.4 Hz, 1 H), 7.35 - 7.26 (m, 3 H), 6.81 - 6.71 (m, 3 H), 3.92 - 3.73 (m, 3 H), 3.59 (d, J = 12.7 Hz, 1 H), 3.18 (d, J = 4.9 Hz, 1 H), 2.88 - 2.73 (m, 2 H), 2.02 (br. s., 1 H), 1.83 (d, J = 12.7 Hz, 1 H), 1.63 (br. s., 1 H), 1.49 (d, J = 13.7 Hz, 1 H), 1.37 - 1.31 (m, 4 H).

Example 80: (S)-4-(1-(5-chloro-2-(3-(3-fluorophenoxy)pyrrolidin-1-yl)nicotinamido)cyclopropyl)benzoic acid (E80)




The title compound **(E80)** (54.8 mg) was prepared according to the experimental procedure described in Example 76 starting from methyl (S)-4-(1-(5-chloro-2-(3-(3-fluorophenoxy)pyrrolidin-1-yl)nicotinamido)cyclopropyl)benzoate (D204) (98 mg, 0.192 mmol)

MS: (ES/+) m/z: 496.2 [MH⁺] C₂₆H₂₃ClFN₃O₄ requires 495.14

¹H NMR (400MHz, DMSO-d₆) δ (ppm): = 12.77 (br. s., 1 H), 9.27 (s, 1 H), 8.19 (d, J = 2.4 Hz, 1 H), 7.87 (d, J = 8.3 Hz, 2 H), 7.70 (d, J = 2.4 Hz, 1 H), 7.35 (d, J = 8.3 Hz, 2 H), 7.33 - 7.27 (m, 1 H), 6.85 - 6.73 (m, 3 H), 5.13 (br. s., 1 H), 3.71 (dd, J = 4.4, 12.2 Hz, 1 H), 3.58 - 3.42 (m, 2 H), 3.34 (s, 1 H), 2.24 - 2.06 (m, 2 H), 1.35 - 1.23 (m, 4 H).

Example 81: (R)-4-(1-(5-chloro-2-(3-(3-fluorophenoxy)pyrrolidin-1-yl)nicotinamido)cyclopropyl)benzoic acid (E81)




The title compound **(E81)** (48.4 mg) was prepared according to the experimental procedure described in Example 76 starting from methyl (R)-4-(1-(5-chloro-2-(3-(3-fluorophenoxy)pyrrolidin-1-yl)nicotinamido)cyclopropyl)benzoate (D205) (94 mg, 0.184 mmol).

MS: (ES/+) m/z: 496.2 [MH⁺] C₂₆H₂₃ClFN₃O₄ requires 495.14

¹H NMR (400MHz, DMSO-d₆) δ (ppm): = 12.77 (br. s., 1 H), 9.27 (s, 1 H), 8.19 (d, J = 2.4 Hz, 1 H), 7.87 (d, J = 8.3 Hz, 2 H), 7.70 (d, J = 2.4 Hz, 1 H), 7.40 - 7.27 (m, 3 H), 6.85 - 6.73 (m, 3 H), 5.13 (br. s., 1 H), 3.71 (dd, J = 4.4, 12.2 Hz, 1 H), 3.59 - 3.42 (m, 2 H), 3.31 (br. s., 1 H), 2.24 - 2.06 (m, 2 H), 1.37 - 1.21 (m, 4 H).

Example 82: N-(1-(4-(1H-tetrazol-5-yl)phenyl)cyclopropyl)-5-chloro-2-(3-(3-fluorophenoxy)azetidin-1-yl)nicotinamide (E82)



5 To mixture of 5-chloro-2-(3-(3-fluorophenoxy)azetidin-1-yl)nicotinic acid (D77) (60 mg, 0.186 mmol) in dry dimethylformamide (1ml), 1-Hydroxybenzotriazole hydrate (28.5 mg, 0.189 mmol), 1-Ethyl-3-[3-dimethylaminopropyl]carbodiimide Hydrochloride (53.5 mg, 0.279 mmol) were added followed by the addition of a solution of 1-(4-(1H-tetrazol-5-yl)phenyl)cyclopropanamine hydrochloride (D17) 10 (44.2 mg, 0.186 mmol) and triethylamine (26µl, 0.189 mmol) in dry dimethylformamide. The mixture was stirred for 1h at room temperature. The solvent was evaporated in vacuo and the resulting residue was taken in NH₄Cl sat. sol (10ml) and extracted with ethylacetate (2x10ml). Collected organics after solvent evaporation afforded a residue that was washed with methanol (2ml) to 15 afford the title compound (**E82**) (30.8 mg)

MS: (ES/+) m/z: 506.2 [MH⁺] C₂₅H₂₁ClFN₇O₂ requires 505.14

1H NMR (400MHz, DMSO-d₆) δ = 9.27 (s, 1 H), 8.23 (d, J = 2.4 Hz, 1 H), 7.95 - 7.90 (m, J = 8.8 Hz, 2 H), 7.81 (d, J = 2.4 Hz, 1 H), 7.47 - 7.41 (m, J = 8.8 Hz, 2 H), 7.27 (d, J = 7.3 Hz, 1 H), 6.75 - 6.67 (m, 2 H), 6.65 (d, J = 8.3 Hz, 1 H), 5.08 20 (d, J = 2.9 Hz, 1 H), 4.35 (dd, J = 6.4, 9.8 Hz, 2 H), 3.82 (dd, J = 3.4, 10.3 Hz, 2 H), 1.33 (s, 4 H).

Example 83: Determination of *in vitro* effects of the invention compounds

25 *Stable expression of human EP₄ receptors in the human embryonic kidney (HEK293) cell line*

The cDNA clone of human EP₄ receptor (NM_000958.2) was obtained from Invitrogen™: Ultimate™ ORF Clone Collection - Clone ID IOH46525. The coding sequence was subcloned in expression vector pcDNATM6.2/V5-DEST by Gateway technology (Invitrogen™).

Human embryonic kidney cells (HEK-293) were stably transfected with expression vector for human EP₄ receptor in according to the method described in FuGENE®6 Transfection Reagent's manual (Roche Applied Science®).

Preparation of membrane fraction:

- 5 The EP₄ transfected cells were grown in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum and 10 µg/ml Blastidicin S HCl (selection medium) at 37°C in a humidified atmosphere of 5% CO₂ in air.

For the membrane preparation, cells in flask were harvested by hypotonical/mechanical lysis with chilled (4°C) TE buffer (5mM TRIS, 5mM
10 ethylenediamine tetra-acetic acid (EDTA), pH 7.4).

Cells were detached and lysed with 10ml of hypotonic lysis buffer and by scraping. The cell lysate was vortexed for 30 sec and centrifuged at 40000x g at 4°C for 22min.

a) Membrane binding assay [³H]-Prostaglandin E₂

- 15 The membrane pellet was resuspended in the same buffer (5mM TRIS, 5mM ethylenediamine tetra-acetic acid (EDTA), pH 7.4), and protein concentration was determined by Bradford method (Bio-Rad® assay).

This membrane preparation was stored at -80°C freezer until use for binding assay.

- 20 ([³H]-PGE₂) membranes binding assays toward hEP₄ receptors (human EP₄/HEK293 transfectant, see above) and hEP₂ receptors (human EP₂/HEK293 transfectant, purchased from PerkinElmer Inc) were performed in 10 mM MES-KOH buffer pH6, containing 10 mM MgCl₂ and 1 mM CaCl₂ for EP₄ binding assay or 50 mM Tris-Cl, BSA 0.5% for EP₂ binding assay (according to supplier
25 indication) .

- Ten microgram of protein from membrane fractions were incubated in a total volume of 0.1ml (EP₄) or 0.2ml (EP₂) with 1nM (EP₄) or 3nM (EP₂) [³H]-PGE₂ (PerkinElmer Inc, 171Ci/mmol). In both assays to determine the total binding or non specific binding, 1% DMSO or 1µM prostaglandin E₂ (EP₄) or 100 µM (EP₂)
30 were added to reaction mixtures, respectively. Incubation was conducted in a polypropylene 96 multiwell for 90 min (EP₄) or 60 min (EP₂) at room temperature prior to separation of the bound and free radioligand by vacuum manifold rapid

filtration on glass fiber filters (Unifilter GFB96, PerkinElmer Inc) pre-soaked in 0.3% polyethyleneimine. Filters were washed with ice cold buffer pH 7.4 (50mM HEPES, NaCl 500mM, BSA 0.1% for EP₄ binding assay or 50mM Tris-Cl for EP₂ binding assays) and the residual [³H]-PGE₂ binding determined by solid
5 scintillation counter (TopCount , PerkinElmer Inc).

In standard competition experiments the compounds were tested in a concentration range from 1nM to 1μM, and IC₅₀ determined. The affinity (K_i) of each compound was calculated according to the Cheng-Prousoff equation: $K_i = IC_{50}/(1+([C]/K_d))$. Results were expressed as pK_i (- log₁₀ K_i (M))

10 Compounds of example 1 to 82 were tested according to method of example 83a in a final concentration range range from 1nM to 1μM. All compounds showed good to excellent EP₄ affinities having pK_i values from 6 to 8.5 at EP₄ receptor.

b) cAMP assay on human EP₄ membrane of transfected cells.

15 The assay is based on the competition between endogenous cAMP and exogenously added biotinylated cAMP. The capture of cAMP is achieved by using a specific antibody conjugated to Donor beads.

Cell membranes prepared as described above, were resuspended in 1ml stimulation buffer (HBSS 1X + BSA 0.1% + IBMX 0.5mM + HEPES 5mM + MgCl₂
20 10mM + GTP 1nM + GDP 10μM + ATP 100μM – pH 7.4). Cell membranes were dispensed into white 384-well microplates at final concentration of 1μg/well and used for the determination of cAMP with the alphascreen cAMP functional assay (EnVision - PerkinElmer). Cell membrane/anti-cAMP Acceptor beads mix (5 μl) and a mixture of analysed compounds (dissolved in 100% DMSO to a final
25 maximal concentration of 0.01% DMSO)/PGE₂ (5 μl) were incubated at room temperature (22-23°C) for 30 min in the dark. The Biotinylated-cAMP and donor beads (15 μl) were dispensed into each well to start the competition reaction. After 1h incubation RT (22-23°C) in the dark the plate was read using EnVision platform to determine the cAMP level (excitation: 680nm; emission:520,620nm).

30 In each experiment:

cAMP standard curve (concentration range from 1x10⁻⁶ to 1x10⁻¹¹ M in . log intervals) with a negative control (no cAMP)

a positive control: forskolin 10 μ M

Antagonism studies were performed stimulating HEK293 cell membrane with PGE2 3nM. The AlphaScreen signal is plotted as a function of log concentration of cAMP and functional IC50 is determined. IC50 value is calculated by linear regression.

Some compounds were tested according to method of example 83b. All compounds showed good to excellent EP4 antagonism having functional IC50 values from 386 nM to 7.7nM at EP4 receptor.

The results of membrane binding assay and cAMP assay on human EP₄ membrane of transfected cells selection of preferred compounds are summarised in table 1.

Table 1:

Example	Binding pKi	functional IC50 (nM)
E 1	6.4	235
E 3	7.5	133
E 4	6.7	102
E 10	7.8	46
E 11	7.0	386
E 12	7.8	102
E 13	7.6	187
E 14	8.3	38
E 15	7.9	70
E 16	8.5	40
E 17	7.7	82
E 18	7.9	22
E 19	7.3	87
E 20	8.0	70
E 21	7.2	191
E 22	7.5	119
E 24	7.5	92
E 25	7.2	135
E 28	7.1	197
E 31	8.1	47
E 32	7.6	76
E 33	8.2	44,5
E 34	8.5	43
E 35	8.2	59
E 36	8.4	30
E 37	7.9	31
E 38	7.9	19,3
E 39	8.1	72
E 40	8.3	10

E 41	8.3	7,7
E 42	8.5	35
E 43	8.5	38
E 44	8.0	17.5
E 45	8.5	10
E 47	7.2	228
E 49	7.6	69
E 50	7.9	23
E 51	8.2	28
E 52	7.7	74
E 53	7.5	80
E 54	7.6	75
E 55	7.5	126
E 56	8.0	46
E 60	7.1	96,5
E 62	7.6	46
E 63	7.5	145
E 64	7.5	99
E 65	7.4	65
E 66	7.4	43
E 68	7.5	66
E 69	7.3	308
E 71	7.4	110
E 76	7.5	24
E 77	8.0	90
E 80	7.4	99
E 82	8.3	27

Example 84: Determination of *PK* of the invention compounds

The pharmacokinetics of compounds E10, E16, E34, E38, E51, were studied in male Han Wistar rats. The rats were treated intravenously and orally (n=3 for each dose route) with a compounds formulated as solutions. The rats were fitted with a jugular cannula for serial sampling. A full profile was acquired for each rat. Plasma extracts were quantitatively analyzed using a specific and sensitive LC-MS/MS bioanalytical method. Inter-individual variations between the three rats in each group were limited (CV for pharmacokinetic parameters was below 50%).


After intravenous injection all compounds showed moderate volume of distribution (*V*_{ss}) ranging between 230 and 1100 ml, below ten fold the rat total body water, suggesting moderate compound distribution outside of the blood compartment. A range of clearance values were obtained for the different structure, ranging from low to high values (from 160 to 860 ml/h).

After oral administration, absorption was quite fast with a clear maximum concentration reached by 15 minutes for all compounds. The absolute oral bioavailability was good for all compounds with F higher than 40%, and reaching 90% for compound E16.

Ex	Route	Dose (mg/kg)	CLp* (ml/h)	Vss* (ml)	t1/2* (h)	AUC 0-t (ng.h/ml)	AUC inf* (ng.h/ml)	F %	Cmax (ng/ml)	Tmax (h)	Tlast (h)
E10	IV	2.0	161	307	3.96	3090	3150				24
	PO	2.0			4.85	1720	1820	56	923	0.25	24
E16	IV	2.0	160	394	5.62	3290	3330				24
	PO	2.0			3.12	2990	3000	91	1800	0.25	24
E34	IV	1.0	863	227	0.34	300	302				2
	PO	1.0			1.16	125	128	42	98.1	0.25	6
E38	IV	1.0	341	1070	5.9	816	832				24
	PO	1.0			2.59	551	598	59	374	0.25	6
E51	IV	1.0	675	447	1.12	385	389				6
	PO	1.0			1.14	225	231	58	151	0.25	6
* Clearance, volume, half-life and AUC inf expressions may automatically be taken from calculations extrapolated to infinity from unrevised regression, indicative only; clearance values and AUC will usually never be much affected by error, volumes of distribution and half-life may or may not be precisely assessable from the data collected.											
In summary tables for preliminary communications volumes may be taken from data until tlast, in which case it will be approximated by default due to lack of terminal phase data.											

CLAIMS

1. A pyridine amide derivative of Formula (I):



or a pharmaceutically acceptable salt thereof,

5 wherein:

R_1 and R_2 are independently hydrogen, linear or branched (C1-C3)alkyl or joined together they form a cyclopropyl ring;


R is independently selected from the group consisting of halogens and trifluoromethyl and p is 1, 2 or 3;

10 A is C or N;

E is a group of formula (B) or (C), wherein

B is $C(O)OH$, $C(O)O(C1-C3)alkyl$, and

C is selected from the group consisting of:



15 m is 1,2 or 3,

n is 0 or 1,

W is $-O-$, $-O(C1-C3 alkyl)-$; $-(C1-C3 alkyl)O-$; $-C(O)-$; $-C(=N-O(C1-C3 alkyl))-$; $-NH-$ or $-NH(C1-C3alkyl)-$;

Ar is phenyl, optionally substituted with one or more substituents selected from the group consisting of halogen, trifluoromethyl, trifluoromethoxy, methyl, $-NH(C1-C3alkyl)-$; $-N(C1-C3alkyl)(C1-C3alkyl)-$, a from 5 to 7 membered heterocyclic ring containing one nitrogen atom which is covalently bonded to Ar and optionally containing one or two heteroatoms selected from N,O and S; and a 5- or 6-membered heteroaromatic ring containing 1 to 3 heteroatoms selected from S, O or N, such heteroaromatic ring being substituted with one or two substituents

selected from the group consisting of (C1-C3)alkyl, (C3-C5)cycloalkyloxy, (C1-C3)alkylcarbonyl.


2. The pyridine amide derivative according to claim 1, wherein p is 1 and R is selected from halogen and trifluoromethyl.

5 3. The pyridine amide derivative according to claim 2, wherein p is 1 and R is alogen, preferably is Chloro.

4. The pyridine amide derivative according to anyone of claims 1 to 3, wherein R1 and R2 are selected from hydrogen, methyl or they form together a cyclopropane ring.

10 5. The pyridine amide derivative according to claim 4, wherein R1 and R2 form together a cyclopropane ring.

6. The pyridine amide derivative according to claim 1, wherein the pyridine amide derivative of Formula (I) is a compound of Formula (Ia), in which E is COOH and A is C:



(Ia)

wherein Rp, R1, R2, W, Ar, m and have the same meaning as per Formula (I).

7. The pyridine amide derivative according to claim 6, wherein m is 1 or 2.

8. The pyridine amide derivative according to claim 6 or 7, wherein n is 0 and W is bond.

20 9. The pyridine amide derivative according to claim 6 or 7, W is selected from the group consisting of O, NH and N(C1-C3)alkyl.


10. The pyridine amide derivative according to anyone of claims 6-9, wherein Ar is phenyl, optionally substituted with one or more substituents selected from the group consisting of halogen, trifluoromethyl, trifluoromethoxy, methyl, -NH(C1-C3alkyl)-; -N(C1-C3alkyl)(C1-C3alkyl)-, a from 5 to 7 membered heterocyclic ring containing one nitrogen atom, which is covalently bonded to Ar, and optionally containing one or two heteroatoms selected from N,O and S.

11. The pyridine amide derivative according to claim 10, wherein Ar is phenyl substituted by alogen, preferably said halogen being F.

12. The pyridine amide derivative according to anyone of claims 6-9, wherein Ar is preferably a 5- or 6-membered heteroaromatic ring containing 1 to 3 heteroatoms selected from S, O e N, such ring being substituted with one or two substituents selected from the group consisting of (C1-C3)alkyl, (C3-C5)cycloalkyloxy, (C1-C3)alkylcarbonyl.

13. The pyridine amide derivative according to claim 12, wherein Ar is pyridine.

14. The pyridine amide derivative according to claim 1, wherein the pyridine amide derivative of Formula (I) is a compound of Formula (Ib), where E is B:



(Ib)

15. The pyridine amide derivative according to claim 14, wherein m is 1 and 2.

16. The pyridine amide derivative according to claim 14 or 15, wherein n is 0 and W is bond.

17. The pyridine amide derivative according to claim 14 or 15, wherein W is selected from the group consisting of O, NH and N(C1-C3)alkyl.

18. The pyridine amide derivative according to anyone of claims 14-17, wherein Ar is phenyl optionally substituted with one or more halogen atoms, trifluoromethyl, trifluoromethoxy, methyl, -NH(C1-C3alkyl)-; -N(C1-C3alkyl)(C1-C3alkyl)-, a from 5 to 7 membered heterocyclic ring containing one nitrogen atom, which is convalently bonded to Ar, and optionally containing one or two heteroatoms selected from N,O and S.

19. The pyridine amide derivative according to claim 18, wherein Ar is phenyl substituted by halogen, preferably said halogen being F.

20. The pyridine amide derivative according to anyone of claims 14-17, wherein Ar is a 5- or 6-membered heteroaromatic ring containing 1 to 3 heteroatoms selected from S, O e N, such ring being substituted with one or two substituents selected

from the group consisting of (C1-C3)alkyl, (C3-C5)cycloalkyloxy, (C1-C3)alkylcarbonyl.

21. The pyridine amide derivative according to claim 20, wherein Ar is pyridine.

22. The pyridine amide derivative according to claim 1, wherein the derivative of

5 Formula (I) is selected from the group consisting of:

4-(1-(5-chloro-2-(2-phenylpyrrolidin-1-yl)nicotinamido)cyclopropyl)benzoic acid
(racemic mixture)

4-(1-(5-chloro-2-(2-phenylpyrrolidin-1-yl)nicotinamido)cyclopropyl)benzoic acid
(enantiomer 1)

10 4-(1-(5-chloro-2-(2-phenylpyrrolidin-1-yl)nicotinamido)cyclopropyl)benzoic acid
(enantiomer 2)

4-(1-(5-chloro-2-(3-phenylpyrrolidin-1-yl)nicotinamido)cyclopropyl)benzoic acid

4-(1-(5-chloro-2-(3-phenylpyrrolidin-1-yl)nicotinamido)cyclopropyl)benzoic acid
(enantiomer 1)

15 4-(1-(5-chloro-2-(3-phenylpyrrolidin-1-yl)nicotinamido)cyclopropyl)benzoic acid
(enantiomer 2)

4-(1-(2-(2-benzylpyrrolidin-1-yl)-5-chloronicotinamido)cyclopropyl)benzoic acid
(racemic mixture)

20 4-(1-(2-(2-benzylpyrrolidin-1-yl)-5-chloronicotinamido)cyclopropyl)benzoic acid
(enantiomer 1)

4-(1-(2-(2-benzylpyrrolidin-1-yl)-5-chloronicotinamido)cyclopropyl)benzoic acid
(enantiomer 2)

4-(1-(5-chloro-2-(3-phenoxyazetidin-1-yl)nicotinamido)cyclopropyl)benzoic acid

25 (S)-4-(1-(5-chloro-2-(3-(4-fluorophenoxy)azetidin-1-yl)nicotinamido)ethyl)benzoic
acid

(S)-4-(1-(5-chloro-2-(3-(3-fluorophenoxy)azetidin-1-yl)nicotinamido)ethyl)benzoic
acid

4-(1-(5-chloro-2-(3-(4-(trifluoromethyl)phenoxy)azetidin-1-yl)nicotinamido)cyclo-
propyl)benzoic acid

30 4-(1-(5-chloro-2-(3-(3-(trifluoromethyl)phenoxy)azetidin-1-yl)nicotinamido)cyclo-
propyl)benzoic acid

- 4-(1-(5-chloro-2-(3-(4-fluorophenoxy)azetidin-1-yl)nicotinamido)cyclopropyl)-benzoic acid
- 4-(1-(5-chloro-2-(3-(3-fluorophenoxy)azetidin-1-yl)nicotinamido)cyclopropyl)-benzoic acid
- 5 4-(1-(5-chloro-2-(3-(4-fluoro-3-(trifluoromethyl)phenoxy)azetidin-1-yl)nicotinamido)cyclopropyl)-benzoic acid
- 4-(1-(5-chloro-2-(3-(3-(trifluoromethoxy)phenoxy)azetidin-1-yl)nicotinamido)cyclopropyl)-benzoic acid
- 4-(1-(5-chloro-2-(3-(2,4-difluorophenoxy)azetidin-1-yl)nicotinamido)cyclopropyl)-benzoic acid
- 10 4-(1-(5-chloro-2-(3-(3,4-difluorophenoxy)azetidin-1-yl)nicotinamido)cyclopropyl)-benzoic acid
- 4-(1-(5-chloro-2-(3-(3-(piperazin-1-yl)phenoxy)azetidin-1-yl)nicotinamido)cyclopropyl)benzoic acid
- 15 4-((5-chloro-2-(3-(3-fluorophenoxy)azetidin-1-yl) nicotinamido) methyl)benzoic acid
- 6-((5-chloro-2-(3-(3-fluorophenoxy)azetidin-1-yl)nicotinamido)methyl)nicotinic acid
- 6-((5-chloro-2-(3-(3-fluorophenoxy)azetidin-1-yl)nicotinamido)methyl)nicotinic acid
- 4-(1-(5-chloro-2-(3-(3-fluorobenzoyl)azetidin-1-yl)nicotinamido)cyclopropyl)benzoic acid
- 20 4-(1-(5-chloro-2-(3-((3-fluorophenyl)(methoxyimino)methyl)azetidin-1-yl)-nicotinamido)cyclopropyl)benzoic acid (isomeric mixture)
- 4-(1-(5-chloro-2-(3-(3-fluorophenyl)-3-hydroxyazetidin-1-yl)nicotinamido)cyclopropyl)benzoic acid
- 4-(1-(5-chloro-2-(3-(4-fluorophenyl)-3-hydroxyazetidin-1-yl)nicotinamido)cyclopropyl)benzoic acid
- 25 4-(1-(5-chloro-2-(3-((4-fluorophenoxy)methyl)azetidin-1-yl)nicotinamido)cyclopropyl)benzoic acid
- 4-(1-(5-chloro-2-(3-((4-fluorophenoxy)methyl)azetidin-1-yl)nicotinamido)cyclopropyl)benzoic acid
- 30 4-(1-(5-chloro-2-(3-((3-(trifluoromethyl)phenyl)amino)azetidin-1-yl)nicotinamido)-cyclopropyl)benzoic acid

- 4-(1-(5-chloro-2-(3-((3-fluorophenyl)amino)azetidin-1-yl)nicotinamido)-cyclopropyl)benzoic acid
- 4-(1-(5-chloro-2-(3-((4-fluorophenyl)amino)azetidin-1-yl)nicotinamido)cyclopropyl)-benzoic acid
- 5 4-(1-(5-chloro-2-(3-((4-fluoro-2-methylphenyl)amino)azetidin-1-yl)nicotinamido)-cyclopropyl)benzoic acid
- 4-(1-(5-chloro-2-(3-((2,4-difluorophenyl)amino)azetidin-1-yl)nicotinamido)-cyclopropyl)benzoic acid
- 4-(1-(5-chloro-2-(3-((2-methyl-4-(trifluoromethyl)phenyl)amino)azetidin-1-yl)-nicotinamido)cyclopropyl) benzoic acid
- 10 4-(1-(5-chloro-2-(3-((4-fluoro-2-methylphenyl)(methyl)amino)azetidin-1-yl)-nicotinamido)cyclopropyl)benzoic acid
- 4-(1-(2-(3-(3-fluorophenoxy)azetidin-1-yl)-5-(trifluoromethyl)nicotinamido)-cyclopropyl)benzoic acid
- 15 4-(1-(2-(3-(4-fluorophenoxy)azetidin-1-yl)-5-(trifluoromethyl)nicotinamido)-cyclopropyl)benzoic acid
- 4-(1-(2-(3-(4-chlorophenoxy)azetidin-1-yl)-5-(trifluoromethyl)nicotinamido)-cyclopropyl)benzoic acid
- 4-(1-(2-(3-(3-chlorophenoxy)azetidin-1-yl)-5-(trifluoromethyl)nicotinamido)-cyclopropyl)benzoic acid
- 20 4-(1-(2-(3-(4-fluoro-3-(trifluoromethyl)phenoxy)azetidin-1-yl)-5-(trifluoromethyl)-nicotinamido)cyclopropyl)benzoic acid
- 4-(1-(2-(3-(3-(trifluoromethoxy)phenoxy)azetidin-1-yl)-5-(trifluoromethyl)-nicotinamido)cyclopropyl)benzoic acid
- 25 4-(1-(2-(3-(2,4-difluorophenoxy)azetidin-1-yl)-5-(trifluoromethyl)nicotinamido)-cyclopropyl)benzoic acid
- 4-(1-(2-(3-(3,4-difluorophenoxy)azetidin-1-yl)-5-(trifluoromethyl)nicotinamido)-cyclopropyl)benzoic acid
- 4-(1-(2-(3-((5-methylisoxazol-3-yl)oxy)azetidin-1-yl)-5-(trifluoromethyl)-nicotinamido)cyclopropyl)benzoic acid
- 30 4-(1-(5-(trifluoromethyl)-2-(3-((6-(trifluoromethyl)pyridin-2-yl)oxy)azetidin-1-yl)nicotinamido)cyclopropyl)benzoic acid

- 4-(1-(2-(3-((5-fluoropyrimidin-2-yl)oxy)azetidin-1-yl)-5-(trifluoromethyl)-nicotinamido)cyclopropyl)benzoic acid
- 4-(1-(2-(3-((3-fluorophenyl)amino)azetidin-1-yl)-5-(trifluoromethyl)-nicotinamido)cyclopropyl)benzoic acid
- 5 4-(1-(2-(3-((4-fluorophenyl)amino)azetidin-1-yl)-5-(trifluoromethyl)nicotinamido)-cyclopropyl)benzoic acid
- 4-(1-(2-(3-((4-fluoro-2-methylphenyl)amino)azetidin-1-yl)-5-(trifluoromethyl)-nicotinamido)cyclopropyl)benzoic acid
- 4-(1-(2-(3-((2,4-difluorophenyl)amino)azetidin-1-yl)-5-(trifluoromethyl)-nicotinamido)cyclopropyl)benzoic acid
- 10 4-(1-(5-fluoro-2-(3-(3-fluorophenoxy)azetidin-1-yl)nicotinamido)cyclopropyl)benzoic acid
- 4-(1-(5-fluoro-2-(3-(3-chlorophenoxy)azetidin-1-yl)nicotinamido)cyclopropyl)-benzoic acid (
- 15 4-(1-(5-fluoro-2-(3-(3-(trifluoromethoxy)phenoxy)azetidin-1-yl)nicotinamido)-cyclopropyl)benzoic acid
- 4-(1-(5-fluoro-2-(3-((4-fluoro-2-methylphenyl)amino)azetidin-1-yl)nicotinamido)-cyclopropyl)benzoic acid
- 4-((1S)-1-(5-chloro-2-(3-(4-(trifluoromethyl)phenoxy)pyrrolidin-1-yl)nicotinamido)-ethyl)benzoic acid
- 20 4-((1S)-1-(5-chloro-2-(3-(3-(trifluoromethyl)phenoxy)pyrrolidin-1-yl)nicotinamido)-ethyl)benzoic acid
- 4-((1S)-1-(5-chloro-2-(3-(4-fluorophenoxy)pyrrolidin-1-yl)nicotinamido)-ethyl)benzoic acid
- 25 4-(1-(5-chloro-2-(3-phenoxy)pyrrolidin-1-yl)nicotinamido)cyclopropyl)benzoic acid (racemic mixture)
- 4-(1-(5-chloro-2-(3-phenoxy)pyrrolidin-1-yl)nicotinamido)cyclopropyl)benzoic acid (enantiomer 1)
- 4-(1-(5-chloro-2-(3-phenoxy)pyrrolidin-1-yl)nicotinamido)cyclopropyl)benzoic acid (enantiomer 2)
- 30 4-(1-(5-chloro-2-(3-(3-(trifluoromethyl)phenoxy)pyrrolidin-1-yl)nicotinamido)-cyclopropyl)benzoic acid (racemic mixture)

- 4-(1-(5-chloro-2-(3-(3-(trifluoromethyl)phenoxy)pyrrolidin-1-yl)nicotinamido)-cyclopropyl)benzoic acid (enantiomer 1)
- 4-(1-(5-chloro-2-(3-(3-(trifluoromethyl)phenoxy)pyrrolidin-1-yl)nicotinamido)-cyclopropyl)benzoic acid (enantiomer 2)
- 5 4-(1-(5-chloro-2-(3-(4-fluorophenoxy)pyrrolidin-1-yl)nicotinamido)cyclopropyl)-benzoic acid (racemic mixture)
- 4-(1-(5-chloro-2-(3-(4-fluorophenoxy)pyrrolidin-1-yl)nicotinamido)cyclopropyl)-benzoic acid (enantiomer 1)
- 4-(1-(5-chloro-2-(3-(4-fluorophenoxy)pyrrolidin-1-yl)nicotinamido)cyclopropyl)-
- 10 benzoic acid (enantiomer 2)
- 4-(1-(5-chloro-2-(3-(3-fluorophenoxy)pyrrolidin-1-yl)nicotinamido)-cyclopropyl)benzoic acid (racemic mixture)
- 4-(1-(5-chloro-2-(3-(3-fluorophenoxy)pyrrolidin-1-yl)nicotinamido)cyclopropyl)-benzoic acid (enantiomer 1)
- 15 4-(1-(5-chloro-2-(3-(3-fluorophenoxy)pyrrolidin-1-yl)nicotinamido)cyclopropyl)-benzoic acid (enantiomer 2)
- 4-(1-(5-chloro-2-(3-(m-tolyloxy)pyrrolidin-1-yl)nicotinamido)cyclopropyl)benzoic acid
- 4-(1-(5-chloro-2-(3-(4-(trifluoromethyl)phenoxy)pyrrolidin-1-yl)nicotinamido)-
- 20 cyclopropyl)benzoic acid (racemic mixture)
- 4-(1-(5-chloro-2-(3-(4-(trifluoromethyl)phenoxy)pyrrolidin-1-yl)nicotinamido)cyclopropyl)benzoic acid (enantiomer 1)
- 4-(1-(5-chloro-2-(3-(4-(trifluoromethyl)phenoxy)pyrrolidin-1-yl)nicotinamido)cyclopropyl)benzoic acid (enantiomer 2)
- 25 4-(1-(5-chloro-2-(3-((3-fluorophenoxy)methyl)pyrrolidin-1-yl)nicotinamido)cyclopropyl)benzoic acid
- 4(R)-4-(1-(5-chloro-2-(2-((3-fluorophenoxy)methyl)pyrrolidin-1-yl)nicotinamido)cyclopropyl)benzoic acid
- 4(S)-4-(1-(5-chloro-2-(2-((3-fluorophenoxy)methyl)pyrrolidin-1-yl)nicotinamido)-
- 30 cyclopropyl)benzoic acid
- 4-(1-(5-chloro-2-(3-((3-fluorophenoxy)methyl)piperidin-1-yl)nicotinamido)cyclopropyl)benzoic acid

(R)-4-(1-(5-chloro-2-(3-(3-fluorophenoxy)pyrrolidin-1-yl)nicotinamido)cyclopropyl)benzoic acid

(S)-4-(1-(5-chloro-2-(3-(3-fluorophenoxy)pyrrolidin-1-yl)nicotinamido)cyclopropyl)benzoic acid, and

5 N-(1-(4-(1H-tetrazol-5-yl)phenyl)cyclopropyl)-5-chloro-2-(3-(3-fluorophenoxy)-azetidin-1-yl)nicotinamide.

23. The pyridine amide derivative according to claim 22, wherein the derivative of Formula (I) is selected from the group consisting of:

4-(1-(5-chloro-2-(2-phenylpyrrolidin-1-yl)nicotinamido)cyclopropyl)benzoic acid
10 (racemic mixture)

4-(1-(5-chloro-2-(2-phenylpyrrolidin-1-yl)nicotinamido)cyclopropyl)benzoic acid
(enantiomer 2)

4-(1-(5-chloro-2-(3-phenylpyrrolidin-1-yl)nicotinamido)cyclopropyl)benzoic acid

4-(1-(5-chloro-2-(3-phenoxyazetidin-1-yl)nicotinamido)cyclopropyl)benzoic acid

15 (S)-4-(1-(5-chloro-2-(3-(4-fluorophenoxy)azetidin-1-yl)nicotinamido)ethyl)benzoic acid

(S)-4-(1-(5-chloro-2-(3-(3-fluorophenoxy)azetidin-1-yl)nicotinamido)ethyl)benzoic acid

4-(1-(5-chloro-2-(3-(4-(trifluoromethyl)phenoxy)azetidin-1-yl)nicotinamido)cyclopropyl)benzoic acid
20

4-(1-(5-chloro-2-(3-(3-(trifluoromethyl)phenoxy)azetidin-1-yl)nicotinamido)-cyclopropyl)benzoic acid

4-(1-(5-chloro-2-(3-(4-fluorophenoxy)azetidin-1-yl)nicotinamido)cyclopropyl)-benzoic acid

25 4-(1-(5-chloro-2-(3-(3-fluorophenoxy)azetidin-1-yl)nicotinamido)cyclopropyl)-benzoic acid

4-(1-(5-chloro-2-(3-(4-fluoro-3-(trifluoromethyl)phenoxy)azetidin-1-yl)nicotinamido)-cyclopropyl)benzoic acid

4-(1-(5-chloro-2-(3-(3-(trifluoromethoxy)phenoxy)azetidin-1-yl)nicotinamido)cyclopropyl)benzoic acid
30

4-(1-(5-chloro-2-(3-(2,4-difluorophenoxy)azetidin-1-yl)nicotinamido)cyclopropyl)-benzoic acid

4-(1-(5-chloro-2-(3-(3,4-difluorophenoxy)azetidin-1-yl)nicotinamido)cyclopropyl)-benzoic acid

4-(1-(5-chloro-2-(3-(3-(piperazin-1-yl)phenoxy)azetidin-1-yl)nicotinamido)cyclopropyl)benzoic acid

5 4-((5-chloro-2-(3-(3-fluorophenoxy)azetidin-1-yl) nicotinamido) methyl)benzoic acid

6-((5-chloro-2-(3-(3-fluorophenoxy)azetidin-1-yl)nicotinamido)methyl)nicotinic acid

4-(1-(5-chloro-2-(3-(3-fluorobenzoyl)azetidin-1-yl)nicotinamido)cyclopropyl)benzoic acid

10 4-(1-(5-chloro-2-(3-(4-fluorophenyl)-3-hydroxyazetidin-1-yl)nicotinamido)cyclopropyl)benzoic acid

4-(1-(5-chloro-2-(3-((4-fluorophenoxy)methyl)azetidin-1-yl)nicotinamido)cyclopropyl)benzoic acid

4-(1-(5-chloro-2-(3-((4-fluorophenoxy)methyl)azetidin-1-yl)nicotinamido)cyclopropyl)benzoic acid

15 4-(1-(5-chloro-2-(3-((3-(trifluoromethyl)phenyl)amino)azetidin-1-yl)nicotinamido)-cyclopropyl)benzoic acid

4-(1-(5-chloro-2-(3-((3-fluorophenyl)amino)azetidin-1-yl)nicotinamido)cyclopropyl)-benzoic acid

20 4-(1-(5-chloro-2-(3-((4-fluorophenyl)amino)azetidin-1-yl)nicotinamido)cyclopropyl)-benzoic acid

4-(1-(5-chloro-2-(3-((4-fluoro-2-methylphenyl)amino)azetidin-1-yl)nicotinamido)-cyclopropyl)benzoic acid

4-(1-(5-chloro-2-(3-((2,4-difluorophenyl)amino)azetidin-1-yl)nicotinamido)-cyclopropyl)benzoic acid

25 4-(1-(5-chloro-2-(3-((2-methyl-4-(trifluoromethyl)phenyl)amino)azetidin-1-yl)-nicotinamido)cyclopropyl) benzoic acid

4-(1-(5-chloro-2-(3-((4-fluoro-2-methylphenyl)(methyl)amino)azetidin-1-yl)-nicotinamido)cyclopropyl)benzoic acid

30 4-(1-(2-(3-(3-fluorophenoxy)azetidin-1-yl)-5-(trifluoromethyl)nicotinamido)-cyclopropyl)benzoic acid

4-(1-(2-(3-(4-fluorophenoxy)azetidin-1-yl)-5-(trifluoromethyl)nicotinamido)-cyclopropyl)benzoic acid





- 4-(1-(2-(3-(4-chlorophenoxy)azetidin-1-yl)-5-(trifluoromethyl)nicotinamido)-cyclopropyl)benzoic acid
- 4-(1-(2-(3-(3-chlorophenoxy)azetidin-1-yl)-5-(trifluoromethyl)nicotinamido)-cyclopropyl)benzoic acid
- 5 4-(1-(2-(3-(4-fluoro-3-(trifluoromethyl)phenoxy)azetidin-1-yl)-5-(trifluoromethyl)-nicotinamido)cyclopropyl)benzoic acid
- 4-(1-(2-(3-(3-(trifluoromethoxy)phenoxy)azetidin-1-yl)-5-(trifluoromethyl)-nicotinamido)cyclopropyl)benzoic acid
- 4-(1-(2-(3-(2,4-difluorophenoxy)azetidin-1-yl)-5-(trifluoromethyl)-
- 10 nicotinamido)cyclopropyl)benzoic acid
- 4-(1-(2-(3-(3,4-difluorophenoxy)azetidin-1-yl)-5-(trifluoromethyl)nicotinamido)-cyclopropyl)benzoic acid
- 4-(1-(5-(trifluoromethyl)-2-(3-((6-(trifluoromethyl)pyridin-2-yl)oxy)azetidin-1-yl)-nicotinamido)cyclopropyl)benzoic acid
- 15 4-(1-(2-(3-((3-fluorophenyl)amino)azetidin-1-yl)-5-(trifluoromethyl)nicotinamido)-cyclopropyl)benzoic acid
- 4-(1-(2-(3-((4-fluorophenyl)amino)azetidin-1-yl)-5-(trifluoromethyl)nicotinamido)-cyclopropyl)benzoic acid
- 4-(1-(2-(3-((4-fluoro-2-methylphenyl)amino)azetidin-1-yl)-5-(trifluoromethyl)-
- 20 nicotinamido)cyclopropyl)benzoic acid
- 4-(1-(2-(3-((2,4-difluorophenyl)amino)azetidin-1-yl)-5-(trifluoromethyl)-nicotinamido)cyclopropyl)benzoic acid
- 4-(1-(5-fluoro-2-(3-(3-fluorophenoxy)azetidin-1-yl)nicotinamido)cyclopropyl)benzoic acid
- 25 4-(1-(5-fluoro-2-(3-(3-chlorophenoxy)azetidin-1-yl)nicotinamido)cyclopropyl)-benzoic acid
- 4-(1-(5-fluoro-2-(3-(3-(trifluoromethoxy)phenoxy)azetidin-1-yl)nicotinamido)cyclopropyl)benzoic acid
- 4-(1-(5-fluoro-2-(3-((4-fluoro-2-methylphenyl)amino)azetidin-1-yl)nicotinamido)-
- 30 cyclopropyl)benzoic acid
- 4-(1-(5-chloro-2-(3-phenoxyprolidin-1-yl)nicotinamido)cyclopropyl)benzoic acid (racemic mixture)

- 4-(1-(5-chloro-2-(3-phenoxy)pyrrolidin-1-yl)nicotinamido)cyclopropyl)benzoic acid
(enantiomer 2)
- 4-(1-(5-chloro-2-(3-(3-(trifluoromethyl)phenoxy)pyrrolidin-1-yl)nicotinamido)cyclopropyl)benzoic acid (racemic mixture)
- 5 4-(1-(5-chloro-2-(3-(3-(trifluoromethyl)phenoxy)pyrrolidin-1-yl)nicotinamido)-cyclopropyl)benzoic acid (enantiomer 1)
- 4-(1-(5-chloro-2-(3-(3-(trifluoromethyl)phenoxy)pyrrolidin-1-yl)nicotinamido)-cyclopropyl)benzoic acid (enantiomer 2)
- 4-(1-(5-chloro-2-(3-(4-fluorophenoxy)pyrrolidin-1-yl)nicotinamido)cyclopropyl)-
10 benzoic acid (racemic mixture)
- 4-(1-(5-chloro-2-(3-(4-fluorophenoxy)pyrrolidin-1-yl)nicotinamido)cyclopropyl)-benzoic acid (enantiomer 2)
- 4-(1-(5-chloro-2-(3-(3-fluorophenoxy)pyrrolidin-1-yl)nicotinamido)cyclopropyl)-benzoic acid (racemic mixture)
- 15 4-(1-(5-chloro-2-(3-(3-fluorophenoxy)pyrrolidin-1-yl)nicotinamido)cyclopropyl)-benzoic acid (enantiomer 2)
- 4-(1-(5-chloro-2-(3-((3-fluorophenoxy)methyl)pyrrolidin-1-yl)nicotinamido)cyclopropyl)benzoic acid
- (R)-4-(1-(5-chloro-2-(2-((3-fluorophenoxy)methyl)pyrrolidin-1-yl)nicotinamido)
20 cyclopropyl)benzoic acid
- (S)-4-(1-(5-chloro-2-(3-(3-fluorophenoxy)pyrrolidin-1-yl)nicotinamido)cyclopropyl)benzoic acid
- N-(1-(4-(1H-tetrazol-5-yl)phenyl)cyclopropyl)-5-chloro-2-(3-(3-fluorophenoxy)-azetidin-1-yl)nicotinamide
- 25 24. The pyridine amide derivative according to claim 23, wherein the derivative of Formula (I) is selected from the group consisting of:
- 4-(1-(5-chloro-2-(3-phenoxyazetidin-1-yl)nicotinamido)cyclopropyl)benzoic acid
- 4-(1-(5-chloro-2-(3-(3-fluorophenoxy)azetidin-1-yl)nicotinamido)cyclopropyl)-benzoic acid
- 30 6-((5-chloro-2-(3-(3-fluorophenoxy)azetidin-1-yl)nicotinamido)methyl)nicotinic acid
- 4-(1-(5-chloro-2-(3-((4-fluoro-2-methylphenyl)amino)azetidin-1-yl)nicotinamido)-cyclopropyl)benzoic acid

4-(1-(2-(3-(3-fluorophenoxy)azetidin-1-yl)-5-(trifluoromethyl)nicotinamido)cyclopropyl)benzoic acid

4-(1-(2-(3-((4-fluoro-2-methylphenyl)amino)azetidin-1-yl)-5-(trifluoromethyl)nicotinamido)cyclopropyl)benzoic acid

- 5 25. A pharmaceutical composition comprising a derivative of Formula (I) according to anyone of claims 1-24 and a pharmaceutically acceptable carrier.
26. A pyridine amide derivative according to anyone of claims 1-24 for use as a medicament.
27. A pyridine amide derivative according to anyone of claims 1-14 for use in the
10 treatment of pathologies which require the use of an antagonist of the EP4 receptor.
28. The pyridine amide derivative according to claim 27, wherein such pathology is selected from the group consisting of acute and chronic pain, inflammatory pain, osteoarthritis, inflammation-associated disorder as arthritis, rheumatoid arthritis,
15 cancer endometriosis and migraine.



(I)